# AUTHOR INDEX


Aalders JG, *see* Duk JM
Aapro M, *see* Coombes RC
Aaronson NK, Visser-Pol E, Leenhouts GHMW, Muller MJ, van der Schot ACM, van Dam FSAM, Keus RB, Koning CCE, ten Bokkel Huinink WW, van Dongen JA, Dubbelman R. Telephone-based nursing intervention improves the effectiveness of the informed consent process in cancer clinical trials, 984
— *see* Simons JPFHA
— *see* Sprangers MAG
Abboudi Z, *see* Elliott C
Abeloff MD, *see* Rivkin SE
Abigerges D, *see* Chabot GG
Ablin A, *see* Willis B
Abrahamson G, *see* Elliott C
Abrams R, *see* Schultz C
Abramson N, *see* Fisher B
Abratt RP. Combined modality therapy of lung cancer and lung tolerance (letter), 1402
Acimovic L, *see* Jeremic B
Adam R, *see* Bertheault-Cvitkovic F
Adde M, *see* Magrath I
Adde MA, *see* Weintraub M
Adenis A, *see* Canal P
— *see* Conroy T
— *see* Zalcberg JR
Adjei AA, *see* Baker SD
Adler JR, *see* Joseph J
Advani SH, *see* Parikh B
Agura E, *see* Rosenfeld C
A'Hern RP, *see* Ahmed FY
Ahles TA, Tope DM, Furstenberg C, Hann D, Mills L. Psychologic and neuropsychologic impact of autologous bone marrow transplantation, 1457
Ahmad N, *see* Mohiuddin M
Ahmed FY, Wiltshaw E, A'Hern RP, Nicol B, Shepherd J, Blake P, Fisher C, Gore ME. Natural history and prognosis of untreated stage I epithelial ovarian carcinoma, 2968
Ahn C, *see* Margolin K
Aisner J. Extensive-disease small-cell lung cancer: The thrill of victory; the agony of defeat, 658
Albain KS, Green SR, Lichter AS, Hutchins LF, Wood WC, Henderson IC, Ingle JN, O'Sullivan J, Osborne CK, Martino S. Influence of patient characteristics, socioeconomic factors, geography, and systemic risk on the use of breast-sparing treatment in women enrolled in adjuvant breast cancer studies: An analysis of two intergroup trials, 3009
Albanell J, *see* Ribas A
Albrecht W, *see* Pont J
Alcalá A, *see* Bladé J
Alcorn MJ, Holyoake TL, Richmond L, Pearson C, Farrell E, Kyle B, Dunlop DJ, Fitzsimons E, Steward WP, Pragnell IB, Franklin IM. CD34-positive cells isolated from cryopreserved peripheral-blood progenitor cells can be expanded ex vivo and used for transplantation with little or no toxicity, 1839
Alexander HR, *see* Fraker DL
Alfano S, *see* Fischer DS
Algeri R, *see* Conte PF
Allegra C, *see* Dahut W
— *see* Yu B
Allen-Mersh TG, *see* Earlam S
Allgayer B, *see* Avril N
Almadrones L, *see* Markman M
Alquati P, *see* Dogliotti L
Amadori D, *see* Coombes RC
Amadori S, *see* Zinzani PL
Amalric R, *see* Solin LJ
Amato S, *see* Leone BA
Ambros IM, *see* Kushner BH
Ambros PF, *see* Kushner BH
American Society of Clinical Oncology. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer, 2843
— Funding for clinical (patient-oriented) oncology research: Current status and recommendations for improvement, 666
— Medical oncology for the general internal medicine trainee, 1040
— Outcomes of cancer treatment for technology assessment and cancer treatment guidelines, 671
— Statement of the American Society of Clinical Oncology: Genetic testing for cancer susceptibility, 1730
— Status of the medical oncology workforce, 2612
— Tobacco control: Reducing cancer incidence and saving lives, 1961
— Update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based clinical practice guidelines, 1957
Amini M, *see* Corona R
Amsterdam A, *see* Motzer RJ
Anasetti C, *see* Anderson JE
— *see* Slattery JT
Anderlini P, Pierce S, Kantarjian H, Estey E. Acute myeloid leukemia–type chemotherapy for myelodysplasia (letter), 1404
Andersen J, *see* Gordon LI
Anderson JE, Appelbaum FR, Schoch G, Gooley T, Anasetti C, Bensinger WI, Bryant E, Buckner CD, Chauncey T, Clift RA, Deeg J, Doney K, Flowers M, Hansen JA, Martin PJ, Matthews DC, Nash RA, Sanders JE, Shulman H, Sullivan KM, Witherspoon RP, Storb R. Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: A phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors, 220
Anderson JE, *see* Vose JM
Anderson JR, *see* Vose JM
Andersson B, *see* van Besien K
Andreola S, *see* Pupa SM
Andrich M, *see* Fraker DL
Andrich MP, *see* Wexler LH
Andrieu J-M, *see* Colonna P
Angel K, *see* Pont J
Anglaret B, *see* Blay J-Y
Anthony L, *see* Hesketh P
Antman K, *see* Ayash LJ

# AUTHOR INDEX


Aalders JG, *see* Duk JM
Aapro M, *see* Coombes RC
Aaronson NK, Visser-Pol E, Leenhouts GHMW, Muller MJ, van der Schot ACM, van Dam FSAM, Keus RB, Koning CCE, ten Bokkel Huinink WW, van Dongen JA, Dubbelman R. Telephone-based nursing intervention improves the effectiveness of the informed consent process in cancer clinical trials, 984
— *see* Simons JPFHA
— *see* Sprangers MAG
Abboudi Z, *see* Elliott C
Abeloff MD, *see* Rivkin SE
Abigerges D, *see* Chabot GG
Ablin A, *see* Willis B
Abrahamson G, *see* Elliott C
Abrams R, *see* Schultz C
Abramson N, *see* Fisher B
Abratt RP. Combined modality therapy of lung cancer and lung tolerance (letter), 1402
Acimovic L, *see* Jeremic B
Adam R, *see* Bertheault-Cvitkovic F
Adde M, *see* Magrath I
Adde MA, *see* Weintraub M
Adenis A, *see* Canal P
— *see* Conroy T
— *see* Zalcberg JR
Adjei AA, *see* Baker SD
Adler JR, *see* Joseph J
Advani SH, *see* Parikh B
Agura E, *see* Rosenfeld C
A'Hern RP, *see* Ahmed FY
Ahles TA, Tope DM, Furstenberg C, Hann D, Mills L. Psychologic and neuropsychologic impact of autologous bone marrow transplantation, 1457
Ahmad N, *see* Mohiuddin M
Ahmed FY, Wiltshaw E, A'Hern RP, Nicol B, Shepherd J, Blake P, Fisher C, Gore ME. Natural history and prognosis of untreated stage I epithelial ovarian carcinoma, 2968
Ahn C, *see* Margolin K
Aisner J. Extensive-disease small-cell lung cancer: The thrill of victory; the agony of defeat, 658
Albain KS, Green SR, Lichter AS, Hutchins LF, Wood WC, Henderson IC, Ingle JN, O'Sullivan J, Osborne CK, Martino S. Influence of patient characteristics, socioeconomic factors, geography, and systemic risk on the use of breast-sparing treatment in women enrolled in adjuvant breast cancer studies: An analysis of two intergroup trials, 3009
Albanell J, *see* Ribas A
Albrecht W, *see* Pont J
Alcalá A, *see* Bladé J
Alcorn MJ, Holyoake TL, Richmond L, Pearson C, Farrell E, Kyle B, Dunlop DJ, Fitzsimons E, Steward WP, Pragnell IB, Franklin IM. CD34-positive cells isolated from cryopreserved peripheral-blood progenitor cells can be expanded ex vivo and used for transplantation with little or no toxicity, 1839
Alexander HR, *see* Fraker DL
Alfano S, *see* Fischer DS
Algeri R, *see* Conte PF
Allegra C, *see* Dahut W
— *see* Yu B
Allen-Mersh TG, *see* Earlam S
Allgayer B, *see* Avril N
Almadrones L, *see* Markman M
Alquati P, *see* Dogliotti L
Amadori D, *see* Coombes RC
Amadori S, *see* Zinzani PL
Amalric R, *see* Solin LJ
Amato S, *see* Leone BA
Ambros IM, *see* Kushner BH
Ambros PF, *see* Kushner BH
American Society of Clinical Oncology. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer, 2843
— Funding for clinical (patient-oriented) oncology research: Current status and recommendations for improvement, 666
— Medical oncology for the general internal medicine trainee, 1040
— Outcomes of cancer treatment for technology assessment and cancer treatment guidelines, 671
— Statement of the American Society of Clinical Oncology: Genetic testing for cancer susceptibility, 1730
— Status of the medical oncology workforce, 2612
— Tobacco control: Reducing cancer incidence and saving lives, 1961
— Update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based clinical practice guidelines, 1957
Amini M, *see* Corona R
Amsterdam A, *see* Motzer RJ
Anasetti C, *see* Anderson JE
— *see* Slattery JT
Anderlini P, Pierce S, Kantarjian H, Estey E. Acute myeloid leukemia–type chemotherapy for myelodysplasia (letter), 1404
Andersen J, *see* Gordon LI
Anderson JE, Appelbaum FR, Schoch G, Gooley T, Anasetti C, Bensinger WI, Bryant E, Buckner CD, Chauncey T, Clift RA, Deeg J, Doney K, Flowers M, Hansen JA, Martin PJ, Matthews DC, Nash RA, Sanders JE, Shulman H, Sullivan KM, Witherspoon RP, Storb R. Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: A phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors, 220
Anderson JE, *see* Vose JM
Anderson JR, *see* Vose JM
Andersson B, *see* van Besien K
Andreola S, *see* Pupa SM
Andrich M, *see* Fraker DL
Andrich MP, *see* Wexler LH
Andrieu J-M, *see* Colonna P
Angel K, *see* Pont J
Anglaret B, *see* Blay J-Y
Anthony L, *see* Hesketh P
Antman K, *see* Ayash LJ

Antman KH, *see* Weissmann LB
Appelbaum FR, *see* Anderson JE
— *see* Bensinger WI
— *see* Slattery JT
— *see* Vose JM
Aprikian A, *see* Brenner PC
Arbuck S, *see* Dahut W
Ardizzoni A, *see* Giaccone G
Ariyoshi Y, *see* Nishio M
Armand J-P, *see* Chabot GG
— *see* Wibault P
Armand JP, *see* Soulié P
Armitage GR, *see* Rusthoven JJ
— *see* Tannock IF
Armitage JO, *see* Bishop MR
— *see* Gajewski JL
— *see* Sharp JG
— *see* Vose JM
Armitage S, *see* Elliott C
Arndt C, *see* Magrath I
— *see* Weintraub M
Arneson M, *see* Bishop MR
Aron BS, *see* Fisher B
Arraras JI, *see* Sprangers MAG
Arriagada R, Lê MG, Rochard F, Contesso G. Conservative treatment versus mastectomy in early breast cancer: Patterns of failure with 15 years of follow-up data, 1558
Arron J, *see* Stemmer SM
Artale S, *see* Bajetta E
Arthur D, *see* Smith M
Arveux P, *see* Joly F
Ascari E, *see* Gobbi PG
Ashley DM, Meier L, Kerby T, Zalduondo FM, Friedman HS, Gajjar A, Kun L, Duffner PK, Smith S, Longee D. Response of recurrent medulloblastoma to low-dose oral etoposide, 1922
Ashley S, *see* Powles TJ
Asou N, *see* Kobayashi T
Atahan L, *see* Çelik I
Athanasiadis I, *see* Vokes EE
Atkins JN, *see* Fisher B
Atkinson JB, *see* Stram DO
Atkinson RJ, *see* Kaye SB
Audhuy B, *see* Diviné M
August C, *see* Finlay JL
Auguste L, *see* Seidman AD
Aust JC, *see* Perloff M
Avanzini P, *see* Gobbi PG
Avila N, *see* Wexler LH
Avril N, Dose J, Jänicke F, Bense S, Ziegler S, Laubenbacher C, Römer W, Pache H, Herz M, Allgayer B, Nathrath W, Graeff H, Schwaiger M. Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose, 1848
Ayash LJ, Elias A, Schwartz G, Wheeler C, Ibrahim J, Teicher BA, Reich E, Warren D, Lynch C, Richardson P, Schnipper L, Frei E III, Antman K. Double dose-intensive chemotherapy with autologous stem-cell support for metastatic breast cancer: No improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, thiotepa, and carboplatin, 2984
Ayers D, *see* Gelmon KA
Ayoub J-P, *see* Younes A
Azab M, *see* Buzdar A
— *see* Zalcberg JR

Baars JW, *see* Rodenhuis S
Babic R, *see* Jauch K-W
Babin S, *see* Feugeas O
Babin-Boilletot A, *see* Feugeas O
Badell I, *see* Sierra J
Badellino F, *see* Percivale P
Bagshawe KD, *see* Rustin GJS
Bailey NP, *see* Lind MJ
Bajetta E, Di Leo A, Biganzoli L, Mariani L, Cappuzzo F, Di Bartolomeo M, Zilembo N, Artale S, Magnani E, Celio L, Buzzoni R, Carnaghi C. Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: Activity in platinum-resistant disease, 2546
Bajorin DF, *see* Brenner PC
— *see* Motzer RJ
— *see* Puc HS
Baker SD, Khor SP, Adjei AA, Doucette M, Spector T, Donehower RC, Grochow LB, Sartorius SE, Noe DA, Hohneker JA, Rowinsky EK. Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase, 3085
— *see* Furman WL
— *see* Rowinsky EK
Balch CM, Buzaid AC. Finally, a successful adjuvant therapy for high-risk melanoma (editorial), 1
Baldeyrou P, *see* Girard P
Baldini EH, *see* Singer S
Balis F, *see* Fisherman JS
Balis FM, *see* Tolcher AW
— *see* Wexler LH
Balmaceda C, Heller G, Rosenblum M, Diez B, Villablanca JG, Kellie S, Maher P, Vlamis V, Walker RW, Leibel S, Finlay JL, the First International Central Nervous System Germ Cell Tumor Study. Chemotherapy without irradiation—A novel approach for newly diagnosed CNS germ cell tumors: Results of an international cooperative trial, 2908
— *see* Hudis CA
Bank A, *see* Perloff M
Banks PM, *see* Travis LB
Barakat R, *see* Markman M
Baranda J, *see* Lenz H-J
Barbieri MR, *see* Leone BA
Bardini T, *see* Guglielmi M
Barkley JE, Green MR. Bronchioloalveolar carcinoma, 2377
Barlier C, *see* Coindre J-M
Barnes CS, *see* Tolcher AW
Barnett T, *see* Bensinger WI
Barr R, Furlong W, Henwood J, Feeny D, Wegener J, Walker I, Brain M. Economic evaluation of allogeneic bone marrow transplantation: A rudimentary model to generate estimates for the timely formulation of clinical policy, 1413
Barrett W, *see* Solin LJ
Barry MJ, *see* Fowler FJ Jr

Bar-Shalom R, *see* Ben-Haim S
Bartels H, *see* Schlegelberger B
Bartoli GC, *see* Guglielmi M
Barylak E, *see* Cole BF
Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L. Phase II study of weekly intravenous recombinant humanized anti-p185$^{HER2}$ monoclonal antibody in patients with HER2/*neu*-overexpressing metastatic breast cancer, 737
— *see* Hudis CA
— *see* Ribas A
— *see* Seidman AD
Basili L, *see* Patenaude AF
Bassot V, *see* Laccourreye O
Bastholt L, Dalmark M, Gjedde SB, Pfeiffer P, Pedersen D, Sandberg E, Kjaer M, Mouridsen HT, Rose C, Nielsen OS, Jakobsen P, Bentzen SM. Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: A randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group, 1146
Bastion Y, *see* Solal-Céligny P
Bates BA, Detterbeck FC, Bernard SA, Qaqish BF, Tepper JE. Concurrent radiation therapy and chemotherapy followed by esophagectomy for localized esophageal carcinoma, 156
Baù MG, *see* Dogliotti L
Baughman S, *see* Baselga J
Bauman A, *see* Winter JN
Bayever E, *see* Bishop MR
Bear HD, *see* Hillner BE
Bearman SI, *see* Stemmer SM
Beaulieu N, *see* Fischer DS
Beck D, *see* Combaret V
Beck WT, *see* Kuttesch JF Jr
Bedenne L, *see* Conroy T
Behm F, *see* Bowman WP
Behr T, *see* Juweid M
Beijnen JH, *see* Taal BG
Beinfield M, *see* Haffty BG
Belardi A, *see* Roselli M
Belissant E, *see* Dieras V
Bell DR, *see* Millward MJ
Belldegrun A, *see* Rosen PJ
Bellina RC, *see* Venturini M
Bellini A, *see* Conte PF
Bellmunt J, *see* Ribas A
Belluco C, Guillem JG, Kemeny N, Huang Y, Klimstra D, Berger MF, Cohen AM. p53 nuclear protein overexpression in colorectal cancer: A dominant predictor of survival in patients with advanced hepatic metastases, 2696
Belpomme D, *see* Kemp G
— *see* Misset J-L
Bendandi M, *see* Zinzani PL
Bender J, *see* Winter JN
Benedict C, *see* Hesketh P
Ben-Haim S, Bar-Shalom R, Israel O, Haim N, Epelbaum R, Ben-Shachar M, Gaitini D, Kolodny GM, Front D. Utility of gallium-67 scintigraphy in low-grade non-Hodgkin's lymphoma, 1936
Benichou J, Gail MH, Mulvihill JJ. Graphs to estimate an individualized risk of breast cancer, 103
Benini E, *see* Silvestrini R
Bennett CL, Smith TJ, Weeks JC, Bredt AB, Feinglass J, Fetting JH, Hillner BE, Somerfield MR, Winn RJ. Use of hematopoietic colony-stimulating factors: The American Society of Clinical Oncology survey, 2511
Bennett K, *see* Rusthoven JJ
Bense S, *see* Avril N
Ben-Shachar M, *see* Ben-Haim S
Bensinger WI, Rowley SD, Demirer T, Lilleby K, Schiffman K, Clift RA, Appelbaum FR, Fefer A, Barnett T, Storb R, Chauncey T, Maziarz RT, Klarnet J, McSweeney P, Holmberg L, Maloney DG, Weaver CH, Buckner CD. High-dose therapy followed by autologous hematopoietic stem-cell infusion for patients with multiple myeloma, 1447
— *see* Anderson JE
— *see* Slattery JT
Bensmaïne, M-E-A, *see* Wibault P
Benson A III, *see* Minsky BD
Bentzen SM, *see* Bastholt L
Ben-Yehuda D, Polliack A, Okon E, Sherman Y, Fields S, Lebenshart P, Lotan H, Libson E. Image-guided core-needle biopsy in malignant lymphoma: Experience with 100 patients that suggests the technique is reliable, 2431
Benz CC, *see* Baselga J
Berard C, *see* Bowman WP
Berchier MC, *see* Sculier JP
Berg C, *see* Swain SM
Berg S, *see* Fisherman JS
Berg SL, *see* Tolcher AW
— *see* Wexler LH
Berger CC, *see* Bokemeyer C
Berger MF, *see* Belluco C
Berger MS, *see* Prados MD
Bergh J, *see* Sandström M
Bergström R, *see* Lindmark G
Berkery R, *see* Saltz LB
Berlin J, *see* Schiller JH
Berman E, *see* Weiss M
Berman M, *see* Kemp G
Bermejo B, *see* Ribas A
Bernal ET, *see* Wibault P
Bernard P, *see* Marit G
Bernard SA, *see* Bates BA
Bernhard G, *see* Jäger E
Bernhard H, *see* Jäger E
Bernstein SH, Brunetto VL, Davey FR, Wurster-Hill D, Mayer RJ, Stone RM, Schiffer CA, Bloomfield CD. Acute myeloid leukemia–type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined by French-American-British criteria: A Cancer and Leukemia Group B study, 2486
Berruti A, *see* Dogliotti L
Berry W, *see* Schiller JH
Bertè R, *see* Gobbi PG
Bertelli G, *see* Venturini M

Bertheault-Cvitkovic F, Jami A, Ithzaki M, Deprés Brummer P, Brienza S, Adam R, Kunstlinger F, Bismuth H, Misset JL, Lévi F. Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer, 2950
Bertino J, *see* Weiss M
Bertino JR, *see* DeAngelis LM
Bertoglio S, *see* Percivale P
Bessell EM, Graus F, Punt JAG, Firth JL, Hope DT, Moloney AJ, Lopez-Guillermo A, Villa S. Primary non-Hodgkin's lymphoma of the CNS treated with BVAM or CHOD/BVAM chemotherapy before radiotherapy, 945
Besses C, *see* Sierra J
Beyer J, Kramar A, Mandanas R, Linkesch W, Greinix A, Droz JP, Pico JL, Diehl A, Bokemeyer C, Schmoll HJ, Nichols CR, Einhorn LH, Siegert W. High-dose chemotherapy as salvage treatment in germ cell tumors: A multivariate analysis of prognostic variables, 2638
— *see* Schwella N
Bezwoda WR. In reply (letter), 687
Bianco AR, *see* Carlomagno C
Bielack S, *see* Bieling P
Bielack SS, Kempf-Bielack B, Winkler K. Osteosarcoma: Relationship of response to preoperative chemotherapy and type of surgery to local recurrence (letter), 683
Bieling P, Rehan N, Bielack S, Winkler K. In reply (letter), 2400
—, Rehan N, Winkler P, Helmke K, Maas R, Fuchs N, Bielack S, Heise U, Jürgens H, Treuner J, Romanowski R, Exner U, Kotz R, Winkler K. Tumor size and prognosis in aggressively treated osteosarcoma, 848
Bieri S, *see* Miralbell R
Bierman P, *see* Sharp JG
Bierman PJ, *see* Bishop MR
— *see* Vose JM
Biganzoli L, *see* Bajetta E
Bin L, *see* Fowler FJ Jr
Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer, 1718
Biron P, *see* Blay J-Y
Bishop JF, *see* Millward MJ
Bishop MR, Iversen PL, Bayever E, Sharp JG, Greiner TC, Copple BL, Ruddon R, Zon G, Spinolo J, Arneson M, Armitage JO, Kessinger A. Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies, 1320
—, Jackson JD, O'Kane-Murphy B, Schmit-Pokorny K, Vose JM, Bierman PJ, Warkentin PI, Armitage JO, Garrison L, Kessinger A. Phase I trial of recombinant fusion protein PIXY321 for mobilization of peripheral-blood cells, 2521
Bismuth H, *see* Bertheault-Cvitkovic F
Bladé J, San Miguel JF, Fontanillas M, Alcalá A, Maldonado J, García-Conde J, Conde E, Conzález-Brito G, Moro M-J, Escudero M-L, Trujillo J, Pascual A, Rozman C, Estapé J, Montserrat E. Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/autotransplantation and who were conventionally treated, 2167
Blaise D, *see* Sweetenham JW
Blake P, *see* Ahmed FY
Blanc M, *see* Diviné M
Blanke C, *see* Johnson DH
Blasko JC, Ragde H, Grimm PD, Cavanagh W. Prostate brachytherapy: Importance of technique (letter), 1965
Blay J-Y, Chauvin F, Le Cesne A, Anglaret B, Bouhour D, Lasset C, Freyer G, Philip T, Biron P. Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia, 636
Blay JY, *see* Tartour E
Bleehen NM, *see* Boote DJ
Bleiberg H, *see* Blijham G
— *see* Conroy T
Blessing JA, *see* McGuire WP
Bleyer A, *see* Smith M
Bleyer AW, *see* Steinherz PG
Bleyer WA, *see* Steinherz PG
Blijham G, Wagener T, Wils J, de Greve J, Buset M, Bleiberg H, Lacave A, Dalmark M, Selleslag J, Collette L, Sahmoud T. Modulation of high-dose infusional fluorouracil by low-dose methotrexate in patients with advanced or metastatic colorectal cancer: Final results of a randomized European Organization for Research and Treatment of Cancer study, 2266
Blijham GH, *see* Simons JPFHA
Bliss JM, *see* Coombes RC
Blomqvist C, *see* Buzdar A
— *see* Saarto T
Bloomfield CD, *see* Bernstein SH
Blum JL, *see* Hainsworth JD
Blum R, *see* Chang A
— *see* Wasserheit C
Blum RH, *see* Kirkwood JM
Boasson M, *see* Colonna P
Bobrow LG, *see* Lee HAS
Boccardo F, *see* Conte PF
Bodurtha AJ, *see* Rusthoven JJ
Body J-J, *see* Pecherstorfer M
Boersma LJ, Damen EMF, de Boer RW, Muller SH, Valdés Olmos RA, van Zandwijk N, Lebesque JV. Recovery of overall and local lung function loss 18 months after irradiation for malignant lymphoma, 1431
Boglino C, *see* Guglielmi M
Boice JD Jr, *see* Travis LB
Boiron JM, *see* Marit G
Bokemeyer C, Berger CC, Kuczyk MA, Schmoll H-J. Evaluation of long-term toxicity after chemotherapy for testicular cancer, 2923
— *see* Beyer J
Bolis G, *see* Creemers GJ
Bonadonna G, *see* Bregni M
— *see* Viviani S
Bonfante V, *see* Viviani S
Bonichon F, *see* Coindre J-M
Bonilla MA, *see* Kushner BH
Bonnay M, *see* Chabot GG
Bonneterre J, *see* Conte PF
— *see* Nabholtz J-M
Bontenbal M, *see* Nabholtz J-M

Bookman MA, McGuire WP III, Kilpatrick D, Keenan E, Hogan WM, Johnson SW, O'Dwyer P, Rowinsky E, Gallion HH, Ozols RF. Carboplatin and paclitaxel in ovarian carcinoma: A phase I study of the Gynecologic Oncology Group, 1895
—, Ozols RF. Factoring outcomes in ovarian cancer (editorial), 325
— *see* O'Dwyer PJ
Booser DJ, *see* Holmes FA
Boot H, *see* Taal BG
Boote DJ, Dennis IF, Twentyman PR, Osborne RJ, Laburte C, Hensel S, Smyth JF, Brampton MH, Bleehen NM. Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer, 610
Borden E, *see* Cole BF
Borden EC, Wadler S. Interferons as biochemical modulators (editorial), 2627
— *see* Kirkwood JM
Bordessoule D, *see* Solal-Céligny P
Borel C, *see* Wibault P
Bornstein BA, *see* Solin LJ
Borowitz M, *see* Winick N
Bortin MM, *see* Gajewski JL
Bosch F, *see* Montserrat E
Bosl GJ, *see* Brenner PC
— *see* Motzer RJ
— *see* Puc HS
Bosly A, *see* Solal-Céligny P
Bostrom B, *see* Finlay JL
Botet J, *see* Kelsen D
Bottini A, *see* Dogliotti L
Bougaran J, *see* Girard P
Bouhour D, *see* Blay J-Y
Boulad F, *see* Kushner BH
Bourhis JH, *see* Marit G
Bow EJ, Sutherland JA, Kilpatrick MG, Williams GJ, Clinch JJ, Shore TB, Rubinger M, Schacter BA. Therapy of untreated acute myeloid leukemia in the elderly: Remission-induction using a non–cytarabine-containing regimen of mitoxantrone plus etoposide, 1345
Bowen T, *see* Mahoney DH Jr
Bowling K, *see* Kennedy MJ
Bowling MK, *see* Rowinsky EK
Bowman DM, *see* Fisher B
Bowman L, *see* Kuttesch JF Jr
Bowman WP, Shuster JJ, Cook B, Griffin T, Behm F, Pullen J, Link M, Head D, Carroll A, Berard C, Murphy S. Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small noncleaved-cell lymphoma: A Pediatric Oncology Group study, 1252
— *see* Winick N
Boyett JM, *see* Finlay JL
Bradford CR, *see* Eisbruch A
Brady MF, *see* Lentz SS
— *see* Rustin GJS
Brain M, *see* Barr R
Brampton MH, *see* Boote DJ
Brandely M, *see* Pujade-Lauraine E
Brandter LB, *see* Heyman M
Brasnu D, *see* Laccourreye O
Brault P, *see* Marit G
Bredt AB, *see* Bennett CL
Bregni M, Siena S, Di Nicola M, Dodero A, Peccatori F, Ravagnani F, Danesini G, Laffranchi A, Bonadonna G, Gianni AM. Comparative effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor after high-dose cyclophosphamide cancer therapy, 628
Breitfeld PP, *see* Rackoff WR
Breneman JC, *see* Steinherz PG
Brennan J, *see* O'Dwyer PJ
Brennan M, *see* Elliott C
— *see* Kelsen D
Brennan MF, *see* Heslin MJ
— *see* Pisters PWT
Brenner PC, Herr HW, Morse MJ, Sheinfeld J, Aprikian A, Bosl GJ, Motzer RJ, Bajorin DF, Schantz S, Fair WR, Burt M. Simultaneous retroperitoneal, thoracic, and cervical resection of postchemotherapy residual masses in patients with metastatic nonseminomatous germ cell tumors of the testis, 1765
Brennscheidt U, *see* Engelhardt M
Breuer N, *see* Stahl M
Briassoulis E, *see* Kosmidis PA
Brice P, *see* Solal-Céligny P
Bridges JD, *see* Johnson BE
Brienza S, *see* Bertheault-Cvitkovic F
Brière J, *see* Colonna P
— *see* Diviné M
Brisson J, *see* Maunsell E
Brodeur GM, *see* Stram DO
Brousse N, *see* Solal-Céligny P
Broustet A, *see* Marit G
Bruera E, Sloan P, Mount B, Scott J, Suarez-Almazor M. A randomized, double-blind, double-dummy, crossover trial comparing the safety and efficacy of oral sustained-release hydromorphone with immediate-release hydromorphone in patients with cancer pain, 1713
Bruijn JA, *see* Bunt AMG
Brunat-Mentigny M, *see* Feugeas O
Brunelli C, *see* De Conno F
Brunet R, *see* Canal P
Brunet S, *see* Sierra J
Brunetti I, *see* Conte PF
— *see* Falcone A
Brunetto VL, *see* Bernstein SH
Bruno R, *see* Hudis CA
Bruno S, *see* Decensi A
Bruzzi P, *see* Guglielmi M
— *see* Venturini M
Bruzzone M, *see* Conte PF
Bryant E, *see* Anderson JE
Bryce C, *see* Gelmon KA
Buchanan GR, *see* Winick N
Buckner CD, *see* Anderson JE
— *see* Bensinger WI
— *see* Slattery JT
Budman DR, *see* Rosner GL
Bueno J, *see* Sierra J
Bufalino R, *see* Pupa SM
Bugat R, *see* Canal P
— *see* Pujade-Lauraine E

Bührer C, Hartmann R, Fengler R, Rath B, Schrappe M, Janka-Schaub G, Henze G, the Berlin-Frankfurt-Münster Relapse Study Group. Peripheral blast counts at diagnosis of late isolated bone marrow relapse of childhood acute lymphoblastic leukemia predict response to salvage chemotherapy and outcome, 2812
Bui NB, *see* Coindre J-M
Buniva T, *see* Dogliotti L
Bunt AMG, Hermans J, Smit VTHBM, van de Velde CJH, Fleuren GJ, Bruijn JA. In reply (letter), 2409
— , Hermans J, van de Velde CJH, Sasako M, Hoefsloot FAM, Fleuren G, Bruijn JA. Lymph node retrieval in a randomized trial on Western-type versus Japanese-type surgery in gastric cancer, 2289
Buonomo O, *see* Roselli M
Burdette-Radoux S, *see* Rusthoven JJ
Bureau G, *see* Sculier JP
Burghouts J, *see* Splinter TAW
Burke D, *see* Earlam S
Burkes R, *see* Shepherd FA
Burman S, *see* Crawford J
Burris HA III, *see* Rothenberg ML
Burt M, *see* Brenner PC
— *see* Schwarz RE
Buset M, *see* Blijham G
Busse PM, *see* Dreyfuss AI
Busson A, *see* Joly F
Buys SS, *see* Greco FA
Buyse M, *see* Greco FA
Buzaid AC, *see* Balch CM
Buzdar A, Jonat W, Howell A, Jones SE, Blomqvist C, Vogel CL, Eiermann W, Wolter JM, Azab M, Webster A, Plourde PV. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: Results of overview analysis of two phase III trials, 2000
Buzdar AU, *see* Diamandidou E
— *see* Greenberg PAC
— *see* Holmes FA
Buzzoni R, *see* Bajetta E
Byar K, *see* Vose JM
Byhardt R, *see* Tester W
Byhardt RW, *see* Lee JS
Byrd K, *see* Winter JN

Cabanillas F, *see* McLaughlin P
— *see* Sarris AH
— *see* Younes A
Cadiou M, *see* Zittoun R
Cafiero F, *see* Percivale P
Cagnoni PJ, *see* Stemmer SM
Cairo M, *see* Finlay JL
Calabresi F, *see* Conte PF
— *see* Martelli M
Callendar D, *see* Sarris AH
Calvert AH, *see* Lind MJ
Camitta B, *see* Mahoney DH Jr
— *see* Smith M
— *see* Steuber CP
Camitta BM. Treatment of rhabdomyosarcoma (letter), 323
Campana D, *see* Ito C
Campbell C, *see* Gelmon KA
Campo E, *see* Montserrat E
Campora E, *see* Percivale P
Campos D, *see* Conte PF
Canal P, Gay C, Dezeuze A, Douillard JY, Bugat R, Brunet R, Adenis A, Herait P, Lokiec F, Mathieu-Boue A, the Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer. Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer, 2688
Canavese G, *see* Percivale P
Canellos GP, *see* Perloff M
Caplan R, *see* Tester W
Cappuzzo F, *see* Bajetta E
Carballo E, *see* Mellado B
Carbone A, *see* Vaccher E
Cardinale J, *see* Salloum E
Carey RW, *see* Perloff M
Carlomagno C, Perrone F, Gallo C, De Laurentiis M, Lauria R, Morabito A, Pettinato G, Panico L, D'Antonio A, Bianco AR, De Placido S. c-*erb*B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases, 2702
Carlson RW, *see* Hillner BE
Carnaghi C, *see* Bajetta E
Carnino F, *see* Conte PF
— *see* Venturini M
Carotenuto M, *see* Gobbi PG
Carpi A, Ferrari E, Toni MG, Sagripanti A, Nicolini A, Di Coscio G. Needle aspiration techniques in preoperative selection of patients with thyroid nodules: A long-term study, 1704
Carrasquillo J, *see* Yu B
Carreras E, *see* Sierra J
Carroll A, *see* Bowman WP
Carroll AJ, *see* Smith M
Carroll WR, *see* Eisbruch A
Carson J, *see* Coppin CML
Carulla J, *see* Ribas A
Casalini P, *see* Mènard S
Casassus P, *see* Colonna P
Casciani CU, *see* Roselli M
Caspard H, *see* Solal-Céligny P
Casper ES, *see* Pisters PWT
Cassidy J, *see* Kaye SB
Cassileth P, *see* Gordon LI
Castel T, *see* Mellado B
Castro P, *see* Lawrence G
Catimel G, *see* Nabholtz J-M
Catsafados E, *see* Conte PF
Cavanagh W, *see* Blasko JC
Cecchetto G, *see* Guglielmi M
Çelik I, Kars A, Özyar E, Tekuzman G, Atahan L, Firat D. Major toxicity of cisplatin, fluorouracil, and leucovorin following chemoradiotherapy in patients with nasopharyngeal carcinoma (letter), 1043
Celio L, *see* Bajetta E
Chabot GG, Armand J-P, Terret C, de Forni M, Abigerges D, Winograd B, Igwemezie L, Schacter L, Kaul S, Ropers J, Bonnay M. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study, 2020

Chachoua A, *see* Wasserheit C
Chaffey JT, *see* Travis LB
Chai A, *see* Stein AS
Champlin R, *see* van Besien K
Champlin RE, *see* Gajewski JL
Chan WK, *see* Chi KH
Chandra M, *see* Parikh B
Chang A, Yeap B, Davis T, Blum R, Hahn R, Khanna O, Fisher H, Rosenthal J, Witte R, Schinella R, Trump D. Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: Flutamide versus diethylstilbestrol, 2250
Chang R, *see* Tolcher AW
Chang SM, *see* Prados MD
Chantada G, *see* Schvartzman E
Chantarawiroj P, *see* Kudelka AP
Chapman F, *see* Lind MJ
Chappell R, *see* Steinherz PG
Chapuis B, *see* Miralbell R
Charnsangavej C, *see* Patt YZ
Chauncey T, *see* Anderson JE
— *see* Bensinger WI
Chauvin F, *see* Blay J-Y
Chauvin P, *see* Figarella-Branger D
Chen A, *see* Dahut W
Chen CC, *see* Wexler LH
Chen E-T, *see* Mohiuddin M
Chen KY, *see* Chi KH
Chen T-L, *see* Kennedy MJ
— *see* Rowinsky EK
Chen TL, *see* O'Reilly S
Chen YM, Liu JM, Tsai CM, Whang-Peng J, Perng RP. Maculopapular rashes secondary to gemcitabine injection for non–small-cell lung cancer (letter), 1743
Cherlow JM, *see* Steinherz PG
Cheung, N-KV, *see* Kushner BH
Cheung WK, *see* Saven A
Chi KH, Chan WK, Chen KY. In reply (letter), 1742
Chiara S, *see* Conte PF
Chilvers CED, *see* Coombes RC
Chollet P, *see* Misset J-L
Chou T-C, *see* Conti JA
Chow C, *see* Fisherman JS
Choy H, *see* Glantz MJ
Christiansen H, *see* Zoubek A
Christiansen I, *see* Juliusson G
Chung Y, *see* Yu B
Civin CI, Trischmann T, Kadan NS, Davis J, Noga S, Cohen K, Duffy B, Groenewegen I, Wiley J, Law P, Hardwick A, Oldham F, Gee A. Highly purified CD34-positive cells reconstitute hematopoiesis, 2224
Clahsen PC, van de Velde CJH, Julien J-P, Floiras J-L, Delozier T, Mignolet FY, Sahmoud TM. Improved local control and disease-free survival after perioperative chemotherapy for early-stage breast cancer: A European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group study, 745
—, van de Velde CJH. In reply (letter), 2886
Clamon G, *see* Crawford J
Clark JR, *see* Dreyfuss AI
Clark PI, *see* Joel SP
Clarke SJ, Hanwell J, de Boer M, Planting A, Verweij J, Walker M, Smith R, Jackman AL, Hughes LR, Harrap KR, Kennealey GT, Judson IR. Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors, 1495
Clemens MR, *see* Pecherstorfer M
Clerico M, *see* Giaccone G
— *see* Splinter TAW
Clift RA, *see* Anderson JE
— *see* Bensinger WI
Clinch JJ, *see* Bow EJ
Cobben EGM, *see* Simons JPFHA
Cobleigh MA, *see* Bines J
Cohen AM, *see* Belluco C
— *see* Zeng ZS
Cohen BH, *see* Finlay JL
Cohen H, *see* Lenz H-J
Cohen HJ. Race and myeloma survival (letter), 3175
Cohen K, *see* Civin CI
Cohen MH. Dose-intensive metastatic breast cancer chemotherapy (letter), 685
Cohen P, *see* Gill PS
Cohn SL, *see* Meitar D
Coia L, *see* Flam M
Coiffier B, *see* Diviné M
Coindre J-M, Terrier P, Bui NB, Bonichon F, Collin F, Le Doussal V, Mandard A-M, Vilain M-O, Jacquemier J, Duplay H, Sastre X, Barlier C, Henry-Amar M, Macé-Lesech J, Contesso G. Prognostic factors in adult patients with locally controlled soft tissue sarcoma: A study of 546 patients from the French Federation of Cancer Centers Sarcoma Group, 869
Colarusso PJ, *see* Essayan DM
Cole BF, Gelber RD, Kirkwood JM, Goldhirsch A, Barylak E, Borden E. Quality-of-life–adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: An Eastern Cooperative Oncology Group study, 2666
— *see* Glantz MJ
Coleman CN, *see* D'Amico AV
Collette L, *see* Blijham G
Collin F, *see* Coindre J-M
Collins B, *see* Lawrence G
Collins FS, *see* Visco FM
Collins R, *see* Rosenfeld C
Colls BM, Harvey VJ, Skelton L, Thompson PI, Frampton CM. Bilateral germ cell testicular tumors in New Zealand: Experience in Auckland and Christchurch 1978–1994, 2061
Colnaghi MI, *see* Mènard S
— *see* Pupa SM
Colombat P, *see* Williams CD
Colombo N, *see* Pujade-Lauraine E
Colomer D, *see* Mellado B
Colonna P, Jais J-P, Desablens B, Harousseau J-L, Brière J, Boasson M, Lemevel A, Casassus P, Le Prisé P-Y, Guilhot F, Ghandour C, Lejeune F, Andrieu J-M. Mediastinal tumor size and response to chemotherapy are the only prognostic factors in supradiaphragmatic Hodgkin's disease treated by ABVD plus radiotherapy: Ten-year results of the Paris-Ouest-France 81/12 trial, including 262 patients, 1928
Combaret V, Gross N, Lasset C, Frappaz D, Peruisseau G,

Philip T, Beck D, Favrot MC. Clinical relevance of CD44 cell-surface expression and N-*myc* gene amplification in a multicentric analysis of 121 pediatric neuroblastomas, 25
Comis RL, *see* O'Dwyer PJ
Conde E, *see* Bladé J
Conklin E, *see* Winter JN
Conlon KC, *see* Gause BL
— *see* Schwarz RE
Connaghan DG, *see* Holland HK
Conroy T, Etienne P-L, Adenis A, Wagener DJT, Paillot B, François E, Bedenne L, Jacob J-H, Seitz J-F, Bleiberg H, Van Pottelsberghe C, Van Glabbeke M, Delgado F-M, Merle S, Wills J, the European Organization for Research and Treatment of Cancer Gastrointesinal Tract Cancer Cooperative Group. Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma, 164
Constantinou A, *see* Joel SP
Conte M, *see* Guglielmi M
Conte P, *see* Nabholtz J-M
Conte PF, Bruzzone M, Carnino F, Gadducci A, Algeri R, Bellini A, Boccardo F, Brunetti I, Catsafados E, Chiara S, Foglia G, Gallo L, Iskra L, Mammoliti S, Parodi G, Ragni N, Rosso R, Rugiati S, Rubagotti A. High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: A randomized study of the Gruppo Oncologico Nord-Ovest, 351
—, Latreille J, Mauriac L, Calabresi F, Santos R, Campos D, Bonneterre J, Francini G, Ford JM. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: Results from a multinational randomized controlled trial, 2552
— *see* Falcone A
— *see* Venturini M
Contesso G, *see* Arriagada R
— *see* Coindre J-M
Conti JA, Kemeny NE, Saltz LB, Huang Y, Tong WP, Chou T-C, Sun M, Pulliam S, Gonzalez C. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer, 709
Cony-Makhoul P, *see* Marit G
Conzález-Brito G, *see* Bladé J
Cook B, *see* Bowman WP
Coombes G, *see* Coombes RC
Coombes RC, Bliss JM, Wils J, Morvan F, Espié M, Amadori D, Gambrosier P, Richards M, Aapro M, Villar-Grimalt A, McArdle C, Pérez-López FR, Vassilopoulos P, Ferreira EP, Chilvers CED, Coombes G, Woods EM, Marty M, the International Collaborative Cancer Group. Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: Results of a randomized trial, 35
Cooper BW, *see* Winter JN
Cooper DL, *see* Salloum E
Copeland DR, Moore BD III, Francis DJ, Jaffe N, Culbert SJ. Neuropsychologic effects of chemotherapy on children with cancer: A longitudinal study, 2826
Coplin MA, *see* Johnson FE
Coppin C, *see* Gelmon KA
Coppin CML, Gospodarowicz MK, James K, Tannock IF, Zee B, Carson J, Pater J, Sullivan LD, the National Cancer Institute of Canada Clinical Trials Group. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation, 2901
— *see* Tannock IF
Copple BL, *see* Bishop MR
Coppola G, *see* Corona R
Cordon-Cardo C, *see* Lacombe L
Cormier Y, *see* Shepherd FA
Corona R, Mele A, Amini M, De Rosa G, Coppola G, Piccardi P, Fucci M, Pasquini P, Faraggiana T. Interobserver variability on the histopathologic diagnosis of cutaneous melanoma and other pigmented skin lesions, 1218
Corse W, *see* Dahut W
Corson JM, *see* Singer S
— *see* Weissmann LB
Costa A, *see* Decensi A
Costantino JP, *see* Fisher B
Costanzi JJ, *see* Rivkin SE
Costello R, *see* Dreyfuss AI
Coustan-Smith E, *see* Ito C
Cowan KH, *see* Fisherman JS
— *see* Tolcher AW
Cox RS, *see* Joseph J
Cozzi F, *see* Guglielmi M
Craigs D, *see* Lind MJ
Crawford J, O'Rourke M, Schiller JH, Spiridonidis CH, Yanovich S, Ozer H, Langleben A, Hutchins L, Koletsky A, Clamon G, Burman S, White R, Hohneker J. Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non–small-cell lung cancer, 2774
Crawford SE, *see* Meitar D
Crawford SM, *see* Kaye SB
Creekmore SP, *see* Gause BL
Creemers GJ, Bolis G, Gore M, Scarfone G, Lacave AJ, Guastalla JP, Despax R, Favalli G, Kreinberg R, Van Belle S, Hudson I, Verweij J, Ten Bokkel Huinink WW. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: Results of a large European phase II study, 3056
—, Gerrits CJH, Schellens JHM, Planting AST, van der Burg MEL, van Beurden VM, de Boer-Dennert M, Harteveld M, Loos W, Hudson I, Stoter G, Verweij J. Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer, 2540
Crist W, *see* Smith M
Crist WM, *see* Kuttesch JF Jr
— *see* Pappo AS
— *see* Relling MV
Critz FA. Prostate interstitial implantation: Half the solution (letter), 1965
—, Levinson AK, Williams WH, Holladay DA. Prostate-specific antigen nadir: The optimum level after irradiation for prostate cancer, 2893
Cronin B, *see* Findlay M
Crookes P, *see* Lenz H-J

Crouch G, *see* Kushner BH
Crouch J, *see* Salloum E
Crouse DA, *see* Sharp JG
Crowley J, *see* Modiano MR
Crown JPA, *see* Hudis CA
Crowther D, *see* Pettengell R
Cruickshank DJ, *see* Kaye SB
Crum E, *see* Winter JN
Crump M, Goss PE, Prince M, Girouard C. Outcome of extensive evaluation before adjuvant therapy in women with breast cancer and 10 or more positive axillary lymph nodes, 66
— *see* Liu G
— *see* Shepherd FA
Cruz AB, *see* Rivkin SE
Cubells J, *see* Sierra J
Cuevas MA, *see* Leone BA
Culbert SJ, *see* Copeland DR
Culine S, Droz J-P. Adjuvant chemotherapy in pathologic stage II nonseminomatous testicular cancer: Are two cycles of etoposide-cisplatin a standard option? (letter), 2187
—, Droz J-P. Optimal management of residual mass after chemotherapy in advanced seminoma: There is time for everything (letter), 2884
Cull A, *see* Sprangers MAG
Cullen MH, Stenning SP, Parkinson MC, Fossa SD, Kaye SB, Horwich AH, Harland SJ, Williams MV, Jakes R. Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: A Medical Research Council report, 1106
Cunningham D, *see* Findlay M
— *see* Seymour MT
— *see* Zalcberg JR
Curran WJ Jr, *see* Lee JS
Currie V, *see* Hudis CA
— *see* Seidman AD
Curt G, *see* Yu B
Curtin J, *see* Markman M
Curtis RE, *see* Travis LB
Cvitkovic E, *see* Soulié P
— *see* Wibault P
Cyrus P, *see* Venturini M

Daghighian F, *see* Welt S
Dahut W, Harold N, Takimoto C, Allegra C, Chen A, Hamilton JM, Arbuck S, Sorensen M, Grollman F, Nakashima H, Lieberman R, Liang M, Corse W, Grem J. Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients, 1236
Daidone MG, *see* Silvestrini R
Dalbagni G, *see* Lacombe L
Dalmark M, *see* Bastholt L
— *see* Blijham G
Dalrymple GV, *see* Vose JM
Damen EMF, *see* Boersma LJ
D'Amico AV, Coleman CN. In reply (letter), 1966
—, Coleman CN. Role of interstitial radiotherapy in the management of clinically organ-confined prostate cancer: The jury is still out, 304
—, Whittington R, Malkowicz SB, Schultz D, Schnall M, Tomaszewski JE, Wein A. Critical analysis of the ability of the endorectal coil magnetic resonance imaging scan to predict pathologic stage, margin status, and postoperative prostate-specific antigen failure in patients with clinically organ-confined prostate cancer, 1770
Dancey J, *see* Liu G
Danenberg KD, *see* Lenz H-J
Danenberg PV, *see* Lenz H-J
Danesi R, *see* Falcone A
Danesini G, *see* Bregni M
D'Angio GJ, *see* Evans ARE
Dantis L, *see* Baselga J
D'Antonio A, *see* Carlomagno C
Dargenio F, *see* Falcone A
Dautzenberg B, *see* Splinter TAW
Davey FR, *see* Bernstein SH
Davidson NE, *see* Passos-Coelho JL
Davis J, *see* Civin CI
Davis JA, *see* Kaye SB
Davis JM, *see* Passos-Coelho JL
Davis T, *see* Chang A
Day T, *see* Stemmer SM
De Bernardi B, *see* Guglielmi M
De Boer CJ, *see* Velders GA
de Boer M, *see* Clarke SJ
de Boer RW, *see* Boersma LJ
de Boer-Dennert M, *see* Creemers GJ
— *see* de Wit R
de Bruijn HWA, *see* Duk JM
De Conno F, Groff L, Brunelli C, Zecca E, Ventafridda V, Ripamonti C. Clinical experience with oral methadone administration in the treatment of pain in 196 advanced cancer patients, 2836
de Dávila MT, *see* Schvartzman E
de Forni M, *see* Chabot GG
— *see* Wibault P
de Greve J, *see* Blijham G
de Haes HCJM, *see* Sprangers MAG
de Jong D, *see* Kramer MHH
de Langen ZJ, *see* Lemmers NWM
De Laurentiis M, *see* Carlomagno C
de Leon CG, *see* Kudelka AP
de Mulder PHM, *see* de Wit R
De Placido S, *see* Carlomagno C
De Rosa G, *see* Corona R
De Sanctis V, *see* Martelli M
De Vaan GAM, *see* Veerman AJP
De Victor B, *see* Figarella-Branger D
de Vries EGE, *see* Vellenga E
de Wit R, Schmitz PIM, Verweij J, de Boer-Dennert M, de Mulder PHM, Planting AST, van der Burg MEL, Stoter G. Analysis of cumulative probabilities shows that the efficacy of $5HT_3$ antagonist prophylaxis is not maintained, 644
— *see* Vellenga E
de Witte T, *see* Zittoun R
de Witte ThJM, *see* Vellenga E
Deakin DP, *see* Pettengell R
DeAngelis LM, Tong WP, Lin S, Fleisher M, Bertino JR. Carboxypeptidase $G_2$ rescue after high-dose methotrexate, 2145

Decensi A, Fontana V, Bruno S, Gustavino C, Gatteschi B, Costa A. Effect of tamoxifen on endometrial proliferation, 434
Declich P, *see* Luoni M
Deeg J, *see* Anderson JE
Degardin M, *see* Pecherstorfer M
deKernion J, *see* Rosen PJ
Del Mastro L, *see* Venturini M
Del Tacca M, *see* Falcone A
Delaney TF, *see* Kuttesch JF Jr
Delattre O, *see* Zoubek A
Delgado F-M, *see* Conroy T
Delgado M, *see* Misset J-L
Delorme F, *see* Trudeau ME
Delozier T, *see* Clahsen PC
Deltetto F, *see* Dogliotti L
Demedts M, *see* Simons JPFHA
Demetri GD, *see* Singer S
Demirer T, *see* Bensinger WI
DeNardo GL, *see* Wilder RB
DeNardo SJ, *see* Wilder RB
Deneux L, *see* Tartour E
Denham CA, *see* Jones SE
Denicoff A, *see* Fisherman JS
Denicoff AM, *see* Tolcher AW
Dennis IF, *see* Boote DJ
Deprés Brummer P, *see* Bertheault-Cvitkovic F
Desablens B, *see* Colonna P
Desch CE, *see* Hillner BE
Deschênes L, *see* Maunsell E
Despax R, *see* Creemers GJ
Detterbeck FC, *see* Bates BA
Devillier P, *see* Pujade-Lauraine E
Devine SM, *see* Holland HK
Devizzi L, *see* Viviani S
DeVore R, *see* Schiller JH
DeVore RF III, *see* Johnson DH
Dezeuze A, *see* Canal P
Dhabhar B, *see* Parikh B
Di Bartolomeo M, *see* Bajetta E
Di Coscio G, *see* Carpi A
Di Leo A, *see* Bajetta E
Di Nicola M, *see* Bregni M
di Palma M, *see* Misset J-L
Di Renzo N, *see* Gobbi PG
Diamandidou E, Buzdar AU, Smith TL, Frye D, Witjaksono M, Hortobagyi GN. Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: The University of Texas M.D. Anderson Cancer Center experience, 2722
Díáz de Heredia C, *see* Sierra J
Dieckmann K-P, Loy V. Prevalence of contralateral testicular intraepithelial neoplasia in patients with testicular germ cell neoplasms, 3126
Diehl A, *see* Beyer J
Dieras V, Extra JM, Belissant E, Espie M, Morvan F, Pierga JY, Mignot L, Tresca P, Marty M. Efficacy and tolerance of vinorelbine and fluorouracil combination as first-line chemotherapy of advanced breast cancer: Results of a phase II study using a sequential group method, 3098
Dietrich M, *see* Tempelhoff G-Fv
Dietz A, *see* Saltz LB
Diez B, *see* Balmaceda C
Dignam J, *see* Fisher B
Dilsizian V, *see* Wexler LH
Dimitrov NV, *see* Fisher B
Dirix LY, Vermeulen PB, Van Oosterom AT, Gasparini G. Microvascular count and prognosis in colorectal cancer (letter), 2400
Divgi CR, *see* Welt S
Diviné M, Lepage E, Brière J, Pautier P, Dupriez B, Lederlin P, Mineur P, Tilly H, Blanc M, Audhuy B, Herbrecht R, Coiffier B, Reyes F, the Groupe d'Etude des Lymphomes de l'Adulte. Is the small non–cleaved-cell lymphoma histologic subtype a poor prognostic factor in adult patients? A case-controlled analysis, 240
Dix SP, *see* Holland HK
Doci R, Zucali R, La Monica G, Meroni E, Kenda R, Eboli M, Lozza L. Primary chemoradiation therapy with fluorouracil and cisplatin for cancer of the anus: Results in 35 consecutive patients, 3121
Dockhorn-Dworniczak B, *see* Zoubek A
Dodero A, *see* Bregni M
Doggett S, *see* Flam M
Dogliotti L, Berruti A, Buniva T, Zola P, Baù MG, Farris A, Sarobba MG, Bottini A, Alquati P, Deltetto F, Gosso P, Monzeglio C, Moro G, Sussio M, Perroni D. Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: Results from a multicenter prospective randomized trial, 1165
Dolan ME, *see* Vokes EE
Dölken G, Illerhaus G, Hirt C, Mertelsmann R. BCL-2/$J_H$ rearrangements in circulating B cells of healthy blood donors and patients with nonmalignant diseases, 1333
Döllner H, *see* Sankila R
Domenge C, *see* Wibault P
Domingo A, *see* Sierra J
Dominguez ME, *see* Leone BA
Donahue B, *see* Schultz C
Donehower RC, *see* Baker SD
— *see* Kennedy MJ
— *see* O'Reilly S
— *see* Rowinsky EK
Doney K, *see* Anderson JE
Donovan C, *see* Fischer DS
Doré-Green F, *see* Lind MJ
Doria R, *see* Salloum E
Doroshow JH, *see* Margolin K
Dorval T, *see* Tartour E
Dose J, *see* Avril N
Doucette M, *see* Baker SD
Douillard JY, *see* Canal P
— *see* Tartour E
Downey A, *see* Wasserheit C
Drenth BM, *see* Simons JPFHA
Dreyfuss AI, Clark JR, Norris CM, Rossi RM, Lucarini JW, Busse PM, Poulin MD, Thornhill L, Costello R, Posner MR. Docetaxel: An active drug for squamous cell carcinoma of the head and neck, 1672
Droste JHJ, *see* Lemmers NWM
Droz JP, *see* Beyer J

Droz J-P, *see* Culine S
Dubbelman R, *see* Aaronson NK
Dubois C, *see* Figarella-Branger D
Ducreux M, *see* Girard P
Duffner PK, *see* Ashley DM
Duffy AM, *see* Seymour MT
Duffy B, *see* Civin CI
Dufton C, *see* Stemmer SM
Duk JM, Groenier KH, de Bruijn HWA, Hollema H, ten Hoor KA, van der Zee AGJ, Aalders JG. Pretreatment serum squamous cell carcinoma antigen: A newly identified prognostic factor in early-stage cervical carcinoma, 111
Duncan ID, *see* Kaye SB
Duncan LA, *see* Jones SE
Dundas GS, *see* Lee JS
Dunlop DJ, *see* Alcorn MJ
Dunn R, *see* Juweid M
Dupas B, *see* Solal-Céligny P
Duplay H, *see* Coindre J-M
Dupriez B, *see* Diviné M
Durant JR. Message from the ASCO home office (letter), 324
Dutcher JP, *see* Sparano JA

Earlam S, Glover C, Fordy C, Burke D, Allen-Mersh TG. Relation between tumor size, quality of life, and survival in patients with colorectal liver metastases, 171
Eboli M, *see* Doci R
Eckardt JR, *see* Rothenberg ML
Eckhardt SG, *see* Rothenberg ML
Edelman B, *see* Seidman AD
Edison M, *see* Johnson BE
Edwards CL, *see* Kudelka AP
Efird J, *see* Suit H
Egan B, *see* Small EJ
Egan E, *see* Swain SM
Eggensperger D, *see* Yu B
Eggermont AMM, Koops HS, Liénard D, Kroon BBR, van Geel AN, Hoekstra HJ, Lejeune FJ. Isolated limb perfusion with high-dose tumor necrosis factor-$\alpha$ in combination with interferon-$\gamma$ and melphalan for nonresectable extremity soft tissue sarcomas: A multicenter trial, 2653
Egorin MJ, *see* Glantz MJ
Ehnholm C, *see* Saarto T
Eiermann W, *see* Buzdar A
Eigler FW, *see* Stahl M
Einhorn L, *see* Greco FA
Einhorn LH, *see* Beyer J
— *see* Stephens AW
Einhorn S, *see* Heyman M
Eisbruch A, Thornton AF, Urba S, Esclamado RM, Carroll WR, Bradford CR, Hazuka MB, Littles FJ, Strawderman M, Wolf GT. Chemotherapy followed by accelerated fractionated radiation for larynx preservation in patients with advanced laryngeal cancer, 2322
Eisenhauer EA, *see* Perrault D
— *see* Trudeau ME
Eissner H-J, *see* Jauch K-W
Elfenbein GJ, *see* Fields KK
Elfring GL, *see* Rothenberg ML
Elias A, *see* Ayash LJ
Elliott C, Samson DM, Armitage S, Lyttelton MP, McGuigan D, Hargreaves R, Giles C, Abrahamson G, Abboudi Z, Brennan M, Kanfer EJ. When to harvest peripheral-blood stem cells after mobilization therapy: Prediction of CD34-positive cell yield by preceding day CD34-positive concentration in peripheral blood, 970
Ellis P, *see* Joel SP
Elmhorn-Rosenborg A, *see* Juliusson G
Elomaa I, *see* Saarto T
Els NV, *see* Hirsch A
El-Sayed S, Nelson N. Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region: A meta-analysis of prospective and randomized trials, 838
Emanuel EJ, *see* Patterson WB
Emi N, *see* Kobayashi T
Encke A, *see* Roukos D
Eng M, *see* Saltz LB
Engelhardt M, Brennscheidt U, Mertelsmann R, Lindemann A. Interleukin-10 and phenomena of tolerance in interleukin-2 therapy (letter), 1405
Epelbaum R, *see* Ben-Haim S
Erdkamp FLG, *see* Simons JPFHA
Eres N, *see* Ribas A
Erlichman C, *see* O'Connell MJ
Ernst DS, *see* Tannock IF
Ernst P, *see* Milpied N
Ernstoff MS, *see* Kirkwood JM
Errante D, *see* Vaccher E
Eschwege F, *see* Wibault P
Esclamado RM, *see* Eisbruch A
Escudero M-L, *see* Bladé J
Escudier B, *see* Tartour E
Espié M, *see* Coombes RC
Espie M, *see* Dieras V
Essayan DM, Kagey-Sobotka A, Lichtenstein LM, Colarusso PJ, Ozols RF, King ED. Paclitaxel hypersensitivity revisited (letter), 1042
Esserman L, *see* Hillner BE
Estapé J, *see* Bladé J
— *see* Mellado B
Estes J, *see* Kaminski MS
Estey E, *see* Anderlini P
Estey EH, *see* Thall PF
Etienne P-L, *see* Conroy T
Ettinger DS, *see* O'Reilly S
— *see* Rowinsky EK
Evans ARE, Silber JH, Shpilsky A, D'Angio GJ. Successful management of low-stage neuroblastoma without adjuvant therapies: A comparison of two decades, 1972 through 1981 and 1982 through 1992, in a single institution, 2504
Evans WE, *see* Furman WL
— *see* Ito C
— *see* Relling MV
Exner U, *see* Bieling P
Extra JM, *see* Dieras V
Ezzat A, *see* Rostom AY

Faberes C, *see* Marit G
Fagnani AM, *see* Guglielmi M
Fair WR, *see* Brenner PC

— *see* Lacombe L
Fairclough D, *see* Kuttesch JF Jr
Fairclough DL, *see* Patenaude AF
Falcone A, Danesi R, Dargenio F, Pfanner E, Brunetti I, Del Tacca M, Nethersell ABW, Conte PF. Intravenous azidothymidine with fluorouracil and leucovorin: A phase I-II study in previously untreated metastatic colorectal cancer patients, 729
Falini B, *see* Zinzani PL
Falk M, *see* Fridrik MA
Fandiño A, *see* Schvartzman E
Fanin R, Silvestri F. Therapy of primary systemic CD30-positive anaplastic large-cell lymphoma of the adult (letter), 3049
Faraggiana T, *see* Corona R
Farber LR, *see* Salloum E
Farbstein H, *see* Kaempfer R
Fargeot P, *see* Misset J-L
Farrar WB, *see* Rivkin SE
Farrell E, *see* Alcorn MJ
Farris A, *see* Dogliotti L
Farrow A, *see* Winick N
Fava S, *see* Luoni M
Favalli G, *see* Creemers GJ
Favrot MC, *see* Combaret V
Federici S, *see* Guglielmi M
Federico M, *see* Gobbi PG
Feeny D, *see* Barr R
Fefer A, *see* Bensinger WI
Feinglass J, *see* Bennett CL
Feld R. Chemotherapy as adjuvant therapy for completely resected non-small-cell lung cancer: Have we made progress? (editorial), 1045
— *see* Shepherd FA
— *see* Siu LL
Feldman E, *see* Weiss M
Feliu E, *see* Sierra J
Fengler R, *see* Bührer C
Fennelly D, *see* Seidman AD
Fenner MC, *see* Kaminski MS
Fenton RG, *see* Gause BL
Ferguson DJ, *see* Quiet CA
Ferrandina G, *see* Scambia G
Ferrari E, *see* Carpi A
Ferreira EP, *see* Coombes RC
Festen J, *see* Splinter TAW
Fetsch PA, *see* Tolcher AW
Fett W, *see* Stahl M
Fetter JE, *see* Johnstone PAS
Fetting JH, *see* Bennett CL
Feuerestein I, *see* Yu B
Feugeas O, Guriec N, Babin-Boilletot A, Marcellin L, Simon P, Babin S, Thyss A, Hofman P, Terrier P, Kalifa C, Brunat-Mentigny M, Patricot L-M, Oberling F. Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma, 467
Fiacchini M, *see* Martelli M
Fielding AK, *see* Milpied N
Fields J, *see* Schultz C
Fields KK, Elfenbein GJ, Trudeau WL, Perkins JB, Janssen WE, Moscinski LC. Clinical significance of bone marrow metastases as detected using the polymerase chain reaction in patients with breast cancer undergoing high-dose chemotherapy and autologous bone marrow transplantation, 1868
Fields S, *see* Ben-Yehuda D
Figarella-Branger D, Dubois C, Chauvin P, De Victor B, Gentet J-C, Rougon G. Correlation between polysialic-neural cell adhesion molecule levels in CSF and medulloblastoma outcomes, 2066
Figlin R, *see* Greco FA
Findlay M, Young H, Cunningham D, Iveson A, Cronin B, Hickish T, Pratt B, Husband J, Flower M, Ott R. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: Correlation with tumor response to fluorouracil, 700
Fine S, *see* Prichard KI
Fink U, *see* Stahl M
Finlay JL, Goldman S, Wong MC, Cairo M, Garvin J, August C, Cohen BH, Stanley P, Zimmerman RA, Bostrom B, Geyer JR, Harris RE, Sanders J, Yates AJ, Boyett JM, Packer RJ. Pilot study of high-dose thiotepa and etoposide with autologous bone marrow rescue in children and young adults with recurrent CNS tumors, 2495
— *see* Balmaceda C
Finn RD, *see* Welt S
Firat D, *see* Çelik I
Firth JL, *see* Bessell EM
Fischer D, *see* Haffty BG
Fischer DS, Alfano S, Knobf MT, Donovan C, Beaulieu N. Improving the cancer chemotherapy use process, 3148
Fischman AJ. Positron emission tomography in the clinical evaluation of metastatic cancer (editorial), 691
Fisher B. Commentary on endometrial cancer deaths in tamoxifen-treated breast cancer patients, 1027
— In reply (letter), 2886
—, Dignam J, Mamounas EP, Costantino JP, Wickerham DL, Redmond C, Wolmark N, Dimitrov NV, Bowman DM, Glass AG, Atkins JN, Abramson N, Sutherland CM, Aron BS, Margolese RG. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor–negative tumors: Eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil, 1982
— *see* Perrault D
— *see* Schultz C
Fisher C, *see* Ahmed FY
Fisher H, *see* Chang A
Fisher RI, *see* Fyfe GA
Fisher S, *see* Kaminski MS
Fisherman JS, Cowan KH, Noone M, Denicoff A, Berg S, Poplack D, Balis F, Venzon D, McCabe M, Goldspiel B, Chow C, Ognibene FP, O'Shaughnessy J. Phase I/II study of 72-hour infusional paclitaxel and doxorubicin with granulocyte colony-stimulating factor in patients with metastatic breast cancer, 774
Fishwick K, *see* Lind MJ
Fitzsimons E, *see* Alcorn MJ
Fjälliskog M-L, *see* Sandström M

Flam M, John M, Pajak TF, Petrelli N, Myerson R, Doggett S, Quivey J, Rotman M, Kerman H, Coia L, Murray K. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: Results of a phase III randomized intergroup study, 2527
Fleisher M, *see* DeAngelis LM
Fletcher JA, *see* Singer S
Fleuren G, *see* Bunt AMG
Fleuren GJ, *see* Bunt AMG
Floiras J-L, *see* Clahsen PC
Flower M, *see* Findlay M
Flowers M, *see* Anderson JE
Foglia G, *see* Conte PF
Fonseca R, *see* Loprinzi CL
Fontana V, *see* Decensi A
Fontanillas M, *see* Bladé J
Forastiere AA, *see* O'Reilly S
— *see* Rowinsky EK
Ford JM, *see* Conte PF
Fordy C, *see* Earlam S
Forman SJ, *see* Stein AS
Fort N, *see* Solal-Céligny P
Fortuna A, *see* Lemoli RM
Foskett M, *see* Rustin GJS
Fossa SD, *see* Cullen MH
Fossella FV, *see* Lee JS
— *see* Perez-Soler R
Foulard L, *see* Williams CD
Fountzilas G, *see* Kosmidis PA
Foures C, *see* Marit G
Fourquet A, *see* Solin LJ
Fowble B, *see* Solin LJ
Fowler FJ Jr, Barry MJ, Lu-Yao G, Wasson JH, Bin L. Outcomes of external-beam radiation therapy for prostate cancer: A study of medicare beneficiaries in three surveillance, epidemiology, and end results areas, 2258
Fraker DL, Alexander HR, Andrich M, Rosenberg SA. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: Results of a tumor necrosis factor dose-escalation study, 479
Frame JN, *see* Johnson BE
Frampton CM, *see* Colls BM
Francini G, *see* Conte PF
Francis DJ, *see* Copeland DR
Francis IR, *see* Kaminski MS
Francis P, *see* Seidman AD
François E, *see* Conroy T
— *see* Pujade-Lauraine E
Francois E, *see* Zalcberg JR
Franklin IM, *see* Alcorn MJ
Franklin J, *see* Sprangers MAG
Franzini L, *see* Sprangers MAG
Frappaz D, *see* Combaret V
Fraschini G, *see* Holmes FA
Frassoldati A, *see* Gobbi PG
Frasure-Smith N, *see* Maunsell E
Frazein A, *see* Wasserheit C
Freedman RS, *see* Kudelka AP
Frei E III, *see* Ayash LJ
Freijs A, *see* Sandström M
Freilich R, *see* Hudis CA
Freyer G, *see* Blay J-Y
Fridman WH, *see* Tartour E
Fridrik MA, Hausmaninger H, Linkesch W, Stöger M, Sill H, Neubauer M, Seewann HL, Klocker J, Haidinger R, Schiller L, Pont J, Raudaschl G, Falk M, Radaszkiewicz T. CEOP-IMVP-DEXA in the treatment of aggressive lymphomas: An Austrian multicenter trial, 227
Friedlander M, *see* Millward MJ
Friedman H, *see* Mahoney DH Jr
Friedman HS, *see* Ashley DM
Froimtchuk MJ, *see* Greco FA
Front D, *see* Ben-Haim S
Frye D, *see* Diamandidou E
Frye DK, *see* Greenberg PAC
Fucci M, *see* Corona R
Fuchs N, *see* Bieling P
Fuller S, *see* Rustin GJS
Fulton D, *see* Prados MD
Fumoleau P, *see* Misset J-L
— *see* Nabholtz J-M
— *see* Pujade-Lauraine E
Funke I, *see* Jauch K-W
Furlong W, *see* Barr R
Furman WL, Baker SD, Pratt CB, Rivera GK, Evans WE, Stewart CF. Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia, 1504
Furstenberg C, *see* Ahles TA
Furukawa K, *see* Yamaguchi A
Furuse K, *see* Kunitoh H
Fyfe GA, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy (letter), 2410

Gadducci A, *see* Conte PF
Gadner H, *see* Zoubek A
Gail MH, *see* Benichou J
Gaitini D, *see* Ben-Haim S
Gajewski J, *see* van Besien K
Gajewski JL, Phillips GL, Sobocinski KA, Armitage JO, Gale RP, Champlin RE, Herzig RH, Hurd DD, Jagannath S, Klein JP, Lazarus HM, McCarthy PL Jr, Pavlovsky S, Petersen FB, Rowlings PA, Russell JA, Silver SM, Vose JM, Wiernik PH, Bortin MM, Horowitz MM. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease, 0572
Gajjar A, *see* Ashley DM
Galán M, *see* Mellado B
Gale RP, *see* Gajewski JL
Gallardo E, *see* Ribas A
Gallion HH, *see* Bookman MA
Gallo C, *see* Carlomagno C
Gallo JM, *see* O'Dwyer PJ
Gallo L, *see* Conte PF
— *see* Venturini M
Gambrosier P, *see* Coombes RC
Garcia Y, *see* Lenz H-J
García-Conde J, *see* Bladé J

Garrison L, *see* Bishop MR
— *see* Vose JM
Garrone O, *see* Venturini M
Garvin J, *see* Finlay JL
Garwicz S, *see* Sankila R
Gasco M, *see* Percivale P
Gasparini G, *see* Dirix LY
Gatterer-Menz I, *see* Zoubek A
Gatteschi B, *see* Decensi A
Gause BL, Sznol M, Kopp WC, Janik JE, Smith JW II, Steis RG, Urba WJ, Sharfman W, Fenton RG, Creekmore SP, Holmlund J, Conlon KC, VanderMolen LA, Longo DL. Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer, 2234
Gay C, *see* Canal P
Gayet B, *see* Girard P
Gaynon P, *see* Smith M
— *see* Steinherz PG
Gaynon PS, *see* Steinherz PG
Gazdar AF, *see* Johnson BE
Gee A, *see* Civin CI
Gee T, *see* Weiss M
Gelber R, *see* Smith M
Gelber RD, *see* Cole BF
Geller RB. Use of cytokines in the treatment of acute myelocytic leukemia: A critical review, 1371
— *see* Holland HK
Gelmon K, *see* Nabholtz J-M
Gelmon KA, O'Reilly SE, Tolcher AW, Campbell C, Bryce C, Ragaz J, Coppin C, Plenderleith IH, Ayers D, McDermott B, Nakashima L, Healey D, Onetto N. Phase I/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer, 1185
Gels ME, *see* Lemmers NWM
Génot J-Y, *see* Joly F
Gentet J-C, *see* Figarella-Branger D
George SL. Reducing patient eligibility criteria in cancer clinical trials, 1364
George TK, *see* Jones SE
Gerald WL, *see* Kushner BH
Gerdes H, *see* Kelsen D
Gerdin B, *see* Lindmark G
Gerez L, *see* Kaempfer R
Gerrits CJH, *see* Creemers GJ
Gerson SL. DNA repair and the risk of secondary leukemias (letter), 681
— *see* Winter JN
Geyer JR, *see* Finlay JL
Ghandour C, *see* Colonna P
Ghavimi F, *see* Kushner BH
Ghazal-Aswad S, *see* Lind MJ
Gherlinzoni F, *see* Lemoli RM
— *see* Martelli M
— *see* Zinzani PL
Ghim T, *see* Mahoney DH Jr
Ghosh C, *see* Rowland KM Jr
Giaccone G, Ardizzoni A, Kirkpatrick A, Clerico M, Sahmoud T, van Zandwijk N. Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma: A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group, 814
— *see* Splinter TAW
Gianni AM, *see* Bregni M
Gianni L. In reply (letter), 1403
Giannitelli C, *see* Scambia G
Gilbert F, *see* Kushner BH
Gilbert MR, *see* Prados MD
Giles C, *see* Elliott C
Gilewski TA, *see* Hudis CA
— *see* Seidman AD
Gill PS, Wernz J, Scadden DT, Cohen P, Mukwaya GM, von Roenn JH, Jacobs M, Kempin S, Silverberg I, Gonzales G, Rarick MU, Myers AM, Shepherd F, Sawka C, Pike MC, Ross ME. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma, 2353
Gilseth M. To test or not to test: Where is the truth? (letters), 1406
Giner V, *see* Sculier JP
Ginsberg R, *see* Minsky BD
Gipponi M, *see* Percivale P
Giralt S, *see* van Besien K
Girard P, Ducreux M, Baldeyrou P, Rougier P, Le Chevalier T, Bougaran J, Lasser P, Gayet B, Ruffié P, Grunenwald D. Surgery for lung metastases from colorectal cancer: Analysis of prognostic factors, 2047
Girault D, *see* Marit G
Girouard C, *see* Crump M
Gisselbrecht C, *see* Sweetenham JW
Gjedde SB, *see* Bastholt L
Glantz MJ, Choy H, Kearns CM, Cole BF, Mills P, Zuhowski EG, Saris S, Rhodes CH, Stopa E, Egorin MJ. Phase I study of weekly outpatient paclitaxel and concurrent cranial irradiation in adults with astrocytomas, 600
Glass AG, *see* Fisher B
Glatstein E, *see* Johnson BE
Glenn SD, *see* Kaminski MS
Glick J, *see* Gordon LI
— *see* Kemp G
— *see* Schiller JH
Glick JH. American Society of Clinical Oncology: A Society in transition, 2387
Glimelius B, *see* Lindmark G
Glisson BS, *see* Perez-Soler R
Glodé LM. Challenges and opportunities of the internet for medical oncology, 2181
Glover C, *see* Earlam S
Gobbi PG, Pieresca C, Frassoldati A, Carotenuto M, Di Renzo N, La Sala A, Bertè R, Avanzini P, Federico M, Silingardi V, Ascari E. Vinblastine, bleomycin, and methotrexate chemotherapy plus extended-field radiotherapy in early, favorably presenting, clinically staged Hodgkin's patients: The Gruppo Italiano per lo Studio dei Linfomi experience, 527
Goi T, *see* Yamaguchi A
Goldberg RM, *see* O'Connell MJ
Golde D, *see* Weiss M
Goldenberg DM, *see* Juweid M
— *see* Moffat FL Jr
Goldhirsch A, *see* Cole BF
Goldman S, *see* Finlay JL
Goldspeil BR, *see* Tolcher AW

Goldspiel B, *see* Fisherman JS
— *see* Tolcher AW
Goldstein D, *see* Millward MJ
Goldstone AH, *see* Milpied N
— *see* Sweetenham JW
— *see* Williams CD
Gollard R, *see* Saven A
Gollub M, *see* Hudis CA
— *see* Seidman AD
Gomez EG, *see* Hirsch A
Gonin R, *see* Rackoff WR
— *see* Stephens AW
Gonzales G, *see* Gill PS
Gonzalez C, *see* Conti JA
Good RH, *see* Jones SE
Gooley T, *see* Anderson JE
Goolsby C, *see* Winter JN
Gootenberg J, *see* Magrath I
— *see* Weintraub M
Gordon HK, *see* Kaye SB
Gordon L, *see* Winter JN
Gordon LI, Andersen J, Habermann TM, Winter JN, Glick J, Schilder RJ, Cassileth P. Phase I trial of dose escalation with growth factor support in patients with previously untreated diffuse aggressive lymphomas: Determination of the maximum-tolerated dose of ProMACE-CytaBOM, 1275
Gore M, *see* Creemers GJ
Gore ME, *see* Ahmed FY
Gorin I, *see* Tartour E
Gorin MB, *see* Nayfield SG
Gorin NC, *see* Williams CD
Gospodarowicz M, *see* Warde P
Gospodarowicz MK, *see* Coppin CML
Goss PE, *see* Crump M
— *see* Liu G
Gossard MR, *see* Tolcher AW
Gosso P, *see* Dogliotti L
Gottlieb A, *see* Perloff M
Graeff H, *see* Avril N
Gralla R, *see* Hesketh P
Grandér D, *see* Heyman M
Grañena A, *see* Sierra J
Grau JJ, *see* Mellado B
Graus F, *see* Bessell EM
— *see* Montserrat E
Graves MC, *see* Rosen PJ
Gray J, *see* Johnson BE
Gray JR, *see* Greco FA
Gray R, *see* Saphner T
Greco FA, Figlin R, York M, Einhorn L, Schilsky R, Marshall EM, Buys SS, Froimtchuk MJ, Schuller J, Schuchter L, Buyse M, Ritter L, Man A, Yap AKL. Phase III randomized study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer, 2674
—, Stroup SL, Gray JR, Hainsworth JD. Paclitaxel in combination chemotherapy with radiotherapy in patients with unresectable stage III non–small-cell lung cancer, 1642
— *see* Hainsworth JD
Green M, *see* Zalcberg JR
Green MR, *see* Barkley JE
— *see* Miller AA
Green S, *see* Rivkin SE
Green SR, *see* Albain KS
Greenberg PAC, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer, 2197
Greiner JW, *see* Roselli M
Greiner TC, *see* Bishop MR
Greinix A, *see* Beyer J
Grem J, *see* Dahut W
— *see* Yu B
Griffin T, *see* Bowman WP
Grimm PD, *see* Blasko JC
Grochow L, *see* Miller CB
Grochow LB, *see* Baker SD
— *see* O'Reilly S
— *see* Rowinsky EK
Groenewegen I, *see* Civin CI
Groenier KH, *see* Duk JM
Groenvold M, *see* Sprangers MAG
Groff L, *see* De Conno F
Grollman F, *see* Dahut W
Groshen S, *see* Lenz H-J
Gross N, *see* Combaret V
Grossman NJ, *see* Steinherz PG
Grote T, *see* Hesketh P
Grote W, *see* Poetsch M
— *see* Schlegelberger B
Gruetzner U, *see* Jauch K-W
Grunberg SM. Strange bedfellows (letter), 1042
Grunenwald D, *see* Girard P
Guadagni F, *see* Roselli M
Guardia R, *see* Sierra J
Guastalla JP, *see* Creemers GJ
Guastalla J-P, *see* Pujade-Lauraine E
Guelfi M, *see* Venturini M
Guerrin J, *see* Misset J-L
Guglielmi M, De Bernardi B, Rizzo A, Federici S, Boglino C, Siracusa F, Leggio A, Cozzi F, Cecchetto G, Musi L, Bardini T, Fagnani AM, Bartoli GC, Pampaloni A, Rogers D, Conte M, Milanaccio C, Bruzzi P. Resection of primary tumor at diagnosis in stage IV-s neuroblastoma: Does it affect the clinical course? 1537
Guilhot F, *see* Colonna P
Guillem JG, *see* Belluco C
— *see* Zeng ZS
Guillot T, *see* Wibault P
Gumbrell L, *see* Lind MJ
Gupta E, *see* Mick R
Guriec N, *see* Feugeas O
Gurney H. Dose calculation of anticancer drugs: A review of the current practice and introduction of an alternative, 2590
Gustavino C, *see* Decensi A
Gustavsson G, *see* Heyman M
Gylling H, Pyrhönen S, Mäenpää H, Miettinen TA, Mäntyla E, Kangas L. In reply (letter), 2408

Haak HL, *see* Kramer MHH
Haase GM, *see* Stram DO

Habermann TM, *see* Gordon LI
Haferlach T, *see* Schlegelberger B
Haffty B, *see* Solin LJ
Haffty BG, Reiss M, Beinfield M, Fischer D, Ward B, McKhann C. Ipsilateral breast tumor recurrence as a predictor of distant disease: Implications for systemic therapy at the time of local relapse, 52
Hagemeister F, *see* Sarris AH
Hagemeister FB, *see* McLaughlin P
— *see* Younes A
Hahka-Kemppinen M, *see* Hernberg M
Hählen K, *see* Veerman AJP
Hahn R, *see* Chang A
Hahne W, *see* Hesketh P
Haidinger R, *see* Fridrik MA
Haim N, *see* Ben-Haim S
Hainsworth J, *see* Hesketh P
Hainsworth JD, Jones SE, Mennel RG, Blum JL, Greco FA. Paclitaxel with mitoxantrone, fluorouracil, and high-dose leucovorin in the treatment of metastatic breast cancer: A phase II trial, 1611
— *see* Greco FA
Haïoun, C, *see* Solal-Céligny P
Hakes T, *see* Markman M
Hakes TB, *see* Hudis CA
Halbherr T, *see* O'Dwyer PJ
Hall M, *see* Joel SP
Ham SJ, Hoekstra HJ, van der Graaf WTA, Kamps WA, Molenaar WM, Koops HS. The value of high-dose methotrexate-based neoadjuvant chemotherapy in malignant fibrous histiocytoma of bone, 490
Hamasaki V, *see* Margolin K
Hami L, *see* Stemmer SM
Hamilton JM, *see* Dahut W
Hamilton TC, *see* O'Dwyer PJ
Hammershaimb L, *see* Moffat FL Jr
Hammond D, *see* Steinherz PG
Hancock SL, *see* Joseph J
Hande KR, *see* Johnson DH
Hankins L, *see* Johnson BE
Hanks GE, Hanlon AL, Hudes G, Lee WR, Suasin W, Schultheiss TE. Patterns-of-failure analysis of patients with high pretreatment prostate-specific antigen levels treated by radiation therapy: The need for improved systemic and locoregional treatment, 1093
Hanley D, *see* Juweid M
Hanlon AL, *see* Hanks GE
Hann D, *see* Ahles TA
Hansen JA, *see* Anderson JE
Hansen MM, *see* Juliusson G
Hanwell J, *see* Clarke SJ
Haraf DJ, *see* Vokes EE
Hardwick A, *see* Civin CI
Hargis JB, *see* Rosner GL
Hargreaves R, *see* Elliott C
Harland SJ, *see* Cullen MH
Harold N, *see* Dahut W
Harousseau J-L, *see* Colonna P
Harousseau JL, *see* Solal-Céligny P
Harper PG, *see* Seymour MT
Harrap KR, *see* Clarke SJ
Harris M, *see* Pettengell R
Harris RE, *see* Finlay JL
Harrison KA, *see* Vose JM
Harrison L, *see* Wallner K
Harrison LB, *see* Pisters PWT
Harteveld M, *see* Creemers GJ
Hartmann O, *see* Williams CD
Hartmann R, *see* Bührer C
Harvey VJ, *see* Colls BM
Hausmaninger H, *see* Fridrik MA
Havemann K, *see* Reckzeh B
Hayat M, *see* Zittoun R
Hayes DF. Should we treat HER, too? (editorial), 697
Hayes FA, *see* Jones SE
Hazuka MB, *see* Eisbruch A
Head D, *see* Bowman WP
Healey D, *see* Gelmon KA
Heaney J, *see* Tester W
Heelan R, *see* Puc HS
Heerema N, *see* Smith M
Heffner LT, *see* Holland HK
Heideman RL, Kun LE. In reply (letter), 1741
Heike M, *see* Jäger E
Heilmann L, *see* Tempelhoff G-Fv
Heise U, *see* Bieling P
Heiss MM, *see* Jauch K-W
Helg C, *see* Miralbell R
Helin H, *see* Kuukasjärvi T
Heller G, *see* Balmaceda C
Hellman S, *see* Quiet CA
Hellmann K. Anthracycline cardiotoxicity prevention by dexrazoxane: Breakthrough of a barrier—sharpens antitumor profile and therapeutic index (editorial), 332
Helmke K, *see* Bieling P
Henderson IC, *see* Albain KS
— *see* Baselga J
— *see* Rosner GL
Henne-Bruns D, *see* Schlegelberger B
Henry DH, *see* Sparano JA
Henry-Amar M, *see* Coindre J-M
— *see* Joly F
Hensel S, *see* Boote DJ
Henwood J, *see* Barr R
Henze G, *see* Bührer C
Herait P, *see* Canal P
Herbrecht R, *see* Diviné M
Hermans J, *see* Bunt AMG
— *see* Kramer MHH
— *see* Velders GA
Hernberg M, Muhonen T, Turunen JP, Hahka-Kemppinen M, Pyrhönen S. The CD4+/CD8+ ratio as a prognostic factor in patients with metastatic melanoma receiving chemoimmunotherapy, 1690
Herr H, *see* Motzer RJ
— *see* Puc HS
Herr HW, *see* Brenner PC
— *see* Lacombe L
Herrmann Z, *see* Pecherstorfer M
Herskovic T, *see* Juweid M
Hertz H, *see* Sankila R
Herz M, *see* Avril N
Herzig RH, *see* Gajewski JL
Hesketh P, Navari R, Grote T, Gralla R, Hainsworth J, Kris

M, Anthony L, Khojasteh A, Tapazoglou E, Benedict C, Hahne W. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer, 2242
Heslin MJ, Woodruff J, Brennan MF. Prognostic significance of a positive microscopic margin in high-risk extremity soft tissue sarcoma: Implications for management, 473
Heuft H-G, *see* Schwella N
Heyman M, Rasool O, Brandter LB, Liu Y, Grandér D, Söderhäll S, Gustavsson G, Einhorn S. Prognostic importance of $p15^{INK4B}$ and $p16^{INK4}$ gene inactivation in childhood acute lymphocytic leukemia, 1512
Hickish T, *see* Findlay M
— *see* Powles TJ
Higgins BP, *see* Trudeau ME
Hill C, *see* Misset J-L
Hillen HFP, *see* Simons JPFHA
Hillner BE, Desch CE, Carlson RW, Smith TJ, Esserman L, Bear HD. Trade-offs between survival and breast preservation for three initial treatments of ductal carcinoma-in-situ of the breast, 70
— *see* Bennett CL
Hillyer CD, *see* Holland HK
Hilsenbeck SG, *see* Rothenberg ML
Hiraoka A, *see* Kobayashi T
Hirose K, *see* Yamaguchi A
Hirsch A, Els NV, Straus DJ, Gomez EG, Leung D, Portlock CS, Yahalom J. Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin's disease, 1297
Hirschman O, *see* Kaempfer R
Hirt C, *see* Dölken G
Hiscox JG, *see* Rustin GJS
Hitomi S, *see* Wada H
Hochhauser D, *see* Seidman AD
Hochster H, *see* Wasserheit C
Hoefnagel CA, *see* Taal BG
Hoefsloot FAM, *see* Bunt AMG
Hoekstra HJ, *see* Eggermont AMM
— *see* Ham SJ
— *see* Lemmers NWM
Hoffman J, *see* O'Dwyer PJ
Hofman P, *see* Feugeas O
Hogan WM, *see* Bookman MA
Hohenadel K, *see* Schlegelberger B
Hohneker J, *see* Crawford J
Hohneker JA, *see* Baker SD
Holbrook T, *see* Steuber CP
Holden D, *see* Johnson BE
Holden L, *see* Rustin GJS
Holford T, *see* Salloum E
Holladay DA, *see* Critz FA
Holland HK, Dix SP, Geller RB, Devine SM, Heffner LT, Connaghan DG, Hillyer CD, Hughes LL, Miller RL, Moore MR, Winton EF, Wingard JR. Minimal toxicity and mortality in high-risk breast cancer patients receiving high-dose cyclophosphamide, thiotepa, and carboplatin plus autologous marrow/stem-cell transplantation and comprehensive supportive care, 1156
Holland JF, *see* Perloff M
Hollema H, *see* Duk JM
Holli K, *see* Kuukasjärvi T
Hollis DR, *see* Rosner GL
Holm B, *see* Sehested M
Holmberg L, *see* Bensinger WI
Holmes FA, Madden T, Newman RA, Valero V, Theriault RL, Fraschini G, Walters RS, Booser DJ, Buzdar AU, Willey J, Hortobagyi GN. Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer, 2713
Holmlund J, *see* Gause BL
Holtkamp MJ, *see* Rodenhuis S
Höltl W, *see* Pont J
Holyoake TL, *see* Alcorn MJ
Homesley H, *see* Kemp G
Hommel G, *see* Tempelhoff G-Fv
Hong WK, *see* Perez-Soler R
Honig SF, *see* Swain SM
Hope DT, *see* Bessell EM
Hoppe RT, *see* Mac Manus MP
Hopwood P, *see* Sprangers MAG
Hoque A, *see* Jones DV Jr
— *see* Patt YZ
Horak ID, *see* Magrath I
— *see* Weintraub M
Hord M, *see* Kudelka AP
Horowitz ME, *see* Kuttesch JF Jr
— *see* Wexler LH
Horowitz MM, *see* Gajewski JL
Hortobagyi GN, *see* Diamandidou E
— *see* Greenberg PAC
— *see* Holmes FA
Horvath N, *see* Winter JN
Horwich AH, *see* Cullen MH
Hoskins W, *see* Markman M
Hoskins WJ, *see* Rustin GJS
Houghton PJ, *see* Kuttesch JF Jr
Hovi L, *see* Saarinen UM
Howe G, *see* Salloum E
Howell A, *see* Buzdar A
Hu X, *see* Sparano JA
Huang Y, *see* Belluco C
— *see* Conti JA
— *see* Kelsen D
— *see* Zeng ZS
Huber MH, *see* Perez-Soler R
Hudes G, *see* Hanks GE
Hudis CA. Cyclophosphamide, methotrexate, and fluorouracil: Still the gold standard? (editorial), 1971
—, Seidman AD, Crown JPA, Balmaceda C, Freilich R, Gilewski TA, Hakes TB, Currie V, Lebwohl DE, Baselga J, Raptis G, Gollub M, Robles M, Bruno R, Norton L. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer, 58
— *see* Baselga J
— *see* Seidman AD
Hudson I, *see* Creemers GJ
Huelskamp A-M, *see* Passos-Coelho JL
Hughes LL, *see* Holland HK

Hughes LR, *see* Clarke SJ
Huhn D, *see* Schwella N
Hurd DD, *see* Gajewski JL
Husband J, *see* Findlay M
Huss H-J, *see* Pecherstorfer M
Hussain HK, *see* Pappa VI
Hutchins GD, *see* Stephens AW
Hutchins L, *see* Crawford J
Hutchins LF, *see* Albain KS
Hutson P, *see* Schiller JH

Ibrahim J, *see* Ayash LJ
Igwemezie L, *see* Chabot GG
Ihde DC, *see* Johnson BE
Illerhaus G, *see* Dölken G
Ingle JN, *see* Albain KS
International Breast Cancer Study Group. Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients, 1885
Invernizzì AM, *see* Pupa SM
Iscoe NA, *see* Rusthoven JJ
Iskra L, *see* Conte PF
Isola J, *see* Kuukasjärvi T
Israel O, *see* Ben-Haim S
Ithzaki M, *see* Bertheault-Cvitkovic F
— *see* Misset J-L
Ito C, Evans WE, McNinch L, Coustan-Smith E, Mahmoud H, Pui C-H, Campana D. Comparative cytotoxicity of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia, 2370
Iversen PL, *see* Bishop MR
Iveson A, *see* Findlay M
— *see* Zalcberg JR

Jacaruso D, *see* Winick N
Jackman AL, *see* Clarke SJ
Jackson JD, *see* Bishop MR
Jacob J-H, *see* Conroy T
Jacobs M, *see* Gill PS
Jacobson J, *see* Wexler LH
Jacquemier J, *see* Coindre J-M
Jaffe DM, *see* Jaffe N
Jaffe E, *see* Magrath I
Jaffe N, Jaffe DM. Tumor size and prognosis in aggressively treated osteosarcoma (letter), 2399
— *see* Copeland DR
Jagannath S, *see* Gajewski JL
Jäger E, Heike M, Bernhard H, Klein O, Bernhard G, Lautz D, Michaelis J, Meyer zum Büschenfelde K-H, Knuth A. Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: Results of a randomized multicenter trial, 2274
Jahnke L, *see* Winter JN
Jais J-P, *see* Colonna P
Jakes R, *see* Cullen MH
Jakobsen P, *see* Bastholt L
James K, *see* Coppin CML
James KW, *see* Rusthoven JJ
James RD, *see* Seymour MT
Jami A, *see* Bertheault-Cvitkovic F
Jänicke F, *see* Avril N

Janik JE, *see* Gause BL
Janisch L, *see* Kobayashi K
Janka-Schaub G, *see* Bührer C
Janot F, *see* Wibault P
Janssen WE, *see* Fields KK
Jarosinski P, *see* Wexler LH
Jauch K-W, Heiss MM, Gruetzner U, Funke I, Pantel K, Babic R, Eissner H-J, Riethmueller G, Schildberg F-W. Prognostic significance of bone marrow micrometastases in patients with gastric cancer, 1810
Jensen J, *see* Rusthoven JJ
Jensen MD, *see* Loprinzi CL
Jensen PB, *see* Sehested M
Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non–small-cell lung cancer: A randomized study, 1065
Jett JR, *see* Rowland KM Jr
Jewell WR, *see* Rivkin SE
Jinnai I, *see* Kobayashi T
Jiroutek MR, *see* McLaughlin PW
Joel SP, Ellis P, O'Byrne K, Papamichael D, Hall M, Penson R, Nicholls S, O'Donnell C, Constantinou A, Woodhull J, Nicholson M, Smith I, Talbot D, Slevin M. Therapeutic monitoring of continuous infusion etoposide in small-cell lung cancer, 1903
—, Shah R, Clark PI, Slevin ML. Predicting etoposide toxicity: Relationship to organ function and protein binding, 257
Johannsen T, *see* Saven A
John M, *see* Flam M
Johnson BE, Bridges JD, Sobczeck M, Gray J, Linnoila RI, Gazdar AF, Hankins L, Steinberg SM, Edison M, Frame JN, Pass H, Nesbitt J, Holden D, Mulshine JL, Glatstein E, Ihde DC. Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine, 806
Johnson D, *see* Schiller JH
Johnson DH, Paul DM, Hande KR, Shyr Y, Blanke C, Murphy B, Lewis M, DeVore RF III. Paclitaxel plus carboplatin in advanced non–small-cell lung cancer: A phase II trial, 2054
Johnson FE, McKirgan LW, Coplin MA, Vernava AM, Longo WE, Wade TP, Virgo KS. Geographic variation in patient surveillance after colon cancer surgery, 183
—, Naunheim KS, Coplin MA, Virgo KS. Geographic variation in the conduct of patient surveillance after lung cancer surgery, 2940
Johnson S, *see* Juliusson G
Johnson SW, *see* Bookman MA
Johnstone HS, *see* Steinherz PG
Johnstone PAS, Rohde DC, Swartz SE, Fetter JE, Wexner SD. Port site recurrences after laparoscopic and thoracoscopic procedures in malignancy, 1950
Joly F, Henry-Amar M, Arveux P, Reman O, Tanguy A, Peny A-M, Lebailly P, Macé-Lesec'h J, Vié B, Génot J-Y, Busson A, Troussard X, Leporrier M. Late psychosocial sequelae in Hodgkin's disease survivors: A French population-based case-control study, 2444

Jonat W, *see* Buzdar A
Jones DV Jr, Lozano R, Hoque A, Markowitz A, Patt YZ. Phase II study of paclitaxel therapy for unresectable biliary tree carcinomas, 2306
— *see* Patt YZ
Jones J, *see* Spiridonidis CH
Jones RB, *see* Stemmer SM
Jones RJ, *see* Miller CB
Jones SE, Schottstaedt MW, Duncan LA, Kirby RL, Good RH, Mennel RG, George TK, Snyder DA, Watkins DL, Denham CA, Hayes FA, Rubin AS. Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer, 2976
— *see* Buzdar A
— *see* Hainsworth JD
Jordan VC. Antiestrogens and the reduction in circulating cholesterol (letter), 2407
Joseph J, Adler JR, Cox RS, Hancock SL. Linear accelerator-based stereotaxic radiosurgery for brain metastases: The influence of number of lesions on survival, 1085
Judson IR, *see* Clarke SJ
Juliá A, *see* Sierra J
Julien J-P, *see* Clahsen PC
Juliusson G, Christiansen I, Hansen MM, Johnson S, Kimby E, Elmhorn-Rosenborg A, Liliemark J. Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia, 2160
Jung S-H, *see* Rowland KM Jr
Jürgens H, *see* Bieling P
— *see* Zoubek A
Juweid M, Sharkey RM, Behr T, Swayne LC, Rubin AD, Herskovic T, Hanley D, Markowitz A, Dunn R, Siegel J, Kamal T, Goldenberg DM. Improved detection of medullary thyroid cancer with radiolabeled antibodies to carcinoembryonic antigen, 1209

Kadan NS, *see* Civin CI
Kaempfer R, Gerez L, Farbstein H, Madar L, Hirschman O, Nussinovich R, Shapiro A. Prediction of response to treatment in superficial bladder carcinoma through pattern of interleukin-2 gene expression, 1778
Kageyama S, *see* Kobayashi T
Kagey-Sobotka A, *see* Essayan DM
Kahn DJ, *see* Passos-Coelho JL
Kahn MJ, *see* O'Connell MJ
Kalhorn TF, *see* Slattery JT
Kalifa C, *see* Feugeas O
Kalra J, *see* Narasimhan P
Kamal T, *see* Juweid M
Kamel OW, *see* van de Rijn M
Kamen BA, *see* Winick N
Kaminski MS, Zasadny KR, Francis IR, Fenner MC, Ross CW, Milik AW, Estes J, Tuck M, Regan D, Fisher S, Glenn SD, Wahl RL. Iodine-131–anti-B1 radioimmunotherapy for B-cell lymphoma, 1974
Kamps WA, *see* Ham SJ
— *see* Veerman AJP
Kanamaru A, *see* Kobayashi T
Kane J, *see* Perez-Soler R
Kanfer EJ, *see* Elliott C
Kangas L, *see* Gylling H
Kanis JA, *see* Powles TJ
Kanowitz J, *see* Saltz LB
Kantarjian H, *see* Anderlini P
Kantarjian HM, *see* Majlis A
— *see* Smith TL
Kappas A, *see* Roukos D
Karlsson MO, *see* Sandström M
Karpeh M, *see* Kelsen D
Kars A, *see* Çelik I
Kaufmann SH, *see* Rowinsky EK
Kaul S, *see* Chabot GG
Kavanagh JJ, *see* Kudelka AP
Kaye SB, Paul J, Cassidy J, Lewis CR, Duncan ID, Gordon HK, Kitchener HC, Cruickshank DJ, Atkinson RJ, Soukop M, Rankin EM, Davis JA, Reed NS, Crawford SM, MacLean A, Parkin D, Sarkar TK, Kennedy J, Symonds RP. Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer, 2113
— *see* Cullen MH
Kearns CM, *see* Glantz MJ
Keating M, *see* McLaughlin P
Keenan E, *see* Bookman MA
Keizer HJ, *see* Vellenga E
Kelleher JF Jr, *see* Kushner BH
Keller A, *see* Miralbell R
Kellie S, *see* Balmaceda C
Kelsen D, Karpeh M, Schwartz G, Gerdes H, Lightdale C, Botet J, Lauers G, Klimstra D, Huang Y, Saltz L, Quan V, Brennan M. Neoadjuvant therapy of high-risk gastric cancer: A phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil, 1818
Kelsen DP, *see* Minsky BD
— *see* Saltz LB
Kemeny N, *see* Belluco C
Kemeny NE, *see* Conti JA
— *see* Saltz LB
— *see* Welt S
Kemp BL, *see* Perez-Soler R
Kemp G, Rose P, Lurain J, Berman M, Manetta A, Roullet B, Homesley H, Belpomme D, Glick J. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: Results of a randomized control trial in patients with advanced ovarian cancer, 2101
Kempf-Bielack B, *see* Bielack SS
Kempin S, *see* Gill PS
Kenda R, *see* Doci R
Kennealey GT, *see* Clarke SJ
Kennedy J, *see* Kaye SB
Kennedy MJ, Zahurak ML, Donehower RC, Noe DA, Sartorius S, Chen T-L, Bowling K, Rowinsky EK. Phase I and pharmacologic study of sequences of paclitaxel and cyclophosphamide supported by granulocyte colony-stimulating factor in women with previously treated metastatic breast cancer, 783
— *see* Miller CB
— *see* Passos-Coelho JL
Kerby T. *see* Ashley DM

Kerman H, *see* Flam M
Kerr DJ, *see* Seymour MT
Kersey JH, *see* Steinherz PG
Kessinger A, *see* Bishop MR
— *see* Sharp JG
— *see* Vose JM
Keus RB, *see* Aaronson NK
Khanna O, *see* Chang A
Khanolkar S, *see* Parikh B
Khayat D, *see* Laccourreye O
Kho GS, *see* Splinter TAW
Khojasteh A, *see* Hesketh P
Khor SP, *see* Baker SD
Khouri I, *see* van Besien K
Kiehl RK, *see* Salloum E
Kies MS, *see* Vokes EE
Kilpatrick D, *see* Bookman MA
— *see* O'Dwyer PJ
Kilpatrick MG, *see* Bow EJ
Kim EE, *see* Kudelka AP
Kim KM, *see* Schiller JH
Kimby E, *see* Juliusson G
King D, *see* Swain SM
King ED, *see* Essayan DM
Kinsella TJ, *see* Sharda NN
Kirby RL, *see* Jones SE
Kirkpatrick A, *see* Giaccone G
— *see* Splinter TAW
Kirkwood JM. In reply (letter), 1968
—, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group trial EST 1684, 7
— *see* Cole BF
Kitchener HC, *see* Kaye SB
Kjaer M, *see* Bastholt L
Klaassen U, *see* Nabholtz J-M
Klarnet J, *see* Bensinger WI
Klastersky J, *see* Sculier JP
Klausner RD. The future of cancer research and the role of the National Cancer Institute, 2878
Klein JP, *see* Gajewski JL
Klein O, *see* Jäger E
Klimstra D, *see* Belluco C
— *see* Kelsen D
Klocker J, *see* Fridrik MA
Kluin PM, *see* Kramer MHH
— *see* Velders GA
Kluin-Nelemans JC, *see* Kramer MHH
— *see* Velders GA
Knobf MT, *see* Fischer DS
Knuth A, *see* Jäger E
Kobayashi K, Vokes EE, Vogelzang NJ, Ratain MJ. Data modifications to phase I study of suramin (letter), 2623
—, Vokes EE, Vogelzang NJ, Janisch L, Soliven B, Ratain MJ. Phase I study of suramin administered by intermittent infusion without adaptive control to cancer patients: Update of two expanded dose levels near the maximally tolerated dose (letter), 2622
Kobayashi T, Miyawaki, Tanimoto M, Kuriyama K, Murakami H, Yoshida M, Minami S, Minato K, Tsubaki K, Ohmoto E, Oh H, Jinnai I, Sakamaki H, Hiraoka A, Kanamaru A, Takahashi I, Saito K, Naoe T, Yamada O, Asou N, Kageyama S, Emi N, Matsuoka A, Tomonaga M, Saito H, Ueda R, Ohno R, the Japan Adult Leukemia Study Group. Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia, 204
Kohler DR, *see* Tolcher AW
Koletsky A, *see* Crawford J
Kolodny GM, *see* Ben-Haim S
Komaki R, *see* Lee JS
Koning CCE, *see* Aaronson NK
Kononen J, *see* Kuukasjärvi T
Koops HS, *see* Eggermont AMM
— *see* Ham SJ
— *see* Lemmers NWM
Kopp WC, *see* Gause BL
Korn EL, *see* Smith M
Korzun AH, *see* Perloff M
Koshikawa T, *see* Nishio M
Kosmidis PA, Tsavaris N, Skarlos D, Theocharis D, Samantas E, Pavlidis N, Briassoulis E, Fountzilas G, the Hellenic Cooperative Oncology Group. Fluorouracil and leucovorin with or without interferon alfa-2b in advanced colorectal cancer: Analysis of a prospective randomized phase III trial, 2682
Kosty M, *see* Saven A
Kotz R, *see* Bieling P
Kovar H, *see* Zoubek A
Kozloff M, *see* Vokes EE
Kramar A, *see* Beyer J
Kramer MHH, Hermans J, Parker J, Krol ADG, Kluin-Nelemans JC, Haak HL, van Groningen K, van Krieken JHJM, de Jong D, Kluin PM. Clinical significance of *bcl*2 and p53 protein expression in diffuse large b-cell lymphoma: A population-based study, 2131
— *see* Velders GA
Kreinberg R, *see* Creemers GJ
Kreissman SG, *see* Rackoff WR
Kreuger A, *see* Sankila R
Kris M, *see* Hesketh P
Krischer J, *see* Steuber CP
Kritz H, Zielinski C, Sinzinger H. Low cholesterol and cancer, 3043
Krol ADG, *see* Kramer MHH
Kroll F, *see* Sculier JP
Kroon BBR, *see* Eggermont AMM
Kuczyk MA, *see* Bokemeyer C
Kudelka AP, Tresukosol D, Edwards CL, Freedman RS, Levenback C, Chantarawiroj P, de Leon CG, Kim EE, Madden T, Wallin B, Hord M, Verschraegen C, Raber M, Kavanagh JJ. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma, 1552
Kugler JW, *see* Rowland KM Jr
Kuhn J, *see* Prados MD
Kuhn JG, *see* Rothenberg ML
Kun L, *see* Ashley DM
Kun LE, *see* Heideman RL
— *see* Kuttesch JF Jr
Kunitoh H, Watanabe K, Onoshi T, Furuse K, Niitani H,

Taguchi T. Phase II trial of docetaxel in previously untreated advanced non–small-cell lung cancer: A Japanese Cooperative study, 1649
Kunstlinger F, *see* Bertheault-Cvitkovic F
Kurie JM, *see* Perez-Soler R
Kuriyama K, *see* Kobayashi T
Kuroishi T, *see* Nishio M
Kuross SA, *see* Rowland KM Jr
Kurtz J, *see* Solin LJ
Kurtz JM, *see* Miralbell R
Kurvinen K, Syrjänen K, Syrjänen S. p53 and *bcl*-2 proteins as prognostic markers in human papillomavirous-associated cervical lesions, 2120
Kuse R, *see* Schlegelberger B
Kushner BH, Cheung N-KV, LaQuaglia MP, Ambros PF, Ambros IM, Bonilla MA, Ladanyi M, Gerald WL. International Neuroblastoma Staging System stage 1 neuroblastoma: A prospective study and literature review, 2174
—, Cheung N-KV, LaQuaglia MP, Ambros PF, Ambros IM, Bonilla MA, Gerald WL, Ladanyi M, Gilbert F, Rosenfield NS, Yeh SDJ. Survival from locally invasive or widespread neuroblastoma without cytotoxic therapy, 373
—, LaQuaglia MP, Wollner N, Meyers PA, Lindsley KL, Ghavimi F, Merchant TE, Boulad F, Cheung N-KV, Bonilla MA, Crouch G, Kelleher JF Jr, Steinherz PG, Gerald WL. Desmoplastic small round-cell tumor: Prolonged progression-free survival with aggressive multimodality therapy, 1526
Kuske R, *see* Solin LJ
Küstner U, *see* Sculier JP
Kuttesch JF Jr, Parham DM, Luo X, Meyer WH, Bowman L, Shapiro DN, Pappo AS, Crist WM, Beck WT, Houghton PJ. P-glycoprotein expression at diagnosis may not be a primary mechanism of therapeutic failure in childhood rhabdomyosarcoma, 886
—, Wexler LH, Marcus RB, Fairclough D, Weaver-McClure L, White M, Mao L, Delaney TF, Pratt CB, Horowitz ME, Kun LE. Second malignancies after Ewing's sarcoma: Radiation dose-dependence of secondary sarcomas, 2818
Kuukasjärvi T, Kononen J, Helin H, Holli K, Isola J. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy, 2584
Kyle B, *see* Alcorn MJ

La Monica G, *see* Doci R
La Sala A, *see* Gobbi PG
Laburte C, *see* Boote DJ
Lacava JA, *see* Leone BA
Lacave A, *see* Blijham G
Lacave AJ, *see* Creemers GJ
Laccourreye H, *see* Laccourreye O
Laccourreye O, Brasnu D, Bassot V, Ménard M, Khayat D, Laccourreye H. Cisplatin-fluorouracil exclusive chemotherapy for T1-T3N0 glottic squamous cell carcinoma complete clinical responders: Five-year results, 2331
Lacombe L, Dalbagni G, Zhang Z-F, Cordon-Cardo C, Fair WR, Herr HW, Reuter VE. Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after bacillus Calmette-Guérin therapy: Correlation to clinical outcome, 2646
LaCreta FP, *see* O'Dwyer PJ
Lacy J, *see* Salloum E
Ladanyi M, *see* Kushner BH
Laffranchi A, *see* Bregni M
Laine L, *see* Lenz H-J
Lambert HE, *see* Rustin GJS
Lambert K, *see* Slattery JT
Lamborn K, *see* Prados MD
Land V, *see* Steuber CP
Landaw EM, *see* Rosen PJ
Langhi MJ, *see* Leone BA
Langleben A, *see* Crawford J
Langmark F, *see* Sankila R
Lanning M, *see* Saarinen UM
— *see* Sankila R
LaQuaglia MP, *see* Kushner BH
Larbaoui S, *see* Pujade-Lauraine E
Larson M, *see* Schiller JH
Larson RA, Mick R, Spielberger RT, O'Brien SM, Ratain MJ. Dose-escalation trial of cladribine using five daily intravenous infusions in patients with advanced hematologic malignancies, 188
Larson SM, *see* Welt S
Larsson R, *see* Sandström M
Lasorella A, *see* Mastrangelo R
Lasser P, *see* Girard P
Lasset C, *see* Blay J-Y
— *see* Combaret V
Latreille J, *see* Conte PF
Laubenbacher C, *see* Avril N
Lauers G, *see* Kelsen D
Laufman LR, *see* Spiridonidis CH
Lauria R, *see* Carlomagno C
Lautz D, *see* Jäger E
Law P, *see* Civin CI
Lawrence G. Changing the behavior of breast cancer (letter), 321
—, Castro P, Collins B. Breast cancer: Systemic benefit of locoregional treatment (letter), 1403
Lazaros A, *see* Roukos D
Lazarus H, *see* Sparano JA
Lazarus HM, *see* Gajewski JL
— *see* Winter JN
Le Cesne A, *see* Blay J-Y
Le Chevalier T, *see* Girard P
— *see* Soulié P
Le Doussal V, *see* Coindre J-M
Le Mevel B, *see* Misset J-L
Lê MG, *see* Arriagada R
Le Prisé P-Y, *see* Colonna P
Lebailly P, *see* Joly F
Lebenshart P, *see* Ben-Yehuda D
Lebesque JV, *see* Boersma LJ
Lebsack ME, *see* Vose JM
Lebwohl DE, *see* Hudis CA
Lecomte J, *see* Sculier JP
Lederlin P, *see* Diviné M
Ledermann JA, *see* Seymour MT
Lee HAS, Bobrow LG. Relationship of histologic grade, c-

*erb*B-2 expression, and inflammatory infiltrate to prognosis in carcinoma of the breast (letter), 2406
Lee J, *see* Stein AS
Lee JJ, *see* Perez-Soler R
— *see* Smith TL
Lee JS, Scott C, Komaki R, Fossella FV, Dundas GS, McDonald S, Byhardt RW, Curran WJ Jr. Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non–small-cell lung cancer: Radiation Therapy Oncology Group protocol 91-06, 1055
— *see* Perez-Soler R
Lee T, *see* Saven A
Lee WR, *see* Hanks GE
Leenhouts GHMW, *see* Aaronson NK
Leggio A, *see* Guglielmi M
Legha SS, *see* Smith TL
Leibel S, *see* Balmaceda C
Leichman CG, *see* Lenz H-J
Leichman L, *see* Lenz H-J
Lejeune F, *see* Colonna P
Lejeune FJ, *see* Eggermont AMM
Lemevel A, *see* Colonna P
Lemkin SR. Cost-effectiveness: Let's get "real" (letter), 687
Lemmers NWM, Gels ME, Sleijfer DTh, Plukker JTh, van der Graaf WTA, de Langen ZJ, Droste JHJ, Koops HS, Hoekstra HJ. Complications of venous access ports in 132 patients with disseminated testicular cancer treated with polychemotherapy, 2916
Lemoli RM, Rosti G, Visani G, Gherlinzoni F, Miggiano MC, Fortuna A, Zinzani PL, Tura S. Concomitant and sequential administration of recombinant human granulocyte colony-stimulating factor and recombinant human interleukin-3 to accelerate hematopoietic recovery after autologous bone marrow transplantation for malignant lymphoma, 3018
Lentz SS, Brady MF, Major FJ, Reid GC, Soper JT. High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study, 357
— *see* McGuire WP
Lenz H-J, Leichman CG, Danenberg KD, Danenberg PV, Groshen S, Cohen H, Laine L, Crookes P, Silberman H, Baranda J, Garcia Y, Li J, Leichman L. Thymidylate synthase mRNA level in adenocarcinoma of the stomach: A predictor for primary tumor response and overall survival, 176
Leone A, *see* Scambia G
Leone BA, Vallejo CT, Romero AO, Perez JE, Cuevas MA, Lacava JA, Sabatini CL, Dominguez ME, Rodriguez R, Barbieri MR, Ortiz EH, Salvadori MA, Romero Acuña LA, Romero Acuña JM, Langhi MJ, Amato S, Machiavelli MR. Ifosfamide and vinorelbine as first-line chemotherapy for metastatic breast cancer, 2993
Leong L, *see* Margolin K
Lepage E, *see* Diviné M
Leporrier M, *see* Joly F
— *see* Solal-Céligny P
Letendre F, *see* Trudeau ME
Leung D, *see* Hirsch A
Leung DHY, *see* Pisters PWT
Levenback C, *see* Kudelka AP
Lévi F, *see* Bertheault-Cvitkovic F
Levi JA, *see* Millward MJ
Levinson AK, *see* Critz FA
Lewis CR, *see* Kaye SB
Lewis M, *see* Johnson DH
Li FP, *see* Patenaude AF
Li J, *see* Lenz H-J
Liang M, *see* Dahut W
Libson E, *see* Ben-Yehuda D
Lichtenstein LM, *see* Essayan DM
Lichter AS, *see* Albain KS
Lieberman R, *see* Dahut W
Liénard D, *see* Eggermont AMM
Lightdale C, *see* Kelsen D
Lilenbaum RC, *see* Miller AA
Liliemark J, *see* Juliusson G
Lilleby K, *see* Bensinger WI
Lin S, *see* DeAngelis LM
Lind MJ, Ghazal-Aswad S, Gumbrell L, Fishwick K, Craigs D, Millward MJ, Bailey NP, Doré-Green F, Chapman F, Simmons D, Proctor M, Oakey A, Robson L, Middleton I, McCann E, Sinha D, Calvert AH. Phase I study of pharmacologically based dosing of carboplatin with filgrastim support in women with epithelial ovarian cancer, 800
Lindemann A, *see* Engelhardt M
Lindmark G, Gerdin B, Sundberg C, Påhlman L, Bergström R, Glimelius B. In reply (letter), 2402
—, Gerdin B, Sundberg C, Påhlman L, Bergström R, Glimelius B. Prognostic significance of the microvascular count in colorectal cancer, 461
Lindsley KL, *see* Kushner BH
Link M, *see* Bowman WP
— *see* Smith M
Linkesch W, *see* Beyer J
— *see* Fridrik MA
Linnoila RI, *see* Johnson BE
Lionetto R, *see* Venturini M
Lippman ME, *see* Swain SM
Lippman SM, *see* Perez-Soler R
Lipsett J, *see* Stein AS
Lipshultz SE. Dexrazoxane for protection against cardiotoxic effects of anthracyclines in children (editorial), 328
Lister TA, *see* Pappa VI
Littles FJ, *see* Eisbruch A
Liu G, Crump M, Goss PE, Dancey J, Sheperd FA. A prospective comparison of the sclerosing agents doxycycline and bleomycin for the primary management of malignant pericardial effusion and cardiac tamponade, 3141
Liu JM, *see* Chen YM
Liu Y, *see* Heyman M
Llorente A, *see* Sierra J
Locker P, *see* Saltz LB
Lofters WS, *see* Trudeau ME
Lohmann RC, *see* Rusthoven JJ
Lokiec F, *see* Canal P
Lombardi L, *see* Pupa SM
Longee D, *see* Ashley DM
Longo DL, *see* Gause BL
Longo WE, *see* Johnson FE
Loos W, *see* Creemers GJ

Lopez-Guillermo A, *see* Bessell EM
López-Guillermo A, *see* Montserrat E
Loprinzi CL. Cessation of follow-up tests with limited utility: A patient's perspective (letter), 1406
—, Fonseca R, Jensen MD. Megestrol acetate-induced adrenal suppression (letter), 689
— *see* Rowland KM Jr
Lotan H, *see* Ben-Yehuda D
Louie AC, *see* Fyfe GA
Love S, *see* Pappa VI
Löwenberg B, Voogt P. Autologous stem-cell transplantation and purging (editorial), 2194
— *see* Vellenga E
Loy V, *see* Dieckmann K-P
Lozano R, *see* Jones DV Jr
— *see* Patt YZ
Lozza L, *see* Doci R
Luboinski B, *see* Wibault P
Lucarini JW, *see* Dreyfuss AI
Luo X, *see* Kuttesch JF Jr
Luoni M, Fava S, Declich P. Bone marrow biopsy for staging Hodgkin's lymphoma: The value of bilateral or unilateral trephine biopsy (letter), 682
Lurain J, *see* Kemp G
Lutz J-M, *see* Rustin GJS
Lu-Yao G, *see* Fowler FJ Jr
Lynch C, *see* Ayash LJ
Lynch P, *see* Patt YZ
Lynch T. Topotecan today (editorial), 3053
Lynch TJ, *see* Miller AA
Lyttelton MP, *see* Elliott C

Maas R, *see* Bieling P
Mac Manus MP, Hoppe RT. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University, 1282
Macé-Lesech J, *see* Coindre J-M
Macé-Lesec'h J, *see* Joly F
Machiavelli MR, *see* Leone BA
Maciá J, *see* Sierra J
MacLean A, *see* Kaye SB
Madar L, *see* Kaempfer R
Madden T, *see* Holmes FA
— *see* Kudelka AP
Mäenpää H, *see* Gylling H
Magnani E, *see* Bajetta E
Magrath I, Adde M, Shad A, Venzon D, Seibel N, Gootenberg J, Neely J, Arndt C, Nieder M, Jaffe E, Wittes RA, Horak ID. Adults and children with small non–cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen, 925
Magrath IT, *see* Weintraub M
Maher P, *see* Balmaceda C
Mahmoud H, *see* Ito C
Mahmoud HH, *see* Relling MV
Mahoney D, *see* Steuber CP
Mahoney DH Jr, Strother D, Camitta B, Bowen T, Ghim T, Pick T, Wall D, Yu L, Shuster JJ, Friedman H. High-dose melphalan and cyclophosphamide with autologous bone marrow rescue for recurrent/progressive malignant brain tumors in children: A pilot Pediatric Oncology Group study, 382
Mailliard JA, *see* Rowland KM Jr
Majlis A, Smith TL, Talpaz M, O'Brien S, Rios MB, Kantarjian HM. Significance of cytogenetic clonal evolution in chronic myelogenous leukemia, 196
Major FJ, *see* Lentz SS
Mäkipernaa A, *see* Saarinen UM
Makoski H-B, *see* Stahl M
Maksymiuk AW, *see* Rowland KM Jr
Maldonado J, *see* Bladé J
Malik U, *see* Sparano JA
Malkowicz SB, *see* D'Amico AV
Maloisel F, *see* Pujade-Lauraine E
Malone D, *see* Vokes EE
Maloney DG, *see* Bensinger WI
Mammoliti S, *see* Conte PF
Mamounas EP, *see* Fisher B
Man A, *see* Greco FA
Mancuso S, *see* Scambia G
Mandanas R, *see* Beyer J
Mandard A-M, *see* Coindre J-M
Mandelli F, *see* Martelli M
— *see* Zinzani PL
— *see* Zittoun R
Manegold C, *see* Pecherstorfer M
Manetta A, *see* Kemp G
Mangan C, *see* Winter JN
Mankin HJ, *see* Suit H
Mann S, *see* Sharp JG
Mansfield P, *see* Sarris AH
Mäntyla E, *see* Gylling H
Manzitti J, *see* Schvartzman E
Mao L, *see* Kuttesch JF Jr
Marcellin L, *see* Feugeas O
Marcellus DC, *see* Miller CB
Marcus RB, *see* Kuttesch JF Jr
Margolese RG, *see* Fisher B
Margolin K, Doroshow JH, Ahn C, Hamasaki V, Leong L, Morgan R, Raschko J, Shibata S, Somlo G, Tetef M. Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support, 2631
Margolin KA, *see* Stein AS
Mariani L, *see* Bajetta E
Mariani-Costantini R, *see* Roselli M
Marit G, Faberes C, Pico JL, Boiron JM, Bourhis JH, Brault P, Bernard P, Foures C, Cony-Makhoul P, Puntous M, Vezon G, Broustet A, Girault D, Reiffers J. Autologous peripheral-blood progenitor-cell support following high-dose chemotherapy or chemoradiotherapy in patients with high-risk multiple myeloma, 1306
Markman M. CA-125: An evolving role in the management of ovarian cancer (editorial), 1411
—, Hakes T, Barakat R, Curtin J, Almadrones L, Hoskins W. Follow-up of Memorial Sloan-Kettering Cancer Center patients treated on National Cancer Institute treatment referral center protocol 9103: Paclitaxel in refractory ovarian cancer, 796
Markowitz A, *see* Jones DV Jr
— *see* Juweid M
— *see* Patt YZ

Marone M, *see* Scambia G
Marques C, *see* Pujade-Lauraine E
Marrero AM, *see* Schwarz RE
Marshall EM, *see* Greco FA
Martelli M, Vignetti M, Zinzani PL, Gherlinzoni F, Meloni G, Fiacchini M, De Sanctis V, Papa G, Martelli MF, Calabresi F, Tura S, Mandelli F. High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: A prospective randomized Italian Multicenter study, 534
— *see* Zinzani PL
Martelli MF, *see* Martelli M
— *see* Zinzani PL
Martin J, *see* Winter JN
— *see* Younes A
Martin M. Is oral ondansetron really efficacious in the control of cisplatin-induced delayed emesis? (letter), 1401
Martin PJ, *see* Anderson JE
Martinez C, *see* Stemmer SM
Martino S, *see* Albain KS
Marty M, *see* Coombes RC
— *see* Dieras V
Mascaró JM, *see* Mellado B
Maslak P, *see* Weiss M
Mason B, *see* Sparano JA
Mastrangelo R, Lasorella A, Tornesello A, Riccardi R. Carboplatin and cisplatin in medulloblastoma at diagnosis: "Comparable efficacy?" (letter), 1741
Mathé G, *see* Misset J-L
Mathieu-Boue A, *see* Canal P
Mathiot C, *see* Tartour E
Matsuoka A, *see* Kobayashi T
Matthay KK, *see* Stram DO
— *see* Willis B
Matthes S, *see* Stemmer SM
Matthews DC, *see* Anderson JE
Maunsell E, Brisson J, Deschênes L, Frasure-Smith N. Randomized trial of a psychologic distress screening program after breast cancer: Effects on quality of life, 2747
Maurer HM, *see* Pappo AS
Mauriac L, *see* Conte PF
Mayer RJ, *see* Bernstein SH
Maziarz RT, *see* Bensinger WI
Mazumdar M, *see* Motzer RJ
— *see* Puc HS
McAdam WAF, *see* Seymour MT
McAllister LD, *see* Prados MD
McArdle C, *see* Coombes RC
McBride JH, *see* Rosen PJ
McCabe M, *see* Fisherman JS
— *see* Tolcher AW
McCann E, *see* Lind MJ
McCarthy PL Jr, *see* Gajewski JL
McClean P, *see* Rustin GJS
McCormick B, *see* Solin LJ
McCulloch PB, *see* Rusthoven JJ
McDermott B, *see* Gelmon KA
McDonald GB, *see* Slattery JT
McDonald S, *see* Lee JS
McGuigan D, *see* Elliott C
McGuire WP, Blessing JA, Moore D, Lentz SS, Photopulos G. Paclitaxel has moderate activity in squamous cervix cancer: A Gynecologic Oncology Group study, 792
— *see* Rustin GJS
McGuire WP III, *see* Bookman MA
McKhann C, *see* Haffty BG
McKirgan LW, *see* Johnson FE
McLaughlin P, Hagemeister FB, Romaguera JE, Sarris AH, Pate O, Younes A, Swan F, Keating M, Cabanillas F. Fludarabine, mitoxantrone, and dexamethasone: An effective new regimen for indolent lymphoma, 1262
— *see* Sarris AH
— *see* Younes A
McLaughlin PW, Sandler HM, Jiroutek MR. Prostate-specific antigen following prostate radiotherapy: How low can you go? (editorial), 2889
McMillan A, *see* Small EJ
McNeese M, *see* Solin LJ
McNinch L, *see* Ito C
McSweeney P, *see* Bensinger WI
Megherian L, *see* Weiss M
Mehra R, *see* van Besien K
Mehta MP, *see* Prados MD
Meier L, *see* Ashley DM
Meijer OWM, *see* Rijlaarsdam JU
Meis-Kindblom J, *see* Schultz C
Meitar D, Crawford SE, Rademaker AW, Cohn SL. Tumor angiogenesis correlates with metastatic disease, N-*myc* amplification, and poor outcome in human neuroblastoma, 405
Mele A, *see* Corona R
Mellado B, Colomer D, Castel T, Muñoz M, Carballo E, Galán M, Mascaró JM, Vives-Corrons JL, Grau JJ, Estapé J. Detection of circulating neoplastic cells by reverse-transcriptase polymerase chain reaction in malignant melanoma: Association with clinical stage and prognosis, 2091
Meloni G, *see* Martelli M
Ménard M, *see* Laccourreye O
Ménard S, Pupa SM, Casalini P, Rilke F, Colnaghi MI. In reply (letter), 2407
— *see* Pupa SM
Mencel P, *see* Puc HS
Mendelsohn J, *see* Baselga J
Mendoza EF, *see* Rosen PJ
Mennel RG, *see* Hainsworth JD
— *see* Jones SE
Merchant TE, *see* Kushner BH
Merle S, *see* Conroy T
Mermillod B, *see* Miralbell R
Meroni E, *see* Doci R
Merte H, *see* Reckzeh B
Mertelsmann R, *see* Dölken G
— *see* Engelhardt M
Mesina O, *see* Sarris AH
Meszaros P, *see* Percivale P
Metz R, *see* Misset J-L
Meyer WH, *see* Kuttesch JF Jr
Meyer zum Büschenfelde K-H, *see* Jäger E
Meyers PA, *see* Kushner BH
Michaelis J, *see* Jäger E

Michel J, *see* Sculier JP
Michelotti A, *see* Venturini M
Mick R, Gupta E, Vokes EE, Ratain MJ. Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: Prediction of biliary index and intestinal toxicity, 2012
— *see* Larson RA
— *see* Vokes EE
Middleton I, *see* Lind MJ
Miettinen TA, *see* Gylling H
Miggiano MC, *see* Lemoli RM
Mignolet FY, *see* Clahsen PC
Mignot L, *see* Dieras V
— *see* Pujade-Lauraine E
Milanaccio C, *see* Guglielmi M
Milbauer A, *see* Patterson JS
Milenic D, *see* Yu B
Milik AW, *see* Kaminski MS
Milisavljevic S, *see* Jeremic B
Miller AA, Lilenbaum RC, Lynch TJ, Rosner GL, Ratain MJ, Green MR, Schilsky RL. Treatment-related fatal sepsis from topotecan/cisplatin and topotecan/paclitaxel (letter), 1964
Miller CB, Piantadosi S, Vogelsang GB, Marcellus DC, Grochow L, Kennedy MJ, Jones RJ. Impact of age on outcome of patients with cancer undergoing autologous bone marrow transplant, 1327
Miller RL, *see* Holland HK
Miller WE, *see* Saven A
Mills L, *see* Ahles TA
Mills P, *see* Glantz MJ
Millward MJ, Bishop JF, Friedlander M, Levi JA, Goldstein D, Olver IN, Smith JG, Toner GC, Rischin D, Bell DR. Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non–small-cell lung cancer, 142
— *see* Lind MJ
Milpied N, Fielding AK, Pearce RM, Ernst P, Goldstone AH. Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease, 1291
Minami S, *see* Kobayashi T
Minato K, *see* Kobayashi T
Mineur P, *see* Diviné M
Minsky BD, Neuberg D, Kelsen DP, Pisansky TM, Ginsberg R, Benson A III. Neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose radiation for squamous cell carcinoma of the esophagus: A preliminary analysis of the phase II Intergroup Trial 0122, 149
Miralbell R, Bieri S, Mermillod B, Helg C, Sancho G, Pastoors B, Keller A, Kurtz JM, Chapuis B. Renal toxicity after allogeneic bone marrow transplantation: The combined effects of total-body irradiation and graft-versus-host disease, 579
Misset J-L, di Palma M, Delgado M, Plagne R, Chollet P, Fumoleau P, Le Mevel B, Belpomme D, Guerrin J, Fargeot P, Metz R, Ithzaki M, Hill C, Mathé G. Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and flourouracil: Final report after a 16-year median follow-up duration, 1136
Misset JL, *see* Bertheault-Cvitkovic F
Mitchell H, *see* Rustin GJS
Miyawaki S, *see* Kobayashi T
Modiano MR, Villar-Werstler P, Crowley J, Salmon SE. Evaluation of race as a prognostic factor in multiple myeloma: An ancillary of Southwest Oncology Group study 8229, 974
Moffat FL Jr, Pinsky CM, Hammershaimb L, Petrelli NJ, Patt YZ, Whaley FS, Goldenberg DM. Clinical utility of external immunoscintigraphy with the IMMU-4 technetium-99m Fab′ antibody fragment in patients undergoing surgery for carcinoma of the colon and rectum: Results of a pivotal, phase III trial, 2295
Mohiuddin M, Chen E-T, Ahmad N. Combined liver radiation and chemotherapy for palliation of hepatic metastases from colorectal cancer, 722
Molea N, *see* Venturini M
Molenaar WM, *see* Ham SJ
Molina A, *see* Stein AS
Möller T, *see* Sankila R
Molls M, *see* Stahl M
Moloney AJ, *see* Bessell EM
Mommen P, *see* Sculier JP
Mondino B, *see* Rosen PJ
Monnet I, *see* Soulié P
Monnier A, *see* Pujade-Lauraine E
Montserrat E, Bosch F, López-Guillermo A, Graus F, Terol M-J, Campo E, Rozman C. CNS involvement in mantle-cell lymphoma, 941
— *see* Bladé J
— *see* Sierra J
Monzeglio C, *see* Dogliotti L
Moore BD III, *see* Copeland DR
Moore D, *see* McGuire WP
— *see* Sarris AH
Moore J, *see* Baselga J
Moore MJ, *see* Tannock IF
Moore MR, *see* Holland HK
Morabito A, *see* Carlomagno C
Morel P, *see* Solal-Céligny P
Morgan R, *see* Margolin K
Morgenstern GR, *see* Pettengell R
Moro G, *see* Dogliotti L
Moro M-J, *see* Bladé J
Morse MJ, *see* Brenner PC
Morvan F, *see* Coombes RC
— *see* Dieras V
Moscinski LC, *see* Fields KK
Moss TJ, *see* Passos-Coelho JL
Mosseri V, *see* Tartour E
Motzer RJ. Selecting patients with cisplatin-resistant germ cell tumors for high-dose chemotherapy (editorial), 2625
—, Herr H. In reply (letter), 2885
—, Mazumdar M, Bosl GJ, Bajorin DF, Amsterdam A, Vlamis V. High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: Treatment results and prognostic factors for survival and toxicity, 1098
—, Sheinfeld J, Herr H. Defining new standards for adjuvant therapy of testis cancer: A reply (letter), 680
—, Sheinfeld J. In reply (letter), 2187

— *see* Brenner PC
— *see* Puc HS
Mount B, *see* Bruera E
Mouridsen HT, *see* Bastholt L
Mousseau M, *see* Pujade-Lauraine E
Moyer M, *see* Saven A
Moynahan ME, *see* Seidman AD
Muhonen T, *see* Hernberg M
Mukwaya GM, *see* Gill PS
Muldal AM, *see* Trudeau ME
Mulder NH, *see* Vellenga E
Muller M, *see* Sprangers MAG
Muller MJ, *see* Aaronson NK
— *see* Simons JPFHA
Muller SH, *see* Boersma LJ
Mulshine JL, *see* Johnson BE
Mulvihill JJ, *see* Benichou J
Muñoz M, *see* Mellado B
Murakami H, *see* Kobayashi T
Murphy B, *see* Johnson DH
Murphy KC, *see* Tannock IF
Murphy S, *see* Bowman WP
— *see* Smith M
Murphy WK, *see* Perez-Soler R
Murray K, *see* Flam M
— *see* Schultz C
Murray N, *see* Siu LL
Murren J, *see* Salloum E
Musi L, *see* Guglielmi M
Myers AM, *see* Gill PS
Myerson R, *see* Flam M

Nabholtz J-M, Gelmon K, Bontenbal M, Spielmann M, Catimel G, Conte P, Klaassen U, Namer M, Bonneterre J, Fumoleau P, Winograd B. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer, 1858
Nademanee A, *see* Stein AS
Nakagawara G, *see* Yamaguchi A
Nakashima H, *see* Dahut W
Nakashima L, *see* Gelmon KA
Namer M, *see* Nabholtz J-M
Naoe T, *see* Kobayashi T
Narasimhan P, Kalra J. Ethical questions on the testicular seminoma study (letter), 684
Nash RA, *see* Anderson JE
Nathanson L. Clinical prognostic factors in adjuvant melanoma trial (letter), 1967
Nathrath W, *see* Avril N
Naunheim KS, *see* Johnson FE
Navari R, *see* Hesketh P
Navari RM. In reply (letter), 1401
Nayfield SG, Gorin MB. Tamoxifen-associated eye disease: A review, 1018
Neely J, *see* Magrath I
Neely JE, *see* Weintraub M
Negrier S, *see* Tartour E
Nelson J, *see* Rothenberg ML
Nelson N, *see* El-Sayed S
Nelstrop ARE, *see* Rustin GJS
Nemunaitis J, *see* Rosenfeld C
Neoptolemos JP, *see* Seymour MT
Nesbitt J, *see* Johnson BE
Nethersell ABW, *see* Falcone A
Netter G, *see* Pujade-Lauraine E
Neubauer M, *see* Fridrik MA
Neuberg D, *see* Minsky BD
Neugut AI. Funerals (letter), 2887
— *see* Weissmann LB
Neville AJ, *see* Tannock IF
Newlands ES, *see* Rustin GJS
Newman RA, *see* Holmes FA
Newman S, *see* Winter JN
Nicholls S, *see* Joel SP
Nichols CR, *see* Beyer J
Nicholson M, *see* Joel SP
— *see* Seymour MT
Nicol B, *see* Ahmed FY
Nicolini A, *see* Carpi A
Niebel W, *see* Stahl M
Nieder M, *see* Magrath I
Nieder ML, *see* Weintraub M
Nielsen OS, *see* Bastholt L
Niggli F, *see* Zoubek A
Niitani H, *see* Kunitoh H
Niland J, *see* Stein AS
Nishio M, Koshikawa T, Kuroishi T, Suyama M, Uchida K, Takagi Y, Washimi O, Sugiura T, Ariyoshi Y, Takahashi T, Ueda R, Takahasi T. Prognostic significance of abnormal p53 accumulation in primary, resected non–small-cell lung cancers, 497
Noe DA, *see* Baker SD
— *see* Kennedy MJ
Noga S, *see* Civin CI
Noga SJ, *see* Passos-Coelho JL
Nooijen WJ, *see* Rodenhuis S
Noone M, *see* Fisherman JS
Noone MH, *see* Tolcher AW
Noordijk EM, *see* Rijlaarsdam JU
— *see* Velders GA
Nooy M, *see* Pujade-Lauraine E
Norris B, *see* Perrault D
Norris BD, *see* Trudeau ME
Norris CM, *see* Dreyfuss AI
North L, *see* Sarris AH
Norton AJ, *see* Pappa VI
Norton L, *see* Baselga J
— *see* Hudis CA
— *see* Perloff M
— *see* Seidman AD
Nussinovich R, *see* Kaempfer R
Nygren P, *see* Sandström M

Oakey A, *see* Lind MJ
Oberling F, *see* Feugeas O
O'Brien S, *see* Majlis A
O'Brien SM, *see* Larson RA
O'Byrne K, *see* Joel SP
O'Connell MJ, Kahn MJ, Erlichman C, Goldberg RM, Shepherd LE. Optimal duration of fluorouracil plus levamisole colon cancer surgical adjuvant therapy, 2887
O'Donaghue M, *see* Seidman AD
O'Donnell C, *see* Joel SP
O'Donnell MR, *see* Stein AS

O'Dwyer P, *see* Bookman MA
O'Dwyer PJ, Hamilton TC, LaCreta FP, Gallo JM, Kilpatrick D, Halbherr T, Brennan J, Bookman MA, Hoffman J, Young RC, Comis RL, Ozols RF. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer, 249
Ognibene F, *see* Tolcher AW
Ognibene FP, *see* Fisherman JS
O'Gorman M, *see* Winter JN
Oh H, *see* Kobayashi T
Ohmoto E, *see* Kobayashi T
Ohno R, *see* Kobayashi T
O'Kane-Murphy B, *see* Bishop MR
Okon E, *see* Ben-Yehuda D
Old LJ, *see* Welt S
Oldham F, *see* Civin CI
O'Leary M, *see* Stram DO
Oleske DM, *see* Bines J
Olivé T, *see* Sierra J
Olsen JH, *see* Sankila R
Olver IN, *see* Millward MJ
Onetto N, *see* Gelmon KA
Ong ST, Vogelzang NJ. Chemotherapy in malignant pleural mesothelioma: A review, 1007
Onoshi T, *see* Kunitoh H
Oratz R, *see* Wasserheit C
O'Reilly S, Rowinsky EK, Slichenmyer W, Donehower RC, Forastiere AA, Ettinger DS, Chen TL, Sartorius S, Grochow LB. Phase I and pharmacologic study of topotecan in patients with impaired renal function, 3062
O'Reilly SE, *see* Gelmon KA
O'Rourke M, *see* Crawford J
Ortega JJ, *see* Sierra J
Ortiz EH, *see* Leone BA
Osborne CK, *see* Albain KS
— *see* Rivkin SE
Osborne RJ, *see* Boote DJ
O'Shaughnessy J, *see* Fisherman JS
O'Shaughnessy JA, *see* Tolcher AW
Osoba D, *see* Tannock IF
O'Sullivan J, *see* Albain KS
— *see* Rivkin SE
Ott R, *see* Findlay M
Owen D, *see* Rowland KM Jr
Ozer H, *see* Crawford J
Ozols RF, *see* Bookman MA
— *see* Essayan DM
— *see* O'Dwyer PJ
Özyar E, *see* Çelik I

Pache H, *see* Avril N
Packer RJ, *see* Finlay JL
Paesmans M, *see* Sculier JP
Påhlman L, *see* Lindmark G
Paik C, *see* Yu B
Paillot B, *see* Conroy T
Pajak TF, *see* Flam M
Pampaloni A, *see* Guglielmi M
Panasci L, *see* Perrault D
Panici PB, *see* Scambia G
Panico L, *see* Carlomagno C
Pantel K, *see* Jauch K-W
Papa G, *see* Martelli M
Papamichael D, *see* Joel SP
Pappa VI, Hussain HK, Reznek RH, Whelan J, Norton AJ, Wilson AM, Love S, Lister TA, Rohatiner AZS. Role of image-guided core-needle biopsy in the management of patients with lymphoma, 2427
Pappo AS, Crist WM, Shapiro DN, Maurer HM. In reply (letter), 323
— *see* Kuttesch JF Jr
Parham DM, *see* Kuttesch JF Jr
Parikh B, Khanolkar S, Advani SH, Dhabhar B, Chandra M. Safety profile of single-dose dexamethasone premedication for paclitaxel (letter), 2189
Parker J, *see* Kramer MHH
Parker PM, *see* Stein AS
Parkin D, *see* Kaye SB
Parkinson DR, *see* Fyfe GA
Parkinson MC, *see* Cullen MH
Parodi G, *see* Conte PF
Pascual A, *see* Bladé J
Pasquini P, *see* Corona R
Pass H, *see* Johnson BE
Passos-Coelho JL, Ross AA, Kahn DJ, Moss TJ, Davis JM, Huelskamp A-M, Noga SJ, Davidson NE, Kennedy MJ. Similar breast cancer cell contamination of single-day peripheral-blood progenitor-cell collections obtained after priming with hematopoietic growth factor alone or after cyclophosphamide followed by growth factor, 2569
Pastoors B, *see* Miralbell R
Pastorino S, *see* Venturini M
Pate O, *see* McLaughlin P
Patenaude AF, Basili L, Fairclough DL, Li FP. Attitudes of 47 mothers of pediatric oncology patients toward genetic testing for cancer predisposition, 415
Pater J, *see* Coppin CML
— *see* Prichard KI
— *see* Siu LL
Paterson AHG, *see* Prichard KI
Patricot L-M, *see* Feugeas O
Patt YZ, Jones DV Jr, Hoque A, Lozano R, Markowitz A, Raijman I, Lynch P, Charnsangavej C. Phase II trial of intravenous fluorouracil and subcutaneous interferon alfa-2b for biliary tract cancer, 2311
— *see* Jones DV Jr
— *see* Moffat FL Jr
Patterson JS, Plourde PV, Milbauer A. A response to commentary on endometrial cancer deaths in tamoxifen-treated breast cancer patients (letter), 2886
Patterson WB, Emanuel EJ. Physician-drug company conflict of interest, 316
Paul DM, *see* Johnson DH
Paul J, *see* Kaye SB
Paul NA, *see* Prichard KI
Pautier P, *see* Diviné M
Pavlidis N, *see* Kosmidis PA
Pavlovsky S, *see* Gajewski JL
Pearce R, *see* Sweetenham JW
Pearce RM, *see* Milpied N
— *see* Williams CD
Pearson C, *see* Alcorn MJ

Peccatori F, *see* Bregni M
Pecherstorfer M, Herrmann Z, Body J-J, Manegold C, Degardin M, Clemens MR, Thürlimann B, Tubiana-Hulin M, Steinhauer EU, van Eijkeren M, Huss H-J, Thiébaud D. Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy, 268
Pedersen D, *see* Bastholt L
Pedersen-Bjergaard J. In reply (letter), 682
Peereboom D, *see* Rowinsky EK
Peetermans M, *see* Zittoun R
Penson R, *see* Joel SP
Peny A-M, *see* Joly F
Percivale P, Bertoglio S, Meszaros P, Canavese G, Cafiero F, Gipponi M, Campora E, Gasco M, Badellino F. Radioimmunoguided surgery after primary treatment of locally advanced breast cancer, 1599
Perentesis P, *see* Yu B
Perez EA. Schedule-dependent edatrexate toxicity (letter), 322
Perez JE, *see* Leone BA
Pérez-López FR, *see* Coombes RC
Perez-Soler R, Fossella FV, Glisson BS, Lee JS, Murphy WK, Shin DM, Kemp BL, Lee JJ, Kane J, Robinson RA, Lippman SM, Kurie JM, Huber MH, Raber MN, Hong WK. Phase II study of topotecan in patients with advanced non–small-cell lung cancer previously untreated with chemotherapy, 503
—, Glisson BS, Lee JS, Fossella FV, Murphy WK, Shin DM, Hong WK. Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan, 2785
Perkins JB, *see* Fields KK
Perkkiö M, *see* Saarinen UM
Perloff M, Norton L, Korzun AH, Wood WC, Carey RW, Gottlieb A, Aust JC, Bank A, Silver RT, Saleh F, Canellos GP, Perry MC, Weiss RB, Holland JF. Postsurgical adjuvant chemotherapy of stage II breast carcinoma with or without crossover to a non-cross–resistant regimen: A Cancer and Leukemia Group B study, 1589
Perng RP, *see* Chen YM
Perrault D, Eisenhauer EA, Pritchard KI, Panasci L, Norris B, Vandenberg T, Fisher B. Phase II study of the progesterone antagonist mifepristone in patients with untreated metastatic breast carcinoma: A National Cancer Institute of Canada Clinical Trials Group study, 2709
Perren TJ, *see* Seymour MT
Perrone F, *see* Carlomagno C
Perroni D, *see* Dogliotti L
Perry MC, *see* Perloff M
Peruisseau G, *see* Combaret V
Petersen FB, *see* Gajewski JL
Petit J, *see* Sierra J
Petrelli N, *see* Flam M
Petrelli NJ, *see* Moffat FL Jr
Pettengell R, Radford JA, Morgenstern GR, Scarffe JH, Harris M, Woll PJ, Deakin DP, Ryder D, Wilkinson PM, Crowther D. Survival benefit from high-dose therapy with autologous blood progenitor-cell transplantation in poor-prognosis non-Hodgkin's lymphoma, 586
Petti MC, *see* Zittoun R
Pettinato G, *see* Carlomagno C
Pfab R, *see* Reckzeh B
Pfanner E, *see* Falcone A
Pfeiffer P, *see* Bastholt L
Pflüger K-H, *see* Reckzeh B
Pharo L, *see* Schiller JH
Philip T, *see* Blay J-Y
— *see* Combaret V
— *see* Williams CD
Phillips GL, *see* Gajewski JL
Photopulos G, *see* McGuire WP
Piantadosi S, *see* Miller CB
Piantelli M, *see* Scambia G
Piccardi P, *see* Corona R
Picci P. In reply (letter), 683
Pick T, *see* Mahoney DH Jr
Pico JL, *see* Beyer J
— *see* Marit G
Pierce S, *see* Anderlini P
Pieresca C, *see* Gobbi PG
Pierga JY, *see* Dieras V
Pike MC, *see* Gill PS
Pileri SA, *see* Zinzani PL
Piñeiro L, *see* Rosenfeld C
Pinkel D. Selecting treatment for children with acute lymphoblastic leukemia (editorial), 4
Pinkus GS. Needle biopsy in malignant lymphoma (editorial), 2415
Pinsky CM, *see* Moffat FL Jr
Piro L, *see* Saven A
Piro LD, *see* Saven A
Pisansky TM, *see* Minsky BD
Pisters PWT, Harrison LB, Leung DHY, Woodruff JM, Casper ES, Brennan MF. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma, 859
—, Leung DHY, Woodruff J, Shi W, Brennan MF. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities, 1679
Pizzo PA, *see* Wexler LH
Plagne R, *see* Misset J-L
Planting A, *see* Clarke SJ
Planting AST, *see* Creemers GJ
— *see* de Wit R
Plassart F, *see* Solal-Céligny P
Plenderleith IH, *see* Gelmon KA
Plendl H-J, *see* Poetsch M
Plourde PV, *see* Buzdar A
— *see* Patterson JS
Plukker JTh, *see* Lemmers NWM
Poetsch M, Weber-Matthiesen K, Plendl H-J, Grote W, Schlegelberger B. Detection of the t(14;18) chromosomal translocation by interphase cytogenetics with yeast-artificial-chromosome probes in follicular lymphoma and nonneoplastic lymphoproliferation, 963
Polliack A, *see* Ben-Yehuda D
Pont J, Albrecht W, Postner G, Sellner F, Angel K, Höltl W. Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: Long-term results of a prospective trial, 441

— *see* Fridrik MA
Poplack D, *see* Fisherman JS
Poplack DG, *see* Wexler LH
Portlock CS, *see* Hirsch A
Posner MR, *see* Dreyfuss AI
Postner G, *see* Pont J
Pouillart P, *see* Tartour E
Poulin MD, *see* Dreyfuss AI
Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women, 78
Prados MD, Schold SC, Spence AM, Berger MS, McAllister LD, Mehta MP, Gilbert MR, Fulton D, Kuhn J, Lamborn K, Rector DJ, Chang SM. Phase II study of paclitaxel in patients with recurrent malignant glioma, 2316
Pragnell IB, *see* Alcorn MJ
Pratt B, *see* Findlay M
Pratt CB, *see* Furman WL
— *see* Kuttesch JF Jr
Prichard KI, Paterson AHG, Paul NA, Zee B, Fine S, Pater J, the National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer, 2731
Prince M, *see* Crump M
Pritchard KI, *see* Perrault D
— *see* Roy JA
Proctor M, *see* Lind MJ
Pronzato P, *see* Venturini M
Przepiorka D, *see* van Besien K
Puc HS, Heelan R, Mazumdar M, Herr H, Scheinfeld J, Vlamis V, Bajorin DF, Bosl GJ, Mencel P, Motzer RJ. Management of residual mass in advanced seminoma: Results and recommendations from the Memorial Sloan-Kettering Cancer Center, 454
Pui C-H, *see* Ito C
— *see* Relling MV
— *see* Smith M
Pujade-Lauraine E, Guastalla J-P, Colombo N, Devillier P, François E, Fumoleau P, Monnier A, Nooy M, Mignot L, Bugat R, Marques C, Mousseau M, Netter G, Maloisel F, Larbaoui S, Brandely M. Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy, 343
Pullen J, *see* Bowman WP
— *see* Smith M
Pulliam S, *see* Conti JA
Punt JAG, *see* Bessell EM
Puntous M, *see* Marit G
Pupa SM, Bufalino R, Invernizzi AM, Andreola S, Rilke F, Lombardi L, Colnaghi MI, Ménard S. Macrophage infiltrate and prognosis in c-*erb*B-2–overexpressing breast carcinomas, 85
— *see* Mènard S
Purdy MH, *see* Stemmer SM
Pyrhönen S, *see* Gylling H
— *see* Hernberg M

Qaqish BF, *see* Bates BA
Qi C-F, *see* Yu B
Quan V, *see* Kelsen D
Quiet CA, Ferguson DJ, Weichselbaum RR, Hellman S. Natural history of node-positive breast cancer: The curability of small cancers with a limited number of positive nodes, 3105
Quirt IC, *see* Rusthoven JJ
Quivey J, *see* Flam M

Raber M, *see* Kudelka AP
Raber MN, *see* Perez-Soler R
— *see* Smith TL
Rackoff WR, Gonin R, Robinson C, Kreissman SG, Breitfeld PP. Predicting the risk of bacteremia in children with fever and neutropenia, 919
Radaszkiewicz T, *see* Fridrik MA
Rademaker A, *see* Winter JN
Rademaker AW, *see* Meitar D
Radford JA, *see* Pettengell R
Ragaz J, *see* Gelmon KA
Ragde H, *see* Blasko JC
Ragni N, *see* Conte PF
Rahder JB, *see* Velders GA
Raijman I, *see* Patt YZ
Rankin EM, *see* Kaye SB
Rapola J, *see* Saarinen UM
Raptis G, *see* Hudis CA
Rarick MU, *see* Gill PS
Raschko J, *see* Margolin K
Raslawski E, *see* Schvartzman E
Rasool O, *see* Heyman M
Ratain MJ, *see* Kobayashi K
— *see* Larson RA
— *see* Mick R
— *see* Miller AA
— *see* Vokes EE
Ratech H, *see* Sparano JA
Rath B, *see* Bührer C
Raudaschl G, *see* Fridrik MA
Ravagnani F, *see* Bregni M
Reaman G, *see* Smith M
Rearden TP, *see* Small EJ
Recht A. High-dose chemotherapy for metastatic breast cancer (letter), 684
— *see* Solin LJ
Reckzeh B, Merte H, Pflüger K-H, Pfab R, Wolf M, Havemann K. Severe lymphocytopenia and interstitial pneumonia in patients treated with paclitaxel and simultaneous radiotherapy for non–small-cell lung cancer, 1071
Recondo G, *see* Wibault P
Rector DJ, *see* Prados MD
Redmond C, *see* Fisher B
Reed NS, *see* Kaye SB
Regan D, *see* Kaminski MS
Rehan N, *see* Bieling P
Reich E, *see* Ayash LJ
Reid GC, *see* Lentz SS
Reiffers J, *see* Marit G
Reiss M, *see* Haffty BG
Reiter A, *see* Schrappe M
Relling MV, Mahmoud HH, Pui C-H, Sandlund JT, Rivera GK, Ribeiro RC, Crist WM, Evans WE. Etoposide

achieves potentially cytotoxic concentrations in CSF of children with acute lymphoblastic leukemia, 399
Reman O, *see* Joly F
Retsas S. Adjuvant interferon alfa-2b for high-risk melanoma (letter), 1968
Reuter VE, *see* Lacombe L
Reyes F, *see* Diviné M
Reynolds CP, *see* Stram DO
Reynolds J, *see* Yu B
Reznek RH, *see* Pappa VI
Rhodes CH, *see* Glantz MJ
Rhodes V, *see* Spiridonidis CH
Ribas A, Albanell J, Bellmunt J, Solé-Calvo L-A, Bermejo B, Gallardo E, Vidal R, Vera R, Eres N, Carulla J, Baselga J. Five-day course of granulocyte colony-stimulating factor in patients with prolonged neutropenia after adjuvant chemotherapy for breast cancer is a safe and cost-effective schedule to maintain dose-intensity, 1573
Ribeiro RC, *see* Relling MV
Ribera JM, *see* Sierra J
Riccardi R, *see* Mastrangelo R
Richards EC, *see* Welt S
Richards M, *see* Coombes RC
Richardson P, *see* Ayash LJ
Richmond L, *see* Alcorn MJ
Rick O, *see* Schwella N
Riehm H, *see* Schrappe M
Riethmueller G, *see* Jauch K-W
Rijlaarsdam JU, Toonstra J, Meijer OWM, Noordijk EM, Willemze R. Treatment of primary cutaneous B-cell lymphomas of follicle center cell origin: A clinical follow-up study of 55 patients treated with radiotherapy or polychemotherapy, 549
Rilke F, *see* Ménard S
— *see* Pupa SM
Rinaldi DA, *see* Rothenberg ML
Rios MB, *see* Majlis A
Ripamonti C, *see* De Conno F
Rischin D, *see* Millward MJ
Ritter L, *see* Greco FA
Ritter MA, *see* Sharda NN
Rivera GK, *see* Furman WL
— *see* Relling MV
Rivkin SE, Green S, O'Sullivan J, Cruz AB, Abeloff MD, Jewell WR, Costanzi JJ, Farrar WB, Osborne CK. Adjuvant CMFVP versus adjuvant CMFVP plus ovariectomy for premenopausal, node-positive, and estrogen receptor–positive breast cancer patients: A Southwest Oncology Group study, 46
Rizzo A, *see* Guglielmi M
Roach M III. In reply (letter), 1402
Robert N, *see* Sparano JA
Roberts KB, *see* Salloum E
Robinson C, *see* Rackoff WR
Robinson RA, *see* Perez-Soler R
Robles M, *see* Hudis CA
Robson L, *see* Lind MJ
Rochard F, *see* Arriagada R
Rodenhuis S, Westermann A, Holtkamp MJ, Nooijen WJ, Baars JW, van der Wall E, Slaper-Cortenbach ICM, Schornagel JH. Feasibility of multiple courses of high-dose cyclophosphamide, thiotepa, and carboplatin for breast cancer or germ cell cancer, 1473
Rodriguez GI, *see* Rothenberg ML
Rodriguez MA, *see* Sarris AH
— *see* Younes A
Rodriguez R, *see* Leone BA
Rogers D, *see* Guglielmi M
Rohatiner AZS, *see* Pappa VI
Rohde DC, *see* Johnstone PAS
Romaguera J, *see* Sarris AH
Romaguera JE, *see* McLaughlin P
— *see* Younes A
Romanowski R, *see* Bieling P
Römer W, *see* Avril N
Romero AO, *see* Leone BA
Romero Acuña JM, *see* Leone BA
Romero Acuña LA, *see* Leone BA
Ropers J, *see* Chabot GG
Rose C, *see* Bastholt L
Rose E, *see* Saven A
Rose P, *see* Kemp G
Roselli M, Guadagni F, Buonomo O, Belardi A, Vittorini V, Mariani-Costantini R, Greiner JW, Casciani CU, Schlom J. Systemic administration of recombinant interferon alfa in carcinoma patients upregulates the expression of the carcinoma-associated antigens tumor-associated glycoprotein-72 and carcinoembryonic antigen, 2031
Rosen PJ, Mendoza EF, Landaw EM, Mondino B, Graves MC, McBride JH, Turcillo P, deKernion J, Belldegrun A. Suramin in hormone-refractory metastatic prostate cancer: A drug with limited efficacy, 1626
Rosen PP, *see* Baselga J
Rosenberg ARE, *see* Suit H
Rosenberg SA, *see* Fraker DL
— *see* Fyfe GA
Rosenblum M, *see* Balmaceda C
Rosenfeld C, Collins R, Piñeiro L, Agura E, Nemunaitis J. Allogeneic blood cell transplantation without post-transplant colony-stimulating factors in patients with hematopoietic neoplasm: A phase II study, 1314
Rosenfield NS, *see* Kushner BH
Rosenthal J, *see* Chang A
Rosner GL, Hargis JB, Hollis DR, Budman DR, Weiss RB, Henderson IC, Schilsky RL. Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: Results from Cancer and Leukemia Group B study 8541, 3000
— *see* Miller AA
Ross AA, *see* Passos-Coelho JL
Ross CW, *see* Kaminski MS
Ross ME, *see* Gill PS
Rossi RM, *see* Dreyfuss AI
Rosso R, *see* Conte PF
— *see* Venturini M
Rosti G, *see* Lemoli RM
Rostom AY, Ezzat A, Zwaan F. Perioperative chemotherapy versus adjuvant hormonal therapy in breast cancer: Claimed benefits (letter), 2885
Rothenberg ML, Eckardt JR, Kuhn JG, Burris HA III, Nelson J, Hilsenbeck SG, Rodriguez GI, Thurman AM, Smith LS, Eckhardt SG, Weiss GR, Elfring GL, Rinaldi DA,

Schaaf LJ, Von Hoff DD. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer, 1128
Rotman M, *see* Flam M
Rougier P, *see* Girard P
Rougon G, *see* Figarella-Branger D
Roukos D, Lazaros A, Kappas A, Encke A. Extended lymph node dissection in gastric cancer induces substantial stage migration and increases stage-specific survival without improvement of overall survival (letter), 2408
Roullet B, *see* Kemp G
Rovira M, *see* Sierra J
Rowinsky E, *see* Bookman MA
Rowinsky EK, Grochow LB, Sartorius SE, Bowling MK, Kaufmann SH, Peereboom D, Donehower RC. Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors, 1224
—, Kaufmann SH, Baker SD, Grochow LB, Chen T-L, Peereboom D, Bowling MK, Sartorius SE, Ettinger DS, Forastiere AA, Donehower RC. Sequences of topotecan and cisplatin: Phase I, pharmacologic, and in vitro studies to examine sequence dependence, 3074
— *see* Baker SD
— *see* Kennedy MJ
— *see* O'Reilly S
Rowland J, *see* Swain SM
Rowland KM Jr, Loprinzi CL, Shaw EG, Maksymiuk AW, Kuross SA, Jung S-H, Kugler JW, Tschetter LK, Ghosh C, Schaefer PL, Owen D, Washburn JH Jr, Webb TA, Mailliard JA, Jett JR. Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive-stage small-cell lung cancer: A North Central Cancer Treatment Group study, 135
Rowley SD, *see* Bensinger WI
Rowlings PA, *see* Gajewski JL
Roy J, *see* Wallner K
Roy JA, Sawka CA, Pritchard KI. Hormone replacement therapy in women with breast cancer: Do the risks outweigh the benefits? 997
Rozman C, *see* Bladé J
— *see* Montserrat E
— *see* Sierra J
Rubagotti A, *see* Conte PF
Rubin AD, *see* Juweid M
Rubin AS, *see* Jones SE
Rubinger M, *see* Bow EJ
Ruddon R, *see* Bishop MR
Ruffié P, *see* Girard P
— *see* Soulié P
Rugiati S, *see* Conte PF
Russell JA, *see* Gajewski JL
Rusthoven JJ, Quirt IC, Iscoe NA, McCulloch PB, James KW, Lohmann RC, Jensen J, Burdette-Radoux S, Bodurtha AJ, Silver HKB, Verma S, Armitage GR, Zee B, Bennett K. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma, 2083
Rustin GJS, Nelstrop ARE, McClean P, Brady MF, McGuire WP, Hoskins WJ, Mitchell H, Lambert HE. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125, 1545
—, Newlands ES, Lutz J-M, Holden L, Bagshawe KD, Hiscox JG, Foskett M, Fuller S, Short D. Combination but not single-agent methotrexate chemotherapy for gestational trophoblastic tumors increases the incidence of second tumors, 2769
Rutten FFH, *see* Vellenga E
Ryder D, *see* Pettengell R

Saarinen UM, Wikström S, Mäkipernaa A, Lanning M, Perkkiö M, Hovi L, Rapola J, Sariola H. In vivo purging of bone marrow in children with poor-risk neuroblastoma for marrow collection and autologous bone marrow transplantation, 2791
Saarto T, Blomqvist C, Ehnholm C, Taskinen M-R, Elomaa I. Antiatherogenic effects of adjuvant antiestrogens: A randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer, 429
Sabatini CL, *see* Leone BA
Sabattini E, *see* Zinzani PL
Sack H, *see* Stahl M
Sagripanti A, *see* Carpi A
Sahmoud T, *see* Blijham G
— *see* Giaccone G
— *see* Splinter TAW
Sahmoud TM, *see* Clahsen PC
Saito H, *see* Kobayashi T
Saito K, *see* Kobayashi T
Saito M, *see* Yamaguchi A
Sakamaki H, *see* Kobayashi T
Saleh F, *see* Perloff M
Sallan SE, *see* Smith M
Salloum E, Cooper DL, Howe G, Lacy J, Tallini G, Crouch J, Schultz M, Murren J. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases, 1943
—, Doria R, Schubert W, Zelterman D, Holford T, Roberts KB, Farber LR, Kiehl RK, Cardinale J, Cooper DL. Second solid tumors in patients with Hodgkin's disease cured after radiation or chemotherapy plus adjuvant low-dose radiation, 2435
—, Lacy J, Cooper DL In reply (letter), 3051
Salmon SE, *see* Modiano MR
Saltz L, *see* Kelsen D
Saltz LB, Kanowitz J, Kemeny NE, Schaaf L, Spriggs D, Staton BA, Berkery R, Steger C, Eng M, Dietz A, Locker P, Kelsen DP. Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors, 2959
— *see* Conti JA
— *see* Tiersten A
Salvadori B, *see* Silvestrini R
Salvadori MA, *see* Leone BA
Salvaggio R, *see* Seidman AD
Samantas E, *see* Kosmidis PA
Samson DM, *see* Elliott C
San Miguel JF, *see* Bladé J
Sancho G, *see* Miralbell R

Sandberg E, *see* Bastholt L
Sanders J, *see* Finlay JL
Sanders JE, *see* Anderson JE
Sandler HM, *see* McLaughlin PW
Sandlund JT, *see* Relling MV
Sandström M, Freijs A, Larsson R, Nygren P, Fjällskog M-L, Bergh J, Karlsson MO. Lack of relationship between systemic exposure for the component drugs of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients, 1581
Sankila R, Garwicz S, Olsen JH, Döllner H, Hertz H, Kreuger A, Langmark F, Lanning M, Möller T, Tulinius H. Risk of subsequent malignant neoplasms among 1,641 Hodgkin's disease patients diagnosed in childhood and adolescence: A population-based cohort study in the five Nordic countries, 1442
Santini G, *see* Williams CD
Santoro A, *see* Viviani S
Santos R, *see* Conte PF
Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy, 2738
Sariola H, *see* Saarinen UM
Saris S, *see* Glantz MJ
Sarkar TK, *see* Kaye SB
Sarobba MG, *see* Dogliotti L
Sarris A, *see* Younes A
Sarris AH, Younes A, McLaughlin P, Moore D, Hagemeister F, Swan F, Rodriguez MA, Romaguera J, North L, Mansfield P, Callendar D, Mesina O, Cabanillas F. Cyclosporin A does not reverse clinical resistance to paclitaxel in patients with relapsed non-Hodgkin's lymphoma, 233
— *see* McLaughlin P
Sarta C, *see* Sparano JA
Sartorius S, *see* Kennedy MJ
— *see* O'Reilly S
Sartorius SE, *see* Baker SD
— *see* Rowinsky EK
Sasako M, *see* Bunt AMG
Sastre X, *see* Coindre J-M
Sather H, *see* Smith M
— *see* Steinherz PG
Sather HN, *see* Steinherz PG
Saven A, Cheung WK, Smith I, Moyer M, Johannsen T, Rose E, Gollard R, Kosty M, Miller WE, Piro LD. Pharmacokinetic study of oral and bolus intravenous 2-chlorodeoxyadenosine in patients with malignancy, 978
—, Lee T, Kosty M, Piro L. Cladribine and mitoxantrone dose escalation in indolent non-Hodgkin's lymphoma, 2139
Sawka C, *see* Gill PS
Sawka CA, *see* Roy JA
Scadden DT, *see* Gill PS
Scambia G, Ferrandina G, Marone M, Panici PB, Giannitelli C, Piantelli M, Leone A, Mancuso S. nm23 in ovarian cancer: Correlation with clinical outcome and other clinicopathologic and biochemical prognostic parameters, 334
Scarffe JH, *see* Pettengell R
— *see* Wardley AM
Scarfone G, *see* Creemers GJ
Schaaf L, *see* Saltz LB
Schaaf LJ, *see* Rothenberg ML
Schacter BA, *see* Bow EJ
Schacter L, *see* Chabot GG
Schaefer PL, *see* Rowland KM Jr
Schantz S, *see* Brenner PC
Scheinberg D, *see* Weiss M
Scheinfeld J, *see* Puc HS
Schellens JHM, *see* Creemers GJ
Schiffer CA, *see* Bernstein SH
Schiffman K, *see* Bensinger WI
Schildberg F-W, *see* Jauch K-W
Schilder RJ, *see* Gordon LI
Schiller JH, Kim KM, Hutson P, DeVore R, Glick J, Stewart J, Johnson D. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: An Eastern Cooperative Oncology Group trial, 2345
—, Storer B, Berlin J, Wittenkeller J, Larson M, Pharo L, Larson M, Berry W. Amifostine, cisplatin, and vinblastine in metastatic non–small-cell lung cancer: A report of high response rates and prolonged survival, 1913
— *see* Crawford J
Schiller L, *see* Fridrik MA
Schilsky R, *see* Greco FA
Schilsky RL, *see* Miller AA
— *see* Rosner GL
Schinella R, *see* Chang A
Schlegelberger B, Zhang Y, Weber-Matthiesen K, Zwingers T. In reply (letter), 2188
—, Zwingers T, Hohenadel K, Henne-Bruns D, Schmitz N, Haferlach T, Tirier C, Bartels H, Sonnen R, Kuse R, Grote W. Significance of cytogenetic findings for the clinical outcome in patients with T-cell lymphoma of angioimmunoblastic lymphadenopathy type, 593
— *see* Poetsch M
Schlom J, *see* Roselli M
— *see* Yu B
Schmidt GM, *see* Stein AS
Schmidt U, *see* Stahl M
Schmit-Pokorny K, *see* Bishop MR
Schmitz N, *see* Schlegelberger B
Schmitz PIM, *see* de Wit R
Schmoll HJ, *see* Beyer J
Schmoll H-J, *see* Bokemeyer C
Schnall M, *see* D'Amico AV
Schnipper L, *see* Ayash LJ
Schoch G, *see* Anderson JE
Schold SC, *see* Prados MD
Schoon EJ, *see* Simons JPFHA
Schornagel J, *see* Zalcberg JR
Schornagel JH on behalf or the European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group. In reply (letter), 322
— *see* Rodenhuis S
Schottstaedt MW, *see* Jones SE
Schouten HC, *see* Simons JPFHA
Schrappe M, Reiter A, Riehm H. Cytoreduction and prognosis in childhood acute lymphoblastic leukemia (letter), 2403
— *see* Bührer C

Schubert W, *see* Salloum E
Schuchter L, *see* Greco FA
Schuller J, *see* Greco FA
Schulman KA. Economics of bone marrow transplantation (editorial), 1409
Schultheiss TE, *see* Hanks GE
Schultz C, Scott C, Sherman W, Donahue B, Fields J, Murray K, Fisher B, Abrams R, Meis-Kindblom J. Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: Initial report of Radiation Therapy Oncology Group protocol 88-06, 556
Schultz D, *see* D'Amico AV
Schultz DJ, *see* Solin LJ
Schultz M, *see* Salloum E
Schulz M, *see* Shepherd FA
Schuuring E, *see* Velders GA
Schvartzman E, Chantada G, Fandiño A, de Dávila MT, Raslawski E, Manzitti J. Results of a stage-based protocol for the treatment of retinoblastoma, 1532
Schwaiger M, *see* Avril N
Schwaner I, *see* Schwella N
Schwartz EL, *see* Sparano JA
Schwartz G, *see* Ayash LJ
— *see* Kelsen D
Schwarz RE, Marrero AM, Conlon KC, Burt M. Inferior vena cava filters in cancer patients: Indications and outcome, 652
Schwella N, Beyer J, Schwaner I, Heuft H-G, Rick O, Huhn D, Serke S, Siegert W. Impact of preleukapheresis cell counts on collection results and correlation of progenitor-cell dose with engraftment after high-dose chemotherapy in patients with germ cell cancer, 1114
Scott AM, *see* Welt S
Scott C, *see* Lee JS
— *see* Schultz C
Scott J, *see* Bruera E
Sculier JP, Paesmans M, Bureau G, Giner V, Lecomte J, Michel J, Berchier MC, Van Cutsem O, Küstner U, Kroll F, Sergysels R, Mommen P, Klastersky J. Randomized trial comparing induction chemotherapy versus induction chemotherapy followed by maintenance chemotherapy in small-cell lung cancer, 2337
Sebban C, *see* Solal-Céligny P
Seeber S, *see* Stahl M
Seeger RC, *see* Stram DO
Seewann HL, *see* Fridrik MA
Sehested M, Holm B, Jensen PB. Dexrazoxane for protection against cardiotoxic effects of anthracyclines (letter), 2884
Seibel N, *see* Magrath I
Seibel NL, *see* Weintraub M
Seidman AD, Hochhauser D, Gollub M, Edelman B, Yao T-J, Hudis CA, Francis P, Fennelly D, Gilewski TA, Moynahan ME, Currie V, Baselga J, Tong W, O'Donaghue M, Salvaggio R, Auguste L, Spriggs D, Norton L. Ninety-six–hour paclitaxel infusion after progression during short taxane exposure: A phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer, 1877
— *see* Baselga J
— *see* Hudis CA
Seiter K, *see* Weiss M
Seitz J-F, *see* Conroy T
Selleslag J, *see* Blijham G
Sellner F, *see* Pont J
Sergysels R, *see* Sculier JP
Serke S, *see* Schwella N
Sertoli MR, *see* Venturini M
Sexauer C, *see* Steuber CP
Seymour I, *see* Zalcberg JR
Seymour MT, Slevin ML, Kerr DJ, Cunningham D, James RD, Ledermann JA, Perren TJ, McAdam WAF, Harper PG, Neoptolemos JP, Nicholson M, Duffy AM, Stephens RJ, Stenning SP, Taylor I. Randomized trial assessing the addition of interferon $\alpha$-2a to fluorouracil and leucovorin in advanced colorectal cancer, 2280
Shad A, *see* Magrath I
Shad AT, *see* Weintraub M
Shah R, *see* Joel SP
Shapiro A, *see* Kaempfer R
Shapiro DN, *see* Kuttesch JF Jr
— *see* Pappo AS
Sharda NN, Kinsella TJ, Ritter MA. Adjuvant radiation versus observation: A cost analysis of alternative management schemes in early-stage testicular seminoma, 2933
Sharfman W, *see* Gause BL
Sharkey RM, *see* Juweid M
Sharma S. Paclitaxel and doxorubicin in metastatic breast cancer (letter), 1403
Sharp JG, Kessinger A, Mann S, Crouse DA, Armitage JO, Bierman P, Weisenburger DD. Outcome of high-dose therapy and autologous transplantation in non-Hodgkin's lymphoma based on the presence of tumor in the marrow or infused hematopoietic harvest, 214
— *see* Bishop MR
Shaw EG, *see* Rowland KM Jr
Sheinfeld J, *see* Brenner PC
— *see* Motzer RJ
Sheperd FA, *see* Liu G
Shepherd F, *see* Gill PS
Shepherd FA, Burkes R, Cormier Y, Crump M, Feld R, Strack T, Schulz M. Phase I dose-escalation trial of gemcitabine and cisplatin for advanced non–small-cell lung cancer: Usefulness of mathematic modeling to determine maximum-tolerable dose, 1656
— *see* Siu LL
Shepherd J, *see* Ahmed FY
Shepherd LE, *see* O'Connell MJ
Sherman W, *see* Schultz C
Sherman Y, *see* Ben-Yehuda D
Shi W, *see* Pisters PWT
Shibamoto Y, *see* Jeremic B
Shibata S, *see* Margolin K
Shiku H, *see* Yamaguchi A
Shin DM, *see* Perez-Soler R
Shipley W, *see* Tester W
Shore TB, *see* Bow EJ
Short D, *see* Rustin GJS
Shpall EJ, *see* Stemmer SM
Shpilsky A, *see* Evans ARE
Shulman H, *see* Anderson JE

Shuster J, *see* Smith M
Shuster JJ. The role of autologous bone marrow transplantation in advanced neuroblastoma (editorial), 2413
— *see* Bowman WP
— *see* Mahoney DH Jr
— *see* Winick N
Shyr Y, *see* Johnson DH
Siegel J, *see* Juweid M
Siegert W, *see* Beyer J
— *see* Schwella N
Siena S, *see* Bregni M
Sierra J, Brunet S, Grañena A, Olivé T, Bueno J, Ribera JM, Petit J, Besses C, Llorente A, Guardia R, Maciá J, Rovira M, Badell I, Vela E, Díaz de Heredia C, Vivancos P, Carreras E, Feliu E, Montserrat E, Juliá A, Cubells J, Rozman C, Domingo A, Ortega JJ. Feasibility and results of bone marrow transplantation after remission induction and intensification chemotherapy in de novo acute myeloid leukemia, 1353
Siewert JR, *see* Stahl M
Silber JH, *see* Evans ARE
Silberman H, *see* Lenz H-J
Siler K, *see* Yu B
Silingardi V, *see* Gobbi PG
Sill H, *see* Fridrik MA
Silver HKB, *see* Rusthoven JJ
Silver RT, *see* Perloff M
Silver SM, *see* Gajewski JL
Silverberg I, *see* Gill PS
Silverman P, *see* Sparano JA
Silvestri F, *see* Fanin R
Silvestrini R, Benini E, Veneroni S, Daidone MG, Tomasic G, Squicciarini P, Salvadori B. p53 and *bcl*-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients, 1604
Simmons D, *see* Lind MJ
Simon P, *see* Feugeas O
Simon R, *see* Smith M
Simon RM, *see* Thall PF
Simonelli C, *see* Vaccher E
Simons JPFHA, Aaronson NK, Vansteenkiste JF, ten Velde GPM, Muller MJ, Drenth BM, Erdkamp FLG, Cobben EGM, Schoon EJ, Smeets JBE, Schouten HC, Demedts M, Hillen HFP, Blijham GH, Wouters EFM. Effects of medroxyprogesterone acetate on appetite, weight, and quality of life in advanced-stage non–hormone-sensitive cancer: A placebo-controlled multicenter study, 1077
Singer S, Baldini EH, Demetri GD, Fletcher JA, Corson JM. Synovial sarcoma: Prognostic significance of tumor size, margin of resection, and mitotic activity for survival, 1201
Sinha D, *see* Lind MJ
Sinzinger H, *see* Kritz H
Siracusa F, *see* Guglielmi M
Siu LL, Shepherd FA, Murray N, Feld R, Pater J, Zee B. Influence of age on the treatment of limited-stage small-cell lung cancer, 821
Skarlos D, *see* Kosmidis PA
Skelton L, *see* Colls BM
Sklarin NT, *see* Baselga J
Skolnick M, *see* Visco FM
Slaper-Cortenbach ICM, *see* Rodenhuis S
Slattery JT, Kalhorn TF, McDonald GB, Lambert K, Buckner CD, Bensinger WI, Anasetti C, Appelbaum FR. Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients, 1484
Sledge GW Jr. Should we dream the impossible dream? The meaning of long-term survival in metastatic breast cancer (editorial), 2191
Sleijfer DTh, *see* Lemmers NWM
Slevin M, *see* Joel SP
Slevin ML, *see* Joel SP
— *see* Seymour MT
Slichenmyer W, *see* O'Reilly S
Sloan P, *see* Bruera E
Small EJ, Srinivas S, Egan B, McMillan A, Rearden TP. Doxorubicin and dose-escalated cyclophosphamide with granulocyte colony-stimulating factor for the treatment of hormone-resistant prostate cancer, 1617
Smeets JBE, *see* Simons JPFHA
Smid WM, *see* Vellenga E
Smit VTHBM, *see* Bunt AMG
Smith EP, *see* Stein AS
Smith I, *see* Joel SP
— *see* Saven A
Smith JG, *see* Millward MJ
Smith JW II, *see* Gause BL
Smith LS, *see* Rothenberg ML
Smith M, Arthur D, Camitta B, Carroll AJ, Crist W, Gaynon P, Gelber R, Heerema N, Korn EL, Link M, Murphy S, Pui C-H, Pullen J, Reaman G, Sallan SE, Sather H, Shuster J, Simon R, Trigg M, Tubergen D, Uckun F, Ungerleider R. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia, 18
—, Bleyer A, Crist W, Murphy S, Sallan SE. Uniform criteria for childhood acute lymphoblastic leukemia risk classification (letter), 680
Smith R, *see* Clarke SJ
Smith S, *see* Ashley DM
Smith TJ, *see* Bennett CL
— *see* Hillner BE
— *see* Kirkwood JM
Smith TL, Lee JJ, Kantarjian HM, Legha SS, Raber MN. Design and results of phase I cancer clinical trials: Three-year experience at M.D. Anderson Cancer Center, 287
— *see* Diamandidou E
— *see* Greenberg PAC
— *see* Majlis A
— *see* Zoubek A
Smyth JF, *see* Boote DJ
Snyder DA, *see* Jones SE
Snyder DS, *see* Stein AS
Sobczeck M, *see* Johnson BE
Sobocinski KA, *see* Gajewski JL
Söderhäll S, *see* Heyman M
Soeiro R, *see* Sparano JA
Solal-Céligny P, Brice P. Brousse N, Caspard H, Bastion Y, Haïoun C, Bosly A, Tilly H, Bordessoule D, Sebban C, Haroussseau JL, Morel P, Dupas B, Plassart F, Vasile N, Fort N, Leporrier M. Phase II trial of fludara-

bine monophosphate as first-line treatment in patients with advanced follicular lymphoma: A multicenter study by the Groupe d'Etudes des Lymphomes de l'Adulte, 514
Solbu G, *see* Veerman AJP
— *see* Zittoun R
Solé-Calvo L-A, *see* Ribas A
Solin LJ, Kurtz J, Fourquet A, Amalric R, Recht A, Bornstein BA, Kuske R, Taylor M, Barrett W, Fowble B, Haffty B, Schultz DJ, Yeh I-T, McCormick B, McNeese M. Fifteen-year results of breast-conserving surgery and definitive breast irradiation for the treatment of ductal carcinoma in situ of the breast, 754
Soliven B, *see* Kobayashi K
Solomon D, *see* Tolcher AW
Somerfield MR, *see* Bennett CL
Somlo G, *see* Margolin K
— *see* Stein AS
Soncini F, *see* Viviani S
Sonnen R, *see* Schlegelberger B
Soper JT, *see* Lentz SS
Sorensen M, *see* Dahut W
Sörenson S, *see* Splinter TAW
Sorich J, *see* Wasserheit C
Soukop M, *see* Kaye SB
Soulié P, Ruffié P, Trandafir L, Monnet I, Tardivon A, Terrier P, Cvitkovic E, Le Chevalier T, Armand JP. Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma: Report of a phase I-II study of weekly cisplatin/interferon alfa-2a, 878
Sparano JA, Robert N, Silverman P, Lazarus H, Malik U, Venkatraj U, Sarta C. Phase I trial of high-dose mitoxantrone plus cyclophosphamide and filgrastim in patients with advanced breast carcinoma, 2576
—, Wiernik PH, Hu X, Sarta C, Schwartz EL, Soeiro R, Henry DH, Mason B, Ratech H, Dutcher JP. Pilot trial of infusional cyclophosphamide, doxorubicin, and etoposide plus didanosine and filgrastim in patients with human immunodeficiency virus–associated non-Hodgkin's lymphoma, 3026
Spector T, *see* Baker SD
Spence AM, *see* Prados MD
Spertus I, *see* Swain SM
Speyer J, *see* Wasserheit C
Spielberger R, *see* Stein AS
Spielberger RT, *see* Larson RA
Spielmann M, *see* Nabholtz J-M
Spina M, *see* Vaccher E
Spinolo J, *see* Bishop MR
Spiridonidis CH, Laufman LR, Rhodes V, Jones J. High-dose chemotherapy for breast cancer (letter), 686
— *see* Crawford J
Spiro I, *see* Suit H
Splinter TAW, Sahmoud T, Festen J, van Zandwijk N, Sörenson S, Clerico M, Burghouts J, Dautzenberg B, Kho GS, Kirkpatrick A, Giaccone G. Two schedules of teniposide with or without cisplatin in advanced non–small-cell lung cancer: A randomized study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group, 127
Sprangers MAG, Groenvold M, Arraras JI, Franklin J, te Velde A, Muller M, Franzini L, Williams A, de Haes HCJM, Hopwood P, Cull A, Aaronson NK. The European Organization for Research and Treatment of Cancer breast cancer–specific quality-of-life questionnaire module: First results from a three-country field study, 2756
Spriggs D, *see* Saltz LB
— *see* Seidman AD
Squicciarini P, *see* Silvestrini R
Srinivas S, *see* Small EJ
St Germain J, *see* Welt S
Stadtmauer EA, *see* Winter JN
Stahl M, Wilke H, Fink U, Stuschke M, Walz MK, Siewert JR, Molls M, Fett W, Makoski H-B, Breuer N, Schmidt U, Niebel W, Sack H, Eigler FW, Seeber S. Combined preoperative chemotherapy and radiotherapy in patients with locally advanced esophageal cancer: Interim analysis of a phase II trial, 829
Stanley P, *see* Finlay JL
Staton BA, *see* Saltz LB
Steger C, *see* Saltz LB
Stein AS, O'Donnell MR, Chai A, Schmidt GM, Nademanee A, Parker PM, Smith EP, Snyder DS, Molina A, Stepan DE, Spielberger R, Somlo G, Margolin KA, Vora N, Lipsett J, Lee J, Niland J, Forman SJ. In vivo purging with high-dose cytarabine followed by high-dose chemoradiotherapy and reinfusion of unpurged bone marrow for adult acute myelogenous leukemia in first complete remission, 2206
Steinberg SM, *see* Johnson BE
— *see* Wexler LH
Steinhauer EU, *see* Pecherstorfer M
Steinherz PG, Gaynon PS, Breneman JC, Cherlow JM, Grossman NJ, Kersey JH, Johnstone HS, Sather HN, Trigg ME, Chappell R, Hammond D, Bleyer WA. Cytoreduction and prognosis in acute lymphoblastic leukemia—The importance of early marrow response: Report from the Childrens Cancer Group, 389
—, Gaynon P, Trigg M, Sather H, Bleyer AW. In reply (letter), 2405
— *see* Kushner BH
Steis RG, *see* Gause BL
Stemmer SM, Cagnoni PJ, Shpall EJ, Bearman SI, Matthes S, Dufton C, Day T, Taffs S, Hami L, Martinez C, Purdy MH, Arron J, Jones RB. High-dose paclitaxel, cyclophosphamide, and cisplatin with autologous hematopoietic progenitor-cell support: A phase I trial, 1463
Stenning SP, *see* Cullen MH
— *see* Seymour MT
Stepan DE, *see* Stein AS
Stephens AW, Gonin R, Hutchins GD, Einhorn LH. Positron emission tomography evaluation of residual radiographic abnormalities in postchemotherapy germ cell tumor patients, 1637
Stephens FO. Tumor necrosis factor: Is it a breakthrough? (letter), 688
Stephens RJ, *see* Seymour MT
Steuber CP, Krischer J, Holbrook T, Camitta B, Land V, Sexauer C, Mahoney D, Weinstein H. Therapy of refractory or recurrent childhood acute myeloid leukemia using amsacrine and etoposide with or without azacitidine: A Pediatric Oncology Group randomized phase II study, 1521

Steward WP, *see* Alcorn MJ
Stewart CF, *see* Furman WL
Stewart J, *see* Schiller JH
Stockler MR, *see* Tannock IF
Stöger M, *see* Fridrik MA
Stone RM, *see* Bernstein SH
Stopa E, *see* Glantz MJ
Storb R, *see* Anderson JE
— *see* Bensinger WI
Storer B, *see* Schiller JH
Stoter G, *see* Creemers GJ
— *see* de Wit R
Stoter GJ, *see* Vellenga E
Stovall M, *see* Travis LB
Strack T, *see* Shepherd FA
Stram DO, Matthay KK, O'Leary M, Reynolds CP, Haase GM, Atkinson JB, Brodeur GM, Seeger RC. Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: A report of two concurrent Children's Cancer Group studies, 2417
Straus DJ, *see* Hirsch A
Strawderman M, *see* Eisbruch A
Strawderman MH, *see* Kirkwood JM
Strother D, *see* Mahoney DH Jr
Stroup SL, *see* Greco FA
Stryckmans P, *see* Zittoun R
Stuschke M, *see* Stahl M
Suarez-Almazor M, *see* Bruera E
Suasin W, *see* Hanks GE
Subar M. Risk stratification for high-dose chemotherapy in metastatic breast cancer (letter), 686
Suciu S, *see* Veerman AJP
— *see* Zittoun R
Sugiura T, *see* Nishio M
Suit H, Spiro I, Mankin HJ, Efird J, Rosenberg ARE. Radiation in management of patients with dermatofibrosarcoma protuberans, 2365
Sullivan KM, *see* Anderson JE
Sullivan LD, *see* Coppin CML
Sun M, *see* Conti JA
Sundberg C, *see* Lindmark G
Sussio M, *see* Dogliotti L
Sutherland CM, *see* Fisher B
Sutherland JA, *see* Bow EJ
Suyama M, *see* Nishio M
Swain SM, Rowland J, Weinfurt K, Berg C, Lippman ME, Walton L, Egan E, King D, Spertus I, Honig SF. Intensive outpatient adjuvant therapy for breast cancer: Results of dose escalation and quality of life, 1565
Swan F, *see* McLaughlin P
— *see* Sarris AH
Swan F Jr, *see* Younes A
Swartz SE, *see* Johnstone PAS
Swayne LC, *see* Juweid M
Sweetenham JW, Pearce R, Taghipour G, Blaise D, Gisselbrecht C, Goldstone AH. Adult Burkitt's and Burkitt-like non-Hodgkin's lymphoma—Outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse: Results from the European Group for Blood and Marrow Transplantation, 2465
Symonds RP, *see* Kaye SB
Syrjänen K, *see* Kurvinen K
Syrjänen S, *see* Kurvinen K
Sznol M, *see* Fyfe GA
— *see* Gause BL

Taal BG, Hoefnagel CA, Valdes Olmos RA, Boot H, Beijnen JH. Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumors, 1829
Taffs S, *see* Stemmer SM
Taghipour G, *see* Sweetenham JW
Taguchi T, *see* Kunitoh H
Takagi Y, *see* Nishio M
Takahashi I, *see* Kobayashi T
Takahashi T, *see* Nishio M
Takahasi T, *see* Nishio M
Takeuchi K, *see* Yamaguchi A
Takimoto C, *see* Dahut W
Talamini R, *see* Vaccher E
Talbot D, *see* Joel SP
Tallini G, *see* Salloum E
Tallman M, *see* Winter JN
Talpaz M, *see* Majlis A
Tanguy A, *see* Joly F
Tanimoto M, *see* Kobayashi T
Tannock IF. Treatment of cancer with radiation and drugs, 3156
—, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CML, Murphy KC. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points, 1756
— *see* Coppin CML
Tapazoglou E, *see* Hesketh P
Tardivon A, *see* Soulié P
Tartour E, Blay JY, Dorval T, Escudier B, Mosseri V, Douillard JY, Deneux L, Gorin I, Negrier S, Mathiot C, Pouillart P, Fridman WH. Predictors of clinical response to interleukin-2-based immunotherapy in melanoma patients: A French multiinstitutional study, 1697
Taskinen M-R, *see* Saarto T
Taylor I, *see* Seymour MT
Taylor M, *see* Solin LJ
te Velde A, *see* Sprangers MAG
Teicher BA, *see* Ayash LJ
Tekuzman G, *see* Çelik I
Tempelhoff G-Fv, Dietrich M, Hommel G, Heilmann L. Blood coagulation during adjuvant epirubicin/cyclophosphamide chemotherapy in patients with primary operable breast cancer, 2560
ten Bokkel Huinink WW, *see* Aaronson NK
Ten Bokkel Huinink WW, *see* Creemers GJ
ten Haaft MA, *see* Vellenga E
ten Hoor KA, *see* Duk JM
ten Velde GPM, *see* Simons JPFHA
Tepper JE, *see* Bates BA
Teramatsu T, *see* Wada H
Terol M-J, *see* Montserrat E
Terret C, *see* Chabot GG
Terrier P, *see* Coindre J-M
— *see* Feugeas O

— *see* Soulié P
Tester W, Caplan R, Heaney J, Venner P, Whittington R, Byhardt R, True L, Shipley W. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: Results of Radiation Therapy Oncology Group phase II trial 8802, 119
Testore F, *see* Venturini M
Tetef M, *see* Margolin K
Thaler J, *see* Zittoun R
Thall PF, Simon RM, Estey EH. New statistical strategy for monitoring safety and efficacy in single-arm clinical trials, 296
The Berlin-Frankfurt-Münster Relapse Study Group, *see* Bührer C
The First International Central Nervous System Germ Cell Tumor Study, *see* Balmaceda C
The Groupe d'Etude des Lymphomes de l'Adulte, *see* Diviné M
The Hellenic Cooperative Oncology Group, *see* Kosmidis PA
The Japan Adult Leukemia Study Group, *see* Kobayashi T
The Nationai Cancer Institute of Canada Clinical Trials Group, *see* Coppin CML
The National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group, *see* Prichard KI
The Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer, *see* Canal P
Theocharis D, *see* Kosmidis PA
Theriault RL, *see* Holmes FA
Thiébaud D, *see* Pecherstorfer M
Thompson PI, *see* Colls BM
Thornhill L, *see* Dreyfuss AI
Thornton AF, *see* Eisbruch A
Thürlimann B, *see* Pecherstorfer M
Thurman AM, *see* Rothenberg ML
Thyss A, *see* Feugeas O
Tibaldi C, *see* Venturini M
Tidy A, *see* Powles TJ
Tiersten A, Saltz LB. Influence of inflammatory bowel disease on the ability of patients to tolerate systemic fluorouracil-based chemotherapy, 2043
Tilly H, *see* Diviné M
— *see* Solal-Céligny P
Tirelli U, *see* Vaccher E
Tirier C, *see* Schlegelberger B
Tolcher AW, Cowan KH, Solomon D, Ognibene F, Goldspiel B, Chang R, Noone MH, Denicoff AM, Barnes CS, Gossard MR, Fetsch PA, Berg SL, Balis FM, Venzon DJ, O'Shaughnessy JA. Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer, 1173
—, Cowan KH, Noone MH, Denicoff AM, Kohler DR, Goldspeil BR, Barnes CS, McCabe M, Gossard MR, Zujewski J, O'Shaughnessy JA. Phase I study of paclitaxel in combination with cyclophosphamide and granulocyte colony-stimulating factor in metastatic breast cancer patients, 95
— *see* Gelmon KA
Tomasic G, *see* Silvestrini R
Tomaszewski JE, *see* D'Amico AV
Tomonaga M, *see* Kobayashi T
Toner GC, *see* Millward MJ
Tong W, *see* Seidman AD
Tong WP, *see* Conti JA
— *see* DeAngelis LM
Toni MG, *see* Carpi A
Toonstra J, *see* Rijlaarsdam JU
Tope DM, *see* Ahles TA
Tormey DC, *see* Saphner T
Tornesello A, *see* Mastrangelo R
Trandafir L, *see* Soulié P
Travis LB, Weeks J, Curtis RE, Chaffey JT, Stovall M, Banks PM, Boice JD Jr. Leukemia following low-dose total body irradiation and chemotherapy for non-Hodgkin's lymphoma, 565
Tresca P, *see* Dieras V
Tresukosol D, *see* Kudelka AP
Treuner J, *see* Bieling P
Trigg M, *see* Smith M
— *see* Steinherz PG
Trigg ME, *see* Steinherz PG
Tripathy D, *see* Baselga J
Trischmann T, *see* Civin CI
Troussard X, *see* Joly F
Trudeau ME, Eisenhauer EA, Higgins BP, Letendre F, Lofters WS, Norris BD, Vandenberg TA, Delorme F, Muldal AM. Docetaxel in patients with metastatic breast cancer: A phase II study of the National Cancer Institute of Canada-Clinical Trials Group, 422
Trudeau WL, *see* Fields KK
True L, *see* Tester W
Trujillo J, *see* Bladé J
Trump D, *see* Chang A
Tsai CM, *see* Chen YM
Tsavaris N, *see* Kosmidis PA
Tschetter LK, *see* Rowland KM Jr
Tsubaki K, *see* Kobayashi T
Tubergen D, *see* Smith M
Tubiana-Hulin M, *see* Pecherstorfer M
Tuck M, *see* Kaminski MS
Tulinius H, *see* Sankila R
Tura S, *see* Lemoli RM
— *see* Martelli M
— *see* Zinzani PL
Turcillo P, *see* Rosen PJ
Turunen JP, *see* Hernberg M
Twaddell T, *see* Baselga J
Twentyman PR, *see* Boote DJ

Uchida K, *see* Nishio M
Uckun F, *see* Smith M
Ueda R, *see* Kobayashi T
— *see* Nishio M
Ungerleider R, *see* Smith M
Urano T, *see* Yamaguchi A
Urba S, *see* Eisbruch A
Urba WJ, *see* Gause BL
Uyl-de Groot CA, *see* Vellenga E

Vaccher E, Tirelli U, Spina M, Talamini R, Errante D, Simonelli C, Carbone A. Age and serum lactate dehydrogenase level are independent prognostic factors in human immunodeficiency virus–related non-Hodgkin's lymphomas: A single-institute study of 96 patients, 2217

Valagussa P, *see* Viviani S
Valdés Olmos RA, *see* Boersma LJ
Valdes Olmos RA, *see* Taal BG
Valero V, *see* Holmes FA
Vallejo CT, *see* Leone BA
Van Belle S, *see* Creemers GJ
van Besien K, Przepiorka D, Mehra R, Giralt S, Khouri I, Gajewski J, Andersson B, Champlin R. Impact of pre-existing CNS involvement on the outcome of bone marrow transplantation in adult hematologic malignancies, 3036
van Beurden VM, *see* Creemers GJ
Van Cutsem E, *see* Zalcberg JR
Van Cutsem O, *see* Sculier JP
van Dam FSAM, *see* Aaronson NK
van de Rijn M, Kamel OW. Clonality of Epstein-Barr virus in lymphoproliferative disorders in patients treated with immunosuppressive therapy for rheumatoid arthritis (letter), 3050
van de Velde CJH, *see* Bunt AMG
— *see* Clahsen PC
Van Deijk WA, *see* Velders GA
van der Burg MEL, *see* Creemers GJ
— *see* de Wit R
Van der Does-Van den Berg A, *see* Veerman AJP
van der Graaf WTA, *see* Ham SJ
— *see* Lemmers NWM
van der Schot ACM, *see* Aaronson NK
van der Wall E, *see* Rodenhuis S
van der Zee AGJ, *see* Duk JM
van Dongen JA, *see* Aaronson NK
van Eijkeren M, *see* Pecherstorfer M
van Geel AN, *see* Eggermont AMM
Van Glabbeke M, *see* Conroy T
van Groningen K, *see* Kramer MHH
van Krieken JHJM, *see* Kramer MHH
Van Krieken JHJM, *see* Velders GA
Van Leeuwen EF, *see* Veerman AJP
Van Oosterom AT, *see* Dirix LY
Van Pottelsberghe C, *see* Conroy T
Van Wering ER, *see* Veerman AJP
van Zandwijk N, *see* Boersma LJ
— *see* Giaccone G
— *see* Splinter TAW
Vandenberg T, *see* Perrault D
Vandenberg TA, *see* Trudeau ME
VanderMolen LA, *see* Gause BL
Vansteenkiste JF, *see* Simons JPFHA
Vasile N, *see* Solal-Céligny P
Vassilopoulos P, *see* Coombes RC
Veerman AJP, Hählen K, Kamps WA, Van Leeuwen EF, De Vaan GAM, Solbu G, Suciu S, Van Wering ER, Van der Does-Van den Berg A. High cure rate with a moderately intensive treatment regimen in non–high-risk childhood acute lymphoblastic leukemia: Results of protocol ALL VI from the Dutch childhood leukemia study group, 911
Vela E, *see* Sierra J
Velders GA, Kluin-Nelemans JC, De Boer CJ, Hermans J, Noordijk EM, Schuuring E, Kramer MHH, Van Deijk WA, Rahder JB, Kluin PM, Van Krieken JHJM. Mantle-cell lymphoma: A population-based clinical study, 1269
Vellenga E, Uyl-de Groot CA, de Wit R, Keizer HJ, Löwenberg B, ten Haaft MA, de Witte ThJM, Verhagen CAH, Stoter GJ, Rutten FFH, Mulder NH, Smid WM, de Vries EGE. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia, 619
Veneroni S, *see* Silvestrini R
Venkatraj U, *see* Sparano JA
Venner P, *see* Tester W
Venner PM, *see* Tannock IF
Ventafridda V, *see* De Conno F
Venturini M, Bruzzi P, Del Mastro L, Garrone O, Bertelli G, Guelfi M, Pastorino S, Rosso R, Sertoli MR. Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first-line cyclophosphamide, epidoxorubicin, and fluorouracil in patients with metastatic breast cancer, 764
—, Michelotti A, Del Mastro L, Gallo L, Carnino F, Garrone O, Tibaldi C, Molea N, Bellina RC, Pronzato P, Cyrus P, Vinke J, Testore F, Guelfi M, Lionetto R, Bruzzi P, Conte PF, Rosso R. Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer, 3112
Venzon D, *see* Fisherman JS
— *see* Magrath I
— *see* Wexler LH
Venzon DJ, *see* Tolcher AW
— *see* Weintraub M
Vera R, *see* Ribas A
Verhagen CAH, *see* Vellenga E
Verma S, *see* Rusthoven JJ
Vermeulen PB, *see* Dirix LY
Vernava AM, *see* Johnson FE
Verschraegen C, *see* Kudelka AP
Verweij J, *see* Clarke SJ
— *see* Creemers GJ
— *see* de Wit R
Vezon G, *see* Marit G
Vidal R, *see* Ribas A
Vié B, *see* Joly F
Vignetti M, *see* Martelli M
Vilain M-O, *see* Coindre J-M
Villa M, *see* Winter JN
Villa S, *see* Bessell EM
Villablanca JG, *see* Balmaceda C
Villar-Grimalt A, *see* Coombes RC
Villar-Werstler P, *see* Modiano MR
Vinke J, *see* Venturini M
Virgo KS, *see* Johnson FE
Visani G, *see* Lemoli RM
Visco FM, Skolnick M, Collins FS. Commentaries on the ASCO statement on genetic testing for cancer susceptibility, 1737
Visser-Pol E, *see* Aaronson NK
Vittorini V, *see* Roselli M
Vivancos P, *see* Sierra J
Vives-Corrons JL, *see* Mellado B
Viviani S, Bonadonna G, Santoro A, Bonfante V, Zanini M, Devizzi L, Soncini F, Valagussa P. Alternating versus

hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: Ten-year results, 1421
Vlamis V, *see* Balmaceda C
— *see* Motzer RJ
— *see* Puc HS
Vogel CL, *see* Buzdar A
Vogelsang GB, *see* Miller CB
Vogelzang NJ. One hundred thirteen men with hormone-refractory prostate cancer died today (editorial), 1753
— *see* Kobayashi K
— *see* Ong ST
Vokes EE, Mick R, Kies MS, Dolan ME, Malone D, Athanasiadis I, Haraf DJ, Kozloff M, Weichselbaum RR, Ratain MJ. Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer, 1663
— *see* Kobayashi K
— *see* Mick R
Von Hoff DD, *see* Rothenberg ML
von Roenn JH, *see* Gill PS
Voogt P, *see* Löwenberg B
Vora N, *see* Stein AS
Vose JM, Anderson JE, Bierman PJ, Appelbaum FR, Anderson JR, Garrison L, Lebsack ME, Armitage JO. Phase I/II trial of PIXY321 to enhance engraftment following autologous bone marrow transplantation for lymphoid malignancy, 520
—, Bierman PJ, Anderson JR, Harrison KA, Dalrymple GV, Byar K, Kessinger A, Armitage JO. Single-photon emission computed tomography gallium imaging versus computed tomography: Predictive value in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation for non-Hodgkin's lymphoma, 2473
— *see* Bishop MR
— *see* Gajewski JL

Wada H, Hitomi S, Teramatsu T, West Japan Study Group for Lung Cancer Surgery. Adjuvant chemotherapy after complete resection in non–small-cell lung cancer, 1048
Wade TP, *see* Johnson FE
Wadler S, *see* Borden EC
Wagener DJT, *see* Conroy T
Wagener T, *see* Blijham G
Wahl RL, *see* Kaminski MS
Walker I, *see* Barr R
Walker M, *see* Clarke SJ
Walker RW, *see* Balmaceda C
Wall D, *see* Mahoney DH Jr
Wallin B, *see* Kudelka AP
Wallner K, Roy J, Harrison L. Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma, 449
Walters RS, *see* Holmes FA
Walton L, *see* Swain SM
Walz MK, *see* Stahl M
Wara WM, *see* Willis B
Ward B, *see* Haffty BG
Warde P, Gospodarowicz M. In reply (letter), 684
Wardley AM, Scarffe JH. Role of granulocyte-macrophage colony-stimulating factor in chemoradiotherapy-induced oral mucositis (letter), 1741
Warkentin PI, *see* Bishop MR
Warren D, *see* Ayash LJ
Washburn JH Jr, *see* Rowland KM Jr
Washimi O, *see* Nishio M
Wasserheit C, Frazein A, Oratz R, Sorich J, Downey A, Hochster H, Chachoua A, Wernz J, Zeleniuch-Jacquotte A, Blum R, Speyer J. Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: An active regimen with limiting neurotoxicity, 1993
Wasson JH, *see* Fowler FJ Jr
Watanabe K, *see* Kunitoh H
Watkins DL, *see* Jones SE
Weaver CH, *see* Bensinger WI
Weaver-McClure L, *see* Kuttesch JF Jr
— *see* Wexler LH
Webb TA, *see* Rowland KM Jr
Weber-Matthiesen K, *see* Poetsch M
— *see* Schlegelberger B
Webster A, *see* Buzdar A
Weeks J, *see* Travis LB
Weeks JC, *see* Bennett CL
Wegener J, *see* Barr R
Weichselbaum RR, *see* Quiet CA
— *see* Vokes EE
Wein A, *see* D'Amico AV
Weinberg V, *see* Willis B
Weinfurt K, *see* Swain SM
Weinstein H, *see* Steuber CP
Weintraub M, Adde MA, Venzon DJ, Shad AT, Horak ID, Neely JE, Seibel NL, Gootenberg J, Arndt C, Nieder ML, Magrath IT. Severe atypical neuropathy associated with administration of hematopoietic colony-stimulating factors and vincristine, 935
Weisenburger DD, *see* Sharp JG
Weiss GR, *see* Rothenberg ML
Weiss M, Maslak P, Feldman E, Berman E, Bertino J, Gee T, Megherian L, Seiter K, Scheinberg D, Golde D. Cytarabine with high-dose mitoxantrone induces rapid complete remissions in adult acute lymphoblastic leukemia without the use of vincristine or prednisone, 2480
Weiss RB, *see* Perloff M
— *see* Rosner GL
Weissmann LB, Corson JM, Neugut AI, Antman KH. Malignant mesothelioma following treatment for Hodgkin's disease, 2098
Welt S, Scott AM, Divgi CR, Kemeny NE, Finn RD, Daghighian F, St. Germain J, Richards EC, Larson SM, Old LJ. Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer, 1787
Wernz J, *see* Gill PS
— *see* Wasserheit C
West Japan Study Group for Lung Cancer Surgery, *see* Wada H
Westermann A, *see* Rodenhuis S
Wexler LH, Andrich MP, Venzon D, Berg SL, Weaver-McClure L, Chen CC, Dilsizian V, Avila N, Jarosinski P, Balis FM, Poplack DG, Horowitz ME. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin, 362
—, Weaver-McClure L, Steinberg SM, Jacobson J, Jaro-

sinski P, Avila N, Pizzo PA, Horowitz ME. Randomized trial of recombinant human granulocyte-macrophage colony-stimulating factor in pediatric patients receiving intensive myelosuppressive chemotherapy, 901
— *see* Kuttesch JF Jr
Wexner SD, *see* Johnstone PAS
Whaley FS, *see* Moffat FL Jr
Whang-Peng J, *see* Chen YM
Wheeler C, *see* Ayash LJ
Whelan J, *see* Pappa VI
White M, *see* Kuttesch JF Jr
White R, *see* Crawford J
Whittington R, *see* D'Amico AV
— *see* Tester W
Wibault P, Bensmaïne M-E-A, de Forni M, Armand J-P, Bernal ET, Guillot T, Recondo G, Domenge C, Janot F, Borel C, Luboinski B, Eschwege F, Cvitkovic E. Intensive concomitant chemoradiotherapy in locally advanced unresectable squamous cell carcinoma of the head and neck: A phase II study of radiotherapy with cisplatin and 7-week continuous infusional fluorouracil, 1192
Wickerham DL, *see* Fisher B
Wiernik PH, *see* Gajewski JL
— *see* Sparano JA
Wikström S, *see* Saarinen UM
Wilder RB, DeNardo GL, DeNardo SJ. Radioimmunotherapy: Recent results and future directions, 1383
Wiley J, *see* Civin CI
Wilke H, *see* Stahl M
Wilkinson PM, *see* Pettengell R
Willemze R, *see* Rijlaarsdam JU
— *see* Zittoun R
Willey J, *see* Holmes FA
Williams A, *see* Sprangers MAG
Williams CD, Goldstone AH, Pearce RM, Philip T, Hartmann O, Colombat P, Santini G, Foulard L, Gorin NC. Purging of bone marrow in autologous bone marrow transplantation for non-Hodgkin's lymphoma: A case-matched comparison with unpurged cases by the European Blood and Marrow Transplant Lymphoma Registry, 2454
Williams GJ, *see* Bow EJ
Williams MV, *see* Cullen MH
Williams WH, *see* Critz FA
Willis B, Ablin A, Weinberg V, Zoger S, Wara WM, Matthay KK. Disease course and late sequelae of Langerhans' cell histiocytosis: 25-year experience at the University of California, San Francisco, 2073
Wills J, *see* Conroy T
Wils J, *see* Blijham G
— *see* Coombes RC
Wilson AM, *see* Pappa VI
Wilson JJ, *see* Tannock IF
Wiltshaw E, *see* Ahmed FY
Wingard JR, *see* Holland HK
Winick N, Shuster JJ, Bowman WP, Borowitz M, Farrow A, Jacaruso D, Buchanan GR, Kamen BA. Intensive oral methotrexate protects against lymphoid marrow relapse in childhood B-precursor acute lymphoblastic leukemia, 2803
Winkler K, *see* Bielack SS
— *see* Bieling P
Winkler P, *see* Bieling P
Winn RJ, *see* Bennett CL
Winograd B, *see* Chabot GG
— *see* Nabholtz J-M
Winter JN, Lazarus HM, Rademaker A, Villa M, Mangan C, Tallman M, Jahnke L, Gordon L, Newman S, Byrd K, Cooper BW, Horvath N, Crum E, Stadtmauer EA, Conklin E, Bauman A, Martin J, Goolsby C, Gerson SL, Bender J, O'Gorman M. Phase I/II study of combined granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor administration for the mobilization of hematopoietic progenitor cells, 277
— *see* Gordon LI
Winton EF, *see* Holland HK
Witherspoon RP, *see* Anderson JE
Witjaksono M, *see* Diamandidou E
Witte R, *see* Chang A
Wittenkeller J, *see* Schiller JH
Wittes RA, *see* Magrath I
Wolf GT, *see* Eisbruch A
Wolf M, *see* Reckzeh B
Woll PJ, *see* Pettengell R
Wollner N, *see* Kushner BH
Wolmark N, *see* Fisher B
Wolter JM, *see* Buzdar A
Wong MC, *see* Finlay JL
Wood WC, *see* Albain KS
— *see* Perloff M
Woodhull J, *see* Joel SP
Woodruff J, *see* Heslin MJ
— *see* Pisters PWT
Woodruff JM, *see* Pisters PWT
Woods EM, *see* Coombes RC
Wouters EFM, *see* Simons JPFHA
Wurster-Hill D, *see* Bernstein SH

Yahalom J, *see* Hirsch A
Yamada O, *see* Kobayashi T
Yamaguchi A, Urano T, Goi T, Saito M, Takeuchi K, Hirose K, Nakagawara G, Shiku H, Furukawa K. Expression of a CD44 variant containing exons 8 to 10 is a useful independent factor for the prediction of prognosis in colorectal cancer patients, 1122
Yanovich S, *see* Crawford J
Yao T-J, *see* Seidman AD
Yap AKL, *see* Greco FA
Yates AJ, *see* Finlay JL
Yeap B, *see* Chang A
Yeh I-T, *see* Solin LJ
Yeh SDJ, *see* Kushner BH
York M, *see* Greco FA
Yoshida M, *see* Kobayashi T
Younes A. Cytogenetic findings in T-cell lymphoma of angioimmunoblastic lymphadenopathy (letter), 2188
—, Ayoub J-P, Hagemeister FB, McLaughlin P, Sarris A, Rodriguez MA, Swan F Jr, Romaguera JE, Martin J, Cabanillas F. No effect of 96-hour paclitaxel infusion in patients with relapsed non-Hodgkin's lymphoma refractory to a 3-hour infusion schedule, 543

— *see* McLaughlin P
— *see* Sarris AH
Young H, *see* Findlay M
Young RC, *see* O'Dwyer PJ
Yu B, Carrasquillo J, Milenic D, Chung Y, Perentesis P, Feuerestein I, Eggensperger D, Qi C-F, Paik C, Reynolds J, Grem J, Curt G, Siler K, Schlom J, Allegra C. Phase I trial of iodine 131-labeled COL-1 in patients with gastrointestinal malignancies: Influence of serum carcinoembryonic antigen and tumor bulk on pharmacokinetics, 1798
Yu L, *see* Mahoney DH Jr

Zahurak ML, *see* Kennedy MJ
Zalcberg JR, Cunningham D, Van Cutsem E, Francois E, Schornagel J, Adenis A, Green M, Iveson A, Azab M, Seymour I. ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer, 716
Zalduondo FM, *see* Ashley DM
Zanini M, *see* Viviani S
Zasadny KR, *see* Kaminski MS
Zecca E, *see* De Conno F
Zee B, *see* Coppin CML
— *see* Prichard KI
— *see* Rusthoven JJ
— *see* Siu LL
Zeleniuch-Jacquotte A, *see* Wasserheit C
Zelterman D, *see* Salloum E
Zeng ZS, Huang Y, Cohen AM, Guillem JG. Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9, 3133
Zhang Y, *see* Schlegelberger B
Zhang Z-F, *see* Lacombe L
Ziegler LD, *see* Greenberg PAC
Ziegler S, *see* Avril N
Zielinski C, *see* Kritz H
Zilembo N, *see* Bajetta E
Zimmerman RA, *see* Finlay JL
Zinzani PL. In reply (letter), 3049
—, Bendandi M, Martelli M, Falini B, Sabattini E, Amadori S, Gherlinzoni F, Martelli MF, Mandelli F, Tura S, Pileri SA. Anaplastic large-cell lymphoma: Clinical and prognostic evaluation of 90 adult patients, 955
— *see* Lemoli RM
— *see* Martelli M
Zittoun R, Suciu S, Mandelli F, de Witte T, Thaler J, Stryckmans P, Hayat M, Peetermans M, Cadiou M, Solbu G, Petti MC, Willemze R. Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: A randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group, 2150
Zoger S, *see* Willis B
Zola P, *see* Dogliotti L
Zon G, *see* Bishop MR
Zoubek A, Dockhorn-Dworniczak B, Delattre O, Christiansen H, Niggli F, Gatterer-Menz I, Smith TL, Jürgens H, Gadner H, Kovar H. Does expression of different *EWS* chimeric transcripts define clinically distinct risk groups of Ewing tumor patients? 1245
Zucali R, *see* Doci R
Zuhowski EG, *see* Glantz MJ
Zujewski J, *see* Tolcher AW
Zwaan F, *see* Rostom AY
Zwingers T, *see* Schlegelberger B

# SUBJECT INDEX

A33 monoclonal antibody, radiolabeled, in colon cancer, 1787-1797
ABVD regimen
alternating with MOPP regimen
in HD, 1421-1430
salvage therapy following, 1426-1427
second malignancies following, 1427
survival following, 1425-1426
ten-year results of, 1425
toxicity of, 1426-1427
in HD, 1297-1305
pulmonary function following, 1297-1305
*see also* Doxorubicin, bleomycin, vinblastine, dacarbazine regimen
Accelerated executive review, 2879
Acivicin, in mesothelioma, 1009
Adaptive control, of chemotherapy dosing, 2596-2597
Adjuvant chemotherapy, *see* Chemotherapy, adjuvant
Adverse effects, following surgery *v* radiotherapy, in prostate cancer, 2258-2265
Age
autologous BMT and, 1327-1332
body size *v*, in chemotherapeutic dosing, 2594-2595
chemotherapy-related amenorrhea and, 1720-1722
cisplatin dose by, 825
in combined modality therapy, for primary CNS lymphomas, 556-564
cyclophosphamide dose by, 825
doxorubicin dose by, 825
effect of, on etoposide pharmacokinetics, 263
etoposide dose by, 825
in HIV-related NHL, 2217-2223
impact of, on selected variables, 1331
in SCLC therapy selection, 821-828
survival by, 825
vincristine dose by, 825
Allergy, radioimmunotherapy-induced, 1392
Alta Vista, 2183
Ambulatory therapy, chronotherapy as, in colorectal cancer, 2950-2958
Amenorrhea, chemotherapy-related, 1718-1729
age and, 1720-1722
definition of, 1719-1720
due to specific agents, 1723-1724
incidence of, 1721
mechanism of, 1720
temporary, 1724-1725

time to development of, 1722-1723
American Association for Cancer Research, American Society of Clinical Oncology relationship with, 2392
American Cancer Association, American Society of Clinical Oncology relationship with, 2392
American Joint Committee on Cancer staging, of anal cancer, 2529
American Society of Clinical Oncology
American Association for Cancer Research relationship with, 2392
American Cancer Association relationship with, 2392
Annual Meeting of, presidential address at, 2387-2398
clinical practice issues of, 2395
clinical trial improvement recommendations by, 2397-2398
credo of, 2388-2389
education committee of, 2390-2391
evidence-based practice guidelines of, 2394-2395
FDA reform advocated by, 2395-2396
goals of, 2388-2389
growth factor survey of, 2511-2520
guidelines of, for colony-stimulating factor use, 1957-1960
improved clinical investigator training by, 2393-2394
membership growth of, 2389
membership of, 2391-2392
mission of, 2388-2389
new clinical coalition proposal by, 2396-2397
patient advocacy organization relationship with, 2392
patient-oriented research funding of, 2393
priorities of, 2389-2390
program committee of, 2390
public policy initiatives of, 2392-2394
recommendations of, on tobacco control, 1961-1963
reorganization of, 2389-2390
statement of, on cancer susceptibility genetic testing, 1730-1736
American Society of Clinical Oncology Online, 2181-2186
Amifostine
for cisplatin-induced toxicities, 2101-2112
for cyclophosphamide-induced toxicities, 2101-2112
hypotension associated with, by dose, 1918
Amifostine, cisplatin, vinblastine regimen
in NSCLC, 1913-1921
toxicity of, 1915-1917
9-Aminocamptothecin
hematologic toxicity of, 1239-1240
nonhematologic toxicity of, 1240
pharmacodynamics of, 1242-1243
pharmacokinetics of, 1241-1242
response to, 1240
72-hour infusion of, phase I trial of, 1236-1244
Amsacrine, in mesothelioma, 1009
Amsacrine, cytarabine regimen, for intensification, 1354
Amsacrine, etoposide regimen
phase II trial of, 1521-1525
toxicity of, 1523
Amsacrine, etoposide, azacitidine regimen
in leukemia, 1521-1525
phase II trial of, 1521-1525
toxicity of, 1523
Anal cancer
chemoradiotherapy in, 2527-2539, 3121-3125
combined modality therapy in, 3167
fluorouracil, cisplatin, radiotherapy regimen in, 3121-3125
mitomycin, fluorouracil, radiotherapy regimen in, 2527-2539
RTOG *v* AJCC-UICC staging of, 2529
Anastrozole
megestrol acetate *v*, in breast cancer, 2000-2011
weight gain following, 2007
Angiogenesis, tumor, in neuroblastoma, 405-414
Angiogram, of hypervascular tumor, 2661
Anorexia, megestrol acetate for, 135-141
Anthracycline chemotherapy, cardiotoxicity due to, dexrazoxane for, 328-333
Anti-B1, radiolabeled, in radioimmunotherapy, for B-cell lymphoma, 1974-1981
Anti-CD20 monoclonal antibody, in radioimmunotherapy, for B-cell lymphoma, 1974-1981
Anti-von Willebrand factor antibody, in colorectal cancer, 461-462
Antibiotics, GM-CSF and, 619-627
Antibody
function of, 1384
production of, 1384-1386
structure of, 1384
Antibody imaging, in medullary thyroid cancer, 1209-1217
Antigenic modulation, 1393
Apoptosis
dexamethasone-induced, 2373-2374
prednisolone-induced, 2373-2374
Appetite, medroxyprogesterone acetate and, 1077-1084
Ascites, drug handling and, 2602
Asparaginase
in combination chemotherapy, for B-precursor acute lymphoblastic leukemia, 2803-2811
in polychemotherapy, for pediatric acute lymphoblastic leukemia, 2813
Asparaginase, vincristine, dexamethasone, methotrexate regimen, for induction, in acute lymphoblastic leukemia, 911-918
Aspiration needle biopsy
fine-needle aspiration *v*, 1704-1712
selection of, for thyroid nodules, 1704-1712
Astrocytoma, paclitaxel plus cranial irradiation for, 600-609
Autograft, quality of, 2795
Autologous bone marrow transplantation, *see* Bone marrow transplantation, autologous
Avidin-biotin-peroxidase complex kit, 87
Azacitidine, amsacrine, etoposide regimen
in leukemia, 1521-1525
phase II trial of, 1521-1525
toxicity of, 1523
Azacytidine, doxorubicin regimen, in malignant mesothelioma, 1013
Azauridine, in combination chemotherapy, second cancer following, 2770
Azidothymidine
intravenous, in combination chemotherapy, for metastatic colorectal cancer, 729-736
pharmacokinetic parameters of, 732
response to, by dose, 733
toxicity of, 733
Azidothymidine, FU, folinic acid regimen, for metastatic colorectal cancer, 729-736
AZT, *see* Azidothymidine

B72.3 monoclonal antibody, 2035, 2036
radiolabeled, in radioimmunoguided surgery, 1599-1603
Bacillus Calmette-Guerin therapy
in mesothelioma, 1009

p53 overexpression and, in bladder cancer, 2646-2652
response to, 2648
prediction of, in bladder cancer, 1778-1786
Bacteremia
admission fever and, 922
predictive model for, 920-921
predictive model validation in, 922
risk of, in neutropenic children, 919-924
Bayesian concept, for monitoring strategy, 297-299
*bcl*-2 protein
in cervical human papillomavirus lesions, 2120-2130
expression of, 2124-2125
breast cancer outcome and, 1604-1610
in large B-cell lymphoma, 2131-2138
immunopositivity of, 2126
p53 coexpression with, 2127
simultaneous expression of, with p53 expression, 2134
BCL-2-Jh rearrangements, in circulating B cells, 1333-1344
BCNU, *see* Carmustine
BDI assessment, 1458-1459
Beery Visual-Motor Integration Test, 2828
Behenoyl cytarabine, in leukemia, 204-213
Bifunctional antibody, 1392-1393
Biliary index
level of, by intestinal toxicity grade, 2018
prediction of, limited sampling models for, 2012-2019
Biliary tract cancer
dexamethasone, diphenhydramine, cimetidine, paclitaxel regimen in, 2306-2310
interferon alfa-2b, 5-FU regimen in, 2311-2315
unresectable, paclitaxel therapy for, 2306-2310
Biomarker(s)
CD44 as, in neuroblastoma, 25-34
polysialic-neural cell adhesion molecule measurement as, in medulloblastoma metastasis, 2066-2072
Biopsy
needle, *see* Needle biopsy
technique for, 2428
tissue, 2427
Bisacetamide, pharmacokinetic parameters of, 2593
Bladder cancer
combined modality therapy in, 3168
with bladder preservation, 119-126
invasive
cisplatin, radiotherapy regimen in, 2901-2907
optimal therapy in, 119-120
treatment schema for, 121
muscle invasive, chemoradiotherapy *v* radiotherapy in, 3168
p53 overexpression in, and Bacillus Calmette-Guerin therapy, 2646-2652
therapy response in
IL-2 genes for, 1778-1786
interferon gamma genes for, 1778-1786
Blast, 2182-2183
Bleomycin
in combination chemotherapy, second cancer following, 2770
for malignant pericardial effusion sclerosis, 3141-3147
Bleomycin, carboplatin, etoposide regimen
for germ cell tumor, of CNS, 2908-2915
outcome following, 2910-2912
survival following, 2912-2913
toxicity of, 2911-2912
Bleomycin, cisplatin, etoposide regimen
adjuvant
acute side effects of, 443
for nonseminomatous testicular germ cell tumor, 1106-1113
high-tone hearing loss following, 445
lung function following, 445
psychosocial self-report following, 444
sperm counts following, 446
in testicular germ cell cancer, 441-448
endocrinologic late toxicity of, 2927
gonadal toxicity of, 2926-2927
long-term toxicity of, 1109
neurotoxicity of, 2925
otoxicity of, 2925-2926
relapse following, 1109-1110
renal late toxicity of, 2927
short-term toxicity of, 1108-1109
in testicular cancer, 2923-2932
vascular toxicity of, 2926
Bleomycin, cisplatin, vinblastine regimen
endocrinologic late toxicity of, 2927
gonadal toxicity of, 2926-2927
neurotoxicity of, 2925
otoxicity of, 2925-2926
renal late toxicity of, 2927
in testicular cancer, 2923-2932
vascular toxicity of, 2926
Bleomycin, cyclophosphamide, doxorubicin, etoposide, prednisone, cytarabine, methotrexate, folinic acid, GM-CSF regimen
maximum-tolerated dose of, in lymphoma, 1275-1281
response to, 1278
toxicity of, 1277-1278
Bleomycin, dacarbazine, vincristine, lomustine, interferon regimen, in melanoma, 1690-1696
Bleomycin, doxorubicin, cyclophosphamide, vincristine, etoposide, prednisolone, methotrexate regimen, in NHL, 586-592
Bleomycin, doxorubicin, cyclophosphamide, vindesine, prednisone regimen, in lymphoma, 240-248
Bleomycin, doxorubicin, vinblastine, dacarbazine regimen
alternating with MOPP regimen, 1421-1430
in HD, 1297-1305
pulmonary function following, 1297-1305
Bleomycin, doxorubicin, vinblastine, dacarbazine, methylprednisone, radiotherapy, in HD, 1928-1935
Bleomycin, doxorubicin, vinblastine, dacarbazine, radiation regimen in HD, 1297-1305
pulmonary function following, 1297-1305
Bleomycin, doxorubicin, vincristine regimen
cardiac toxicity following, 2361
in Kaposi's sarcoma, 2353-2364
quality of life following, 2359
response to, 2356-2358
survival following, 2358-2360
toxicity of, 2359-2361
Bleomycin, methotrexate, vincristine, doxorubicin, cyclophosphamide, dactinomycin regimen, neoadjuvant, for bone histiocytoma, 490-496
Bleomycin, mitomycin, cisplatin, doxorubicin regimen, in malignant mesothelioma, 1013
Bleomycin, vinblastine, methotrexate, radiation regimen
in HD, 527-533
survival following, 530

toxicity of, 529-531
Blood cell transplantation
allogeneic, without colony-stimulating factors, 1314-1319
*see also* Peripheral-blood stem-cell transplantation
Blood coagulation, during adjuvant epirubicin, cyclophosphamide regimen, 2560-2568
BMT, *see* Bone marrow transplantation
Body size, age *v*, in chemotherapeutic dosing, 2594-2595
Body weight
chemotherapy dosing by, 3000-3008
medroxyprogesterone acetate and, 1077-1084
medroxyprogesterone acetate-induced changes in, 1081
Bone
malignant fibrous histiocytoma of
high-dose methotrexate-based neoadjuvant chemotherapy in, 490-496
histologic criteria for, 494
metastases to, pamidronate delay of, in breast cancer, 2552-2559
Bone marrow
assay of, for cytoreduction, as prognostic factor, in leukemia, 389-398
examination of, methods of, 2792
harvesting of, 383, 521
in vivo purging of, 2794
conventional chemotherapy for, 2795
neuroblastoma infiltration of, reduction of, 2796
occult metastasis in, of breast cancer, 1868-1876
purging of
in autologous BMT, 2454-2464
methods of, 2455-2456
Bone marrow transplantation
allogeneic
economic evaluation of, 1413-1420
in HD, 572-578
in myelodysplastic syndrome, 220-226
renal toxicity following, 579-585
allogeneic *v* autologous, in relapsed HD, 1291-1296
autologous
age and, 1327-1332
bone marrow purging in, 2454-2464
plus carmustine, etoposide, cytarabine, cyclophosphamide regimen
for NHL, in partial response, 534-542
survival following, 538-540
treatment algorithm for, 535
clinical results of, 2228
with consolidation chemoradiotherapy, in neuroblastoma, 2417-2426
eligibility criteria for, 1328
eligibility for, 2792-2793
following in vivo bone marrow purging, in neuroblastoma, 2791-2802
G-CSF plus IL-3 following, 3018-3025
with high-dose carboplatin, etoposide, cyclophosphamide regimen, for germ cell tumors, 1098-1105
marrow tumor burden and, 214-219
mortality related to, 1329-1330
in neuroblastoma, 2413-2414
neuropsychologic functioning during, 1457-1462
PIXY321 following, 520-526
with preexisting CNS disease, 3036-3042
psychologic impact of, 1457-1462
purging and, 2194-2196
relapse following, 1330
response to, 2456
survival following, 1330-1331
tumor contamination assessment in, 2793-2794
cost of, 1415-1416
cost-effectiveness of, 1416-1417
economics of, 1409-1410
historical overview of, 1413-1414
HLA-identical sibling, in HD, 572-578
immune function following, 2230-2231
intensification chemotherapy plus, in leukemia, 1353-1363
outcome of, with preexisting CNS disease, 3036-3042
Bone marrow transplantation, cyclophosphamide, thiotepa, carboplatin, supportive care regimen
in breast cancer, 1156-1164
infection following, 1160
nonhematologic toxicities due to, 1158-1160
survival following, 1161
Bone marrow transplantation, melphalan, cyclophosphamide regimen
for CNS tumors, 382-388
dosing plan for, 384
response to, 385
survival following, 386
toxic deaths due to, 385
Bone mineral density, tamoxifen and, 78-84
Bowel movement, following surgery *v* radiotherapy, in prostate cancer, 2261
Brachytherapy
adjuvant, in soft tissue sarcoma, 859-868
interstitial, historical perspective of, 304-305
prostate, tumor control following, 449-453
Brain tumor
combined modality therapy for, 3162
progressive malignant, melphalan, cyclophosphamide, BMT regimen for, 382-388
thiotepa, etoposide regimen for, with autologous bone marrow rescue, 2495-2503
Breakpoint region, major, 1333
Breast
conservation therapy of
by geography, 3012
by prognostic risk category, 3012
by tumor size, 3012
selection of, 3009-3017
selection rate of, 3013
ductal carcinoma-in-situ of, 70-77
preservation of, and survival, 70-77
Breast cancer
adjuvant chemotherapy in, 1136-1145
ovarian function following, 1718-1729
adjuvant chemotherapy toxicity in, and obesity, 3000-3008
adjuvant cyclophosphamide, methotrexate, fluorouracil, vincristine, prednisone regimen in, 46-51
advanced
epirubicin in, 1165-1172
lonidamine, epirubicin regimen in, 1165-1172
mitoxantrone, cyclophosphamide, G-CSF regimen in, 2576-2583
paclitaxel, cisplatin regimen in, 1993-1999
advanced postmenopausal, anastrozole *v* megestrol acetate for, 2000-2011

anti-HER2 antibody therapy for, 737-744
breast-sparing therapy in, selection of, 3009-3017
c-*erb*B2 in
definition of, 2863
future research with, 2865
gene amplification of, 2863
guidelines for, 2863
immunoblotting of, 2863-2864
immunohistochemistry of, 2864
literature review of, 2863-2865
methodology for, 2863
overexpressing, macrophage infiltrates in, 85-94
and resistance to therapy, 2864-2865
CA 15-3 in
for asymptomatic recurrence, 2856-2857
definition of, 2855
future research with, 2857
guidelines for, 2855
literature review of, 2855
methodology for, 2855
for response monitoring, 2857
for screening, 2855-2856
carcinoembryonic antigen in
for asymptomatic recurrence, 2858
definition of, 2857
guidelines for, 2857
literature review of, 2858
methodology for, 2857
for response monitoring, 2858-2859
cathepsin-D marker in
guidelines for, 2866
literature review of, 2866-2867
methodology for, 2866
cyclophosphamide, thiotepa, carboplatin, stem-cell regimen in, 1473-1483
distress screening following, 2747-2755
dose-intensity maintenance in, G-CSF for, 1573-1580
early-stage
breast-conserving surgery *v* mastectomy in, 1558-1564
perioperative chemotherapy for, 745-753
epirubicin in, with dexrazoxane, 3112-3120
estrogen receptor in
for adjuvant therapy response monitoring, 2861
definition of, 2859
future research with, 2862
guidelines for, 2857
literature review of, 2860
for metastatic therapy response monitoring, 2860-2861
methodology for, 2859-2860
for recurrence prognosis, 2861-2862
as tumor marker, 2859-2862
estrogen replacement therapy and, 1002-1004
five-year relapse in, biologic variables and, 1609
five-year relapse-free survival in, biologic variables and, 1608
flow cytometric proliferation analysis in
definition of, 2862
future research with, 2863
guidelines for, 2862
literature review of, 2862-2863
methodology for, 2862
fluorouracil, doxorubicin, cyclophosphamide, radiation regimen in, leukemia following, 2722-2730
following HD therapy, 1442-1446
high- *v* low-dose paclitaxel in, 1858-1867
high-dose cyclophosphamide, thiotepa, carboplatin, BMT, comprehensive supportive care regimen in, 1156-1164
high-risk, comprehensive supportive care regimen in, 1156-1164
hormone receptors in, 2584-2589
ifosfamide, carboplatin, etoposide regimen in, 1869
individualized risk of, graphs for, 103-110
intensive outpatient adjuvant therapy in, 1565-1572
intraductal
breast-conserving surgery plus radiation for, 754-763
15-year treatment results for, 754-763
local recurrence following, 758-759
locally advanced, radioimmunoguided surgery in, 1599-1603
long-term complete remissions in, 2197-2205
Markov cycle tree in, 71
metabolic characterization of, with F-18 fluorodeoxyglucose PET, 1848-1857
metastatic
adjuvant chemotherapy in, 764-773
combination chemotherapy in, 2197-2205
cyclophosphamide, epidoxorubicin, fluorouracil regimen in, 764-773
docetaxel in, 58-65, 422-428
double dose-intensive chemotherapy in, 2984-2992
ifosfamide, vinorelbine regimen in, 2993-2999
long-term survival in, 2191-2193
melphalan, cyclophosphamide, thiotepa, carboplatin regimen in, 2984-2992
paclitaxel, cisplatin regimen in, 1185-1191
paclitaxel, cyclophosphamide, G-CSF regimen in, 95-102
paclitaxel, doxorubicin, G-CSF regimen in, 774-782
paclitaxel, mitoxantrone, fluorouracil, folinic acid regimen in, 1611-1616
paclitaxel with r-verapamil in, 1173-1184
sequential paclitaxel-doxorubicin pharmacokinetics in, 2713-2721
weekly anti-HER2 antibody therapy for, 737-744
metastatic to bone, pamidronate delay of, 2552-2559
mifepristone in, 2709-2712
node-negative estrogen-negative
cyclophosphamide, methotrexate, fluorouracil regimen in, 1982-1992
methotrexate, fluorouracil regimen in, 1982-1992
node-positive
*bcl*-2 expression in, 1604-1610
cyclophosphamide, doxorubicin, fluorouracil, vincristine regimen in, 1136-1145
cyclophosphamide, methotrexate, fluorouracil regimen in, 1136-1145
natural history of, 3105-3111
node-positive premenopausal, cyclophosphamide, methotrexate, fluorouracil regimen in, 1885-1894
occult bone marrow metastases in, 1868-1876
outpatient cyclophosphamide, doxorubicin, G-CSF regimen in, 1565-1572
p53 marker in
definition of, 2865
future research with, 2866
guidelines for, 2865
literature review of, 2865-2866
methodology for, 2865

peripheral-blood progenitor-cell contamination by, 2569-2575
postmenopausal metastatic, epirubicin in, 1146-1155
postmenopausal node-positive, tamoxifen *v* toremifene in, 429-433
premenopausal node-positive
adjuvant cyclophosphamide, methotrexate, fluorouracil regimen in, 35-45
epirubicin, cyclophosphamide, fluorouracil regimen in, 35-45
premenopausal node-positive ER-positive, cyclophosphamide, methotrexate, fluorouracil, vincristine, prednisone regimen in, 46-51
previous history of, and hormone replacement therapy, 1002-1004
previously treated metastatic, paclitaxel, cyclophosphamide, G-CSF regimen in, 783-791
primary chemotherapy in, radioimmunoguided surgery following, 1599-1603
progesterone receptor in
for adjuvant therapy response monitoring, 2861
definition of, 2859
future research with, 2862
guidelines for, 2857
literature review of, 2860
methodology for, 2859-2860
for metastatic therapy response monitoring, 2860-2861
for recurrence prognosis, 2861-2862
as tumor marker, 2859-2862
radioimmunotherapy clinical trials in, 1390-1392
recurrence of
characteristics of, 54
estrogen receptor loss in, 2584-2589
hazard rates for, 2738-2746
as metastasis predictor, 52-57
relative risk summary in, 105-106
relative risks in, for survival model, 72
risk of
estrogen replacement therapy and, 997-1006
hormone replacement therapy and, 997-1006
screening women in, with > 10 positive axillary nodes, 66-69
stage II, postsurgical adjuvant chemotherapy in, 1589-1598
stage II-III, fluorouracil, doxorubicin, cyclophosphamide, sargramostim regimen in, 2976-2983
survival in, breast-conserving surgery and, 70-77
tamoxifen plus chemotherapy in, thromboembolism following, 2731-2737
tamoxifen-treated, p53 expression in, 1604-1610
taxane in, paclitaxel following, 1877-1884
tumor marker in
CA 15-3 as, 2855
carcinoembryonic antigen as, 2857-2859
estrogen receptor as, 2859-2862
practice guidelines for, 2843-2877
progesterone receptor as, 2859-2862
untreated metastatic, mifepristone in, 2709-2712
vinorelbine, fluorouracil regimen in, 3097-3104
Breast Cancer Detection Demonstration Project model, 103-110
clinical use of, 107-108
risk factors for, relative risks of, 108
Breast-sparing therapy, selection of, 3009-3017
Brequinar, pharmacokinetic parameters of, 2593
Bronchioloalveolar carcinoma
clinical features of, 2380-2383
CT of, 2381
definition of, 2377
diagnostic criteria for, 2379
epidemiology of, 2377-2379
histopathology of, 2379-2380
history of, 2377
molecular biology of, 2380
photomicrograph of, 2378
plain chest radiography of, 2381, 2382
treatment of, 2383
Busulfan
pharmacokinetic parameter variations of, 2591
pharmacokinetics of, 2593
Busulfan, cyclophosphamide, total-body irradiation regimen, in myelodysplastic syndrome, 220-226
Busulfan, ifosfamide, cytarabine, cyclophosphamide, stem-cell transplantation regimen, high-dose, in NHL, 586-592
Busulfan, thiotepa, cyclophosphamide regimen, autologous BMT plus, with preexisting CNS disease, 3036-3042
Buthionine sulfoximine, melphalan regimen
clinical toxicity of, 251-252
pharmacokinetics of, 253-254
phase I trial of, 249-256
responses to, 252

c-*erb*B-2
as breast tumor marker
definition of, 2863
future research with, 2865
and gene amplification, 2863
and gene expression correlation, 2863
guidelines for, 2863
and immunoblotting, 2863-2864
and immunohisotchemistry, 2864
literature review of, 2863-2865
methodology for, 2863
and therapy resistance, 2864-2865
overexpression of
and adjuvant tamoxifen efficacy, 2702-2708
in breast cancer, macrophage infiltrates in, 85-94
as tumor marker, practice guidelines for, 2843-2877
C-reactive protein, in melanoma, 1697-1703
CA 15-3
as colorectal tumor marker
for asymptomatic recurrence, 2856-2857
definition of, 2855
future research with, 2857
guidelines for, 2855
literature review of, 2855
methodology for, 2855
for response monitoring, 2857
for screening, 2855-2856
as tumor marker
in breast cancer, 2855
practice guidelines for, 2843-2877
CA 19.9
as colon tumor marker
for asymptomatic recurrence, 2851
definition of, 2851
guidelines for, 2851
methodology for, 2851
for screening, 2851
for therapy response, 2851-2852

as tumor marker, practice guidelines for, 2843-2877
CA 125
assay kit for, 1546
for chemotherapeutic response monitoring, in ovarian cancer, 1545-1551
evolving role of, in ovarian cancer, 1411-1412
Cachexia
drug handling and, 2602
megestrol acetate for, 135-141
Calcium folate, in combination chemotherapy, for lymphoma, 228
Camptothecin
chemical structure of, 504
overview of, 503-504
Cancer
advanced-stage non-hormone-sensitive, medroxyprogesterone acetate in, 1077-1084
genetic testing for, mothers' attitude toward, 415-421
low cholesterol and, 3043-3048
metastatic, PET evaluation of, 691-696
National Cancer Institute role in, for research, 2878-2883
quality care of, definition of, 2396-2397
predisposition to, testing for, 1733
research in, future of, 2878-2883
treatment of
cost-effectiveness of, 675-676
defining outcomes of, 671-679
defining quality of life following, 673-674
defining survival following, 672-673
defining toxicity of, 674
guideline development in, 676-677
patient outcomes following, 676
response to, measures of, 674-675
Cancer syndrome, hereditary, 1733
*Candida glabrata,* 1160
*Candida kruseii,* 1160
Carboplatin
blood counts following, 1074
dose-intensity for, trials of, 2118
dosing of, in high-dose chemotherapy, for germ cell cancer, 2644
in mesothelioma, 1009
in myeloablative chemoradiotherapy regimen, 2418
paclitaxel and, interactions between, 2598
pharmacokinetic parameter variations of, 2591
pharmacokinetic parameters of, 2593, 2596
Carboplatin, cyclophosphamide, thiotepa, BMT, supportive care regimen
in breast cancer, 1156-1164
infection following, 1160
nonhematologic toxicities due to, 1158-1160
survival following, 1161
Carboplatin, cyclophosphamide, thiotepa, stem-cell regimen
multiple courses of, 1473-1483
toxicity of, 1477-1479
Carboplatin, etoposide, bleomycin regimen
for germ cell tumor, of CNS, 2908-2915
outcome following, 2910-2912
survival following, 2912-2913
toxicity of, 2911-2912
Carboplatin, etoposide, cyclophosphamide, BMT regimen, high-dose
for germ cell tumors, 1098-1105
response to, 1101
survival following, 1101-1102
toxicity of, 1100, 1103
Carboplatin, etoposide, ifosfamide regimen, for conditioning, 1115
Carboplatin, etoposide, radiation regimen
in NSCLC, 1065-1070
response to, 1067-1068
toxicity of, 1068
Carboplatin, G-CSF regimen
hematological toxicity of, 802-803
nonhematological toxicity of, 803
in ovarian cancer, 800-805
toxicity of, 802
Carboplatin, ifosfamide, etoposide regimen, in breast cancer, 1869
Carboplatin, ifosfamide, etoposide, stem cell regimen, high-dose, in germ cell cancer, 2631-2637
Carboplatin, melphalan, cyclophosphamide, thiotepa regimen, in breast cancer, 2984-2992
Carboplatin, methotrexate, epidoxorubicin regimen, neoadjuvant, for bone histiocytoma, 490-496
Carboplatin, paclitaxel regimen
in NSCLC, 2054-2060
in ovarian cancer, 1895-1902
response to, 2056-2058
toxicities of, 2056-2057
Carboplatin, radiation regimen, hematologic parameters following, 1075
Carboplatin, thiotepa, stem-cell regimen, as myeloablative regimen, 1527
Carboxylesterase activity, interpatient variations in, 2688-2695
Carboxypeptidase G2
activity of, in plasma, 2148
pharmacokinetics of, 2147
rescue with, following high-dose methotrexate, 2145-2149
Carcinoembryonic antigen
as colorectal tumor marker
against routine use of, 2849-2850
for asymptomatic recurrence, 2848, 2858
definition of, 2846-2847, 2857
guidelines for, 2846, 2857
literature review of, 2858
for metastatic disease detection, 2850
methodology for, 2847, 2857
for postoperative prognosis, 2847-2848
for preoperative prognosis, 2847
for response monitoring, 2858-2859
for screening, 2847
for therapy monitoring, 2848-2849
as tumor marker
in breast cancer, 2857-2859
in colorectal cancer, 2846-2850
practice guidelines for, 2843-2877
interferon alfa upregulation of, 2031-2042
iodine 131-labeled monoclonal antibody for, 1789-1809
hematologic toxicity of, 1805
pharmacology of, 1789-1809
radiolabeled antibodies to, in medullary thyroid cancer, 1209-1217
serum, practice guidelines for, 2843-2877
Carcinoid tumor, metastatic, metaiodobenzylguanidine in, 1829-1838
Cardioprotection
dexrazoxane for, 328-333
ICRF-187 for, in pediatric sarcomas, 362-372

Cardiopulmonary toxicity
of cyclophosphamide, thiotepa, carboplatin, stem-cell regimen, 1478
radioimmunotherapy-induced, 1392
Cardiotoxicity
anthracycline-induced, dexrazoxane for, 328-333
doxorubicin-induced, ICRF-187 for, 362-372
of epirubicin, dexrazoxane for, 3112-3120
of mitoxantrone, 1762
Carmustine, dacarbazine, cisplatin regimen, in melanoma, 2083-2090
Carmustine, etoposide, cytarabine, cyclophosphamide, BMT regimen
high-dose, for NHL, in partial response, 534-542
survival following, 538-540
treatment algorithm for, 535
Carmustine, tamoxifen, dacarbazine, cisplatin regimen, in melanoma, 2083-2090
Carmustine, vincristine, cytarabine, methotrexate regimen
in chemoradiotherapy, for CNS lymphoma, 945-954
hematologic toxicity of, 949
relapse patterns following, 951
survival following, 950-952
Carmustine, vincristine, doxorubicin, prednisone regimen, in multiple myeloma, 2167-2173
Cataracts, tamoxifen-associated, 1023
Cathepsin-D
as breast tumor marker
guidelines for, 2866
literature review of, 2866-2867
methodology for, 2866
as tumor marker, practice guidelines for, 2843-2877
CD3, anti-T-lymphocyte marker, 91
CD4+ to CD8+ ratio, as prognostic factor, in melanoma, 1690-1696
CD11c, antimacrophage marker, 91
CD20 B-lymphocyte surface antigen, for radioimmunotherapy, 1974-1981
CD34+ cell
ex vivo expansion of, 1839-1847
preleukapheresis optimal counts of, for transplantation, 1114-1121
procedures for, 2225
reconstitute hematopoiesis, 2224-2233
selected, morphology of, 1844
yield, prediction of, 970-973
CD44 glycoprotein
N-*myc* gene amplification and, 27-29
as prognostic marker, in neuroblastoma, 25-34
variant of, as prognostic factor, in colorectal cancer, 1122-1127
CEA-scan, immunogenicity of, 2301-2302
Central nervous system
germ cell tumor of
carboplatin, etoposide, bleomycin regimen for, 2908-2915
chemotherapy alone for, 2908-2915
involvement of, in mantle-cell lymphoma, 941-944
primary NHL of, 945-954
tumor of, melphalan, cyclophosphamide, BMT regimen for, 382-388
Cerebral spinal fluid, etoposide penetration of, 399-404
Cervical cancer
clinical staging in, 111-112
combined modality therapy in, 3167-3168
pretreatment serum squamous cell carcinoma antigen in, 111-118
squamous, paclitaxel in, 792-795
Chemoimmunotherapy
in malignant mesothelioma, 878-885
in metastatic melanoma, prognostic factors for, 1690-1696
Chemoradiotherapy
acute toxicity of, 160
in bladder cancer, 123
in anal cancer, 2527-2539, 3121-3125
for astrocytoma, 600-609
with bladder preservation
in bladder cancer, 119-126
studies of, 124
in cancer, 3156-3174
with carboplatin, etoposide, radiation regimen, for NSCLC, 1065-1070
*v* chemoradiotherapy plus esophagectomy, 159
for CNS lymphoma, 945-954
colony-stimulating factor use in, guideline recommendations for, 1959
consolidation, plus BMT, in neuroblastoma, 2417-2426
in esophageal cancer, 149-155
with etoposide, cisplatin, radiation regimen, for NSCLC, 1055-1064
in HD, 527-533, 1928-1935
pulmonary function following, 1297-1305
in head and neck cancer, 1192-1200
for hepatic metastasis, 722-728
high-dose, following cytarabine purging, 2206-2216
in high-risk multiple myeloma, 1306-1313
for inoperable NSCLC, 1055-1064
leukemia following, for breast cancer, 2722-2730
for limited-cell SCLC, 806-813
in NHL, leukemia following, 565-571
with paclitaxel, radiation regimen, for NSCLC, 1071-1076
preoperative
failure pattern following, 833-834
in esophageal cancer, 156-163, 828-837
survival following, 833
toxicity of, 834
in primary CNS lymphomas, 556-564
radiotherapy *v*
in bladder cancer, 3168
in head and neck cancer, 3165
for malignant glioma, 3163
in rectal cancer, 3167
sequencing of, 3160
standard *v* high-dose, in NHL, 586-592
treatment scheme for, in esophageal cancer, 151
*see also* Combined modality therapy
Chemosensitization, with cytokines, 1371-1373
Chemotherapy
acute myeloid leukemia-type, in myelodysplastic syndromes, 2486-2494
adjuvant
in breast cancer, 35-45
cyclophosphamide, epidoxorubicin, fluorouracil regimen and, 764-773
in metastatic breast cancer, 764-773
methotrexate, cyclophosphamide, fluorouracil regimen and, 764-773
ovarian function following, in breast cancer, 1718-1729

in soft tissue sarcoma, 859-868
agents of, interactions between, 2598
alkylating type of, in malignant mesothelioma, 1010-1011
amenorrhea associated with, 1718-1729
anthracycline
dexrazoxane and, 328-331
in malignant mesothelioma, 1008-1010
anthracycline-based adjuvant, in breast cancer, 1136-1145
antifolate type of, in malignant mesothelioma, 1011
antimetabolite type of, in malignant mesothelioma, 1011-1012
body-surface-area based dosing of, 2590-2611
combination, *see* Combination chemotherapy
concurrent, definition of, 841
consolidation
cytokines during, 1378
high-dose cytarabine as, 2206-2216
dose calculation of, 2590-2611
dose-intensity of, 2595
dosing of
age *v* body size and, 2594-2595
by body weight, 3000-3008
simulated adjustment score table for, 2603
handling of, patient characteristics impacting on, 2602
hepatic metastasis response to, FDG-PET analysis of, 700-708
high-dose regimens of, 2467
with autologous stem-cell transplantation, 2465-2472
for cisplatin-resistant germ cell cancer, 2625-2626
comprehensive supportive care regimen following, 1156-1164
definition of, 638
in germ cell cancer, 2638-2645
multiple courses of, 1473-1483
in multiple myeloma, 1306-1313
regimens of, 2643
response to, 2467
treatment outcome following, in germ cell cancer, 2643
hospital monitoring of, 3154
induction, *see* Induction chemotherapy
intensification
plus BMT, in leukemia, 1353-1363
with cyclophosphamide, thiotepa, carboplatin, marrow, blood-stem cell, G-CSF regimen, 2985
daunorubicin, cytarabine, etoposide regimen as, 1354
with melphalan, stem-cell regimen, 2985
intrathecal, for retinoblastoma, 1533
maintenance
definition of, 841
with etoposide, vindesine regimen, 2337-2344
in malignant pleural mesothelioma, 1007-1017
modified dosing of, 2590-2611
in myeloablative regimen, 1527
neoadjuvant
definition of, 841
in osteosarcoma, 848-858
neuropsychologic effects of, 2826-2835
nonhematologic toxicity of, 2605
order practices in, survey of, 3153-3155
orders for, by non-oncologists, 3150-3153
perioperative, in breast cancer, 745-753
pharmacokinetic-guided dosing calculation of, 2599
pharmacokinetic parameter variations of, 2591
pharmacokinetic parameters of, 2593-2594
pharmacokinetics of, response correlation with, 2595-2596
platinum type of, in malignant mesothelioma, 1010
PMT dosing of, 2590-2611
poly-, *see* Polychemotherapy
postoperative adjuvant, in NSCLC, 1045-1054
prescribing of, 3150
prime dosing of, 2590-2611
protocols of, relative hazard rates of, 842
radiation and, sequencing of, 3160
radiation plus, *see* Chemoradiotherapy
regimens of, in combined modality therapy, for SCLC, 809
resistance mechanisms to, 3157-3158
risk-adapted, in osteosarcoma, 848-858
scheduling of, and drug combinations, 2605-2606
in SCLC, age and, 821-828
second tumors following, 2769-2773
sequencing of, in topotecan, cisplatin regimen, 3074-3084
survey questionnaire in, 3153
in synovial sarcoma, 1206
therapeutic monitoring of, and pharmacologic adaptive control, 2596-2597
toxicity-adjusted dosing of, 2590-2611
toxicity of, and drug combinations, 2605
use of, improving process for, 3148-3155
verbal orders for, 3149-3150
vinca alkaloid type of, in malignant mesothelioma, 1010
Child(ren)
colony-stimulating factor use in, guideline recommendations for, 1959
HD therapy in, second malignancy following, 1442-1446
neutropenic, bacteremia risk in, 919-924
recurrent leukemia in, topotecan for, 1504-1511
stage IV-S neuroblastoma in, primary tumor resection for, at diagnosis, 1537-1544
Chimeric antibody, 1392-1393
2-Chlorodeoxyadenosine, *see* Cladribine
Cholangiocarcinoma, 2313
Cholesterol
biosynthetic pathway of, 3045-3046
inhibition of, cancer therapy and, 3046-3047
low, and cancer, 3043-3048
Chromosome, aberrations of, in circulating B cells, 1333-1344
Chromosome 9, 1517
Chronotherapy
ambulatory, in colorectal cancer, 2950-2958
intensified, 2950-2958
Chymopapain, 2225
CI-973, dose-toxicity curve for, 292
Cimetidine, paclitaxel interaction with, 2718
Cimetidine, dexamethasone, diphenhydramine, paclitaxel regimen
in biliary tract cancer, 2306-2310
toxicity of, 2308
Cisplatin
in combination chemotherapy, for SCLC, age and, 821-828
delivered dose of, by age, 825
docetaxel and, interactions between, 2598
dose-intensity for, trials of, 2118
dosing of, for ovarian cancer, 2113-2119
germ cell tumors refractory to, high-dose carboplatin, etoposide, cyclophosphamide, BMT regimen in, 1098-1105
high *v* low-dose, in cisplatin, cyclophosphamide, epidoxorubicin regimen, 351-356
with intraperitoneal and intravenous fluorouracil, in gastric cancer, 1818-1828

in mesothelioma, 1009
in myeloablative chemoradiotherapy regimen, 2418
ovarian cancer refractory to, paclitaxel in, 796-799
paclitaxel interaction with, 2598, 2718
persisting late toxicity associated with, 2930
pharmacokinetic parameter variations of, 2591
pharmacokinetics of, 2596
in preoperative combination chemotherapy, for SCLC, 830
in preoperative combined modality therapy, for SCLC, 830
preoperative radiotherapy plus, for invasive bladder cancer, 2901-2907
resistance mechanisms of, 3158
second cancer following, 2770
survival following, in ovarian cancer, 2114-2117
topotecan interaction with, 2598, 3081
topotecan sequence dependence on, 3081
topotecan synergy with, 3080-3081
toxicities associated with, amifostine for, 2101-2112
worst toxicity associated with, 2117
Cisplatin, amifostine, vinblastine regimen
in NSCLC, 1913-1921
toxicity of, 1915-1917
Cisplatin, bleomycin, etoposide regimen
adjuvant, for nonseminomatous testicular germ cell tumor, 1106-1113
endocrinologic late toxicity of, 2927
gonadal toxicity of, 2926-2927
long-term toxicity of, 1109
neurotoxicity of, 2925
otoxicity of, 2925-2926
relapse following, 1109-1110
renal late toxicity of, 2927
short-term toxicity of, 1108-1109
in testicular cancer, 2923-2932
vascular toxicity of, 2926
Cisplatin, bleomycin, vinblastine regimen
endocrinologic late toxicity of, 2927
gonadal toxicity of, 2926-2927
neurotoxicity of, 2925
otoxicity of, 2925-2926
renal late toxicity of, 2927
in testicular cancer, 2923-2932
vascular toxicity of, 2926
Cisplatin, carmustine, dacarbazine regimen, in melanoma, 2083-2090
Cisplatin, cyclophosphamide, epidoxorubicin regimen, high *v* low-dose cisplatin in, 351-356
Cisplatin, dexamethasone, cytarabine regimen, for NHL, in partial response, 534-542
Cisplatin, dihydroazacytidine regimen, in malignant mesothelioma, 1013
Cisplatin, doxorubicin regimen, in malignant mesothelioma, 1013
Cisplatin, doxorubicin, cyclophosphamide regimen, in malignant mesothelioma, 1013
Cisplatin, etoposide regimen
in malignant mesothelioma, 1013
in malignant thymoma, 814-820
toxicity of, 816
Cisplatin, etoposide, bleomycin regimen, adjuvant
acute side effects of, 443
high-tone hearing loss following, 445
lung function following, 445
psychosocial self-report following, 444
sperm counts following, 446
in testicular germ cell cancer, 441-448
Cisplatin, etoposide, megestrol acetate regimen
in SCLC, 135-141
toxicity of, 140
Cisplatin, etoposide, radiation regimen
in combined modality therapy, for SCLC, 806-813
failure pattern following, 1059-1060
in NSCLC, 1055-1064
response to, 1058
survival following, 1059
toxicity of, 810, 1058
treatment schema for, 1056
Cisplatin, fluorouracil regimen, in glottic carcinoma, 2331-2336
Cisplatin, fluorouracil, interferon alfa-2b regimen
in head and neck cancer, 1663-1671
predictive toxicity models for, 1666
toxicity of, 1666
Cisplatin, fluorouracil, radiation regimen
in anal cancer, 3121-3125
in head and neck cancer, 1192-1200
response to, 1195
survival following, 1196
toxicity of, 1194-1195
Cisplatin, gemcitabine regimen
dose-escalation schema in, 1657
hematologic toxicity of, 1658-1659
in NSCLC, 1656-1662
Cisplatin, interferon alfa regimen, in malignant mesothelioma, 1013
Cisplatin, interferon alfa-2a regimen
response to, 881-882
survival following, 882
toxicity of, 880-881
weekly, in malignant mesothelioma, 878-885
Cisplatin, mitomycin regimen, in malignant mesothelioma, 1013
Cisplatin, mitomycin, bleomycin, doxorubicin regimen, in malignant mesothelioma, 1013
Cisplatin, mitomycin, interferon alfa regimen, in malignant mesothelioma, 1013
Cisplatin, paclitaxel regimen
biweekly
in breast cancer, 1185-1191
toxicity of, 1188-1189
in breast cancer, 1993-1999
neurotoxicity of, 1996
response to, 1189
Cisplatin, paclitaxel, cyclophosphamide, stem-cell regimen
pharmacokinetics of, 1467
phase I trial of, 1463-1472
toxicity of, 1466-1467
Cisplatin, paclitaxel, etoposide, radiation regimen
in NSCLC, 1642-1648
toxicity of, 1645-1646
Cisplatin, pirarubicin regimen, in malignant mesothelioma, 1013
Cisplatin, radiation regimen
for invasive bladder cancer, 2901-2907
survival following, 2904-2905
Cisplatin, tamoxifen, carmustine, dacarbazine regimen, in melanoma, 2083-2090
Cisplatin, teniposide regimen
in NSCLC, 127-134

survival following, 130-132
toxicity of, 129-130
Cisplatin, topotecan regimen
hematologic toxicity of, 3078
nonhematologic toxicity of, 3078-3079
pharmacokinetics of, 3079-3080
sequence of, 3074-3084
Cisplatin, vindesine, tegafur, uracil regimen, postoperative
adverse effects of, 1051
causes of death following, 1052
mean total dosing of, 1050
in NSCLC, 1048-1054
Cladribine
bioavailability of, 978-983
clinical response to, 192
dosing of, for hematologic malignancies, 188-195
five 1-hour infusions of, 188-195
hematologic toxicity of, 191-192
nonhematologic toxicity of, 190-191
oral, in B-cell chronic lymphocytic leukemia, 2160-2166
pharmacokinetics of, 978-983
therapy with, infections following, 191
toxicity of, 980-981
Cladribine, mitoxantrone regimen
for indolent NHL, 2139-2144
toxicity of, 2140-2142
Clinical investigator training, American Society of Clinical Oncology approach to, 2392-2394
Clinical oncology research
basic research *v*, 667-668
definition of, 666
funding for, 666-670
funding impediments in, 667
increasing support for, 669
need for, 666-667
NIH funding of, 668-669
Clinical research, in oncology, 2617
Clinical trial(s)
of combined modality therapy, guidelines for, 3160-3162
commonly used eligibility criteria in, 1370
design of, 299-300
design operating characteristics for, 301-302
early-stopping criteria in, 300-301
eligibility criteria in, need for, 1365
eligibility criteria reduction in, proposals for, 1369-1370
improvement of, 2397
ineligible patient entry in, implications of, 1368-1369
informed consent in, telephone-based nursing intervention for, 984-996
meta-analysis of, 3162
monitoring efficacy in, 296-303
monitoring safety in, 296-303
nonrandomized, 3160
participation in, telephone-based intervention and, 991
patient care coverage in, 2397
phase I, design of, 287-295
phase III, reduced eligibility criteria in, 1364-1370
randomized, 3161-3162
relaxed eligibility criteria in, effects of, 1368
restrictive eligibility criteria in, problems resulting from, 1366-1367
safety in, 1367-1368
sample size in, 1367-1368
stage migration in, 3161
system of, review of, 2880
Clonal evolution, prognostic significance of, in leukemia, 196-203
CNS, *see* Central nervous system
Coagulation, during adjuvant epirubicin, cyclophosphamide regimen, 2560-2568
Cockcroft-Gault formula, 1918
COL-1 monoclonal antibody, 2038, 2039
iodine 131-labeled
hematologic toxicity of, 1805
pharmacology of , 1789-1809
phase I trial of, 1789-1809
Colon cancer
advanced, iodine 125-labeled monoclonal antibody A33 in, 1787-1797
CA 19.9 in
for asymptomatic recurrence, 2851
definition of, 2851
guidelines for, 2851
methodology for, 2851
for screening, 2851
for therapy response, 2851-2852
COL-1 in, 1801
DNA ploidy in
definition of, 2852
future research with, 2853
guidelines for, 2852
methodology for, 2852
for postoperative prognosis, 2852-2853
flow cytometric proliferation analysis in
definition of, 2852
future research with, 2853
guidelines for, 2852
methodology for, 2852
for postoperative prognosis, 2852-2853
radioimmunotherapy clinical trials in, 1390-1392
surgery in, patient surveillance following, 183-187
Colony-stimulating factor
in acute myeloid leukemia, 1958-1959
in afebrile patients, 1958
American Society of Clinical Oncology survey of, 2511-2520
in chemoradiotherapy, 1959
in children, 1959
dosing of, 1959
in febrile patients, 1958
general use patterns of, 2513
GM-CSF *v*, comparative clinical activity of, 1959
to increase chemotherapy dose-intensity, 1958
initiation of, 1959
neuropathy due to, 935-940
in progenitor-cell transplantation, 1958
survey questionnaire for, 2516-2520
use of
for specific clinical situations, 2514
updated recommendations for, 1957-1960
utilization scores of, by practice setting, 2513-2514
Colorectal cancer
advanced
fluorouracil in, 2674-2681
fluorouracil, folinic acid, interferon alfa-2b regimen in, 2682-2687

interferon alfa-2a, fluorouracil regimen in, 2674-2681
ZD1694 in, 716-721
antibody imaging in, 2295-2305
carcinoembryonic antigen in
against routine use of, 2849-2850
for asymptomatic recurrence, 2848
definition of, 2846-2847
guidelines for, 2846
for metastatic disease detection, 2850
methodology for, 2847
for postoperative prognosis, 2847-2848
for preoperative prognosis, 2847
for screening, 2847
for therapy monitoring, 2848-2849
CD44 variant in, 1122-1127
combined modality therapy in, 3167
FDG-PET in, 700-708
hepatic metastases from, interferon-alpha plus fluorouracil for, 700-708
high-dose infusional fluorouracil plus low-dose methotrexate in, 2266-2273
incidence of, 709, 2674
intensified chronotherapy in, 2950-2958
interferon biomodulation for, 2280-2288
irinotecan in, 2688-2695
lipid-associated sialic acid in
definition of, 2850
guidelines for, 2850
literature of, 2850-2851
methodology for, 2850
metastatic
AZT, fluorouracil, folinic acid regimen in, 729-736
weekly high-dose *v* low-dose folinic acid plus fluorouracil in, 2274-2279
microvessel count in, as prognostic factor, 461-466
outcome in, matrix metalloproteinase-9 predictor of, 3133-3140
p53 in
definition of, 2853
future research with, 2854
guidelines for, 2853
methodology for, 2853-2854
overexpression of, with advanced hepatic metastases, 2696-2701
for postoperative prognosis, 2854
pulmonary metastases of, prognostic factors in, 2047-2053
rapidly recurrent, irinotecan in, 1128-1135
*ras* in
definition of, 2854
future research with, 2855
guidelines for, 2854
literature review of, 2854-2855
methodology for, 2854
relapse in, matrix metalloproteinase-9 predictor of, 3133-3140
topotecan in, 2540-2545
tumor marker in
carcinoembryonic antigen as, 2846-2850
p53 as, 2853
practice guidelines for, 2843-2877
*ras* as, 2854
untreated metastatic, irinotecan in, 709-715
Combination chemotherapy
in chemoradiotherapy protocol, for CNS lymphoma, 945-954
cisplatin-based, in NSCLC, 127-134
with GM-CSF, in diffuse aggressive NHL, 1275-1281
in malignant mesothelioma, 1012-1014
risk of febrile neutropenia and, 638
second cancer, following, 2769-2773
venous access ports for, 2916-2922
Combined modality therapy
in anal cancer, 3167
for astrocytoma, 600-609
in bladder cancer, 3168
with bladder preservation, in bladder cancer, 119-126
with carboplatin, etoposide, radiation regimen, for NSCLC, 1065-1070
in cancer, 3156-3174
in cervical cancer, 3167-3168
clinical trials of, guidelines for, 3160-3162
in colorectal cancer, 3167
for different tumor sites, 3162-3169
in esophageal cancer, 3166
with etoposide, cisplatin, radiation regimen, for NSCLC, 1055-1064
in gastric cancer, 3166
in HD, 527-533
pulmonary function following, 1297-1305
in head and neck cancer, 1192-1200
in high-risk multiple myeloma, 1306-1313
in limited-stage SCLC, 806-813
neoadjuvant chemotherapy plus, in esophageal cancer, 149-155
new approaches in, 3169
in NHL, leukemia following, 565-571
nonrandomized trials of, 3160
in NSCLC, 3165-3166
paclitaxel in, for NSCLC, 1642-1648
with paclitaxel, radiation regimen, for NSCLC, 1071-1076
in pancreatic cancer, 3166-3167
preoperative, for limited-cell SCLC, 806-813
in primary CNS lymphomas, 556-564
in prostate cancer, 3168-3169
randomized trials of, 3161-3162
in SCLC, 3166
sequencing of, 3160
standard *v* high-dose, in NHL, 586-592
for therapeutic benefit, 3156
therapeutic index in, 3156-3157
toxicity of, 1646
trial results of, for inoperable NSCLC, 1060
*see also* Chemoradiotherapy
Community hospital, work activities of, in oncology, 2617
Complementarity-determining region-grafted antibody, 1392-1393
Computed tomography
of neuroblastoma, 376-377
SPECT gallium imaging *v*, in NHL, 2473-2479
Constant, lumped, 692
Controlled Oral Work Association, 1458
Cost
of adjuvant radiotherapy *v* observation, in stage I seminoma, 2933-2939
of BMT, 1415-1416
cumulative, in early seminoma, 2937
of patient care, in clinical trials, 2397
seminoma-specific medical, 2936
in stage I seminoma, 2933-2939

Cost-effectiveness
of BMT, 1416-1417
of cancer treatment, 675-676
of G-CSF dose-intensity maintenance, 1573-1580
Cox model, 476, 1561-1562
CPT-11, *see* Irinotecan
Cranial irradiation, weekly outpatient paclitaxel plus
for astrocytoma, 600-609
toxicity of, 602-604
CSF, *see* Cerebral spinal fluid
CT, *see* Computed tomography
Cyclophosphamide
amenorrhea due to, 1723
in combination chemotherapy
for SCLC, age and, 821-828
second cancer following, 2770
for small non-cleaved-cell lymphoma, 925-934
delivered dose of, by age, 825
high-dose
CM-CSF *v* G-CSF following, 628-635
for autologous peripheral-blood progenitor-cell support, 1306-1313
in mesothelioma, 1009, 1010
metabolism of, partial scheme of, 1485
in myeloablative chemoradiotherapy regimen, 2419
overview of, 1484
paclitaxel interaction with, 2598, 2718
pharmacokinetic parameter variations of, 2591
pharmacokinetic parameters of, 2596
pharmacokinetics of, 1484-1494
simulated dose adjustment score table for, 2603
toxicities associated with, amifostine for, 2101-2112
Cyclophosphamide, busulfan, total-body irradiation regimen, in myelodysplastic syndrome, 220-226
Cyclophosphamide, carboplatin, etoposide, BMT regimen, high-dose
for germ cell tumors, 1098-1105
response to, 1101
survival following, 1101-1102
toxicity of, 1100, 1103
Cyclophosphamide, carmustine, etoposide, cytarabine, BMT regimen
high-dose, for NHL, in partial response, 534-542
survival following, 538-540
treatment algorithm for, 535
Cyclophosphamide, cisplatin, epidoxorubicin regimen, high *v* low-dose cisplatin in, 351-356
Cyclophosphamide, doxorubicin regimen, in malignant mesothelioma, 1013
Cyclophosphamide, doxorubicin, cisplatin regimen, in malignant mesothelioma, 1013
Cyclophosphamide, doxorubicin, dacarbazine regimen, in malignant mesothelioma, 1013
Cyclophosphamide, doxorubicin, etoposide, didanosine, G-CSF regimen, in HIV-associated NHL, 3026-3035
Cyclophosphamide, doxorubicin, etoposide, prednisone, bleomycin, cytarabine, methotrexate, folinic acid, GM-CSF regimen
maximum-tolerated dose of, in lymphoma, 1275-1281
response to, 1278
toxicity of, 1277-1278
Cyclophosphamide, doxorubicin, fluorouracil regimen
dosing of
by body weight, 3000-3008
schedule for, 3001
in early-phase breast cancer, 745-753
perioperative, 745-753
Cyclophosphamide, doxorubicin, fluorouracil, vincristine regimen
in breast cancer, 1136-1145
dose analysis of, 1138-1139
radiotherapy and, 1141-1142
relapse site following, 1141
schedule for, 1137
toxicity of, 1139
Cyclophosphamide, doxorubicin, G-CSF regimen
outpatient, in breast cancer, 1565-1572
in prostate cancer, 1617-1625
survival following, 1620
toxicity following, 1620-1622
Cyclophosphamide, doxorubicin, methotrexate, fluorouracil regimen, G-CSF dose-intensity maintenance of, 1573-1580
Cyclophosphamide, doxorubicin, vincristine regimen
in combined modality therapy, for SCLC, 806-813
toxicity of, 810
Cyclophosphamide, doxorubicin, vincristine, bleomycin, etoposide, prednisolone, methotrexate regimen, in NHL, 586-592
Cyclophosphamide, doxorubicin, vincristine, dexamethasone regimen
in chemoradiotherapy, for CNS lymphoma, 945-954
hematologic toxicity of, 949
pre-irradiation, in primary CNS lymphomas, 556-564
relapse patterns following, 951
survival following, 950-952
Cyclophosphamide, doxorubicin, vincristine, dexamethasone, radiation regimen
age and, 563
survival following, 559-560
toxicity of, 560-561
treatment schema for, 558
Cyclophosphamide, doxorubicin, vincristine, ifosfamide, etoposide regimen, for desmoplastic tumor, 1526-1531
Cyclophosphamide, doxorubicin, vincristine, methotrexate, cytarabine regimen
in pediatric leukemia, 1252-1261
in stage IV small non-cleaved-cell lymphoma, 1252-1261
Cyclophosphamide, doxorubicin, vincristine, prednisone regimen, in primary cutaneous follicle center cell lymphoma, 549-555
Cyclophosphamide, doxorubicin, vindesine, bleomycin, prednisone regimen, in lymphoma, 240-248
Cyclophosphamide, epidoxorubicin, fluorouracil regimen, adjuvant chemotherapy and, in metastatic breast cancer, 764-773
Cyclophosphamide, epirubicin regimen, adjuvant, blood coagulation during, 2560-2568
Cyclophosphamide, epirubicin, fluorouracil regimen, in breast cancer, 35-45
Cyclophosphamide, epirubicin, vincristine, prednisolone regimen, in lymphoma, 227-232
Cyclophosphamide, fluorouracil, doxorubicin, radiation regimen, leukemia following, 2722-2730
Cyclophosphamide, fluorouracil, doxorubicin, sargramostim regimen
in breast cancer, 2976-2983
neutropenia associated with, 2979
Cyclophosphamide, ifosfamide, cytarabine, busulfan, stem cell transplantation regimen, high-dose, in NHL, 586-592
Cyclophosphamide, melphalan, BMT regimen

for CNS tumors, 382-388
dosing plan for, 384
response to, 385
survival following, 386
toxic deaths due to, 385
Cyclophosphamide, melphalan, thiotepa, carboplatin regimen, in breast cancer, 2984-2992
Cyclophosphamide, methotrexate, fluorouracil regimen
in breast cancer, 1885-1894, 1982-1992
G-CSF dose-intensity maintenance of, 1573-1580
as gold standard, 1971-1973
PMT dosing of, 2601
tamoxifen plus, thromboembolism following, 2731-2737
toxicity of, 1988
Cyclophosphamide, methotrexate, fluorouracil, vincristine, prednisone regimen
in breast cancer, 1589-1598
dosing of, 1591
survival following, 1593-1595
toxicity of, 1594-1596
Cyclophosphamide, methotrexate, fluorouracil regimen
adjuvant chemotherapy and, in metastatic breast cancer, 764-773
in breast cancer, 35-45, 1136-1145
dose analysis of, 1138-1139
radiotherapy and, 1141-1142
relapse site following, 1141
schedule for, 1137
toxicity of, 1139
Cyclophosphamide, methotrexate, fluorouracil, vincristine, prednisone regimen
in breast cancer, 46-51
ovariectomy plus, 46-51
toxicity of, 49
Cyclophosphamide, methotrexate, vincristine, doxorubicin, bleomycin, dactinomycin regimen, neoadjuvant, for bone histiocytoma, 490-496
Cyclophosphamide, mitoxantrone, G-CSF regimen
in breast cancer, 2576-2583
hematologic toxicity of, 2579
nonhematologic toxicity of, 2580
Cyclophosphamide, paclitaxel, cisplatin, stem-cell regimen
pharmacokinetics of, 1467
phase I trial of, 1463-1472
toxicity of, 1466-1467
Cyclophosphamide, paclitaxel, G-CSF regimen
dose-limiting toxicity of, 787
dosing of, 784, 98
drug sequencing in, 785
hematologic toxicity of, 787-788, 97-98
in metastatic breast cancer, 95-102
nonhematologic toxicity of, 788, 98-99
pharmacology of, 788-789
in previously treated metastatic breast cancer, 783-791
response to, 99
Cyclophosphamide, thiotepa, busulfan regimen, autologous BMT plus, with preexisting CNS disease, 3036-3042
Cyclophosphamide, thiotepa, carboplatin, BMT, supportive care regimen
in breast cancer, 1156-1164
infection following, 1160
nonhematologic toxicities due to, 1158-1160
survival following, 1161
Cyclophosphamide, thiotepa, carboplatin, stem-cell regimen
multiple courses of, 1473-1483
toxicity of, 1477-1479
Cyclophosphamide, vincristine, melphalan, prednisone regimen, in multiple myeloma, 2167-2173
Cyclophosphamide, vincristine, prednisone regimen, in primary cutaneous follicle center cell lymphoma, 549-555
Cyclophosphamide, vincristine, prednisone, doxorubicin regimen, high-dose mitoxantrone plus cytarabine *v*, 2480-2485
Cyclosporin A, in paclitaxel-resistant NHL, 233-239
Cyclosporine, methotrexate regimen, for graft-versus-host disease prophylaxis, 1355
Cytarabine
in chemoradiotherapy protocol, for CNS lymphoma, 945-954
in combination chemotherapy
for acute lymphoblastic leukemia, 2805
for pediatric B-precursor acute lymphoblastic leukemia, 2803-2811
high-dose, for in vivo purging, 2206-2216
intrathecal, for retinoblastoma, 1533
in leukemia, 204-213
pharmacokinetic parameters of, and tumor response, 2597
in polychemotherapy, for pediatric acute lymphoblastic leukemia, 2813
Cytarabine, amsacrine regimen, for intensification, 1354
Cytarabine, carmustine, etoposide, cyclophosphamide, BMT regimen
high-dose, for NHL, in partial response, 534-542
survival following, 538-540
treatment algorithm for, 535
Cytarabine, carmustine, vincristine, methotrexate regimen
in chemoradiotherapy, for CNS lymphoma, 945-954
hematologic toxicity of, 949
relapse patterns following, 951
survival following, 950-952
Cytarabine, cyclophosphamide, doxorubicin, etoposide, prednisone, bleomycin, methotrexate, folinic acid, GM-CSF regimen
maximum-tolerated dose of, in lymphoma, 1275-1281
response to, 1278
toxicity of, 1277-1278
Cytarabine, cyclophosphamide, doxorubicin, vincristine, methotrexate regimen
in pediatric leukemia, 1252-1261
in stage IV small non-cleaved-cell lymphoma, 1252-1261
Cytarabine, daunorubicin, etoposide regimen, for intensification, 1354
Cytarabine, daunorubicin, GM-CSF regimen, in acute myeloid leukemia, 2150-2159
Cytarabine, dexamethasone, cisplatin regimen, for NHL, in partial response, 534-542
Cytarabine, ifosfamide, busulfan, cyclophosphamide, stem cell regimen, high-dose, in NHL, 586-592
Cytarabine, ifosfamide, etoposide regimen, in combination chemotherapy protocol, for small non-cleaved-cell lymphoma, 925-934
Cytarabine, mitoxantrone regimen
in leukemia, 2480-2485
vincristine, prednisone, doxorubicin, cyclophosphamide regimen *v*, 2480-2485
Cytokeratin, in gastric cancer, 1810-1817
Cytokeratin 19, 1868
Cytokine(s)

chemosensitization with, 1371-1373
clinical trials with, 1373-1378
during consolidation therapy, 1378
during induction therapy, 1373-1378
following induction therapy, 1373-1378
future, 1379-1380
in leukemia, 1371-1382
pharmacoeconomic issues and, 1378-1379
phase III trials of, in de novo acute myelocytic leukemia, 1373-1377
PIXY321 type of, following autologous BMT, 520-526
priming with, before chemotherapy, 1371-1373
safety of, 1377
in younger patients, 1378
*see also* Granulocyte colony-stimulating factor; Granulocyte-macrophage colony-stimulating factor
Cytoreduction, as prognostic factor, in leukemia, 389-398
Cytotoxin, hypoxic, 1394

Dacarbazine, carmustine, cisplatin regimen, in melanoma, 2083-2090
Dacarbazine, doxorubicin, bleomycin, vinblastine regimen
alternating with MOPP regimen, 1421-1430
in HD, 1297-1305
pulmonary function following, 1297-1305
Dacarbazine, doxorubicin, bleomycin, vinblastine, methylprednisone, radiation therapy, in HD, 1928-1935
Dacarbazine, doxorubicin, bleomycin, vinblastine, radiation regimen
in HD, 1297-1305
pulmonary function following, 1297-1305
Dacarbazine, doxorubicin, cyclophosphamide regimen, in malignant mesothelioma, 1013
Dacarbazine, rubidazone regimen, in malignant mesothelioma, 1013
Dacarbazine, tamoxifen, carmustine, cisplatin regimen, in melanoma, 2083-2090
Dacarbazine, vincristine, lomustine, bleomycin, interferon regimen, in melanoma, 1690-1696
Dactinomaycin, methotrexate, vincristine, doxorubicin, cyclophosphamide, bleomycin regimen, neoadjuvant, for bone histiocytoma, 490-496
Dactinomycin, in combination chemotherapy, second cancer following, 2770
Daunorubicin
in combination chemotherapy, for acute lymphoblastic leukemia, 2805
liposomal
cardiac toxicity following, 2361
in Kaposi's sarcoma, 2353-2364
opportunistic infections following, 2361
quality of life following, 2359
response to, 2356-2358
survival following, 2358-2360
toxicity of, 2359-2361
in polychemotherapy, for pediatric acute lymphoblastic leukemia, 2813
Daunorubicin, cytarabine, etoposide regimen, for intensification, 1354
Daunorubicin, cytarabine, GM-CSF regimen, in acute myeloid leukemia, 2150-2159
Death, determining cause of, 1028-1029
Deep vein thrombosis, inferior vena cava filters for, 652-657
Deletion analysis, 1515
Dermatofibrosarcoma protuberans, radiotherapy in, 2365-2369
Design primer, 2183
Desmoplastic tumor
aggressive multimodality therapy in, 1526-1531
cyclophosphamide, doxorubicin, vincristine, ifosfamide, etoposide regimen for, 1526-1531
Detorubicin, in mesothelioma, 1009
Dexamethasone
apoptosis induced by, 2373-2374
intrathecal, for retinoblastoma, 1533
prednisolone *v*, in acute lymphoblastic leukemia, 2370-2376
in polychemotherapy, for pediatric acute lymphoblastic leukemia, 2813
Dexamethasone, cisplatin, cytarabine regimen, for NHL, in partial response, 534-542
Dexamethasone, cyclophosphamide, doxorubicin, vincristine regimen
in chemoradiotherapy, for CNS lymphoma, 945-954
hematologic toxicity of, 949
pre-irradiation, in primary CNS lymphomas, 556-564
relapse patterns following, 951
survival following, 950-952
Dexamethasone, cyclophosphamide, doxorubicin, vincristine, radiation regimen
age and, 563
survival following, 559-560
toxicity of, 560-561
treatment schema for, 558
Dexamethasone, diphenhydramine, cimetidine, paclitaxel regimen
in biliary tract cancer, 2306-2310
toxicity of, 2308
Dexamethasone, fludarabine, mitoxantrone regimen
for indolent lymphoma, 1262-1268
response to, 1263-1264
survival following, 1265
toxicity of, 1264-1266
Dexamethasone, ifosfamide, etoposide, methotrexate regimen, in lymphoma, 227-232
Dexamethasone, vincristine regimen, for maintenance, in acute lymphoblastic leukemia, 911-918
Dexamethasone, vincristine, asparaginase, methotrexate regimen, for induction, in acute lymphoblastic leukemia, 911-918
Dexrazoxane
cardioprotection of, 328-333
for epirubicin cardiotoxicity, 3112-3120
Diagnosis, of cutaneous melanoma, interobserver agreement on, 1218-1223
Diarrhea
diphenhydramine plus loperamide for, 709-715
irinotecan-induced, loperamide for, 1129
Diaziquone, in mesothelioma, 1009
Diazohydroxide, pharmacokinetic parameters of, 2593
Dichloromethotrexate, pharmacokinetic parameters of, 2593
Didanosine, cyclophosphamide, doxorubicin, etoposide, G-CSF regimen, in HIV-associated NHL, 3026-3035
Dideazafolic acid, in mesothelioma, 1009
Diethylstilbestrol
flutamide *v*, in prostate cancer, 2250-2257
response to, 2253
survival following, 2253-2255
toxicities of, 2252-2253
Dihydroazacytidine, in mesothelioma, 1009

Dihydroazacytidine, cisplatin regimen, in malignant mesothelioma, 1013
Dihydropyrimidine dehydrogenase, 76C85 inactivation of, 3085-3096
Dimethyl sulfoxide, 1514
Diphenhydramine, loperamide plus, for diarrhea, 709-715
Diphenhydramine, dexamethasone, cimetidine, paclitaxel regimen
in biliary tract cancer, 2306-2310
toxicity of, 2308
Distress screening, following breast cancer, 2747-2755
DNA, flow cytometry
for tamoxifen-induced endometrial proliferation, 434-440
as tumor marker, practice guidelines for, 2843-2877
DNA index, as tumor marker, practice guidelines for, 2843-2877
DNA microchip, 2182-2183
DNA ploidy, as colon tumor marker
definition of, 2852
for postoperative prognosis, 2852-2853
future research with, 2853
guidelines for, 2852
methodology for, 2852
Docetaxel
as single agent, dosing of, 425
cisplatin and, interactions between, 2598
dose-toxicity curve for, 292
fluid retention due to, 63
in head and neck cancer, 1672-1678
hematologic toxicity of, 60-61, 1652
in mesothelioma, 1010
in metastatic breast cancer, 58-65, 422-428
nonhematologic toxicity of, 60-63, 425, 1652
in NSCLC, 1649-1655
pharmacokinetic parameters of, 2593
pharmacokinetics of, 64
phase II trials of, 1653
response to, 425-427
survival following, 427
in NSCLC, 1652
toxicity of, 1675-1676, 424
Dolasetron
adverse effects of, 2247
efficacy of, 2246
ondansetron *v*, for cisplatin-induced emesis, 2242-2249
Dosing
body-surface-area based, 2590-2611
of chemotherapy
adaptive control for, 2596-2597
age *v* body size and, 2594-2595
conventional method of, 2591-2592
intensity of, 2595
modified, 2599-2603
pharmacokinetic-guided calculation of, 2599
PMT, 2599-2605
of chemotherapy, 2590-2611
of cyclophosphamide, methotrexate, fluorouracil regimen, 2601
development of, 2603-2604
schema of, 2604
prime, 2599-2600
simulated adjustment score table for, 2603
toxicity-adjusted, 2599-2600
Doxorubicin
cardiotoxic effects of
following childhood malignancy, 328-331
ICRF-187 for, 362-372
in combination chemotherapy
for SCLC, age and, 821-828
for small non-cleaved-cell lymphoma, 925-934
second cancer following, 2770
delivered dose of, by age, 825
following paclitaxel, pharmacokinetics of, 2713-2721
in mesothelioma, 1008-1009
paclitaxel interaction with, 2598, 2718
pharmacokinetic parameter variations of, 2591
pharmacokinetics of, 2596
and tumor response, 2597
resistance mechanisms of, 3158
72-hour infusion of, plus paclitaxel, G-CSF regimen, 774-782
Doxorubicin, azacytidine regimen, in malignant mesothelioma, 1013
Doxorubicin, bleomycin, vinblastine, dacarbazine regimen
alternating with MOPP regimen
in HD, 1421-1430
salvage therapy following, 1426-1427
second malignancies following, 1427
survival following, 1425-1426
ten-year results of, 1425
toxicity of, 1426-1427
in HD, 1297-1305
pulmonary function following, 1297-1305
Doxorubicin, bleomycin, vinblastine, dacarbazine, methylprednisone, radiation regimen, in HD, 1928-1935
Doxorubicin, bleomycin, vinblastine, dacarbazine, radiation regimen
in HD, 1297-1305
pulmonary function following, 1297-1305
Doxorubicin, bleomycin, vincristine regimen
cardiotoxicity following, 2361
in Kaposi's sarcoma, 2353-2364
opportunistic infections following, 2361
quality of life following, 2359
response to, 2356-2358
survival following, 2358-2360
toxicity of, 2359-2361
Doxorubicin, cisplatin regimen, in malignant mesothelioma, 1013
Doxorubicin, cisplatin, cyclophosphamide regimen, in malignant mesothelioma, 1013
Doxorubicin, cyclophosphamide regimen, in malignant mesothelioma, 1013
Doxorubicin, cyclophosphamide, etoposide, didanosine, G-CSF regimen, in HIV-associated NHL, 3026-3035
Doxorubicin, cyclophosphamide, etoposide, prednisone, bleomycin, cytarabine, methotrexate, folinic acid, GM-CSF regimen
maximum-tolerated dose of, in lymphoma, 1275-1281
response to, 1278
toxicity of, 1277-1278
Doxorubicin, cyclophosphamide, fluorouracil regimen, dosing of by body weight, 3000-3008
schedule for, 3001
Doxorubicin, cyclophosphamide, FU regimen
in early-phase breast cancer, 745-753
perioperative, 745-753
Doxorubicin, cyclophosphamide, fluorouracil, vincristine regimen
in breast cancer, 1136-1145
dose analysis of, 1138-1139
radiotherapy and, 1141-1142
relapse site following, 1141

schedule for, 1137
toxicity of, 1139
Doxorubicin, cyclophosphamide, G-CSF regimen
in prostate cancer, 1617-1625
outpatient, in breast cancer, 1565-1572
survival following, 1620
toxicity following, 1620-1622
Doxorubicin, cyclophosphamide, methotrexate, fluorouracil regimen, G-CSF dose-intensity maintenance of, 1573-1580
Doxorubicin, cyclophosphamide, vincristine regimen
in combined modality therapy, for SCLC, 806-813
toxicity of, 810
Doxorubicin, cyclophosphamide, vincristine, bleomycin, etoposide, prednisolone, methotrexate regimen, in NHL, 586-592
Doxorubicin, cyclophosphamide, vincristine, dexamethasone regimen
in chemoradiotherapy, for CNS lymphoma, 945-954
hematologic toxicity of, 949
preirradiation, in primary CNS lymphomas, 556-564
relapse patterns following, 951
survival following, 950-952
Doxorubicin, cyclophosphamide, vincristine, dexamethasone, radiation regimen
age and, 563
survival following, 559-560
toxicity of, 560-561
treatment schema for, 558
Doxorubicin, cyclophosphamide, vincristine, ifosfamide, etoposide regimen, for desmoplastic tumor, 1526-1531
Doxorubicin, cyclophosphamide, vincristine, methotrexate, cytarabine regimen
in pediatric leukemia, 1252-1261
in stage IV small non-cleaved-cell lymphoma, 1252-1261
Doxorubicin, cyclophosphamide, vincristine, prednisone regimen, in primary cutaneous follicle center cell lymphoma, 549-555
Doxorubicin, cyclophosphamide, vindesine, bleomycin, prednisone regimen, in lymphoma, 240-248
Doxorubicin, dacarbazine, cyclophosphamide regimen, in malignant mesothelioma, 1013
Doxorubicin, fluorouracil, cyclophosphamide, radiation regimen, leukemia following, 2722-2730
Doxorubicin, fluorouracil, cyclophosphamide, sargramostim regimen
in breast cancer, 2976-2983
neutropenia associated with, 2979
Doxorubicin, fluorouracil, methotrexate regimen, preoperative, in gastric cancer, 1818-1828
Doxorubicin, ifosfamide regimen, in malignant mesothelioma, 1013
Doxorubicin, ifosfamide, etoposide regimen, in SCLC, 2337-2344
Doxorubicin, interferon alfa regimen, in malignant mesothelioma, 1013
Doxorubicin, methotrexate, vincristine, cyclophosphamide, bleomycin, dactinomycin regimen, neoadjuvant, for bone histiocytoma, 490-496
Doxorubicin, mitomycin, bleomycin, cisplatin regimen, in malignant mesothelioma, 1013
Doxorubicin, paclitaxel, G-CSF regimen
in metastatic breast cancer, 774-782
pharmacokinetics of, 778-779
toxicity of, 777
Doxorubicin, vinblastine, thiotepa, fluoxymesterone regimen
in breast cancer, 1589-1598
dosing of, 1591-1592
survival following, 1593-1595
toxicity of, 1594-1596
Doxorubicin, vincristine, carmustine, prednisone regimen, in multiple myeloma, 2167-2173
Doxorubicin, vincristine, prednisone, cyclophosphamide regimen, high-dose mitoxantrone plus cytarabine *v*, 2480-2485
Doxycycline
complications of, 3145
for malignant pericardial effusion sclerosis, 3141-3147
Drug companies, physicians and, conflict of interest of, 312-320
Drug monitoring, therapeutic, 2596-2597
problems with, 2597-2599
Drug resistance, multi-, PSC 833 for, 610-618
DTIC, *see* Dacarbazine
Ductal carcinoma in situ
breast-conserving surgery plus radiation for, 754-763
local recurrence following, 758-759
Durie-Salmon stage, as prognostic factor, in multiple myeloma, 1310, 1311
Dutch Childhood Leukemia Study Group, 911-918

Economics
of allogeneic BMT, 1413-1420
of BMT, 1409-1410
Edatrexate, in mesothelioma, 1009
Efficacy, monitoring of, in clinical trials, 296-303
Elderly patient(s)
in acute myeloid leukemia, 1345-1352
mitoxantrone, etoposide regimen in, 1345-1352
Emesis
cisplatin-induced, ondansetron *v* dolasetron for, 2242-2249
tropisetron prophylaxis for, maintained efficacy of, 644-651
Endocrinologic toxicity, late
of cisplatin, bleomycin, etoposide regimen, 2927
of cisplatin, bleomycin, vinblastine regimen, 2927
Endometrial cancer
determining cause of death in, 1028-1029
tamoxifen-associated
assessing death risk for, 1035-1036
deaths due to, 1027-1039
informed consent regarding, 1036-1039
organizing data in, 1029-1030
reporting deaths of, 1030-1035
Endometrium, tamoxifen-induced proliferation of, 434-440
Energy index, in prostate cancer, following surgery *v* radiotherapy, 2262
*Enterobacter cloacae*, 1160
Entrez nucleotide query, 2182-2183
Epidermoid cancer, of anal canal, fluorouracil, cisplatin, radiation regimen in, 3121-3125
Epidermoid carcinoma, of anal canal, mitomycin, fluorouracil, radiation regimen in, 2527-2539
Epidoxorubicin, cisplatin, cyclophosphamide regimen, high *v* low-dose cisplatin in, 351-356
Epidoxorubicin, cyclophosphamide, fluorouracil regimen, adjuvant chemotherapy and, in metastatic breast cancer, 764-773
Epidoxorubicin, methotrexate, carboplatin regimen, neoadjuvant, for bone histiocytoma, 490-496
Epirubicin
in breast cancer, 1146-1155, 1165-1172
cardiotoxicity of, dexrazoxane for, 3112-3120

dose-intensity of, 1148-1149
dose-response relationship of, in breast cancer, 1146-1155
efficacy of, 1149-1150
hematologic toxicity following, 1151
in mesothelioma, 1009
nausea following, 1152
nonhematologic toxicity following, 1151
pharmacodynamics of, 1151-1152
pharmacokinetic parameters of, 2593
pharmacokinetics of, 1151-1152, 1583-1584
published studies of, in breast cancer, 1153
response to, 1150, 1168-1169
by disease site, 1170
stomatitis following, 1152
survival following, Cox proportional hazards model for, 1150-1151
toxicity of, 1168-1169
vomiting following, 1152
Epirubicin, cyclophosphamide regimen, adjuvant, blood coagulation during, 2560-2568
Epirubicin, cyclophosphamide, vincristine, prednisolone regimen, in lymphoma, 227-232
Epirubicin, fluorouracil, cyclophosphamide regimen, in breast cancer, 35-45
Epirubicin, fluorouracil, 4-hydroxycyclophosphamide regimen
in breast cancer, 1581-1588
pharmacokinetics of, 1581-1588
Epirubicin, ifosfamide regimen, in malignant mesothelioma, 1013
Epirubicin, ifosfamide, etoposide regimen, in SCLC, 2337-2344
Epirubicin, lonidamine regimen
in breast cancer, 1165-1172
response to, 1168-1169
by disease site, 1170
toxicity of, 1168-1169
Epstein-Barr virus, in tumor cells, and methotrexate withdrawal, 1943-1949
*ERG* gene, variants of, in Ewing tumor, 1245-1251
ERICA, use of, 697
Esophageal cancer
chemoradiotherapy in, 149-155
combined modality therapy in, 3166
epidermoid, vinorelbine in, 164-170
incidence of, 829
localized, preoperative chemoradiotherapy in, 156-163
locally advanced, preoperative chemoradiotherapy in, 828-837
metastatic squamous cell, vinorelbine, 164-170
neoadjuvant chemotherapy in, plus concurrent chemoradiotherapy, 149-155
preresection esophagogastroduodenoscopy in, 156-163
squamous cell, fluorouracil, cisplatin, radiation regimen in, 149-155
therapy for, overview of, 164-165
Esophagectomy, chemoradiotherapy prior to, in esophageal cancer, 156-163
Esophagitis, following combined modality therapy, in NSCLC, 1642-1648
Esophagogastroduodenoscopy, preresection, 156-163
Estrogen receptor
immunohistochemical analysis of, 2585
immunohistochemical staining of, 2586
loss of, in recurrent breast cancer, 2584-2589
as tumor marker
for adjuvant therapy response monitoring, 2861
definition of, 2859
future research with, 2862
in breast cancer, 2859-2862
literature review of, 2860
for metastatic therapy response monitoring, 2860-2861
methodology for, 2859-2860
for recurrence prognosis, 2861-2862
Estrogen receptor immunocytochemical assay, 2860
Estrogen replacement therapy
breast cancer risk and, 997-1006
cancer risk and, 999-1002
disease risk alteration with, 1002
long-term effects of, 998-1002
previous breast cancer history and, 1002-1004
quality of life and, 998
Etoposide
bioavailability of, following etoposide phosphate, 2020-2030
chemical structure of, 2021
for CNS-directed therapy, in pediatric leukemia, 399-404
in combination chemotherapy
for acute lymphoblastic leukemia, 2805
for pediatric B-precursor acute lymphoblastic leukemia, 2803-2811
for SCLC, age and, 821-828
second cancer following, 2770
continuous infusion of, therapeutic monitoring of, in SCLC, 1903-1912
CSF penetration by, in acute lymphoblastic leukemia, 399-404
delivered dose of, by age, 825
dosing of, in high-dose chemotherapy, for germ cell cancer, 2644
liver function and, 261
low-dose oral, in recurrent medulloblastoma, 1922-1927
in myeloablative chemoradiotherapy regimen, 2418-2419
paclitaxel interaction with, 2598
pharmacokinetic parameter variations of, 2591
pharmacokinetic parameters of, 2593, 2596
tumor response and, 2597
pharmacokinetics of, 613-615, 2024-2027
age and, 263
in polychemotherapy, for pediatric acute lymphoblastic leukemia, 2813
predicting toxicity of, 257-267
in preoperative combination chemotherapy, for SCLC, 830
in preoperative combined modality therapy, for SCLC, 830
protein binding of, 258
PSC 833 plus
pharmacokinetics of, 615, 617
response to, 615
toxicity of, 614-616
renal function and, 260-261
toxicity of, 2023-2024
Etoposide phosphate
chemical structure of, 2021
etoposide bioavailability following, 2020-2030
pharmacokinetics of, 2024-2027
toxicity of, 2023-2024
Etoposide, amsacrine regimen
phase II trial of, 1521-1525
toxicity of, 1523
Etoposide, amsacrine, azacitidine regimen
in leukemia, 1521-1525

phase II trial of, 1521-1525
toxicity of, 1523
Etoposide, carboplatin, bleomycin regimen
for germ cell tumor, of CNS, 2908-2915
outcome following, 2910-2912
survival following, 2912-2913
toxicity of, 2911-2912
Etoposide, carboplatin, cyclophosphamide, BMT regimen, high-dose
for germ cell tumors, 1098-1105
response to, 1101
survival following, 1101-1102
toxicity of, 1100, 1103
Etoposide, carboplatin, ifosfamide regimen, for conditioning, 1115
Etoposide, carboplatin, radiation regimen
in NSCLC, 1065-1070
response to, 1067-1068
toxicity of, 1068
Etoposide, carmustine, cytarabine, cyclophosphamide, BMT regimen
high-dose, for NHL, in partial response, 534-542
survival following, 538-540
treatment algorithm for, 535
Etoposide, cisplatin regimen
in malignant mesothelioma, 1013
in malignant thymoma, 814-820
toxicity of, 816
Etoposide, cisplatin, bleomycin regimen
adjuvant
acute side effects of, 443
for nonseminomatous testicular germ cell tumor, 1106-1113
high-tone hearing loss following, 445
in testicular germ cell cancer, 441-448
lung function following, 445
psychosocial self-report following, 444
sperm counts following, 446
endocrinologic late toxicity of, 2927
gonadal toxicity of, 2926-2927
long-term toxicity of, 1109
neurotoxicity of, 2925
otoxicity of, 2925-2926
relapse following, 1109-1110
renal late toxicity of, 2927
short-term toxicity of, 1108-1109
in testicular cancer, 2923-2932
vascular toxicity of, 2926
Etoposide, cisplatin, megestrol acetate regimen
in SCLC, 135-141
toxicity of, 140
Etoposide, cisplatin, radiation regimen
in combined modality therapy, for SCLC, 806-813
failure pattern following, 1059-1060
in NSCLC, 1055-1064
response to, 1058
survival following, 1059
toxicity of, 1058, 810
treatment schema for, 1056
Etoposide, cyclophosphamide, doxorubicin, didanosine, G-CSF regimen, in HIV-associated NHL, 3026-3035
Etoposide, cyclophosphamide, doxorubicin, prednisone, bleomycin, cytarabine, methotrexate, folinic acid, GM-CSF regimen
maximum-tolerated dose of, in lymphoma, 1275-1281
response to, 1278
toxicity of, 1277-1278
Etoposide, cyclophosphamide, doxorubicin, vincristine, ifosfamide regimen, for desmoplastic tumor, 1526-1531
Etoposide, daunorubicin, cytarabine regimen, for intensification, 1354
Etoposide, doxorubicin, cyclophosphamide, vincristine, bleomycin, prednisolone, methotrexate regimen, in NHL, 586-592
Etoposide, ifosfamide, carboplatin regimen, in breast cancer, 1869
Etoposide, ifosfamide, carboplatin, stem cell regimen, high-dose, in germ cell cancer, 2631-2637
Etoposide, ifosfamide, doxorubicin regimen, in SCLC, 2337-2344
Etoposide, ifosfamide, epirubicin regimen, in SCLC, 2337-2344
Etoposide, ifosfamide, high-dose cytarabine regimen, in combination chemotherapy protocol, for small non-cleaved-cell lymphoma, 925-934
Etoposide, ifosfamide, methotrexate, dexamethasone regimen, in lymphoma, 227-232
Etoposide, mitoxantrone regimen
in acute myeloid leukemia, 1345-1352
in elderly, 1345-1352
quality of life following, 1349
response to, 1347-1348
toxicity of, 1348
Etoposide, paclitaxel, cisplatin, radiation therapy regimen
in NSCLC, 1642-1648
toxicity of, 1645-1646
Etoposide, thiotepa regimen, with autologous bone marrow rescue
for CNS tumors, 2495-2503
nonhematopoietic toxicity following, 2498-2499
survival following, 2499-2501
toxic mortality following, 2498
Etoposide, vindesine maintenance regimen, in SCLC, 2337-2344
Evans staging, of neuroblastoma, 2177
Ewing's sarcoma
*EWS* chimeric transcript variants in, 1245-1251
second malignancy following, 2818
Exon 8 to 10, variant CD44 with, in colorectal cancer, 1122-1127
Extremity, melanoma of, isolated limb perfusion, melphalan, tumor necrosis factor, interferon gamma regimen for, 479-489
Eye disease, tamoxifen-associated, 1018-1026

*18*F 2-fluoro-2-deoxy-D-glucose, *see* Fluorodeoxyglucose
Fabry's disease, 1024
Familial polyposis coli, genetic testing for, mothers' attitude toward, 415-421
Fazarabine, dose-toxicity curve for, 292
FDA reform, American Society of Clinical Oncology approach to, 2395-2398
FDG, *see* Fluorodeoxyglucose
Felty's syndrome, methotrexate in, and lymphoproliferative disorders, 1943-1949
Ferritin, serum, in neuroblastoma, 2507-2508
Fever
admission, bacteremia risk and, 922
neutropenic children with, bacteremia risk in, 919-924
Fibroadenoma, MRI of, 1852
FICTION, control studies for, 964-966
Filgrastim, *see* Granulocyte colony-stimulating factor
Fine-needle aspiration
aspiration needle biopsy *v*, 1704-1712
selection of, for thyroid nodules, 1704-1712
Finger tapping, 2828

FISH analysis, in t(14;18) chromosomal translocational detection, 963-969
*FLI1* gene, variants of, in Ewing tumor, 1245-1251
Flow cytometric proliferation analysis, 279
  as breast tumor marker
    definition of, 2862
    future research with, 2863
    guidelines for, 2862
    literature review of, 2862-2863
    methodology for, 2862
  as colon tumor marker
    definition of, 2852
    future research with, 2853
    guidelines for, 2852
    methodology for, 2852
    for postoperative prognosis, 2852-2853
Fluconazole, paclitaxel interaction with, 2718
Fludarabine
  in follicular lymphomas, 514-519
  studies of, in low-grade NHL, 518
  survival following, 516-517
Fludarabine, mitoxantrone, dexamethasone regimen
  for indolent lymphoma, 1262-1268
  response to, 1263-1264
  survival following, 1265
  toxicity of, 1264-1266
Fluid retention, docetaxel-induced, 63
Fluorescence in situ hybridization technique, in t(14;18) chromosomal translocation detection, 963-969
Fluorodeoxyglucose
  in clinical PET, 691
  F-18, PET with, for breast tumor metabolic characterization, 1848-1857
  kinetics of, 692
  PET-, in hepatic metastasis analysis, 700-708
Fluorouracil
  -based chemotherapy, and thymidylate synthase mRNA level, 176-182
  in colorectal cancer, 2674-2681
  colorectal cancer resistant to, irinotecan for, 1128-1135
  plus folinic acid, pharmacokinetic parameters of, and tumor response, 2597
  high-dose infusional, in colorectal cancer, 2266-2273
  induction chemotherapy based on, in head and neck cancer, 1663-1671
  interferon-alfa interactions with, 2598
  interferon-alfa plus, in hepatic metastases, 700-708
  intravenous and intraperitoneal, with cisplatin, 1818-1828
  plus low-dose methotrexate
    in colorectal cancer, 2266-2273
    response to, 2268
    survival following, 2269-2270
    toxicity of, 2271
  in mesothelioma, 1009
  oral
    bioavailability of, 3090
    with dihydropyrimidine dehydrogenase inactivator 776C85, 3085-3096
  pharmacokinetic parameter variations of, 2591
  pharmacokinetic parameters of, 2593, 2596
    and tumor response, 2597
  pharmacokinetics of, 1583, 1668
  in preoperative combination chemotherapy, for SCLC, 830
  in preoperative combined modality therapy, for SCLC, 835
  protracted venous infusion of, in hepatic metastases, 700-708
  simulated dose adjustment score table for, 2603
  structure of, 3086
  tolerance of, inflammatory bowel disease and, 2043-2046
  weekly high-dose *v* low-dose folinic acid plus
    in colorectal cancer, 2274-2279
    response to, 2276
    toxicity of, 2277
    hematologic toxicity of, 3090-3092
    nonhematologic toxicity of, 3092-3093
    response to, 3093
Fluorouracil, AZT, folinic acid regimen, for metastatic colorectal cancer, 729-736
Fluorouracil, cisplatin regimen, in glottic carcinoma, 2331-2336
Fluorouracil, cisplatin, interferon alfa-2b regimen
  in head and neck cancer, 1663-1671
  predictive toxicity models for, 1666
  toxicity of, 1666
Fluorouracil, cisplatin, radiation regimen
  in anal cancer, 3121-3125
  in head and neck cancer, 1192-1200
  response to, 1195
  survival following, 1196
  toxicity of, 1194-1195, 3122
Fluorouracil, cyclophosphamide, doxorubicin regimen, dosing of
  by body weight, 3000-3008
  dosing schedule of, 3001
Fluorouracil, cyclophosphamide, doxorubicin, vincristine regimen
  in breast cancer, 1136-1145
  dose analysis of, 1138-1139
  radiotherapy and, 1141-1142
  relapse site following, 1141
  schedule for, 1137
  toxicity of, 1139
Fluorouracil, cyclophosphamide, epidoxorubicin regimen, adjuvant chemotherapy and, in metastatic breast cancer, 764-773
Fluorouracil, cyclophosphamide, methotrexate regimen
  adjuvant chemotherapy and, in metastatic breast cancer, 764-773
  in breast cancer, 35-45, 1136-1145, 1885-1894, 1982-1992
  dose analysis of, 1138-1139
  G-CSF dose-intensity maintenance of, 1573-1580
  as gold standard, 1971-1973
  PMT dosing of, 2601
  radiotherapy and, 1141-1142
  relapse site following, 1141
  schedule for, 1137
  tamoxifen plus, thromboembolism following, 2731-2737
  toxicity of, 1139, 1988
Fluorouracil, cyclophosphamide, methotrexate, vincristine, prednisone regimen
  in breast cancer, 46-51, 1589-1598
  dosing of, 1591
  ovariectomy plus, 46-51
  survival following, 1593-1595
  toxicity of, 1594-1596, 49
Fluorouracil, doxorubicin, cyclophosphamide regimen
  in early-phase breast cancer, 745-753
  neutropenia associated with, 2979
  perioperative, 745-753
Fluorouracil, doxorubicin, cyclophosphamide, methotrexate regimen, G-CSF dose-intensity maintenance of, 1573-1580

Fluorouracil, doxorubicin, cyclophosphamide, radiation regimen, leukemia following, 2722-2730
Fluorouracil, doxorubicin, cyclophosphamide, sargramostim regimen, in breast cancer, 2976-2983
Fluorouracil, doxorubicin, methotrexate regimen, preoperative, in gastric cancer, 1818-1828
Fluorouracil, epirubicin, cyclophosphamide regimen, in breast cancer, 35-45
Fluorouracil, epirubicin, 4-hydroxycyclophosphamide regimen
  in breast cancer, 1581-1588
  pharmacokinetics of, 1581-1588
Fluorouracil, folinic acid regimen, vinorelbine *v*, in NSCLC, 2774-2784
Fluorouracil, folinic acid, interferon alfa-2b regimen, in colorectal cancer, 2682-2687
Fluorouracil, folinic acid, oxaliplatin regimen, chronomodulated
  efficacy of, 2955
  in colorectal cancer, 2950-2958
  survival following, 2956
  toxicity of, 2953-2954
Fluorouracil, interferon alfa-2a regimen, in colorectal cancer, 2674-2681
Fluorouracil, interferon alfa-2a, folinic acid regimen
  in colorectal cancer, 2280-2288
  quality of life following, 2283-2285
  response to, 2282-2283
  survival following, 2282-2284
  toxicity of, 2282-2283, 2285
Fluorouracil, interferon alfa-2b regimen, in biliary tract cancer, 2311-2315
Fluorouracil, irinotecan, folinic acid regimen
  pharmacokinetics of, 2962-2963, 2965
  phase I trial of, 2959-2967
  toxicity of, 2962-2964
Fluorouracil, methotrexate regimen
  in breast cancer, 1982-1992
  toxicity of, 1988
Fluorouracil, mitomycin, radiation regimen
  in anal cancer, 2527-2539
  disease-free survival following, 2533, 2535
  toxicity of, 2534-2535
Fluorouracil, paclitaxel, mitoxantrone, folinic acid regimen
  in breast cancer, 1611-1616
  survival following, 1613
  toxicity following, 1613-1614
Fluorouracil, vinorelbine regimen
  in breast cancer, 3097-3104
  toxicity of, 3099-3100
Fluoxymesterone, vinblastine, doxorubicin, thiotepa regimen
  in breast cancer, 1589-1598
  dosing of, 1591-1592
  survival following, 1593-1595
  toxicity of, 1594-1596
Flutamide
  diethylstilbestrol *v*, in prostate cancer, 2250-2257
  response to, 2253
  survival following, 2253-2255
  toxicities of, 2252-2253
Fluvastatin, 3046
FO23C5 monoclonal antibody, radiolabeled, in radioimmunoguided surgery, 1599-1603
Folinic acid
  in combination chemotherapy, for acute lymphoblastic leukemia, 2805
  plus fluorouracil, pharmacokinetic parameters of, and tumor response, 2597
  in mesothelioma, 1009
  in preoperative combination chemotherapy, for SCLC, 830
  weekly high-dose *v* low-dose, plus fluorouracil, in colorectal cancer, 2274-2279
    response to, 2276
    toxicity of, 2277
Folinic acid, AZT, fluorouracil regimen, for metastatic colorectal cancer, 729-736
Folinic acid, cyclophosphamide, doxorubicin, etoposide, prednisone, bleomycin, cytarabine, methotrexate, GM-CSF regimen
  maximum-tolerated dose of, in lymphoma, 1275-1281
  response to, 1278
  toxicity of, 1277-1278
Folinic acid, fluorouracil interferon alfa-2b regimen, in colorectal cancer, 2682-2687
Folinic acid, fluorouracil regimen, vinorelbine *v*, in NSCLC, 2774-2784
Folinic acid, fluorouracil, oxaliplatin regimen, chronomodulated
  in colorectal cancer, 2950-2958
  efficacy of, 2955
  survival following, 2956
  toxicity of, 2953-2954
Folinic acid, interferon alfa-2a, fluorouracil regimen
  in colorectal cancer, 2280-2288
  quality of life following, 2283-2285
  response to, 2282-2283
  survival following, 2282-2284
  toxicity of, 2282-2283, 2285
Folinic acid, irinotecan, fluorouracil regimen
  pharmacokinetics of, 2962-2963, 2965
  phase I trial of, 2959-2967
  toxicity of, 2962-2964
Folinic acid, paclitaxel, mitoxantrone, fluorouracil regimen
  in breast cancer, 1611-1616
  survival following, 1613
  toxicity following, 1613-1614
Freedom from Distractibility Deviation Quotient, 2828
FU, *see* Fluorouracil

G-CSF, *see* Granulocyte colony-stimulating factor
Gail model, 103-110
Gallbladder, adenocarcinoma of, pactlitaxel therapy for, 2306-2310
Gallium-67 scintigraphy, in low-grade NHL, 1936-1942
Gamma-detecting probe, in radioimmunoguided surgery, 1599-1603
Gastric cancer
  bone marrow micrometastases in, 1810-1817
  combined modality therapy in, 3166
  high-risk
    neoadjuvant therapy of, 1818-1828
    postoperative intraperitoneal and intravenous fluorouracil plus cisplatin in, 1818-1828
    preoperative fluorouracil, doxorubicin, methotrexate regimen in, 1818-1828
  Japanese- *v* Western-type surgery in, 2289-2294
  lymph node retrieval in, 2289-2294
  thymidylate synthase mRNA level in, fluorouracil-based chemotherapy and, 176-182
Gemcitabine

dose-toxicity curve for, 292
pharmacokinetic parameters of, 2593
Gemcitabine, cisplatin regimen
dose-escalation schema in, 1657
hematologic toxicity of, 1658-1659
in NSCLC, 1656-1662
General health index, in prostate cancer, following surgery *v* radiotherapy, 2262
Genetic testing, 2881
for cancer susceptibility
American Society of Clinical Oncology statement on, 1730-1736
categories for, 1733
commentary on, 1737-1740
coverage of, 1735
indications for, 1732-1734
informed consent and, 1731-1732
regulation of, 1734
research needs in, 1735
mothers' attitude toward, 415-421
Germ cell cancer
bilateral testicular, 2061-2065
carboplatin, etoposide, bleomycin regimen for, of CNS, 2908-2915
chemotherapy for, PET monitoring following, 1637-1641
cisplatin-refractory, carboplatin, etoposide, cyclophosphamide, BMT regimen in, 1098-1105
cisplatin-resistant, high-dose chemotherapy for, 2625-2626
of CNS, chemotherapy alone for, 2908-2915
cyclophosphamide, thiotepa, carboplatin, stem-cell regimen in, 1473-1483
high-dose chemotherapy in, 2638-2645
high-risk stage I nonseminomatous testicular
cisplatin, bleomycin, etoposide regimen in, 1106-1113
histologic risk factors in, 1108-1109
ifosfamide, carboplatin, etoposide, stem cell regimen in, 2631-2637
metastatic nonseminomatous, postchemotherapy residual masses of, simultaneous resection of, 1765-1769
preleukapheresis peripheral-blood progenitor cell count in, 1114-1121
stage I nonseminomatous testicular, adjuvant cisplatin, etoposide, bleomycin regimen in, 441-448
Germinoma, melphalan, cyclophosphamide, BMT regimen for, 382-388
Gestational trophoblastic tumor, combination chemotherapy for, second cancer following, 2769-2773
Glioma, malignant
chemoradiotherapy *v* radiotherapy for, 3163
radioimmunotherapy clinical trials in, 1390-1392
randomized trials in, 3163
recurrent, paclitaxel for, 2316-2321
Glottic carcinoma, cisplatin, fluorouracil regimen in, 2331-2336
Glucocorticoid cytotoxicity, in acute lymphoblastic leukemia, 2370-2376
Glucose, metabolic rate of, 691-692
Glutathione, 249
Glycoprotein-72, tumor-associated, interferon alfa upregulation of, 2031-2042
GM-CSF, *see* Granulocyte-macrophage colony-stimulating factor
Gonadal toxicity
of cisplatin, bleomycin, etoposide regimen, 2926-2927
of cisplatin, bleomycin, vinblastine regimen, 2926-2927
Graft-versus-host disease
following allogeneic blood cell transplantation, 1314-1319
in HD, 1293-1295
prophylaxis for, 1355
renal toxicity and, 579-585
Granulocyte colony-stimulating factor
donor of, 1316
with double dose-intensive chemotherapy, in breast cancer, 2984-2992
five-day course of, for dose-intensity maintenance, 1573-1580
GM-CSF plus
for progenitor cell mobilization, 277-286
toxicity of, 280
GM-CSF *v*
following high-dose cyclophosphamide, 628-635
infectious complications following, 1377-1378
hematopoietic effects of, 1576
IL-3 plus, following autologous BMT, 3018-3025
projected dose-intensity following, 1576
side effects of, 631, 632
toxicity of, 1577
*see also* Cytokine(s)
Granulocyte colony-stimulating factor, carboplatin regimen
hematological toxicity of, 802-803
in ovarian cancer, 800-805
nonhematological toxicity of, 803
toxicity of, 802
Granulocyte colony-stimulating factor, cyclophosphamide, doxorubicin regimen, outpatient, in breast cancer, 1565-1572
Granulocyte colony-stimulating factor, cyclophosphamide, doxorubicin, etoposide, didanosine regimen, in HIV-associated NHL, 3026-3035
Granulocyte colony-stimulating factor, doxorubicin, cyclophosphamide regimen
in prostate cancer, 1617-1625
survival following, 1620
toxicity following, 1620-1622
Granulocyte colony-stimulating factor, paclitaxel, cyclophosphamide regimen
dose-limiting toxicity of, 787
dosing of, 98, 784
drug sequencing in, 785
hematologic toxicity of, 97-98, 787-788
in metastatic breast cancer, 95-102
nonhematologic toxicity of, 98-99, 788
pharmacology of, 788-789
in previously treated metastatic breast cancer, 783-791
response to, 99
Granulocyte colony-stimulating factor, paclitaxel, doxorubicin regimen
in metastatic breast cancer, 774-782
pharmacokinetics of, 778-779
toxicity of, 777
Granulocyte colony-stimulating factor, topotecan regimen
dose-escalation scheme for, 1226
hematologic toxicity of, 1227-1228
nonhematologic toxicity of, 1228
pharmacokinetics of, 1226, 1229-1230
sequential, phase I trial of, 1224-1235
Granulocyte-colony stimulating factor, mitoxantrone, cyclophosphamide regimen

in breast cancer, 2576-2583
hematologic toxicity of, 2579
nonhematologic toxicity of, 2580
Granulocyte-macrophage colony-stimulating factor
adverse effects of, 624-625
antibiotics and, 623
for chemotherapy-related neutropenia, 620
cost analysis of, 620, 624
dose-intensity of, 907
G-CSF plus
for progenitor cell mobilization, 277-286
toxicity of, 280
G-CSF *v*
following high-dose cyclophosphamide, 623-[illegible]
infectious complications following, 1377-1378
hematologic toxicity of, 904-906
hospitalization rate and, 906
for induction therapy, of acute myeloid leukemia, 2150-2159
infectious complications and, 906
nonhematologic toxicity of, 906-907
in pediatric sarcoma, 901-910
sargramostim type of, 2976-2983
side effects of, 631
in small non-cleaved-cell lymphoma, 931-932
supportive care and, 907
survival and, 908
*see also* Cytokine(s)
Granulocyte-macrophage colony-stimulating factor, cyclophosphamide, doxorubicin, etoposide, prednisone, bleomycin, cytarabine, methotrexate, folinic acid regimen, in lymphoma, 1275-1281
Granulocyte-macrophage colony-stimulating factor, daunorubicin, cytarabine regimen, in acute myeloid leukemia, 2150-2159
Grooved Pegboard, 2828
Growth factor
American Society of Clinical Oncology survey of, 2516-2520
survey questionnaire for, 2516-2520
*see also specific type*
Growth factor receptor, in metastatic breast cancer, 737-744
Guanidinium thiocyanate-acid phenol-chloroform extraction, 888
Guanosine triphosphate-dependent protein, 334
Guideline, practice, *see* Practice guideline(s)

HAMA reactivity, 1393
of intact murine monoclonal antibodies, 2303
HD, *see* Hodgkin's disease
Head and neck cancer
advanced
docetaxel in, 1672-1678
fluorouracil-based induction chemotherapy in, 1663-1671
chemoradiotherapy *v* radiotherapy in, 3165
chemotherapy in, 838-847
combined modality therapy for, 3162-3163
induction chemotherapy in, 3163-3164
squamous cell, adjuvant chemotherapy in, 838-847
survival in, prognostic factors for, 1196
unresectable, chemoradiotherapy in, 1192-1200
Health Maintenance Organizations, work activities of, in oncology, 2617
Health Services Research Committee, for defining cancer treatment outcomes, 671-672
Hearing loss, high-tone, following cisplatin, etoposide, bleomycin regimen, 445
Hematologic toxicity, of etoposide, 257-267
Hematology, work activities in, 2616
Hematopoietic harvest, marrow tumor burden in, outcome relating to, 214-219
Hepatic function
drug handling and, 2602
following ZD 1694, 1499
quantitative tests for, 2602
Hepatic metastasis
boost radiation for, 722-728
FDG-PET analysis of, 694, 700-708
interferon-alpha plus fluorouracil for, 700-708
palliation of, chemoradiotherapy for, 722-728
protracted fluorouracil venous infusion for, 700-708
Hepatic toxicity, radioimmunotherapy-induced, 1392
Hepatoma, radioimmunotherapy clinical trials in, 1390-1392
HER2 antibody therapy, anti-
administration of, 738
for breast cancer, 737-744
pharmacokinetics of, 739-740
response rate to, 741
toxicity of, 738
HER2-*neu* oncogene, overexpression of, overview of, 697-699
Hexamethylene, pharmacokinetic parameters of, 2593
Hexamethylene bisacetamide, pharmacokinetic parameters of, 2596
High-dose chemotherapy, *see* Chemotherapy, high-dose regimens of
Histiocytoma, of bone
high-dose methotrexate-based neoadjuvant chemotherapy in, 490-496
histologic criteria for, 494
Histogram, dose-volume, 307
Histopathologic diagnosis, of cutaneous melanoma, interobserver agreement on, 1218-1223
HIV, NHL associated with, cyclophosphamide, doxorubicin, etoposide, didanosine, G-CSF regimen in, 3026-3035
Hodgkin's disease
advanced
allogeneic BMT in, 572-578
alternating *v* hybrid MOPP and ABVD regimens in, 1421-1430
HLA-identical sibling BMT in, 572-578
second-line treatments in, 1423
doxorubicin, bleomycin, vinblastine, dacarbazine, methylprednisone, radiation therapy in, 1928-1935
doxorubicin, bleomycin, vinblastine, dacarbazine, radiation regimen in, 1297-1305
early-stage
doxorubicin, bleomycin, vinblastine, dacarbazine regimen in, 1297-1305
doxorubicin, bleomycin, vinblastine, dacarbazine, radiation regimen in, 1297-1305
vinblastine, bleomycin, methotrexate, radiation regimen in, 527-533
image-guided core-needle biopsy in, 2433
radiotherapy in
malignant mesothelioma following, 2098-2100
second solid tumors following, 2435-2443
relapsed, allogeneic *v* autologous BMT in, 1291-1296
subsequent neoplasms in, 1442-1446
supradiaphragmatic, chemoradiotherapy in, 1928-1935
therapy of, late psychosocial sequelae following, 2444-2453
Hormone receptor, in breast cancer, 2584-2589
Hormone replacement therapy

breast cancer risk and, 997-1006
cancer risk and, 999-1002
disease risk alteration with, 1002
long-term effects of, 998-1002
previous breast cancer history and, 1002-1004
quality of life and, 998
Hospital Anxiety and Depression Scale, 171-175
Human antimouse antibody, 1393
of intact murine monoclonal antibodies, 2303
Human immunodeficiency virus, NHL associated with, cyclophosphamide, doxorubicin, etoposide, didanosine, G-CSF regimen in, 3026-3035
Human papillomavirus, cervical lesions associated with, p53 in, 2120-2130
Hydromorphone, sustained- *v* immediate-release, in cancer pain, 1713-1717
Hydroxycyclophosphamide
absorbance spectra of, 1489
assay of, 1487-1488
electrospray mass spectra for, 1487-1488
overview of, 1484-1485
pharmacokinetics of, 1484-1494
4-Hydroxycyclophosphamide, pharmacokinetics of, 1584
4-Hydroxycyclophosphamide, fluorouracil, epirubicin regimen
in breast cancer, 1581-1588
pharmacokinetics of, 1581-1588
Hydroxyruea, in combination chemotherapy, second cancer following, 2770
Hypercalcemia, tumor-associated, ibandronate for, 268-276
Hypercholesterolemia
development of, mechanisms for, 3044-3045
drug for, cancer and, 3043-3048
Hypervascular tumor, 2661

Ibandronate, for tumor-associated hypercalcemia, 268-276
ICRF-187
for cardioprotection, in pediatric sarcomas, 362-372
noncardiac toxicities of, 368-369
pharmacokinetics of, 369
Ifosfamide
in mesothelioma, 1009, 1010
pharmacokinetic parameter variations of, 2591
pharmacokinetic parameters of, 2593, 2596
in polychemotherapy, for pediatric acute lymphoblastic leukemia, 2813
Ifosfamide, carboplatin, etoposide regimen
in breast cancer, 1869
for conditioning, 1115
Ifosfamide, carboplatin, etoposide, stem-cell regimen, high-dose, in germ cell cancer, 2631-2637
Ifosfamide, cyclophosphamide, doxorubicin, vincristine, etoposide regimen, for desmoplastic tumor, 1526-1531
Ifosfamide, cytarabine, busulfan, cyclophosphamide, stem-cell regimen, high-dose, in NHL, 586-592
Ifosfamide, doxorubicin regimen, in malignant mesothelioma, 1013
Ifosfamide, epirubicin regimen, in malignant mesothelioma, 1013
Ifosfamide, etoposide, doxorubicin regimen, in SCLC, 2337-2344
Ifosfamide, etoposide, epirubicin regimen, in SCLC, 2337-2344
Ifosfamide, etoposide, high-dose cytarabine regimen, in combination chemotherapy protocol, for small noncleaved-cell lymphoma, 925-934
Ifosfamide, etoposide, methotrexate, dexamethasone regimen, in lymphoma, 227-232
Ifosfamide, vinorelbine regimen
in breast cancer, 2993-2999
toxicity of, 2996-2997
IMMU-4
external immunoscintigrapy with, in colorectal cancer, 2295-2305
in occult disease, 2300-2301
Immune alkaline phosphatase study, of p-glycoprotein, 887, 889-893
Immunoblotting, 2863-2864
of p-glycoprotein, 888
Immunochemical staining, for CD44, 27
Immunocytochemical analysis, use of, 697
Immunodiagnosis, interferon alfa for, 2031-2042
Immunoglobulins, 1384
Immunohistochemistry, 2864
of p-glycoprotein, 889-890, 893-897
Immunoperoxidase assay, of p-glycoprotein, 887-888, 893-896
Immunophenotyping
in acute lymphoblastic leukemia, 22
with in situ hybridization, 964
Immunoscintigraphy, external, with IMMU-4, in colorectal cancer, 2295-2305
Immunotherapy
IL-2-based, for melanoma, response predictors of, 1697-1703
with ubenimex, in leukemia, 204-213
Induction chemotherapy, 3163-3164
with daunorubicin, cytarabine, GM-CSF regimen, in acute myeloid leukemia, 2150-2159
definition of, 841
with doxorubicin, fluorouracil, G-CSF, peripheral blood stem cell regimen, 2985
with epirubicin, ifosfamide, etoposide regimen, in SCLC, 2337-2344
following accelerated radiotherapy, in laryngeal cancer, 2322-2330
fluorouracil-based, in head and neck cancer, 1663-1671
in head and neck cancer, 3164
with ifosfamide, etoposide, doxorubicin regimen, in SCLC, 2337-2344
Infant, stage IV-S neuroblastoma in, primary tumor resection for, 1537-1544
Infection, following cyclophosphamide, thiotepa, carboplatin, BMT, supportive care regimen, 1160
Inferior vena cava filter
for deep vein thrombosis, 652-657
placement of
cumulative survival following, 655
indications for, 654
untoward outcomes following, 654
Inflammatory bowel disease, fluorouracil tolerance in, 2043-2046
Informed consent
about endometrial cancer death risk, 1036-1039
in cancer susceptibility genetic testing, 1731-1732
in oncology clinical trials, 984-996
patient anxiety and, 990-991
patient awareness levels and, 989-990
procedures for, 986
telephone-based nursing intervention for, 984-996
INSS staging, of neuroblastoma, 2505
Interferon, 1393
as biochemical modulator, 2627-2630
Interferon, dacarbazine, vincristine, lomustine, bleomycin regimen, in melanoma, 1690-1696

Interferon alfa
carcinoembryonic antigen upregulation following, 2031-2042
effects of, 1451-1452
tumor-associated glycoprotein-72 upregulation following, 2031-2042
Interferon alfa, cisplatin regimen, in malignant mesothelioma, 1013
Interferon alfa, doxorubicin regimen, in malignant mesothelioma, 1013
Interferon alfa, fluorouracil plus, in hepatic metastases, 700-708
Interferon alfa, fluorouracil and, interactions between, 2598
Interferon alfa, mitomycin, cisplatin regimen, in malignant mesothelioma, 1013
Interferon alfa-2a, in mesothelioma, 1009
Interferon alfa-2a, cisplatin regimen
response to, 881-882
survival following, 882
toxicity of, 880-881
weekly, in malignant mesothelioma, 878-885
Interferon alfa-2a, fluorouracil regimen, in colorectal cancer, 2674-2681
Interferon alfa-2a, fluorouracil, folinic acid regimen
in colorectal cancer, 2280-2288
quality of life following, 2283-2285
response to, 2282-2283
survival following, 2282-2284
toxicity of, 2282-2283, 2285
Interferon alfa-2a, IL-2 plus
biologic response of, 2238-2239
clinical response to, 2237-2238
hematologic effects of, 2238
phase I trial of, 2234-2241
Interferon alfa-2b
adjuvant high-dose, in cutaneous melanoma, 2666-2673
adjuvant, in melanoma, 7-17
survival following, 10-11
toxicity of, 12-15
Interferon alfa-2b, cisplatin, fluorouracil regimen
in head and neck cancer, 1663-1671
predictive toxicity models for, 1666
toxicity of, 1666
Interferon alfa-2b, fluorouracil regimen, in biliary tract cancer, 2311-2315
Interferon alfa-2b, fluorouracil, folinic acid, regimen, in colorectal cancer, 2682-2687
Interferon gamma
gene expression of, for therapy response prediction, 1778-1786
intraperitoneal, in ovarian cancer, 343-350
in mesothelioma, 1009
response to, 345
survival following, 347
toxicity of, 346-347
Interferon gamma, isolated limb perfusion, melphalan, tumor necrosis factor regimen
for extremity melanoma, 479-489
regional toxicity of, 485-486
response to, 482-484
systemic toxicity of, 484-486
Interferon gamma, tumor necrosis factor-alpha, melphalan regimen
for soft tissue sarcoma, 2653-2665
toxicity of, 2659-2660
Interleukin-2
alfa-2a plus
biologic response of, 2238-2239
clinical response to, 2237-2238
hematologic effects of, 2238
phase I trial of, 2234-2241
effects of, 1452
gene expression of, for therapy response prediction, 1778-1786
for melanoma, response predictors of, 1697-1703
in mesothelioma, 1009
radiation plus, 1393-1394
Interleukin-3, 1379
G-CSF plus, following autologous BMT, 3018-3025
Interleukin-6, in melanoma, 1697-1703
International Index, 240-241
International Neuroblastoma Staging System, 2174-2180, 374
International Prognostic Factors Project, 231
International Prognostic Index, 1270
International Union Against Cancer, 1166
in anal cancer staging, 2529
in pleural mesothelioma staging, 879
Internet, medical oncology on, 2181-2186
Intestinal toxicity, prediction of, limited sampling models for, 2012-2019
Iodine 125, radioactive, transperineal implantation of, in prostate cancer, 449-453
Iodine-131, anti-B1 labeled with, in radioimmunotherapy, for B-cell lymphoma, 1974-1981
Irinotecan
in colorectal cancer, 2688-2695
in fluorouracil-resistant colorectal cancer, 1128-1135
hematologic toxicity of, 1132
limited sampling models for, 2012-2019
nonhematologic toxicity of, 1132
overview of, 1128
pharmacodynamics of, 2688-2695
pharmacokinetic parameter variations of, 2591
pharmacokinetic parameters of, 2596
pharmacokinetics of, 712, 1132-1133, 2688-2695
phase II studies of, 713
in recurrent colorectal cancer, 1128-1135
response to, 1130-1131
survival following, 1130-1131
toxicity of, 1131-1132, 711
in untreated metastatic colorectal cancer, 709-715
Irinotecan, fluorouracil, folinic acid regimen
pharmacokinetics of, 2962-2963, 2965
phase I trial of, 2959-2967
toxicity of, 2962-2964
Isolated limb perfusion, melphalan, tumor necrosis factor, interferon gamma regimen
for extremity melanoma, 479-489
regional toxicity of, 485-486
response to, 482-484
systemic toxicity of, 484-486

Journal of Clinical Oncology, 2391
*Journal of Biological Chemistry*, 2183

Kaposi's sarcoma
doxorubicin, bleomycin, vincristine regimen in, 2353-2364
liposomal daunorubicin in, 2353-2364
Keratopathy, tamoxifen-associated, 1023

L-PAM, amenorrhea due to, 1723

Lactate dehydrogenase
in melanoma, 1697-1703
serum, in HIV-related NHL, 2217-2223
Langerhans' cell histiocytosis
course of, at diagnosis, 2075
disease course of, 2073-2082
late sequelae of, 2077-2079
survival in, 2075-2077
Laparoscopy, port site recurrence following, 1950-1956
Laparotomy
open, port site recurrence following, 1950-1956
staging, in stage I-II low-grade follicular NHL, 1287
Laryngeal cancer, advanced, chemotherapy plus accelerated radiotherapy in, 2322-2330
Leucovorin, *see* Folinic acid
Leukapheresis, CD34+ yield in, prediction of, 970-973
Leukemia
acute lymphoblastic, cytoreduction in, for prognosis, 389-398
acute myelocytic, cytokines in, 1371-1382
acute myeloid
colony-stimulating factor use in, guideline recommendations for, 1959
in elderly, 1345-1352
GM-CSF induction of, 2150-2159
mitoxantrone, etoposide regimen in, 1345-1352
adult acute lymphoblastic, cytarabine, mitoxantrone regimen in, 2480-2485
adult acute myelogenous, treatment for, in first remission, 2206-2216
adult acute myeloid
behenoyl cytarabine in, 204-213
cytarabine in, 204-213
ubenimex in, 204-213
B-cell chronic lymphocytic, oral cladribine in, 2160-2166
childhood acute lymphoblastic
combination chemotherapy in, 911-918
dexamethasone *v* prednisolone in, 2370-2376
methotrexate, mercaptopurine maintenance regimen in, 911-918
prognostic factors in, 914-916
vincristine, dexamethasone maintenance regimen in, 911-918
vincristine, dexamethasone, asparaginase, methotrexate induction regimen in, 911-918
chronic myelogenous, cytogenetic clonal evolution in, 196-203
de novo acute myeloid, intensification chemotherapy plus BMT in, 1353-1363
following chemoradiotherapy
for breast cancer, 2722-2730
in NHL, 565-571
following fluorouracil, doxorubicin, cyclophosphamide, radiation regimen, 2722-2730
pediatric acute lymphoblastic
CNS disease status in, 22-23
CNS-directed therapy in, 399-404
cytogenetics in, for risk assignment, 21-22
early marrow response in, 389-398
early therapy response in, 21
etoposide CSF concentration in, 399-404
immunophenotype in, 22
prognostic factors in, uniform approach to, 20-21
risk classification in, 18-24
uniform approach to, 18-24
pediatric acute lymphocytic, p15-p16 gene inactivation in, 1512-1520
pediatric B-cell acute lymphoblastic
improved survival in, 1252-1261
prognostic factors in, 1257
pediatric B-precursor acute lymphoblastic, intensive oral methotrexate in, 2803-2811
pediatric refractory acute myeloid, amsacrine, etoposide, azacitidine regimen in, 1521-1525
pediatric acute lymphoblastic, therapy selection in, 4-6
radioimmunotherapy clinical trials in, 1388
recurrent pediatric, topotecan for, 1504-1511
relapsed pediatric acute lymphoblastic, peripheral blast counts at, 2812-2817
as second cancer, 2772
following chemoradiotherapy, for NHL, 565-571
Leukocyte
infiltration of, in c-*erb*B-2 overexpressing breast cancer, 85-94
subtypes of, tumor variables and, 90-91
Li-Fraumeni syndrome, genetic testing for, mothers' attitude toward, 415-421
Lifetech, 2183
Lipid-associated sialic acid
as colorectal tumor marker
definition of, 2850
guidelines for, 2850
literature of, 2850-2851
methodology for, 2850
as tumor marker, practice guidelines for, 2843-2877
Lipoprotein, plasma levels of, tamoxifen *v* toremifene and, 429-433
Liver
advanced colorectal cancer metastases to, with p53 overexpression, 2696-2701
colorectal cancer metastases to, survival following, 171-175
Liver function, *see* Hepatic function
Lomustine, dacarbazine, vincristine, bleomycin, interferon regimen, in melanoma, 1690-1696
Lonidamine, description of, 1165-1166
Lonidamine, epirubicin regimen
in breast cancer, 1165-1172
response to, 1168-1169
by disease site, 1170
toxicity of, 1168-1169
Loperamide
diphenhydramine plus, for diarrhea, 709-715
in irinotecan-induced diarrhea, 1129
Loss of heterozygosity, of RB gene, in osteosarcoma, 467-472
Lumpectomy, mastectomy *v*, in early breast cancer, 1558-1564
Lung, colorectal cancer metastases to, prognostic factors in, 2047-2053
Lung cancer
advanced non-small-cell
cisplatin-based combination chemotherapy in, 127
gemcitabine, cisplatin regimen in, 1656-1662
teniposide regimen in, 127-134
teniposide, cisplatin regimen in, 127-134
three-hour paclitaxel in, 142-148
extensive-disease small-cell
aggressive therapy in, 663
intermediate regimens for, 661
minimal therapy approaches in, 660-662
recent outcome data in, 660

single agents in, 662-663
survival in, 658-659
treatment philosophies in, 659-660
extensive-stage small-cell
cisplatin, etoposide, megestrol acetate regimen in, 135-141
topotecan in, 2345-2352
follow-up survey in, for patient surveillance, 2946-2948
incidence of, 497-498, 821, 1055-1056, 1913
limited-stage small-cell
combined modality regimen in, 806-813
cyclophosphamide, doxorubicin, vincristine therapy in, with etoposide, cisplatin, radiation regimen, 806-813
death in, causes of, 811
etoposide, cisplatin, radiation regimen in, with vincristine, cyclophosphamide, doxorubicin regimen, 806-813
relapse sites in, 811
therapy in, age and, 821-828
metastatic non-small-cell, amifostine, cisplatin, vinblastine regimen in, 1913-1921
non-small-cell
combined modality therapy in, 3165-3166
inoperable
chemoradiotherapy in, 1055-1064
etoposide, cisplatin, radiation regimen for, 1055-1064
paclitaxel, radiation regimen in, 1071-1076
postoperative adjuvant chemotherapy in, 1048-1054
postoperative cisplatin, vindesine, tegafur, uracil regimen in, 1048-1054
p53 abnormalities in, 497-502
paclitaxel, carboplatin regimen in, 2054-2060
topotecan in, 503-513
patient surveillance following, by geography, 2940-2949
poor-prognosis extensive-disease small-cell, therapy for, 662
refractory to cisplatin, topotecan in, 2785-2790
refractory to etoposide, topotecan in, 2785-2790
small-cell
combined modality therapy in, 3166
continuous infusion etoposide in, therapeutic monitoring of, 1903-1912
etoposide, vindesine maintenance regimen in, 2337-2344
topotecan in, 2785-2790
stage III non-small-cell
carboplatin, etoposide, radiation regimen in, 1065-1070
incidence of, 1065
treatment program for, 1643-1644
stage IV non-small-cell, vinorelbine *v* fluorouracil, folinic acid regimen in, 2774-2784
unresectable stage III non-small-cell, paclitaxel in, with combined modality therapy, 1642-1648
untreated non-small-cell, docetaxel in, 1649-1655
Lung function
correlation of, with therapy response, 1436-1437
following cisplatin, etoposide, bleomycin regimen, 445
recovery of, eighteen months following radiotherapy, 1431-1441
standard parameters of, 1435-1436
Lymph node(s)
paraaortic, core-needle biopsy of, 2432
retrieval of, in gastric cancer, 2289-2294
retrieval yield of, experience and, 2291-2292
retroperitoneal, core-needle biopsy of, 2432
Lymphocytopenia, associated with paclitaxel, radiation regimen, 1071-1076
Lymphoma
adult anaplastic large-cell, 955-962
adult Burkitt's, high-dose therapy with stem-cell transplantation in, 2465-2472
angioimmunoblastic lymphadenopathy-type T-cell
clinical findings in, 595
cytogenetic finding in, 593-599
survival in, 594-598
autologous BMT in, G-CSF plus IL-3 following, 3018-3025
B-cell, radioimmunotherapy for, 1974-1981
cyclophosphamide, epirubicin, vincristine, prednisolone regimen in, 227-232
diffuse, CT *v* SPECT gallium imaging in, 2475-2476
diffuse aggressive, cyclophosphamide, doxorubicin, etoposide, prednisone, bleomycin, cytarabine, methotrexate, folinic acid, GM-CSF regimen in, 1275-1281
follicular
CT *v* SPECT gallium imaging in, 2475-2477
fludarabine in, 514-519
t(14;18) chromosomal translocation detection in, 963-969
Hodgkin's, *see* Hodgkin's disease
ifosfamide, etoposide, methotrexate, dexamethasone regimen in, 227-232
image-guided core-needle biopsy in, 2427-2430
reliability of, 2431-2434
indolent, fludarabine, mitoxantrone, dexamethasone regimen in, 1262-1268
large B-cell
*bcl*-2 protein in, 2131-2138
p53 protein in, 2131-2138
malignant
needle biopsy in, 2415-2416
radiotherapy of, lung function recovery following, 1431-1441
mantle-cell, 1269-1274
CNS involvement in, 941-944
histologic criteria for, 1270
survival in, 1272
non-Hodgkin's, *see* Non-Hodgkin's lymphoma
pediatric stage IV small non-cleaved-cell
improved survival in, 1252-1261
prognostic factors in, 1257
primary CNS, pre-irradiation cyclophosphamide, doxorubicin, vincristine, dexamethasone regimen in, 556-564
primary cutaneous B-cell, overview of, 549
primary cutaneous follicle center cell, radiotherapy *v* polychemotherapy in, 549-555
radioimmunotherapy clinical trials in, 1389-1391
Revised European American classification of, 2465
small non-cleaved-cell
childhood chemotherapy for adults in, 925-934
doxorubicin, cyclophosphamide, vindesine, bleomycin, prednisone regimen in, 240-248
GM-CSF in, 931-932
ifosfamide, etoposide, high-dose cytarabine regimen in, 925-934
prognosis of, 240-248
stage I-II low-grade follicular
extranodal sites in, 1283
prognostic factors in, 1285-1286, 1288
radiation in, 1282-1290
staging laparotomy in, 1287
Lymphopenia, early, following chemotherapy, 636-643

Lymphoplasmacytic infiltrate, in c-*erb*B-2 overexpressing breast cancer, 85-94
Lymphoproliferative disorder, following methotrexate, in rheumatoid arthritis, 1943-1949

Magnetic resonance imaging
of breast tumor, 1851
endorectal coil, in prostate cancer staging, 1770-1777
Major breakpoint region, 1333
Malignant pericardial effusion
bleomycin sclerosis of, 3141-3147
chest radiograph findings in, 3144
doxycycline sclerosis of, 3141-3147
ECG findings of, 3144
echocardiographic findings in, 3144
physical signs of, 3143
sclerosis of, 3141-3147
symptoms of, 3143
Mann-Whitney test, 1150
Mantel-Haenszel analysis, 840
Margin of resection, prognostic significance of, in synovial sarcoma, 1201-1208
Marker, tumor
c-*erb*B2 overexpression as, for tamoxifen efficacy, 2702-2708
clinical practice guidelines for, in breast cancer, 2843-2877
in colorectal cancer, 2843-2877
definition of, 2846
in neuroblastoma, 373
polysialic-neural cell adhesion molecule measurement as, in medulloblastoma metastasis, 2066-2072
usefulness of, level of evidence for, 2845
uses of, 2845
utility grading system for, 2845
Markov cycle tree, 71
Mastectomy, breast-conserving surgery *v*, 1558-1564
and survival, 70-77
Mathematic modeling, for maximum-tolerable dose determination, 1656-1662
Matrix metalloproteinase-9, for colorectal cancer relapse prediction, 3133-3140
Maximum-tolerated systemic exposure
definition of, 1505
of topotecan, 1504-1511
McCarthy Scales of Children's Abilities, 2828
mdm2 protein
in cervical human papillomavirus lesions, 2120-2130
immunopositivity of, 2125
p53 coexpression with, 2126-2127
Mechlorethamine, vincristine, procarbazine, prednisone regimen, alternating with ABVD regimen
in HD, 1421-1430
salvage therapy following, 1426-1427
second malignancies following, 1427
survival following, 1425-1426
ten-year results of, 1425
toxicity of, 1426-1427
Medical oncology
for general internal medicine trainee, overview of, 1040
special expertise of, 1040
training in, for the general internist, 1040-1041
training sites in, 1041
Medical school, work activities of, in oncology, 2617
Medroxyprogesterone acetate, appetite and, 1077-1084
Medulloblastoma
melphalan, cyclophosphamide, BMT regimen for, 382-388
metastasis of, polysialic-neural cell adhesion molecule in, 2066-2072
recurrent, low-dose oral etoposide in, 1922-1927
Megestrol acetate
adverse effects of, 360
anastrozole *v*, in breast cancer, 2000-2011
beneficial effects of, 140
high-dose, in endometrial cancer, 357-361
quality of life following, 139
response to, 358-359
weight gain following, 2007
Megestrol acetate, cisplatin, etoposide regimen
in SCLC, 135-141
toxicity of, 140
Melanoma
cutaneous
diagnosis of, interobserver agreement on, 1218-1223
incidence of, 7-8
of extremity, isolated limb perfusion, melphalan, tumor necrosis factor, interferon gamma regimen for, 479-489
high-risk
adjuvant interferon alfa-2b in, 7-17
successful adjuvant therapy for, 1-3
high-risk resected cutaneous, adjuvant high-dose interferon alfa-2b in, 2666-2673
interferon alfa-2b in, Q-TWiST of, 2666-2673
interleukin-2-based immunotherapy for, response predictors of, 1697-1703
metastatic
carmustine, dacarbazine, cisplatin regimen in, 2083-2090
chemoimmunotherapy in, prognostic factors for, 1690-1696
tamoxifen, carmustine, dacarbazine, cisplatin regimen in, 2083-2090
radioimmunotherapy clinical trials in, 1390-1392
staging of, 8
therapy of, CD4+ to CD8+ ratio during, 1690-1696
Melanoma cell, reverse-transcriptase polymerase chain detection of, 2091-2097
Melphalan
in combination chemotherapy, second cancer following, 2770
in myeloablative chemoradiotherapy regimen, 2418
Melphalan, buthionine sulfoximine regimen
clinical toxicity of, 251-252
pharmacokinetics of, 253-254
phase I trial of, 249-256
responses to, 252
Melphalan, cyclophosphamide, BMT regimen
dosing plan for, 384
for CNS tumors, 382-388
response to, 385
survival following, 386
toxic deaths due to, 385
Melphalan, cyclophosphamide, thiotepa, carboplatin regimen, in breast cancer, 2984-2992
Melphalan, isolated limb perfusion, tumor necrosis factor, interferon gamma regimen
for extremity melanoma, 479-489
regional toxicity of, 485-486
response to, 482-484

systemic toxicity of, 484-486
Melphalan, prednisone regimen, in multiple myeloma, 2167-2173
Melphalan, tumor necrosis factor-alpha, interferon-gamma regimen
for soft tissue sarcoma, 2653-2665
toxicity of, 2659-2660
Melphalan, vincristine, cylcophosphamide, prednisone regimen, in multiple myeloma, 2167-2173
Menogaril
pharmacokinetic parameters of, 2593, 2596
Menopause
chemotherapy induced, 1718-1729
natural, by age group, 1719
physiology of, 997-998
symptomatology of, 997-998
symptoms of, relief of, 998
Mental health index, in prostate cancer, following surgery *v* radiotherapy, 2262
Mercaptopurine
in combination chemotherapy
for pediatric B-precursor acute lymphoblastic leukemia, 2803-2811
second cancer following, 2770
pharmacokinetic parameter variations of, 2591
pharmacokinetic parameters of, and tumor response, 2597
in polychemotherapy, for pediatric acute lymphoblastic leukemia, 2813
Mercaptopurine, methotrexate regimen, for maintenance, in acute lymphoblastic leukemia, 911-918
Mesna, in combination chemotherapy, for lymphoma, 228
Mesothelioma
clinical trials in, 1008
diffuse malignant
chemoimmunotherapy in, 878-885
cisplatin, interferon alfa-2a regimen in, 878-885
doxorubicin in, 1008-1009
malignant
combination chemotherapy in, 1012-1014
following HD therapy, 2098-2100
malignant pleural
chemotherapy in, 1007
future therapy directions in, 1014-1015
incidence of, 1007
intracavity therapy in, 1014
pleural, UICC staging of, 879
single-agent chemotherapy in, 1008, 1009
Meta-analysis, benefits of, 3162
Metabolic rate, of glucose, 691-692
Metaiodobenzylguanidine
in carcinoid tumor, 1829-1838
radiolabeled, in carcinoid tumor, 1829-1838
Metastasis
advanced hepatic, with p53 overexpression, in colorectal cancer, 2696-2701
brain, linear accelerator-based stereotaxic radiosurgery for, 1085-1092
PET evaluation of, 691-696
predictor of, breast relapse as, 52-57
prognostic factor for, CD44 variant as, 1122-1127
Methadone
administration of, 2837-2838
for cancer-related pain, 2836-2842
Methotrexate
in combination chemotherapy
for acute lymphoblastic leukemia, 2805
for pediatric B-precursor acute lymphoblastic leukemia, 2803-2811
second cancer following, 2770
high-dose
carboxypeptidase G2 rescue following, 2145-2149
in combination chemotherapy, for small non-cleaved-cell lymphoma, 925-934
intensive oral, in pediatric B-precursor acute lymphoblastic leukemia, 2803-2811
intrathecal
for retinoblastoma, 1533
in combination chemotherapy, for small non-cleaved-cell lymphoma, 925-934
low-dose, plus 5-FU
in colorectal cancer, 2266-2273
response to, 2268
survival following, 2269-2270
toxicity of, 2271
in mesothelioma, 1009
pharmacokinetic parameters of, 2593, 2596
and tumor response, 2597
in polychemotherapy, for pediatric acute lymphoblastic leukemia, 2813
reduced lymphoid marrow relapse with, 2803-2811
in rheumatoid arthritis, and lymphoproliferative disorders, 1943-1949
simulated dose adjustment score table for, 2603
toxicity of, 2807-2808
Methotrexate, carmustine, vincristine, cytarabine regimen
in chemoradiotherapy, for CNS lymphoma, 945-954
hematologic toxicity of, 949
relapse patterns following, 951
survival following, 950-952
Methotrexate, cyclophosphamide, doxorubicin, etoposide, prednisone, bleomycin, cytarabine, folinic acid, GM-CSF regimen
maximum-tolerated dose of, in lymphoma, 1275-1281
response to, 1278
toxicity of, 1277-1278
Methotrexate, cyclophosphamide, doxorubicin, vincristine, cytarabine regimen
in pediatric leukemia, 1252-1261
in stage IV small non-cleaved-cell lymphoma, 1252-1261
Methotrexate, cyclophosphamide, fluorouracil regimen
adjuvant chemotherapy and, in metastatic breast cancer, 764-773
in breast cancer, 35-45, 1136-1145, 1885-1894, 1982-1992
dose analysis of, 1138-1139
G-CSF dose-intensity maintenance of, 1573-1580
as gold standard, 1971-1973
PMT dosing of, 2601
radiotherapy and, 1141-1142
relapse site following, 1141
schedule for, 1137
tamoxifen plus, thromboembolism following, 2731-2737
toxicity of, 1139, 1988
Methotrexate, cyclophosphamide, fluorouracil, vincristine, prednisone regimen
in breast cancer, 46-51, 1589-1598
dosing of, 1591
ovariectomy plus, 46-51

survival following, 1593-1595
toxicity of, 49, 1594-1596
Methotrexate, cyclosporine regimen, for graft-versus-host disease prophylaxis, 1355
Methotrexate, doxorubicin, cyclophosphamide, fluorouracil regimen, G-CSF dose-intensity maintenance of, 1573-1580
Methotrexate, doxorubicin, cyclophosphamide, vincristine, bleomycin, etoposide, prednisolone regimen, in NHL, 586-592
Methotrexate, epidoxorubicin, carboplatin regimen, neoadjuvant, for bone histiocytoma, 490-496
Methotrexate, fluorouracil regimen
in breast cancer, 1982-1992
toxicity of, 1988
Methotrexate, fluorouracil, doxorubicin regimen, preoperative, in gastric cancer, 1818-1828
Methotrexate, ifosfamide, etoposide, dexamethasone regimen, in lymphoma, 227-232
Methotrexate, mercaptopurine regimen, for maintenance, in acute lymphoblastic leukemia, 911-918
Methotrexate, vinblastine, bleomycin, radiation regimen
in HD, 527-533
survival following, 530
toxicity of, 529-531
Methotrexate, vincristine, dexamethasone, asparaginase regimen, for induction, in acute lymphoblastic leukemia, 911-918
Methotrexate, vincristine, doxorubicin, cyclophosphamide, bleomycin, dactinomycin regimen, for bone histiocytoma, 490-496
Methylprednisone, doxorubicin, bleomycin, vinblastine, dacarbazine, radiotherapy, in HD, 1928-1935
MICK applicator, 305, 306
Micrometastasis, bone marrow, prognostic significance of, in gastric cancer, 1810-1817
Microsatellite analysis, 1514
Microvessel, count of, as prognostic factor, 461-466
Mifepristone
in metastatic breast cancer, 2709-2712
response to, 2711
Mitomycin, in mesothelioma, 1009, 1011
Mitomycin, bleomycin, cisplatin, doxorubicin regimen, in malignant mesothelioma, 1013
Mitomycin, cisplatin regimen, in malignant mesothelioma, 1013
Mitomycin, cisplatin, interferon alfa regimen, in malignant mesothelioma, 1013
Mitomycin, fluorouracil, radiotherapy regimen
in anal cancer, 2527-2539
disease-free survival following, 2533, 2535
toxicity of, 2534-2535
Mitotic activity, prognostic significance of, in synovial sarcoma, 1201-1208
Mitoxantrone
amenorrhea due to, 1723
cardiotoxicity of, 1762
high-dose
in breast cancer, 2576-2583
plus cytarabine, in leukemia, 2480-2485
in mesothelioma, 1009
Mitoxantrone, cladribine regimen
for indolent NHL, 2139-2144
toxicity of, 2140-2142
Mitoxantrone, cyclophosphamide, G-CSF regimen
in breast cancer, 2576-2583
hematologic toxicity of, 2579
nonhematologic toxicity of, 2580
Mitoxantrone, cytarabine regimen
in leukemia, 2480-2485
vincristine, prednisone, doxorubicin, cyclophosphamide regimen *v*, 2480-2485
Mitoxantrone, etoposide regimen
in acute myeloid leukemia, 1345-1352
in elderly, 1345-1352
quality of life following, 1349
response to, 1347-1348
toxicity of, 1348
Mitoxantrone, fludarabine, dexamethasone regimen
for indolent lymphoma, 1262-1268
response to, 1263-1264
survival following, 1265
toxicity of, 1264-1266
Mitoxantrone, paclitaxel, fluorouracil, folinic acid regimen
in breast cancer, 1611-1616
survival following, 1613
toxicity following, 1613-1614
Mitoxantrone, prednisone regimen, in hormone-resistant prostate cancer, 1756-1764
Model
area under curve, 2014-2015
limited sampling, for irinotecan, 2012-2019
mathematic, for maximum-tolerable dose determination, 1656-1662
of survival, in breast cancer, 70-77
Monoclonal antibody
A33, iodine 125-labeled, in colon cancer, 1787-1797
Ab3, anti-c-*erb*B-2 oncoprotein, 91
with anti-carcinoembryonic antigen specificity, in colorectal cancer, 2295-2305
anti-CD31, in colorectal cancer, 461-462
anti-HER2, in breast cancer, 737-744
iodine 125-labeled, in radioimmunoguided surgery, 1599-1603
iodine 131-labeled, for carcinoembryonic antigen, 1789-1809
hematologic toxicity of, 1805
pharmacology of, 1789-1809
production of, 1386
radiolabeled, in medullary thyroid cancer, 1209-1217
MOPP regimen
alternating with ABVD regimen
in HD, 1421-1430
salvage therapy following, 1426-1427
second malignancies following, 1427
survival following, 1425-1426
ten-year results of, 1425
toxicity of, 1426-1427
*see also* Mechlorethamine, vincristine, procarbazine, prednisone regimen
Multidrug resistance
paclitaxel with r-verapamil and, 1173-1174
PSC 833 for, 610-618
Multiple endocrine neoplasia 2, genetic testing for, mothers' attitude toward, 415-421
Multiple myeloma
high-dose therapy in
with autologous peripheral-blood progenitor-cell support in, 1306-1313
survival and, 2167-2173

with peripheral-blood stem-cell transplantation, 1447-1456
high-risk, chemoradiotherapy in, 1306-1313
melphalan, prednisone regimen in, 2167-2173
prognostic factors in, 1310, 1311
race as, 974-977
vincristine, carmustine, doxorubicin, prednisone regimen in, 2167-2173
vincristine, cyclophosphamide, melphalan, prednisone regimen in, 2167-2173
Multiple-tube approach, 1335
Myelodysplastic syndrome
advanced, allogeneic BMT for, 220-226
chemotherapy in, 2486-2494
prognostic factors in, 2488-2490
Myelosuppression, radioimmunotherapy-induced, 1392

N-*myc* amplification
CD44 and, 27-29
in neuroblastoma, 405-414
in pediatric neuroblastoma, 25-34
National Cancer Genetics Network, 2881
National Cancer Institute, role of, in cancer research, 2878-2883
Nausea
following epirubicin, 1152
tropisetron prophylaxis for, maintained efficacy of, 644-651
Needle biopsy
core-, of paraaortic lymph node, 2432
image-guided core-
in lymphoma, 2427-2430
reliability of, in lymphoma, 2431-2434
in malignant lymphoma, 2415-2416
Nentrez, 2182-2183
Neosar, *see* Cyclophosphamide
Netscape WWW browser, 2184
Neuroblastoma
advanced, autologous BMT in, 2413-2414
angiogenesis in, 405-414
biologic features of, 377
biologic findings in, 2175
biologic markers in, 2177
overview of, 25-34
biologic variables in, 28
CD44 in, as prognostic marker, 25-34
clinical studies of, 2175-2177
CT of, 376-377
Evans stage II, 2177
incidence of, 373
International Neuroblastoma Staging System, 374, 2505
stage I, 2174-2180
N-*myc* gene amplification in, 25-34
non-stage 4, without cytotoxic therapy, 373-381
pediatric, prognostic marker in, 25-34
pediatric low-stage, successful management of, 2504-2510
pediatric metastatic, consolidation chemoradiotherapy plus BMT in, 2417-2426
pediatric poor-risk, in vivo bone marrow purging in, 2791-2802
prognostic factors in, 409
prognostic markers in, 373-374
radioimmunotherapy clinical trials in, 1390-1392
stage I, clinical findings in, 2175
stage IV, consolidation chemoradiotherapy plus BMT in, 2417-2426
stage IV-S
definition of, 1538
primary tumor resection in, at diagnosis, 1537-1544
untreated, 2504-2510
Neuropathy
due to colony-stimulating factors, 935-940
vincristine-induced, 935-940
Neuropsychologic functioning
assessment of, 1458-1459
during autologous BMT therapy, 1457-1462
Neuropsychologic status
of patients, chemotherapy impact on, 2826-2835
tests of, 2828
Neurotoxicity
associated with cisplatin, in ovarian cancer, 2117
of cisplatin, bleomycin, etoposide regimen, 2925
of cisplatin, bleomycin, vinblastine regimen, 2925
of cyclophosphamide, thiotepa, carboplatin, stem-cell regimen, 1477-1478
of paclitaxel, cisplatin regimen, in breast cancer, 1993-1999
Neutropenia
associated with fluorouracil, doxorubicin, cyclophosphamide regimen, 2979
chemotherapy-related, GM-CSF for, 619-627
chemotherapy-related febrile
assessing risk of, 636-643
defining risk of, 640
risk model for, 640-641
colony-stimulating factor use in, guideline recommendations for, 1958
febrile children with, bacteremia risk in, 919-924
following buthionine sulfoximine, melphalan regimen, 252
prolonged, five-day G-CSF course following, 1573-1580
NHL, *see* Non-Hodgkin's lymphoma
Nicholas Negroponte, 2183
nm23 gene, in ovarian cancer, 334-342
nm23-H1
immunohistochemical analysis of, 339
Northern blot analysis of, 336-337
Western blot analysis of, 336-338
nm23-H2
Northern blot analysis of, 336-337
Western blot analysis of, 336-338
Non-Hodgkin's lymphoma
autologous BMT in, marrow tumor burden and, 214-219
B-cell, 1269-1274
Burkitt-like, high-dose therapy with stem-cell transplantation in, 2465-2472
chemoradiotherapy in, leukemia following, 565-571
chemotherapy dose escalation schema in, 1276
chemotherapy dose-intensity in, 1277
of CNS
carmustine, vincristine, cytarabine, methotrexate regimen in, 945-954
chemoradiotherapy in, 945-954
combination chemotherapy in, overview of, 1275-1276
combination chemotherapy dosing modifications in, 1277
CT *v* SPECT gallium imaging in, 2473-2479
diffuse aggressive, cyclophosphamide, doxorubicin, etoposide, prednisone, bleomycin, cytarabine, methotrexate, folinic acid, GM-CSF regimen in, 1275-1281
dose-intensity in, by regimen, 1280

fludarabine studies in, 518
HIV-related
age in, 2217-2223
cyclophosphamide, doxorubicin, etoposide, didanosine, G-CSF regimen in, 3026-3035
serum lactate dehydrogenase in, 2217-2223
image-guided core-needle biopsy in, 2432-2433
indolent, cladribine, mitoxantrone regimen in, 2139-2144
low-grade, gallium-67 scintigraphy in, 1936-1942
mantle-cell, 1269-1274
96-hour paclitaxel infusion in, refractory to 3-hour infusion, 543-548
paclitaxel-resistant, cyclosporin A in, 233-239
in partial response
dexamethasone, cisplatin, cytarabine regimen for, 534-542
high-dose carmustine, etoposide, cytarabine, cyclophosphamide, BMT regimen for, 534-542
poor-prognosis
doxorubicin, cyclophosphamide, vincristine, bleomycin, etoposide, prednisolone, methotrexate regimen in, 586-592
ifosfamide, cytarabine, busulfan, cyclophosphamide, stem-cell regimen in, 586-592
stage I-II low-grade follicular
extranodal sites in, 1283
prognostic factors in, 1285-1286, 1288
radiation in, 1282-1290
staging laparotomy in, 1287
Nonverbal Selective Reminding Test, 2828
Nor-verapamil, 1178
Northern blot analysis
of *mdr1* expression, 888
of nm23, 336-337
of *PRAD1* gene, 941
Northern blot hybridization, 3134
NSCLC, *see* Lung cancer, non-small-cell
Nucleotide sequencing, 1514
Nurse, telephone-based intervention by, for informed consent, 984-996
*N*-methyl-formamide, pharmacokinetic parameters of, 2593, 2596

Obesity
chemotherapy toxicity and, 3000-3008
drug handling and, 2602
Observation, radiotherapy *v*
cost of, 2933-2939
outcomes of, 2934-2935
in stage I seminoma, 2933-2939
Oligomenorrhea, 1725
Oligonucleotide OL(1)p53
in vitro effect of, 1322
pharmacokinetics of, 1324
phase I trial of, 1320-1326
proposed mechanism for, 1325
toxicity of, 1324
Oncology
administration in, 2617
changes in, workforce response to, 2617-2620
clinical research in, 2617
community hospitals in, work activities in, 2617
field of, definition of, 1040
HMO in, work activities in, 2617
on Internet, 2181-2186
medical
work activities in, 2616
*see also* Medical oncology
medical schools in, work activities in, 2617
medical workforce in
status of, 2612-2621
survey of, 2613-2614
number of patients seen in, 2615-2616
patient care in, 2617
primary care service delivery in, 2616-2618
private practice in, work activities for, 2617
scientific research in, 2617
survey in
double-sample design for, 2613
mail response in, 2614
respondent characteristics in, 2614
time reporting in, 2616
university hospitals in, work activities for, 2617
work activities for, 2615
Oncology Certified Nurse, 3153
Oncology research, *see* Clinical oncology research
Oncology-hematology, work activities in, 2616
Ondansetron
adverse effects of, 2247
dolasetron, *v*, for cisplatin-induced emesis, 2242-2249
efficacy of, 2246
Optic neuritis, tamoxifen-associated, 1020
Osteosarcoma
intensive neoadjuvant chemotherapy in, 848-858
prognostic factor in, tumor size as, 848-858
RB gene in, loss of heterozygosity of, 467-472
tumor size in, 848-858
Ototoxicity
associated with cisplatin, in ovarian cancer, 2117
of cisplatin, bleomycin, etoposide regimen, 2925
of cisplatin, bleomycin, vinblastine regimen, 2925-2926
of cyclophosphamide, thiotepa, carboplatin, stem-cell regimen, 1477-1478
Outcomes Working Group, 672
Outpatient therapy, intensive adjuvant, in breast cancer, 1565-1572
Ovarian cancer
amifostine pretreatment in, 2101-2112
CA-125 in, 1411-1412
carboplatin, paclitaxel regimen in, 1895-1902
chemotherapeutic response in
accepted definitions of, 1547
CA 125 monitoring of, 1545-1551
discarded definitions of, 1546-1547
proposed definitions of, 1547
cisplatin dosing for, 2113-2119
cisplatin-refractory
paclitaxel in, 796-799
topotecan in, 1552-1557
cisplatin, cyclophosphamide, epidoxorubicin regimen in, 351-356
combination chemotherapy in, high *v* low-dose cisplatin for, 351-356
epithelial, carboplatin, G-CSF regimen in, 800-805
factoring outcomes in, 325-327
fifty percent chemotherapeutic response in, 1548
intraperitoneal interferon gamma in, 343-350
nm23 in, 334-342
pharmacologically-based carboplatin dosing in, 800-805

pretreated, vinorelbine in, 2546-2551
radioimmunotherapy clinical trials in, 1390-1392
refractory epithelial, 5-day intravenous topotecan infusion in, 1552-1557
second-line therapy in, topotecan as, 3056-3061
seventy-five percent chemotherapeutic response in, 1548
therapy of, overview of, 343-344
untreated stage I epithelial
natural history of, 2968-2975
relapse in, factors predicting, 2969-2970
relapse therapy in, 2973
survival from relapse in, 2974
survival in, 2970-2973
Ovarian function, following adjuvant chemotherapy, in breast cancer, 1718-1729
Ovariectomy, cyclophosphamide, methotrexate, fluorouracil, vincristine, prednisone regimen plus, in breast cancer, 46-51
Oxaliplatin, fluorouracil, folinic acid regimen, chronomodulated
in colorectal cancer, 2950-2958
efficacy of, 2955
survival following, 2956
toxicity of, 2953-2954

P-glycoprotein
immunohistochemical analysis of, 887-888
in pediatric rhabdomyosarcoma, 886-900
prior to and following paclitaxel, 1181
as prognostic factor, in pediatric rhabdomyosarcoma, 886-900
p53 protein
abnormalities of, in NSCLC, 497-502
antibodies against, detection of, 2127
as breast tumor marker
definition of, 2865
future research with, 2866
guidelines for, 2865
literature review of, 2865-2866
methodology for, 2865
*bcl*-2 coexpression with, 2127
in cervical human papillomavirus lesions, 2120-2130
as colorectal tumor marker
definition of, 2853
future research with, 2854
guidelines for, 2853
methodology for, 2853-2854
for postoperative prognosis, 2854
expression of, 2124
breast cancer outcome and, 1604-1610
in large B-cell lymphoma, 2131-2138
immunopositivity of, 2125, 2126
in lymph nodes, 2697
mdm2 coexpression with, 2126-2127
mutational analysis of, 2127
overexpression of
in bladder cancer, and Bacillus Calmette-Guerin therapy, 2646-2652
in colorectal cancer, with hepatic metastases, 2696-2701
phenotypes of, 2123
in primary colorectal adenocarcinoma, 2697
proposed mechanisms of, 2121
as prognostic factor
for survival, in colorectal cancer, with hepatic metastases, 2696-2701
in bladder cancer, 2646-2652
simultaneous expression of, with bcl-2 expression, 2134
as tumor marker
in colorectal cancer, 2853
practice guidelines for, 2843-2877
Paclitaxel
adverse effects of, 794
for biliary tract cancer, 2306-2310
carboplatin interactions with, 2598
cisplatin interactions with, 2598
in cisplatin-refractory ovarian cancer, 796-799
in combined modality therapy, for NSCLC, 1642-1648
cyclophosphamide interactions with, 2598
doxorubicin interactions with, 2598
doxorubicin following, pharmacokinetics of, 2713-2721
drug interaction with, 2718
etoposide interactions with, 2598
following taxane, in breast cancer, 1877-1884
following topotecan-refractory ovarian cancer, 1555
high- *v* low-dose
in breast cancer, 1858-1867
response to, 1861
safety of, 1862-1864
survival following, 1862
in mesothelioma, 1009, 1010
neutropenia-based dosing alterations of, 794
NHL resistant to, cyclosporin A in, 233-239
96-hour infusion of
phase II trial of, 1877-1884
plasma concentration following, 546
refractory to 3-hour infusion, 543-548
toxicity of, 544-546
pharmacokinetic parameter variations of, 2591
pharmacokinetic parameters of, 2593, 2596
pharmacokinetics of, 604-605
r-verapamil with
in breast cancer, 1173-1184
hematologic toxicity of, 1177-1178
neurologic toxicity of, 1177
radiosensitizing effect of, 1071-1076
for recurrent malignant glioma, 2316-2321
schedule dependency of, 95
schedule-dependency of, 543-548
72-hour continuous intravenous infusion
as ambulatory regimen, 99
in cyclophosphamide, G-CSF regimen, 95-102
72-hour infusion of, plus doxorubicin, G-CSF regimen, 774-782
in squamous cervix cancer, 792-795
survival following, 798
3-hour infusion of, 1858-1867
hematologic toxicity of, 145
in NSCLC, 142-148
nonhematologic toxicity of, 145-146
for recurrent malignant glioma, 2316-2321
response to, 144-145
survival following, 145
toxicity of, 797, 2319
weekly outpatient, plus cranial irradiation
for astrocytoma, 600-609
toxicity of, 602-604
Paclitaxel, carboplatin regimen
in NSCLC, 2054-2060

in ovarian cancer, 1895-1902
response to, 2056-2058
toxicities of, 2056-2057
Paclitaxel, cisplatin regimen
biweekly, 1185-1191
in breast cancer, 1993-1999
neurotoxicity of, 1996
response to, 1189
toxicity of, 1188-1189
Paclitaxel, cisplatin, etoposide, radiation regimen
in NSCLC, 1642-1648
toxicity of, 1645-1646
Paclitaxel, cyclophosphamide, cisplatin, stem-cell regimen
pharmacokinetics of, 1467
phase I trial of, 1463-1472
toxicity of, 1466-1467
Paclitaxel, cyclophosphamide, G-CSF regimen
dose-limiting toxicity of, 787
dosing of, 98, 784
drug sequencing in, 785
hematologic toxicity of, 97-98, 787-788
in metastatic breast cancer, 95-102
nonhematologic toxicity of, 98-99, 788
pharmacology of, 788-789
in previously treated metastatic breast cancer, 783-791
response to, 99
Paclitaxel, dexamethasone, diphenhydramine, cimetidine regimen
in biliary tract cancer, 2306-2310
toxicity of, 2308
Paclitaxel, doxorubicin, G-CSF regimen
in metastatic breast cancer, 774-782
pharmacokinetics of, 778-779
toxicity of, 777
Paclitaxel, mitoxantrone, fluorouracil, folinic acid regimen
in breast cancer, 1611-1616
survival following, 1613
toxicity following, 1613-1614
Paclitaxel, radiation regimen
hematologic parameters following, 1075
infectious complications following, 1072
interstitial pneumonia associated with, 1071-1076
lymphocytes following, 1074
lymphocytopenia associated with, 1071-1076
toxicity of, 1072-1074
Pain, cancer
methadone for, 2836-2842
sustained- *v* immediate-release hydromorphone in, 1713-1717
Palliation Index, 2839
Pamidronate
for bone metastasis delay, 2552-2559
in metastatic breast cancer, 2552-2559
Pancreatic cancer, combined modality therapy in, 3166-3167
Pasteur effect, 691
Patient advocacy organizations, American Society of Clinical Oncology relationship with, 2392
Patient care, in oncology, 2617
Patient surveillance
by geography, following lung cancer, 2940-2949
following surgery, in colon cancer, 183-187
following testicular cancer, 2061-2065
modalities of
frequency of use of, 2943
by geography, following lung cancer, 2942
Peabody Individual Achievement Test, 2828
Peabody Picture Vocabulary Test, revised, 2828
PEPI trial, 999
Pericardiocentesis, in malignant pericardial effusion, 3147
Peripheral blast count, as prognostic factor, in relapsed pediatric acute lymphoblastic leukemia, 2812-2817
Peripheral-blood stem-cell
collections of, breast cancer contamination of, 2569-2575
with double dose-intensive chemotherapy, in breast cancer, 2984-2992
for ex vivo CD34+ expansion, 1839-1847
harvesting of, 1474, 1476
mobilization of, 1474, 1476
preleukapheresis count of, for transplantation, 1114-1121
procurement of, 1449
yield of, prediction of, 970-973
Peripheral-blood stem-cell transplantation
autologous
following high-dose chemotherapy, in multiple myeloma, 1306-1313
hematologic recovery following, 1308
with high-dose chemotherapy, 2465-2472
high-dose cyclophosphamide for, 1307-1308
high-dose ifosfamide, cytarabine, busulfan, cyclophosphamide regimen plus, in NHL, 586-592
colony-stimulating factor use in, guideline recommendations for, 1958
following high-dose chemotherapy, in multiple myeloma, 1447-1456
Peripheral-blood stem-cell transplantation, cyclophosphamide, thiotepa, carboplatin regimen
multiple courses of, 1473-1483
toxicity of, 1477-1479
Peripheral-blood stem-cell transplantation, ifosfamide, carboplatin, etoposide regimen, in germ cell cancer, 2631-2637
Peripheral-blood stem-cell transplantation, paclitaxel, cyclophosphamide, cisplatin regimen
pharmacokinetics of, 1467
phase I trial of, 1463-1472
toxicity of, 1466-1467
Peripheral-blood stem-cell transplantation, thiotepa, carboplatin regimen, as myeloablative regimen, 1527
Perkin-Elmer, 2183
PET, *see* Positron-emission tomography
Pharmaceutical manufacturer, physician and, conflict of interest of, 312-320
Pharmacodynamics, of irinotecan, 2688-2695
Pharmacogenetics, 2602
Pharmacokinetics
of doxorubicin following paclitaxel, 2713-2721
of irinotecan, 2688-2695
Phase I trial
of buthionine sulfoximine, melphalan regimen, 249-256
of carboplatin, G-CSF regimen, in ovarian cancer, 800-805
of carboplatin, paclitaxel regimen, in ovarian cancer, 1895-1902
conducted in 1991-1993, 289
of cyclophosphamide, doxorubicin, etoposide, prednisone, bleomycin, cytarabine, methotrexate, folinic acid, GM-CSF regimen, in lymphoma, 1275-1281
design of, 287-295
of etoposide bioavailability, from etoposide phosphate, 2020-2030

of etoposide plus PSC 833, 610-618
of gemcitabine, cisplatin regimen, in NSCLC, 1656-1662
of high-dose mitoxantrone, cyclophosphamide, G-CSF regimen, in breast cancer, 2576-2583
of IL-2 with interferon alfa-2a regimen, 2234-2241
of iodine 131-labeled COL-1, 1798-1809
of irinotecan, fluorouracil, folinic acid regimen, 2959-2967
of oligonucleotide OL(1)p53, 1320-1326
of paclitaxel plus cranial irradiation, for astrocytoma, 600-609
of paclitaxel with r-verapamil, in breast cancer, 1173-1184
of paclitaxel, cyclophosphamide, cisplatin, stem-cell regimen, 1463-1472
of paclitaxel, cyclophosphamide, G-CSF regimen, 95-102
in breast cancer, 783-791
of PIXY321, for peripheral-blood mobilization, 2521-2526
of sequential cisplatin-topotecan regimen, 3074-3084
of sequential paclitaxel-doxorubicin pharmacokinetics, 2713-2721
of sequential topotecan, G-CSF regimen, 1224-1235
of 72-hour aminocamptothecin infusion, 1236-1244
standard design of, 287-288
of topotecan, in impaired renal function, 3062-3073
of ZD 1694, 1495-1503
Phase I-II trial
of AZT, fluorouracil, folinic acid regimen, for metastatic colorectal cancer, 729-736
of biweekly paclitaxel, cisplatin regimen, in breast cancer, 1185-1191
of combined G-CSF and GM-CSF, for progenitor-cell mobilization, 277-286
of iodine 125-labeled monoclonal antibody A33, in colon cancer, 1787-1797
of paclitaxel, doxorubicin, G-CSF regimen, in breast cancer, 774-782
of PIXY321, following BMT, 520-526
of weekly cisplatin, interferon alfa-2a regimen, in malignant mesothelioma, 878-885
Phase II trial
of amifostine, cisplatin, vinblastine regimen, in NSCLC, 1913-1921
of amsacrine, etoposide, azacitidine regimen, in pediatric leukemia, 1521-1525
of busulfan, cyclophosphamide, total-body irradiation regimen, in myelodysplastic syndrome, 220-226
of continuous infusion topotecan, for colorectal cancer, 2540-2545
of docetaxel
in metastatic breast cancer, 58-65, 422-428
in NSCLC, 1649-1655
of docetaxel, in head and neck cancer, 1672-1678
efficacy monitoring strategy for, 296-303
of etoposide, amsacrine regimen, in pediatric leukemia, 1521-1525
of etoposide, cisplatin, radiation regimen, with vincristine, cyclophosphamide, doxorubicin regimen, in SCLC, 806-813
of 5-day intravenous topotecan infusion, in refractory ovarian cancer, 1552-1557
of fludarabine, in follicular lymphomas, 514-519
of fludarabine, mitoxantrone, dexamethasone regimen, for indolent lymphoma, 1262-1268
of fluorouracil, cisplatin, radiotherapy regimen, in anal cancer, 3121-3125
of ibandronate, for tumor-associated hypercalcemia, 268-276
of irinotecan, 713
in colorectal cancer, 1128-1135, 2688-2695
of mifepristone, in breast cancer, 2709-2712
of neoadjuvant combined modality therapy, in bladder cancer, 119-126
of 96 hour paclitaxel infusion, in breast cancer, 1877-1884
of paclitaxel
in biliary tract cancer, 2306-2310
for recurrent malignant glioma, 2316-2321
in squamous cervix cancer, 792-795
of paclitaxel, carboplatin regimen, in NSCLC, 2054-2060
of paclitaxel, cisplatin regimen, in breast cancer, 1993-1999
of paclitaxel, mitoxantrone, fluorouracil, folinic acid regimen, in breast cancer, 1611-1616
of postoperative intraperitoneal fluorouracil, cisplatin, intravenous fluorouracil regimen, 1818-1828
of preoperative fluorouracil, doxorubicin, methotrexate regimen, in gastric cancer, 1818-1828
safety monitoring strategy for, 296-303
of 3-hour paclitaxel, in NSCLC, 142-148
of topotecan
in NSCLC, 503-513
in SCLC, 2345-2352
of vinorelbine
in esophageal cancer, 164-170
in pretreated ovarian cancer, 2546-2551
of vinorelbine, fluorouracil regimen, in breast cancer, 3097-3104
of weekly anti-HER2 antibody therapy, for breast cancer, 737-744
Phase III trial
of anastrozole *v* megestrol acetate, in breast cancer, 2000-2011
of cytokines, in de novo acute myelocytic leukemia, 1373-1377
of doxorubicin, bleomycin, vincristine regimen, in Kaposi's sarcoma, 2353-2364
of fluorouracil *v* fluorouracil plus interferon alfa-2a, in colorectal cancer, 2674-2681
of fluorouracil, folinic acid, interferon alfa-2b regimen, in colorectal cancer, 2682-2687
of high-dose fluorouracil plus low-dose methotrexate, in colorectal cancer, 2266-2273
of IMMU-4, in colorectal cancer, 2295-2305
of liposomal daunorubicin, in Kaposi's sarcoma, 2353-2364
of mitomycin, fluorouracil, radiotherapy regimen, in anal cancer, 2527-2539
Physicians, drug companies and, conflict of interest of, 312-320
Pirarubicin, in mesothelioma, 1009
Pirarubicin, cisplatin regimen, in malignant mesothelioma, 1013
Piroxantrone, pharmacokinetic parameters of, 2593
PIXY321, 1379
administration routes for, 523
biologic activity of, 522
constituents of, 520-521
dosing of, 523
following autologous BMT, 520-526
infectious complications following, 523-524
for peripheral blood mobilization, 2521-2526
safety of, 524
tolerability of, 524
Pneumonia, interstitial
associated with paclitaxel, radiation regimen, 1071-1076
onset of, 1072
Polychemotherapy
alternating courses of, in relapsed pediatric acute lymphoblastic leukemia, 2813

radiation *v*, in primary cutaneous follicle center cell lymphoma, 549-555
venous access ports for, 2916-2922
*see also* Combination chemotherapy
Polyclonal antibody, production of, 1386
Polymerase chain reaction
for t(14;18)-positive cell detection, 1333-1344
reverse-transcriptase, *see* Reverse-transcriptase polymerase chain reaction
Polyposis coli, familial, genetic testing for, mothers' attitude toward, 415-421
Polysialic-neural cell adhesion molecule
comparative evaluation of, 2069-2070
levels of, sensitivity of, 2071
in medulloblastoma metastasis, 2066-2072
Port site recurrence
following thoracoscopy, 1950-1956
in malignancy, following laparoscopy, 1950-1956
Positron emission tomography
clinical, in metastatic cancer, 691-696
FDG-, 691
in hepatic metastasis analysis, 700-708
postchemotherapy monitoring with, for residual germ cell tumors, 1637-1641
with F-18 fluorodeoxyglucose, for breast tumor metabolic characterization, 1848-1857
Postmenopausal Estrogen-Progestin Interventions trial, 999
Practice guideline(s)
American Society of Clinical Oncology approach to, 2394-2395
in breast cancer, for tumor markers, 2843-2877
for colony-stimulating factor use, 1957-1960
in colorectal cancer, for tumor markers, 2843-2877
evidence-based, 2394-2395
summary of, for tumor markers, 2844
Prednisolone
apoptosis induced by, 2373-2374
dexamethasone *v*, in acute lymphoblastic leukemia, 2370-2376
Prednisolone, cyclophosphamide, epirubicin, vincristine regimen, in lymphoma, 227-232
Prednisolone, doxorubicin, cyclophosphamide, vincristine, bleomycin, etoposide, methotrexate regimen, in NHL, 586-592
Prednisone
in combination chemotherapy
for acute lymphoblastic leukemia, 2805
for small non-cleaved-cell lymphoma, 925-934
in hormone-resistant prostate cancer, 1756-1764
in polychemotherapy, for pediatric acute lymphoblastic leukemia, 2813
Prednisone, cyclophosphamide, doxorubicin, etoposide, bleomycin, cytarabine, methotrexate, folinic acid, GM-CSF regimen
maximum-tolerated dose of, in lymphoma, 1275-1281
response to, 1278
toxicity of, 1277-1278
Prednisone, cyclophosphamide, doxorubicin, vincristine regimen, in primary cutaneous follicle center cell lymphoma, 549-555
Prednisone, cyclophosphamide, methotrexate, fluorouracil, vincristine regimen
in breast cancer, 1589-1598
dosing of, 1591
survival following, 1593-1595
toxicity of, 1594-1596
Prednisone, cyclophosphamide, methotrexate, fluorouracil, vincristine regimen
in breast cancer, 46-51
ovariectomy plus, 46-51
toxicity of, 49
Prednisone, cyclophosphamide, vincristine regimen, in primary cutaneous follicle center cell lymphoma, 549-555
Prednisone, doxorubicin, cyclophosphamide, vindesine, bleomycin regimen, in lymphoma, 240-248
Prednisone, mechlorethamine, vincristine, procarbazine regimen, alternating with ABVD regimen, in HD, 1421-1430
Prednisone, vincristine, carmustine, doxorubicin regimen, in multiple myeloma, 2167-2173
Prednisone, vincristine, cyclophosphamide, melphalan regimen, in multiple myeloma, 2167-2173
Prednisone, vincristine, doxorubicin, cyclophosphamide regimen, high-dose mitoxantrone plus cytarabine *v*, 2480-2485
Probe, yeast-artificial-chromosome
generation of, 964
for t(14;18) chromosomal translocation detection, 963-969
Procarbazine, mechlorethamine, vincristine, prednisone regimen, alternating with ABVD regimen, in HD, 1421-1430
Prodrug, etoposide phosphate as, etoposide bioavailability following, 2020-2030
Profile of Mood States, 1458-1459, 1566
Progesterone receptor
immunohistochemical analysis of, 2585
as tumor marker
for adjuvant therapy response monitoring, 2861
in breast cancer, 2859-2862
definition of, 2859
future research with, 2862
literature review of, 2860
for metastatic therapy response monitoring, 2860-2861
methodology for, 2859-2860
for recurrence prognosis, 2861-2862
Progesterone receptor immunocytochemical assay, 2860
Progestins, overview of, in endometrial cancer, 357
Prognostic factor(s)
in acute lymphoblastic leukemia, 20-21, 914-916
in advanced seminoma, 456
age as
for combined modality therapy, in primary CNS lymphomas, 556-564
in HIV-related NHL, 2217-2223
*bcl-2* expression as, in breast cancer, 1604-1610
in breast cancer overexpressing c-*erb*B-2, 85-94
CD4+ to CD8+ ratio as, in melanoma, 1690-1696
CD44 variant as, in colorectal cancer, 1122-1127
cytogenetic clonal evolution as, 198-200
cytoreduction as, in leukemia, 389-398
Durie-Salmon as, in multiple myeloma, 1310, 1311
for in vivo marrow purging, 2795-2796
International Prognostic Factors Project for, 231
microvessel count as, in colorectal cancer, 461-466
in multiple myeloma, 1310, 1311
in myelodysplastic syndromes, 2488-2490
in neuroblastoma, 409
nm23 expression as, in ovarian cancer, 334-342
p15-p16 gene inactivation as, in pediatric leukemia, 1512-1520
p53 as
in bladder cancer, 2646-2652
in breast cancer, 1604-1610
in NSCLC, 497-502

for survival, in colorectal cancer, with hepatic metastases, 2696-2701
p-glycoprotein expression as, in pediatric rhabdomyosarcoma, 886-900
in pediatric B-cell acute lymphoblastic leukemia, 1257
peripheral blast count as, in relapsed pediatric acute lymphoblastic leukemia, 2812-2817
of positive margins, in extremity soft tissue sarcoma, 473-478
prostate-specific antigen nadir level as, 2897-2898
in pulmonary metastases, of colorectal cancer, 2047-2053
race as, in multiple myeloma, 974-977
Sanz classification as, in myelodysplastic syndromes, 2486-2494
serum lactate dehydrogenase as, in HIV-related NHL, 2217-2223
serum squamous cell carcinoma antigen as, in cervical cancer, 111-118
in soft tissue sarcoma, 859-868, 1679-1689
in stage I-II low-grade follicular NHL, 1285-1286, 1288
in stage IV small noncleaved-cell lymphoma, 1257
for survival, in head and neck cancer, 1196
in synovial sarcoma, 1201-1208
tumor size as, in osteosarcoma, 848-858
Prostate cancer
bowel movements in, following surgery *v* radiotherapy, 2261
combined modality therapy in, 3168-3169
energy index in, following surgery *v* radiotherapy, 2262
extracapsular extension in, endorectal coil MRI of, 1770-1777
general health index in, following surgery *v* radiotherapy, 2262
with high pretreatment PSA levels, patterns of failure in, 1093-1097
hormone-refractory, mortality of, 1753-1755
hormone-refractory metastatic, suramin in, 1626-1636
hormone-resistant
doxorubicin, cyclophosphamide, G-CSF regimen in, 1617-1625
mitoxantrone, prednisone regimen in, 1756-1764
prednisone in, 1756-1764
interstitial radiotherapy in, 304-315
mental health index in, following surgery *v* radiotherapy, 2262
perceived status in, following surgery *v* radiotherapy, 2261
radiation in, outcomes of, 2258-2265
radioimmunotherapy clinical trials in, 1390-1392
radiotherapy in, prostate-specific antigen nadir level following, 2889-2900
radiotherapy *v* surgery in, 2258-2265
seminal vesicle invasion in, endorectal coil MRI of, 1770-1777
sexual function in, following surgery *v* radiotherapy, 2260
stage D2, flutamide *v* diethylstilbestrol in, 2250-2257
stage T1-T2, transperineal iodine 125 implantation in, 449-453
stage T1c, pathologic characteristics of, 312
staging of, endorectal coil MRI for, 1770-1777
survival in, by prostate-specific antigen nadir level, 2894-2895
urine leaking in, following surgery *v* radiotherapy, 2260
Prostate gland, radiotherapy of, prostate-specific antigen following, 2889-2900
Prostate-specific antigen
high levels of, radiation following, 1093-1097
level of, following doxorubicin, cyclophosphamide, G-CSF regimen, 1621
nadir of, following radiotherapy, 2889-2900
optimum level of, following radiotherapy, 2889-2900
pretreatment level of, outcome by, 1094
as tumor marker, overview of, 1093
PSA, *see* Prostate-specific antigen
PSC 833
activity bioassay of, 612
dose escalation of, 611
etoposide plus
pharmacokinetics of, 615, 617
response to, 615
toxicity of, 614-616
for multidrug resistance, 610-618
Psychiatric Diagnostic Interview, 1458
Psychologic functioning
assessment of, 1458
during autologous BMT therapy, 1457-1462
Psychosocial Adjustment to Illness Scale-Self Report, 1566-1567
following cisplatin, etoposide, bleomycin regimen, 444
Pulmonary function
following doxorubicin, bleomycin, vinblastine, dacarbazine regimen, 1297-1305
following doxorubicin, bleomycin, vinblastine, dacarbazine, radiation regimen, 1297-1305
Pulmonary toxicity
following combined modality therapy, in HD, 1297-1305
following doxorubicin, bleomycin, vinblastine, dacarbazine regimen, 1297-1305
following doxorubicin, bleomycin, vinblastine, dacarbazine, radiation regimen, 1297-1305
Radiation Therapy Oncology Group scale for, 1298
Purging, in vivo, with high-dose cytarabine, 2206-2216
Pyrazine, pharmacokinetic parameters of, 2593

Q-TWiST
definition of, 2666
of interferon alfa-2b, in melanoma, 2666-2673
QLQ-BR23
EORTC, 2766-2767
hypothesized scale structure of, 2757-2758
validity of, 2756-2768
version 2.0 of, 2766
Quality of life
definition of, 673-674
dimensions of, 673
following distress screening, in breast cancer, 2747-2755
following HD therapy, 2444-2453
following intensive outpatient adjuvant therapy, in breast cancer, 1565-1572
following megestrol acetate, 139
following mitoxantrone, etoposide regimen, 1349
following surgery *v* radiotherapy, in prostate cancer, 2258-2265
measures of, 674
medroxyprogesterone acetate and, 1077-1084
medroxyprogesterone acetate-induced changes in, 1081, 1082
from patient perspective, 2777-2778
Profile of Mood States assessment of, 1566
in prostate cancer, following radiotherapy, 2258-2265
Psychosocial Adjustment to Illness Scale-Self Report assessment of, 1566-1567
questionnaire module for, 2756-2768
survival adjusted for, and interferon alfa-2b, 2666-2673
as survival predictor, in colorectal cancer, with hepatic metastases, 171-175
Quality-Adjusted Time Without Symptoms and Toxicity, definition of, 2666

R-verapamil, paclitaxel with

in breast cancer, 1173-1184
hematologic toxicity of, 1177-1178
neurologic toxicity of, 1177
Race, as prognostic factor, in multiple myeloma, 974-977
Radiation, carboplatin regimen, hematologic parameters following, 1075
Radiation, carboplatin, etoposide regimen
in NSCLC, 1065-1070
response to, 1067-1068
toxicity of, 1068
Radiation, cisplatin regimen
for invasive bladder cancer, 2901-2907
survival following, 2904-2905
Radiation, cisplatin, fluorouracil regimen
in anal cancer, 3121-3125
in head and neck cancer, 1192-1200
response to, 1195
survival following, 1196
toxicity of, 1194-1195
Radiation, cyclophosphamide, doxorubicin, vincristine, dexamethasone regimen
age and, 563
survival following, 559-560
toxicity of, 560-561
treatment schema for, 558
Radiation, doxorubicin, bleomycin, vinblastine, dacarbazine regimen
in HD, 1297-1305
pulmonary function following, 1297-1305
Radiation, doxorubicin, bleomycin, vinblastine, dacarbazine, methylprednisone, in HD, 1928-1935
Radiation, etoposide, cisplatin regimen
in combined modality therapy, for SCLC, 806-813
failure pattern following, 1059-1060
in NSCLC, 1055-1064
response to, 1058
survival following, 1059
toxicity of, 810, 1058
treatment schema for, 1056
Radiation, fluorouracil, mitomycin regimen
in anal cancer, 2527-2539
disease-free survival following, 2533, 2535
toxicity of, 2534-2535
Radiation, paclitaxel regimen
hematologic parameters following, 1075
infectious complications following, 1072
interstitial pneumonia associated with, 1071-1076
lymphocytes following, 1074
lymphocytopenia associated with, 1071-1076
toxicity of, 1072-1074
Radiation, paclitaxel, cisplatin, etoposide regimen
in NSCLC, 1642-1648
toxicity of, 1645-1646
Radiation, vinblastine, bleomycin, methotrexate regimen
in HD, 527-533
survival following, 530
toxicity of, 529-531
Radiation Therapy Oncology Group scale, for pulmonary toxicity, 1298
Radiation Therapy Oncology Group staging, of anal cancer, 2529
Radiobiology, 1387-1388
Radiocytotoxicity, iodine 125-labeled monoclonal antibody A33-mediated, of serum, 1794
Radioimmunodetection, with IMMU-4, in colorectal cancer, 2295-2305
Radioimmunotherapy
for B-cell lymphoma, 1974-1981
challenges to, possible approaches to, 1393
clinical trials of
in leukemia, 1388
in lymphoma, 1389-1391
in solid tumors, 1390-1392
dosimetry in, 1387
enhancing, strategies for, 1393
future directions in, 1392-1394
hypoxic cytotoxins and, 1394
local hyperthermia and, 1394
overview of, 1383-1384
radionuclides for, 1385-1387
toxicity of, 1392
with iodine 125-labeled monoclonal antibody A33, in colon cancer, 1787-1797
Radioiodination, of monoclonal antibody A33, in colon cancer, 1787-1797
Radioisotope, for radioimmunotherapy, 1385-1387
Radionuclide, for radioimmunotherapy, 1385
Radiosensitization, of paclitaxel, 1071-1076
Radiosurgery
of brain metastases, survival following, 1088-1091
linear accelerator-based stereotaxic, for brain metastases, 1085-1092
Radiotherapy
accelerated
following induction chemotherapy, in laryngeal cancer, 2322-2330
late morbidity associated with, 2325-2326
adjuvant, *v* observation
cost of, 2933-2939
outcomes of, 2934-2935
in stage I seminoma, 2933-2939
alone, following high PSA levels, 1093-1097
boost, for hepatic metastasis, 722-728
breast-conserving surgery plus
actuarial outcome following, 757
for intraductal breast cancer, 754-763
local recurrence following, 758-759
chemoradiotherapy *v*
in bladder cancer, 3168
in head and neck cancer, 3165
for malignant glioma, 3163
in rectal cancer, 3167
chemotherapy plus, *see* Chemoradiotherapy
in combined modality therapy, for NSCLC, 1642-1648
concurrent twice-daily, in combined modality regimen, for SCLC, 806-813
cyclophosphamide, doxorubicin, vincristine, dexamethasone regimen prior to, in primary CNS lymphomas, 556-564
in dermatofibrosarcoma protuberans, 2365-2369
drugs and, sequencing of, 3160
eighteen months following, lung function recovery at, 1431-1441
energy index following, *v* surgery, in prostate cancer, 2262
extended-field, plus vinblastine, bleomycin, methotrexate regimen, in HD, 527-533
external-beam, 157
interleukin-2 plus, 1393-1394

in prostate cancer, 2258-2265
full- *v* low-dose involved-field, second cancer following, 2435-2443
general health index following, *v* surgery, in prostate cancer, 2262
in HD, second solid tumors following, 2435-2443
interstitial
in prostate cancer, 304-315
maximizing therapeutic ratio of, for prostate cancer, 313-314
TRUS-guided transperineal, 305-306
low-dose total body, plus chemotherapy, leukemia following, 565-571
malignant mesothelioma following, 2098-2100
mantle, in combined modality therapy, pulmonary function following, 1297-1305
mediastinal, in combined modality therapy, pulmonary function following, 1297-1305
mental health index following, *v* surgery, in prostate cancer, 2262
polychemotherapy *v*, in primary cutaneous follicle center cell lymphoma, 549-555
preoperative, plus cisplatin, for invasive bladder cancer, 2901-2907
in preoperative combined modality therapy, for SCLC, 830
of prostate gland, prostate-specific antigen following, 2889-2892, 2893-2900
resistance mechanisms to, 3157-3158
secondary sarcomas, following Ewing's sarcoma, 2818-2825
surgery plus, in dermatofibrosarcoma protuberans, 2365-2369
surgery *v*, in prostate cancer, 2258-2265
survey in, questions for, 2264-2265
two field technique in, 2530
whole-brain, *v* linear accelerator-based stereotaxic radiosurgery, 1085-1092
with or without chemotherapy, for hepatic metastases, 726
*Ras* oncogene
as colorectal tumor marker
definition of, 2854
future research with, 2855
guidelines for, 2854
literature review of, 2854-2855
methodology for, 2854
as tumor marker, practice guidelines for, 2843-2877
Ratio, tumor-to-normal liver, 701
RB gene, loss of heterozygosity of, in osteosarcoma, 467-472
Rectal cancer, radiotherapy *v* chemoradiotherapy, 3167
Recursive partitioning technique, in chronic myelogenous leukemia, 196, 200-202
Relative hazard
of chemotherapy protocols, 842
definition of, 841
in survival analysis, 841, 843
Renal function
drug handling and, 2602
impaired, topotecan in, 3062-3073
Renal toxicity
following total body irradiation, in allogeneic BMT, 579-585
graft-versus-host disease and, 579-585
late
of cisplatin, bleomycin, etoposide regimen, 2927
of cisplatin, bleomycin, vinblastine regimen, 2927
Repopulation, of tumor cells, 3158-3159
Research funding, American Society of Clinical Oncology approach to, 2393
Restriction fragment length polymorphism analysis, 1514
Retinal pigment epithelium, tamoxifen-associated changes in, 1020
Retinoblastoma
combined modality therapy for
survival following, 1534
vincristine, cyclophosphamide, doxorubicin, cisplatin, etoposide regimen in, 1532-1536
hereditary, genetic testing for, mothers' attitude toward, 415-421
incidence of, 1532
stage-based protocol for, 1532-1536
treatment protocols for, 1533
Retinopathy, tamoxifen-associated, 1023
Reverse-transcriptase polymerase chain reaction
assay with, sensitivity test of, 2094
in cytokeratin 19 detection, 1868-1876
for melanoma cell detection, 2091-2097
methodology for, 2092
results of, 2093
by stage, 2094
Revised European American Lymphoma classification, 2465
Rhabdomyosarcoma, pediatric, p-glycoprotein expression in, 886-900
Rheumatoid arthritis, methotrexate in, and lymphoproliferative disorders, 1943-1949
Risk, classification of, uniform approach to, in leukemia, 18-24
RNA, estrogen receptor messenger, in situ hybridization of, 2585-2587
RNA analysis, 3134-3135
RNA level, of matrix metalloproteinase-9, for colorectal cancer relapse prediction, 3133-3140
Rotterdam Symptom Checklist, 171-175
RTOG, *see* Radiation Therapy Oncology Group
Rubidazone, dacarbazine regimen, in malignant mesothelioma, 1013

Safety, monitoring of, in clinical trials, 296-303
Sanz classification, prognostic value of, 2486-2494
Sarcoma
of extremity soft tissue, positive margins in, 473-478
pediatric
GM-CSF in, 901-910
ICRF-187 cardioprotection in, 362-372
secondary, radiation dose-dependency of, 2818-2825
soft tissue
adjuvant brachytherapy in, 859-868
distant recurrences in, 1683
histologic types of, 2657
incidence of, 2653
limb perfusion in, with tumor necrosis factor-alpha, interferon-gamma, melphalan regimen, 2653-2665
local recurrences in, 1679-1682
postmetastasis survival in, 1685
prognostic factors in, 869-877, 1679-1689
synovial
chemotherapy in, 1206
survival in, prognostic factors for, 1201-1208
Sargramostim, fluorouracil, doxorubicin, cyclophosphamide regimen, in breast cancer, 2976-2983
Schedule-dependency, of paclitaxel, 543-548
Science, 2183
Scientific research, in oncology, 2617
Scintigraphy, gallium-67, in low-grade NHL, 1936-1942
Screening, in breast cancer, with > 10 positive axillary nodes, 66-69

Second malignancy
following alternating *v* hybrid MOPP and ABVD regimens, 1427
following combination chemotherapy, 2769-2773
following Ewing's sarcoma, 2818
following HD radiotherapy, 2435-2443
following HD therapy, 1442-1446
malignant mesothelioma as, following radiotherapy, 2098-2100
leukemia as, following chemoradiotherapy, for NHL, 565-571
Seminoma
advanced
prognostic factors in, 456
residual mass management in, 454-460
residual mass size in, 456-457
stage I
cost analysis of, 2933-2939
management options in, 2934
*Serratia marcens*, 1160
Serum albumin, drug handling and, 2602
Serum squamous cell carcinoma antigen, pretreatment, as cervical cancer prognostic factor, 111-118
Sexual function, following surgery *v* radiotherapy, in prostate cancer, 2260
Sickness Impact Profile, 171-175
Side effects, of radiotherapy *v* surgery, in prostate cancer, 2258-2265
Simvastatin, 3046
Single-strand conformation polymorphism analysis, 1514-1515
Sjogren's syndrome, methotrexate in, and lymphoproliferative disorders, 1943-1949
Skin, pigmented lesions of, diagnosis of, interobserver agreement on, 1218-1223
SN38, glucuronidation of, interpatient variations in, 2688-2695
Soft tissue sarcoma
distant recurrences in, 1683
histologic types of, 2657
incidence of, 2653
limb perfusion in, with tumor necrosis factor-alpha, interferon-gamma, melphalan and, 2653
local recurrences in, 1679-1682
postmetastasis survival in, 1685
prognostic factors in, 1679-1689
Southern blot analysis, of N-*myc*, 27
SPECT gallium imaging, CT *v*, in NHL, 2473-2479
Sperm count, following cisplatin, etoposide, bleomycin regimen, 446
Squamous cell carcinoma
glottic, cisplatin, fluorouracil regimen in, 2331-2336
of head and neck, chemoradiotherapy in, 1192-1200
Staging
International Neuroblastoma System for, 2174-2180
in neuroblastoma, 2175
RTOG *v* AJCC-UICC, of anal cancer, 2529
STAI assessment, 1458-1459
Standardized uptake value, 692, 701-703
calculation of, 706
definition of, 1638
by histology, in germ cell tumor patients, 1640
*Staphylococcus aureus*, 1160
*Staphylococcus epidermidis*, 1160
Stem cell, peripheral-blood, *see* Peripheral-blood stem-cell
Stomatitis
associated with sequential paclitaxel-doxorubicin, 2713-2721
following epirubicin, 1152
Supportive care
algorithms for, 1157
following high-dose cyclophosphamide, thiotepa, carboplatin, BMT regimen, in breast cancer, 1156-1164
Suramin
plasma concentrations of, 1630
in prostate cancer, 1626-1636
response to, 1631
definition of, 1628
studies of, 1634
survival following, 1631-1632
toxicity of, 1630-1631
Surgery
breast-conserving
mastectomy *v*, 1558-1564
radiation plus
actuarial outcome following, 757
for intraductal breast cancer, 754-763
local recurrence following, 758-759
survival and, 70-77
in colon cancer, patient surveillance following, 183-187
energy index following, *v* radiotherapy, in prostate cancer, 2262
general health index following, *v* radiotherapy, 2262
mental health index following, *v* radiotherapy, 2262
perioperative chemotherapy following, in early-phase breast cancer, 745-753
radioimmunoguided, in breast cancer, 1599-1603
radiotherapy plus, in dermatofibrosarcoma protuberans, 2365-2369
radiotherapy *v*, in prostate cancer, 2258-2265
in soft tissue sarcoma, 1681
Western- *v* Japanese-type, in gastric cancer, 2289-2294
Survey, questions for, in radiotherapy, 2264-2265
Survival
breast-conserving surgery and, 70-77
in c-*erb*B-2overexpressing breast cancer, 85-94
prediction of, quality of life for, 171-175
prognostic factor for, p53 overexpression as, in colorectal cancer, with hepatic metastases, 2696-2701
in prostate cancer, by prostate-specific antigen nadir level, 2894-2895
statistical analysis of, 839-840

t(14;18) chromosomal translocation
fluorescence in situ hybridization detection of, 963-969
polymerase chain reaction detection of, 1333-1344
Tactile Form Perception Test, 2828
Tamoxifen
bone mineral density and, 78-84
cataracts associated with, 1023
plus chemotherapy, thromboembolism following, 2731-2737
efficacy of, and c-*erb*B2 overexpression, 2702-2708
endometrial cancer deaths and, 1027-1039
endometrial proliferation due to, 434-440
eye disease associated with, 1018-1026
keratopathy associated with, 1023
ocular effects of, 1018-1022
ocular toxicity of
differential diagnosis of, 1023-1024
pathophysiology of, 1022
profile of, 78-79
retinopathy-associated with, 1023

toremifene *v*, antiatherogenic effects of, 429-433
user recommendations for, 1024-1025
Tamoxifen, carmustine, dacarbazine, cisplatin regimen, in melanoma, 2083-2090
Taxane, paclitaxel following, in breast cancer, 1877-1884
Taxol, *see* Paclitaxel
Taxotere, *see* Docetaxel
*Taxus brevifolia*, 796
Tegafur, cisplatin, vindesine, uracil regimen, postoperative
adverse effects of, 1051
causes of death following, 1052
mean total dosing of, 1050
in NSCLC, 1048-1054
Telephone, intervention by
for informed consent, 984-996
patient satisfaction with, 991-992
Teniposide
in myeloablative chemoradiotherapy regimen, 2418-2419
in NSCLC, 127-134
pharmacokinetic parameter variations of, 2591
pharmacokinetic parameters of, and tumor response, 2597
survival following, 130-132
toxicity of, 129-130
Teniposide, cisplatin regimen
in NSCLC, 127-134
survival following, 130-132
toxicity of, 129-130
Testicular cancer
bilateral germ cell, 2061-2065
chemotherapy for, long-term toxicity of, 2923-2932
cisplatin, bleomycin, etoposide regimen in, 2923-2932
cisplatin, bleomycin, vinblastine regimen in, 2923-2932
postchemotherapy residual masses of, simultaneous resection of, 1765-1769
Testicular intraepithelial neoplasia
contralateral, 3126-3132
published studies of, 3129
Testing
for cancer predisposition, 417-418
genetic, for cancer, mothers' attitude toward, 415-421
Therapeutic drug monitoring, 2596-2597
problems with, 2597-2599
Therapeutic index, 3156-3157
Thioguanine, in polychemotherapy, for pediatric acute lymphoblastic leukemia, 2813
Thiotepa
amenorrhea due to, 1723
high-dose, plus etoposide, with autologous bone marrow rescue, 2495-2503
Thiotepa, busulfan, cyclophosphamide regimen, autologous BMT plus, with preexisting CNS disease, 3036-3042
Thiotepa, carboplatin, stem-cell regimen, as myeloablative regimen, 1527
Thiotepa, cyclophosphamide, carboplatin, BMT, supportive care regimen
in breast cancer, 1156-1164
infection following, 1160
nonhematologic toxicities due to, 1158-1160
survival following, 1161
Thiotepa, cyclophosphamide, carboplatin, stem-cell regimen
multiple courses of, 1473-1483
toxicity of, 1477-1479
Thiotepa, etoposide regimen, with autologous bone marrow rescue
for CNS tumors, 2495-2503
nonhematopoietic toxicity following, 2498-2499
survival following, 2499-2501
toxic mortality following, 2498
Thiotepa, melphalan, cyclophosphamide, carboplatin regimen, in breast cancer, 2984-2992
Thiotepa, vinblastine, doxorubicin, fluoxymesterone regimen
in breast cancer, 1589-1598
dosing of, 1591-1592
survival following, 1593-1595
toxicity of, 1594-1596
Thoracoscopy, in malignancy, port site recurrence following, 1950-1956
Thrombocytopenia
due to GM-CSF, in pediatric sarcoma, 901-910
following buthionine sulfoximine, melphalan regimen, 252
Thromboembolism, following tamoxifen plus chemotherapy, 2731-2737
Thymidylate synthase inhibitor, ZD 1694 type of, phase I trial of, 1495-1503
Thymidylate synthase mRNA level, fluorouracil-based chemotherapy and, in gastric cancer, 176-182
Thymoma
incidence of, 814
malignant
cisplatin, etoposide regimen in, 814-820
tumor characteristics of, 815
Thyroid cancer, medullary, antibody imaging of, 1209-1217
Thyroid nodule, needle aspiration techniques for, 1704-1712
Time-activity curve, 691-692
Tirapazamine, 1394
Tobacco, control of, American Society of Clinical Oncology recommendations for, 1961-1963
Tomudex, *see* ZD1694
Topotecan
antileukemic activity of, 1508-1509
chemical structure of, 504
cisplatin interaction with, 2598, 3081
cisplatin sequence dependence on, 3081
cisplatin synergy with, 3080-3081
continuous infusion, escalating systemic exposure of, 1504-1511
description of, 1504, 1552
dose-limiting toxicities of, 3067
five-day intravenous infusion of, phase II trial of, 1552-1557
for recurrent leukemia, in children, 1504-1511
hematologic toxicity of, 506-509, 1554-1555, 3058, 3064-3066
in impaired renal function, 3062-3073
initial pharmacokinetic model of, 2347
modified pharmacokinetic model of, 2347
nonhematologic toxicity of, 508-509, 1507-1508, 3058, 3066-3067
ovarian cancer refractory to, paclitaxel following, 1555
overview of, 3053-3055
pharmacodynamics of, 2350, 3069-3071
pharmacokinetic parameter variations of, 2591
pharmacokinetic parameters of, 1507, 2596
pharmacokinetics of, 1506-1507, 2347, 2349-2350, 2543, 3067-3068
in refractory ovarian cancer, 1552-1557
in SCLC, 2345-2352, 2785-2790
as second-line therapy, in ovarian cancer, 3056-3061

survival following, in ovarian cancer, 1556
toxicity of, 1554, 2542, 2348-2349
21 day continuous infusion of, in colorectal cancer, 2540-2545
in untreated NSCLC, 503-513
Topotecan, cisplatin regimen
hematologic toxicity of, 3078
nonhematologic toxicity of, 3078-3079
pharmacokinetics of, 3079-3080
sequence of, 3074-3084
Topotecan, G-CSF regimen
dose-escalation scheme for, 1226
hematologic toxicity of, 1227-1228
nonhematologic toxicity of, 1228
pharmacokinetics of, 1226, 1229-1230
sequential, phase I trial of, 1224-1235
Toremifene, tamoxifen *v*, antiatherogenic effects of, 429-433
Total-body irradiation
in allogeneic BMT, renal toxicity following, 579-585
low-dose, plus chemotherapy, leukemia following, 565-571
in myeloablative chemoradiotherapy regimen, 2418
Total-body irradiation, busulfan, cyclophosphamide regimen, in myelodysplastic syndrome, 220-226
Toxicity
of chemotherapy, associated with obesity, 3000-3008
cumulative, amifostine reduction of, 2101-2112
defining, 674
of sequential paclitaxel-doxorubicin, 2713-2721
Tracer, trapped, 691
Trail Making A and B, 2828
Trail Making Test B, 1458
Transperineal implant
CT-directed, 306
therapy with
clinical stage and, 311-312
complications of, 308-309
gastrointestinal toxicity and, 311
Gleason score and, 312
ideal candidate subgroup for, 312
outcome of, 309
prostate cancer location and, 310-311
*v* three-dimensional conformal radiotherapy, 310
urethral toxicity and, 311
TRUS-guided, 305-306
Transplantation, peripheral-blood stem-cell, *see* Peripheral-blood stem-cell transplantation
Triangular test, 3101
Trimetrexate
in mesothelioma, 1009
pharmacokinetic parameter variations of, 2591
pharmacokinetic parameters of, 2593, 2596
Tropisetron, prophylaxis with, maintained efficacy of, 644-651
TRUS-guided transperineal interstitial radiotherapy, 305-306
Tumor
cell proliferation in, 3158-3159
genetic instability of, 3157-3158
microenvironmental factors of, 3158
repopulation in, 3158-3159
Tumor marker
c-*erb*B2 overexpression as, for tamoxifen efficacy, 2702-2708
clinical practice guidelines for, in breast cancer, 2843-2877
in colorectal cancer, 2843-2877
definition of, 2846
in neuroblastoma, 373
polysialic-neural cell adhesion molecule measurement as, in medulloblastoma metastasis, 2066-2072
usefulness of, level of evidence for, 2845
uses of, 2845
utility grading system for, 2845
Tumor necrosis factor, isolated limb perfusion, melphalan, interferon gamma regimen
for extremity melanoma, 479-489
regional toxicity of, 485-486
response to, 482-484
systemic toxicity of, 484-486
Tumor necrosis factor-alpha, interferon-gamma, melphalan regimen
for soft tissue sarcoma, 2653-2665
toxicity of, 2659-2660
Tumor response, FDG-PET analysis of, to chemotherapy , 700-708
Tumor size
as prognostic factor, in osteosarcoma, 848-858
prognostic significance of, in synovial sarcoma, 1201-1208
Tumor-to-normal liver ratio, 701
Tumorectomy, mastectomy *v*, in early breast cancer, 1558-1564

Ubenimex, immunotherapy with, in leukemia, 204-213
UICC, *see* International Union Against Cancer
Ulex Europaeus Lectin, in colorectal cancer, 461-462
University hospital, work activities of, in oncology, 2617
Uracil, cisplatin, vindesine, tegafur regimen, postoperative
adverse effects of, 1051
causes of death following, 1052
mean total dosing of, 1050
in NSCLC, 1048-1054
Urinary bladder, preservation of, with combined modality therapy, for bladder cancer, 119-126
Urine leaking, following surgery *v* radiotherapy, in prostate cancer, 2260

Vascular toxicity
of cisplatin, bleomycin, etoposide regimen, 2926
of cisplatin, bleomycin, vinblastine regimen, 2926
Vena cava filter, inferior, 652-657
Venous access port
complications of, 2916-2922
definitions of, 2917
incidence of, 2920
odds ratios for, 2919
late complications of, 2918-2919
perioperative complications of, 2918
Verapamil
nor-, 1178
r-, 1173-1184
Verbal Selective Reminding Test, 2828
Vinblastine
in combination chemotherapy, second cancer following, 2770
in mesothelioma, 1009
Vinblastine, amifostine, cisplatin regimen
in NSCLC, 1913-1921
toxicity of, 1915-1917
Vinblastine, bleomycin, methotrexate, radiation regimen
in HD, 527-533
survival following, 530
toxicity of, 529-531
Vinblastine, cisplatin, bleomycin regimen

endocrinologic late toxicity of, 2927
gonadal toxicity of, 2926-2927
neurotoxicity of, 2925
otoxicity of, 2925-2926
renal late toxicity of, 2927
in testicular cancer, 2923-2932
vascular toxicity of, 2926
Vinblastine, doxorubicin, bleomycin, dacarbazine regimen
alternating with MOPP regimen, 1421-1430
in HD, 1297-1305
pulmonary function following, 1297-1305
Vinblastine, doxorubicin, bleomycin, dacarbazine, methylprednisone, radiation regimen, in HD, 1928-1935
Vinblastine, doxorubicin, bleomycin, dacarbazine, radiation regimen
in HD, 1297-1305
pulmonary function following, 1297-1305
Vinblastine, doxorubicin, thiotepa, fluoxymesterone regimen
in breast cancer, 1589-1598
dosing of, 1591-1592
survival following, 1593-1595
toxicity of, 1594-1596
Vincristine
in combination chemotherapy
for acute lymphoblastic leukemia, 2805
for SCLC, age and, 821-828
for small noncleaved-cell lymphoma, 925-934
second cancer following, 2770
delivered dose of, by age, 825
in mesothelioma, 1009
neuropathy due to, 935-940
pharmacokinetic parameter variations of, 2591
pharmacokinetic parameters of, 2596
in polychemotherapy, for pediatric acute lymphoblastic leukemia, 2813
Vincristine, carmustine, cytarabine, methotrexate regimen
in chemoradiotherapy, for CNS lymphoma, 945-954
hematologic toxicity of, 949
relapse patterns following, 951
survival following, 950-952
Vincristine, carmustine, doxorubicin, prednisone regimen, in multiple myeloma, 2167-2173
Vincristine, cyclophosphamide, doxorubicin regimen
in combined modality therapy, for SCLC, 806-813
toxicity of, 810
Vincristine, cyclophosphamide, doxorubicin, cisplatin, etoposide regimen
in combined modality therapy, for retinoblastoma, 1532-1536
Vincristine, cyclophosphamide, doxorubicin, dexamethasone regimen
in chemoradiotherapy, for CNS lymphoma, 945-954
hematologic toxicity of, 949
preirradiation, in primary CNS lymphomas, 556-564
relapse patterns following, 951
survival following, 950-952
Vincristine, cyclophosphamide, doxorubicin, dexamethasone, radiation regimen
age and, 563
survival following, 559-560
toxicity of, 560-561
treatment schema for, 558
Vincristine, cyclophosphamide, doxorubicin, fluorouracil regimen
in breast cancer, 1136-1145
dose analysis of, 1138-1139
radiotherapy and, 1141-1142
relapse site following, 1141
schedule for, 1137
toxicity of, 1139
Vincristine, cyclophosphamide, doxorubicin, methotrexate, cytarabine regimen
in pediatric leukemia, 1252-1261
in stage IV small non-cleaved-cell lymphoma, 1252-1261
Vincristine, cyclophosphamide, doxorubicin, prednisone regimen, in primary cutaneous follicle center cell lymphoma, 549-555
Vincristine, cyclophosphamide, epirubicin, prednisolone regimen, in lymphoma, 227-232
Vincristine, cyclophosphamide, methotrexate, fluorouracil, prednisone regimen
in breast cancer, 1589-1598
dosing of, 1591
survival following, 1593-1595
toxicity of, 1594-1596
Vincristine, cyclophosphamide, methotrexate, fluorouracil, prednisone regimen
in breast cancer, 46-51
ovariectomy plus, 46-51
toxicity of, 49
Vincristine, cyclophosphamide, prednisone regimen, in primary cutaneous follicle center cell lymphoma, 549-555
Vincristine, cyclophosphamide, melphalan, prednisone regimen, in multiple myeloma, 2167-2173
Vincristine, dacarbazine, lomustine, bleomycin, interferon regimen, in melanoma, 1690-1696
Vincristine, dexamethasone regimen, for maintenance, in acute lymphoblastic leukemia, 911-918
Vincristine, dexamethasone, asparaginase, methotrexate regimen, for induction, in acute lymphoblastic leukemia, 911-918
Vincristine, doxorubicin, bleomycin regimen
cardiac toxicity following, 2361
in Kaposi's sarcoma, 2353-2364
opportunistic infections following, 2361
quality of life following, 2359
response to, 2356-2358
survival following, 2358-2360
toxicity of, 2359-2361
Vincristine, doxorubicin, cyclophosphamide, bleomycin, etoposide, prednisolone, methotrexate regimen, in NHL, 586-592
Vincristine, ifosfamide, cyclophosphamide, doxorubicin, etoposide regimen, for desmoplastic tumor, 1526-1531
Vincristine, mechlorethamine, procarbazine, prednisone regimen, alternating with ABVD regimen, in HD, 1421-1430
Vincristine, methotrexate, doxorubicin, cyclophosphamide, bleomycin, dactinomycin regimen, for bone histiocytoma, 490-496
Vincristine, prednisone, doxorubicin, cyclophosphamide regimen, high-dose mitoxantrone plus cytarabine *v*, 2480-2485
Vindesine
in mesothelioma, 1009
in polychemotherapy, for pediatric acute lymphoblastic leukemia, 2813
Vindesine, cisplatin, tegafur, uracil regimen, postoperative
adverse effects of, 1051
causes of death following, 1052
mean total dosing of, 1050
in NSCLC, 1048-1054

Vindesine, doxorubicin, cyclophosphamide, bleomycin, prednisone regimen, in lymphoma, 240-248
Vindesine, etoposide maintenance regimen, in SCLC, 2337-2344
Vinorelbine
in epidermoid esophageal carcinoma, 164-170
fluorouracil, folinic acid regimen *v*, in NSCLC, 2774-2784
in pretreated ovarian cancer, 2546-2551
response to, 167
side effects of, 2549
toxicity of, 166-167
Vinorelbine, fluorouracil regimen
in breast cancer, 3097-3104
toxicity of, 3099-3100
Vinorelbine, ifosfamide regimen
in breast cancer, 2993-2999
toxicity of, 2996-2997
Visual Retention Test, 1458
Vomiting
following epirubicin, 1152
tropisetron prophylaxis for, maintained efficacy of, 644-651

Wechsler Adult Intelligence Scale, 2828
Wechsler Intelligence Scale for Children, revised, 2828
Wechsler Subtest Block Design,
Wechsler Subtests Information, Similarities, Comprehension, 2828
Weight, body
chemotherapy dosing by, 3000-3008
medroxyprogesterone acetate and, 1077-1084
medroxyprogesterone acetate-induced changes in, 1081
Weight gain
following megestrol acetate, 2007
following anastrozole, 2007
Western Blot analysis, of nm23, 336-338
Western yew, 796
Wide Range Achievement Test, 2828
Wilm's tumor, genetic testing for, mothers' attitude toward, 415-421
Word Fluency, 2828
World wide web, medical oncology on, 2181-2186

Yeast-artificial-chromosome probe
generation of, 964
in t(14;18) chromosomal translocation detection, 963-969
Yew, Western, 796

ZD 1694
in advanced colorectal cancer, 716-721
antitumor activity of, 1500
grade 3-4 adverse effects of, 719
liver function following, 1499
mechanism of action of, 717
pharmacokinetics of, 1497, 1500
phase I trial of, 1495-1503
plasma elimination of, 1500
structure of, 1496
toxicity of, 718-720, 1497-1499